The biology of the first 1000 days by unknown
THE BIOLOGY 
OF THE FIRST 
1,000 DAYS
 1. Oxidative Stress in Cancer, AIDS, and Neurodegenerative Diseases,  
edited by Luc Montagnier, René Olivier, and Catherine Pasquier 
 2. Understanding the Process of Aging: The Roles of Mitochondria, Free 
Radicals, and Antioxidants, edited by Enrique Cadenas and Lester Packer 
 3. Redox Regulation of Cell Signaling and Its Clinical Application, edited by  
Lester Packer and Junji Yodoi 
 4. Antioxidants in Diabetes Management, edited by Lester Packer, Peter Rösen,  
Hans J. Tritschler, George L. King, and Angelo Azzi 
 5. Free Radicals in Brain Pathophysiology, edited by Giuseppe Poli, Enrique 
Cadenas, and Lester Packer 
 6. Nutraceuticals in Health and Disease Prevention, edited by Klaus Krämer,  
Peter-Paul Hoppe, and Lester Packer 
 7. Environmental Stressors in Health and Disease, edited by Jürgen Fuchs and  
Lester Packer 
 8. Handbook of Antioxidants: Second Edition, Revised and Expanded,  
edited by Enrique Cadenas and Lester Packer 
 9. Flavonoids in Health and Disease: Second Edition, Revised and Expanded,  
edited by Catherine A. Rice-Evans and Lester Packer 
 10. Redox–Genome Interactions in Health and Disease, edited by Jürgen Fuchs, 
Maurizio Podda, and Lester Packer 
 11. Thiamine: Catalytic Mechanisms in Normal and Disease States,  
edited by Frank Jordan and Mulchand S. Patel 
 12. Phytochemicals in Health and Disease, edited by Yongping Bao and  
Roger Fenwick 
 13. Carotenoids in Health and Disease, edited by Norman I. Krinsky,  
Susan T. Mayne, and Helmut Sies 
 14. Herbal and Traditional Medicine: Molecular Aspects of Health, edited by  
Lester Packer, Choon Nam Ong, and Barry Halliwell 
 15. Nutrients and Cell Signaling, edited by Janos Zempleni and  
Krishnamurti Dakshinamurti 
 16. Mitochondria in Health and Disease, edited by Carolyn D. Berdanier 
 17. Nutrigenomics, edited by Gerald Rimbach, Jürgen Fuchs, and Lester Packer 
 18. Oxidative Stress, Inflammation, and Health, edited by Young-Joon Surh and  
Lester Packer 
OXIDATIVE STRESS AND DISEASE 
Series Editors 
Lester Packer, PhD 
Enrique Cadenas, MD, PhD 
University of Southern California School of Pharmacy 
Los Angeles, California
 19. Nitric Oxide, Cell Signaling, and Gene Expression, edited by Santiago Lamas 
and Enrique Cadenas 
 20. Resveratrol in Health and Disease, edited by Bharat B. Aggarwal and  
Shishir Shishodia 
 21. Oxidative Stress and Age-Related Neurodegeneration, edited by Yuan Luo 
and Lester Packer 
 22. Molecular Interventions in Lifestyle-Related Diseases, edited by  
Midori Hiramatsu, Toshikazu Yoshikawa, and Lester Packer 
 23. Oxidative Stress and Inflammatory Mechanisms in Obesity, Diabetes, and the 
Metabolic Syndrome, edited by Lester Packer and Helmut Sies 
 24. Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects,  
edited by Mulchand S. Patel and Lester Packer 
 25. Dietary Modulation of Cell Signaling Pathways, edited by Young-Joon Surh,  
Zigang Dong, Enrique Cadenas, and Lester Packer 
 26.  Micronutrients and Brain Health, edited by Lester Packer, Helmut Sies,  
Manfred Eggersdorfer, and Enrique Cadenas 
 27. Adipose Tissue and Inflammation, edited by Atif B. Awad and  
Peter G. Bradford
 28. Herbal Medicine: Biomolecular and Clinical Aspects, Second Edition,  
edited by Iris F. F. Benzie and Sissi Wachtel-Galor
 29. Inflammation, Lifestyle and Chronic Diseases: The Silent Link,  
edited by Bharat B. Aggarwal, Sunil Krishnan, and Sushovan Guha
 30. Flavonoids and Related Compounds: Bioavailability and Function,  
edited by Jeremy P. E. Spencer and Alan Crozier
 31. Mitochondrial Signaling in Health and Disease, edited by Sten Orrenius, 
Lester Packer, and Enrique Cadenas 
 32. Vitamin D: Oxidative Stress, Immunity, and Aging, edited by  
Adrian F. Gombart 
 33. Carotenoids and Vitamin A in Translational Medicine, edited by  
Olaf Sommerburg, Werner Siems, and Klaus Kraemer
 34. Hormesis in Health and Disease, edited by Suresh I. S. Rattan and  
Éric Le Bourg
 35. Liver Metabolism and Fatty Liver Disease, edited by Oren Tirosh
 36. Nutrition and Epigenetics, edited by Emily Ho and Frederick Domann
 37. Lipid Oxidation in Health and Disease, edited by Corinne M. Spickett and 
Henry Jay Forman
 38. Diversity of Selenium Functions in Health and Disease, edited by  
Regina Brigelius-Flohé and Helmut Sies
 39. Mitochondria in Liver Disease, edited by Derick Han and Neil Kaplowitz
 40. Fetal and Early Postnatal Programming and its Influence on Adult Health, 
edited by Mulchand S. Patel and Jens H. Nielsen
 41. Biomedical Application of Nanoparticles, edited by Bertrand Rihn
 42. The Biology of the First 1,000 Days, edited by Crystal D. Karakochuk,  
Kyly C. Whitfield, Tim J. Green, and Klaus Kraemer

THE BIOLOGY 
OF THE FIRST 
1,000 DAYS
EDITED BY
CRYSTAL D. KARAKOCHUK, KYLY C. WHITFIELD, 
TIM J. GREEN, AND KLAUS KRAEMER
1,000 Days® is a registered trademark of 1,000 Days, a 501(c)(3) nonprofit organization. The 1,000 Days 
mark is used with permission from 1,000 Days.
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
© 2018 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Printed on acid-free paper
International Standard Book Number-13: 978-1-4987-5679-2 (Hardback)
This book contains information obtained from authentic and highly regarded sources. Reasonable efforts 
have been made to publish reliable data and information, but the author and publisher cannot assume 
responsibility for the validity of all materials or the consequences of their use. The authors and publishers 
have attempted to trace the copyright holders of all material reproduced in this publication and apologize 
to copyright holders if permission to publish in this form has not been obtained. If any copyright material 
has not been acknowledged please write and let us know so we may rectify in any future reprint.
The Open Access version of this book, available at www.taylorfrancis.com, has been made available under 
a Creative Commons Attribution-Non Commercial-No Derivatives 4.0 license.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are 
used only for identification and explanation without intent to infringe.
Library of Congress Cataloging‑in‑Publication Data
Names: Karakochuk, Crystal D., editor. | Whitfield, Kyly C., editor. | Green, Tim J., 
1967- editor. | Kraemer, Klaus, 1960- editor.
Title: The biology of the first 1,000 days / [edited by] Crystal D. Karakochuk, Kyly C. 
Whitfield, Tim J. Green, and Klaus Kraemer. Other titles: Biology of the first thousand 
days | Oxidative stress and disease ; 42.
Description: Boca Raton : Taylor & Francis, 2018. | Series: Oxidative stress and disease; 
42 | Includes bibliographical references.
Identifiers: LCCN 2017013475 | ISBN 9781498756792 (hardback : alk. paper)
Subjects: | MESH: Pregnancy--physiology | Pregnancy Trimester, First--physiology | 
Maternal Nutritional Physiological Phenomena | Fetal Development | Nutritional 
Requirements | Pregnancy Complications--etiology | Pregnancy Complications--
prevention & control
Classification: LCC RG525 | NLM WQ 200.1 | DDC 618.2--dc23
LC record available at https://lccn.loc.gov/2017013475
Visit the Taylor & Francis Web site at
http://www.taylorandfrancis.com










Chapter 1 The Importance of the First 1,000 Days: An Epidemiological 
Perspective ............................................................................................3
Christine M. McDonald and Andrew L. Thorne-Lyman
Section ii What is normal Growth?
Chapter 2 World Health Organization Child Growth Standards ........................ 17
Mercedes de Onis
Section iii  nutritional Requirements 
in the Life Stages
Chapter 3 Nutrient Requirements and Recommendations during Pregnancy .... 35
Magali Leyvraz and Lynnette M. Neufeld
Chapter 4 Nutrient Requirements during Lactation ........................................... 53
Victoria Hall Moran
Chapter 5 Nutrient Requirements of Infants and Young Children ..................... 75
Minghua Tang, Kathryn G. Dewey, and Nancy F. Krebs
viii Contents
Section iV  endocrinology in the 
Regulation of Growth
Chapter 6 Hormonal Regulation during Lactation and Human Milk 
Production .......................................................................................... 89
William R. Crowley
Chapter 7 Thyroid Function and Growth: The Mechanisms of Iodine ............ 105
Jessica Farebrother and Fabian Rohner
Section V  Adverse Pregnancy and Birth 
outcomes (Pathophysiology 
and consequences)
Chapter 8 Neural Tube Defects: Mechanisms of Folate ................................... 123
Anne M. Molloy
Chapter 9 Cleft Lip and Palate .......................................................................... 137
Eman Allam, Ahmed Ghoneima, and Katherine Kula
Chapter 10 Obesity and Gestational Diabetes .................................................... 145
Maria Farren and Michael J. Turner
Chapter 11 Nutrition and Hypertensive Disorders of Pregnancy ....................... 155
Antonia W. Shand and Tim J. Green
Chapter 12 Low Birth Weight and Small for Gestational Age in the Context 
of 1,000 Days .................................................................................... 171
Amira M. Khan, Bianca Carducci, and Zulfiqar A. Bhutta
Section Vi  Pathophysiology and nutrition 
Requirements in child Malnutrition
Chapter 13 Acute Malnutrition ........................................................................... 191
André Briend
ixContents
Chapter 14 Management of Acute Malnutrition in Infants under 6 Months 
of Age ...............................................................................................207
Marko Kerac and Marie McGrath
Chapter 15 Chronic Malnutrition........................................................................ 221
Saskia de Pee
Chapter 16 Nutritional Regulation of the Growth Plate ..................................... 237
Julian C. Lui
Section Vii Body composition
Chapter 17 Gestational Weight Gain and Body Composition in Pregnant 
and Postpartum Women ................................................................... 255
Elisabet Forsum
Chapter 18 Body Composition Changes from Infancy to Young Childhood .....269
Daniel J. Hoffman and Pamela L. Barrios
Section Viii the Gut Microbiome
Chapter 19 Early Life Gut Microbiome .............................................................. 289
Christopher J. Stewart and Stephen P. Cummings
Chapter 20 Impact of Different Exposures, Including Environmental 
Enteropathies, on Gut Flora and Integrity ........................................303
Fayrouz A. Sakr Ashour
Section iX  effects of early Life 
exposures and nutrition
Chapter 21 Effects of Early Diet on Childhood Allergy .................................... 323
Merryn Netting and Maria Makrides
x Contents
Chapter 22 Epigenetics, Nutrition, and Infant Health......................................... 335
Philip T. James, Matt J. Silver, and Andrew M. Prentice
Chapter 23 Fetal Origins of Obesity, Cardiovascular Disease, and Type 2 
Diabetes ............................................................................................ 355
Herculina Salome Kruger and Naomi S. Levitt
Section X  effective interventions 
during the First 1,000 Days
Chapter 24 Effectiveness of Nutrition-Specific Interventions in Pregnancy 
and Early Childhood ........................................................................ 371
Rebecca Heidkamp, Adrienne Clermont, and Robert E. Black
Chapter 25 Nutrition-Sensitive Interventions for the First 1,000 Days .............. 389
Jessica Fanzo and Haley Swartz
Chapter 26 Global Progress in the Scaling Up Nutrition (SUN) Movement ......409
Tom Arnold
Section Xi  Before and Beyond the First 1,000 Days
Chapter 27 A Role for Preconception Nutrition ................................................. 423
Taylor Marie Snyder, Homero Martinez, Sara Wuehler, 
and Luz Maria De-Regil
Chapter 28 Interpregnancy Intervals and Birth Spacing .................................... 439
Amanda Wendt and Usha Ramakrishnan
Chapter 29 Adolescent Nutrition: A Critical Opportunity for Intervention ....... 457
Emily Mates and Anne Bush
xiContents
Section Xii Discovery Research
Chapter 30 Metabolomics and Proteomics: Methodological Advances to 
Increase Our Knowledge of Biology during the First 1,000 Days ... 473





OXIDATIVE STRESS IN HEALTH AND DISEASE
Oxidative stress is an underlying factor in health and disease. In this series of books 
the importance of oxidative stress and disease associated with cell and organ sys-
tems of the body is highlighted by exploring the scientific evidence and the clinical 
applications of this knowledge. This series is intended for researchers in the bio-
medical sciences and clinicians and all persons with interest in the health sciences. 
The potential of such knowledge for healthy development, healthy aging, and disease 
prevention warrants further knowledge about how oxidants and antioxidants modu-
late cell and tissue function.
Crystal D. Karakochuk, Kyly C. Whitfield, Tim J. Green, and Klaus Kraemer are 
to be congratulated for producing this very excellent and timely book, The Biology 







The first 1,000 days, from conception to 2 years of age, is a critical window of growth 
and development. Exposures to dietary, environmental, hormonal, and other stress-
ors during this period have been associated with an increased risk of adverse health 
outcomes. Researchers using cell culture, animal models, and humans have identi-
fied this time as a period of rapid physiological change and plasticity with significant 
potential for lasting effects. As such, interventions during the first 1,000 days will 
have the greatest impact on outcomes, particularly in low- and middle-income coun-
tries where the need is greatest.
To date, there is no single resource that compiles our knowledge of the biology 
of the first 1,000 days. Our knowledge and understanding of the biology behind 
the first 1,000 days is still limited. This greater understanding is helping us inform 
effective nutrition policy and programming. The strength of this book lies in its 
cross- disciplinary nature that encompasses the full range of human biology, provid-
ing a more holistic perspective during this critical time frame. Moreover, we have 
broadened the scope and included important periods before and after the 1,000 days.
We have designed this book as a comprehensive resource for those involved in 
global health and nutrition policy, strategy, programming, or research. This book 
will also be a resource for students learning about nutrition and health across the 
1,000 days. The book includes an exceptional group of contributors who are experts 
in their given fields. As biology underlies the core of each discussion, it allows 
the readers to answer the what and why, and, we hope, the how for new discovery 
research and more effective interventions.
Each chapter in this volume provides insight into a specific life stage, disease 
state, nutrient, and stressor in the first 1,000 days. As such, each chapter can be read 
independently, providing a comprehensive overview of that subject. However, there 
is continuity between chapters allowing this collection of chapters to be read cover 
to cover. The first chapters set the stage, providing a succinct resource to understand 
the well-established biological mechanisms that underlie growth regulation and 
nutrient recommendations throughout the first 1,000 days. The next chapters move 
on to the evidence behind nutrition-specific and nutrition-sensitive interventions 
to combat adverse outcomes and disease states in the first 1,000 days. This book 
also features emerging research areas, such as the gut microbiome, environmental 
enteric dysfunction, and the role of epigenetics in health and development. The final 
chapter pushes the boundaries of discovery research, exploring novel areas such as 
proteomics and metabolomics, and how insults such as environmental enteric dys-
function affect metabolism in the first 1,000 days.
xvi Preface
We approached this book with the ambition to shed more light on the biology dur-
ing 1,000 days, but there was also a need to put the biology into a broader context of 
nutrition and health. There are still many gaps in our understanding of the biology 
of the first 1,000 days. It is only by bridging this knowledge gap through research 
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1 The Importance of 
the First 1,000 Days
An Epidemiological 
Perspective
Christine M. McDonald and 
Andrew L. Thorne-Lyman
EPIDEMIOLOGICAL BURDEN AND DISTRIBUTION 
OF THE PROBLEM OF MALNUTRITION
According to current estimates, 23% of the world’s children under 5 years of age 
are stunted, a condition that is measured using short height-for-age (see Box 1.1) [1]. 
Although this represents a decline from 33% in 2000, the fact that 156 million chil-
dren globally still suffer from chronic undernutrition underscores the continued need 
for renewed efforts and innovative approaches for growth promotion. Progress has 
been particularly slow in Africa, where one out of every three children is stunted 
(Figure 1.1) [1]. In fact, despite a decline in stunting prevalence, the absolute number 
of stunted children in Africa increased from 50.4 million in 2000 to 58.5 million 
in 2015 [1]. Although Asia has seen an average annual decline in the prevalence of 
child stunting of about 1.5%, from 38% in 2000 to 24% in 2015, countries in East 
Asia have accounted for most of this progress [1]. Reductions have been much slower 
among countries in South Asia where more than one out of every three children 
under age 5 is stunted. At a subregional level, more than 30% of children under 
5 in Western Africa, Middle Africa, Eastern Africa, Southern Asia, and Oceania 
are stunted [1]. In addition to these geographical differences, there are also dras-
tic sociodemographic disparities in the prevalence of chronic undernutrition. An 
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4 The Biology of the First 1,000 Days
analysis of 79 population-based surveys has illustrated that the prevalence of stunt-
ing is, on average, 2.5 times higher among children living in the poorest quintile of 
households than the richest quintile [1]. Similarly, the child stunting prevalence is 
1.45 times higher in rural versus urban areas [2].
Globally, an estimated 50 million children are wasted, an indicator of thin-
ness that is strongly associated with mortality [1]. Moderately and severely wasted 
children are, respectively, 3.0 and 9.4 times more likely to die than children with a 
weight-for-height z-score >–1 [3]. Although the global burden of child wasting is 
considerably smaller than that of stunting, efforts to enhance the coverage of inter-
ventions to prevent and treat acute malnutrition are urgently needed, particularly 
given the increased risk of mortality faced by wasted children. Approximately two-
thirds of the world’s wasted children live in Asia and one-quarter live in Africa. At 
14%, the prevalence of child wasting in South Asia is near the 15% threshold used to 
define a critical public health emergency [1,4].
Of equal concern is the growing burden of overweight children. Worldwide, there 
are now 42 million overweight children under 5 years of age [1]. Since 2000, the 
number of overweight children under 5 has increased by more than 50% in Africa, 
BOX 1.1 ANTHROPOMETRIC INDICATORS OF MALNUTRITION
• Stunting refers to impaired linear growth and can reflect chronic or 
recurrent undernutrition. The indicator can also be defined as having 
a short height for a given age compared with a reference population or 
standard. A cutoff of <–2 height-for-age z-scores (HAZ) is most com-
monly used to define stunting among children under 5 years of age.
• Wasting is a type of acute malnutrition resulting from recent weight 
loss or failure to gain weight. A cutoff of <–2 weight-for-height 
z-scores (WHZ) is most commonly used to define wasting among 
children under 5 years of age, and <–3 z-scores are used to define 
severe wasting.
• Underweight is used to describe a child whose weight is low in rela-
tion to his or her age. Underweight was historically used as a com-
posite indicator of malnutrition but is now used less often since it fails 
to differentiate between chronic and acute malnutrition. A cutoff of 
<–2 weight-for-age z-scores (WAZ) is most commonly used to define 
underweight among children under 5 years of age.
• Low birth weight is typically defined as a birth weight <2,500 g.
• Small for gestational age (SGA) is usually defined by a birth weight 
below the 10th percentile for gestational age based on a reference 
population. Small for gestational age is an indicator that reflects an 
infant’s growth rate in utero, as well as his or her gestational age at 
birth.





































































































































































































































































































































































































































































6 The Biology of the First 1,000 Days
with gains being particularly pronounced in low- and middle-income countries [1]. 
At a subregional level, the prevalence of overweight among children under 5 now 
exceeds 10% in Central Asia, Northern Africa, and Southern Africa [1].
Intrauterine growth restriction is a key risk factor for stunting, wasting, and under-
weight in childhood. Recent estimates indicate that 15% to 20% of all births globally 
are low birth weight (LBW), which translates to more than 20 million LBW births 
per year [5]. Half of these births occur in only three countries: India, Pakistan, and 
Nigeria. India alone makes up 38% of the global total [5]. The prevalence of small-
for-gestational-age (SGA) births is approximately twice the prevalence of LBW in all 
regions of the world [6]. In 2010, more than 32 million infants were born SGA, which 
represents more than one-quarter of all births in low- and middle-income countries [6]. 
The highest prevalence of SGA is found in South Asia and the Sahelian countries 
of Africa. As with LBW, the burden of SGA is particularly high in India; in 2010, 
12.8 million infants, representing ~47% of all births, were SGA [6].
In addition to anthropometric indicators that reflect physical growth during the 
first 1,000 days, indicators of the micronutrient status of pregnant women and young 
children provide useful insight into the dietary quality of vulnerable subgroups, as 
they influence the risk of mortality, morbidity, and adverse developmental outcomes. 
Iron, vitamin A, iodine, zinc, and folate are the micronutrient deficiencies that have 
received the greatest attention in terms of their public health burden, and are esti-
mated to account for approximately 7% of the global burden of disease every year 
[7]. Globally, an estimated 2 billion people are affected by deficiencies in at least one 
essential micronutrient. Figure 1.2 summarizes the global prevalence of vitamin A 
deficiency and iron deficiency anemia among pregnant women and children under 5.
The estimated global prevalence of iodine deficiency and zinc deficiency is 29% 
and 17%, respectively [2]. Unfortunately, limited data are available on the global 














Pregnant women Children under 5
FIGURE 1.2 Global prevalence of vitamin A deficiency and iron deficiency anemia among 
pregnant women and children under 5. (Adapted from Black RE, Victora CG, Walker SP 
et al., Lancet 2013, 382(9890):427–51.)
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the regional distribution of these micronutrient deficiencies and the anthropometric 
deficits previously described. Africa exhibits the highest levels of iron deficiency 
anemia among pregnant women and children under 5, vitamin A deficiency among 
children under 5, iodine deficiency and zinc deficiency, while Asia exhibits the high-
est prevalence of vitamin A deficiency among pregnant women [2]. Just as various 
forms of an anthropometric deficit can coexist, it is also common for women and 
children to suffer from multiple micronutrient deficits simultaneously, although the 
extent of overlap is often uncertain.
WINDOW OF OPPORTUNITY
One of the main epidemiological drivers for the focus on the first 1,000 days was the 
realization that height-for-age z-scores in countries throughout the world plummet 
during the first 24 months of life, as presented in blue in Figure 1.3 [3,8]. Such pat-
terns suggest a rapid acceleration of growth faltering, followed by a leveling out of 
height-for-age z-scores and the prevalence of child stunting around 2 years of age. 
This pattern is apparent in all World Health Organization (WHO) regions. One strik-
ing difference, however, is that in South Asia, where 38% of under-5s are stunted, 
the average height-for-age z-score is –0.75 at birth. This dynamic reflects the high 
prevalence of intrauterine growth restriction and preterm delivery in South Asia, 
























Weight for age (WAZ)
Weight for length (WHZ)
Height for age (HAZ)
FIGURE 1.3 Mean anthropometric z-scores by age and WHO region from 54 stud-
ies. WHO Regions: Euro, Europe; EMRO, Eastern Mediterranean; AFRO, Africa; PAHO, 
Americas; SEARO, South East Asia. (Reproduced from Victora CG, de Onis M, Hallal PC 
et al., Pediatrics 2010, 125(3):e473–80. With permission.)
8 The Biology of the First 1,000 Days
THE FIRST 300 DAYS
Starting around the time of conception, the first 300 days span a window that encap-
sulates the time of an average human female pregnancy (280 days), as well as the 
first several weeks of life. A woman’s nutritional status as she enters pregnancy (the 
periconceptional period) is an important focus of growing scientific interest. Certain 
micronutrients have roles in regulating aspects of implantation, placentation, and 
cell differentiation, processes that can have both short- and long-term effects on 
pregnancy outcomes, fetal growth, and development [9]. During this window, a defi-
ciency or excess of certain micronutrients may also lead to birth defects including 
teratogenicity. Perhaps the most prominent example of the effects of early micro-
nutrient deficiencies is that folic acid supplementation can reduce the risk of neural 
tube defects, by an average of 41% [10]. While observational studies have suggested 
that the status of certain micronutrients (notably tocopherols) can influence the risk 
of miscarriage, and there is some suggestion of a protective effect of micronutrient 
supplementation on stillbirth risk, evidence remains inconsistent [11,12].
There are many nutritional influences on fetal growth. During pregnancy, a wom-
an’s energy and protein needs are 13% and 54% higher compared with a nonpreg-
nant woman [13]. During the second and third trimesters, energy and protein intake 
appear to have greater importance, supported by meta-analyses of five pooled trials 
suggesting that balanced protein-energy supplementation trials in pregnancy reduces 
the risk of LBW by 32%, with greater effects on undernourished women; SGA by 
34%; and stillbirth by 38% [14,15]. Studies show that a woman’s weight gain during 
pregnancy and body mass entering pregnancy are also important factors influencing 
pregnancy outcomes [16].
According to a recent systematic review and meta-analysis, iron supplementation 
in pregnancy significantly decreases maternal anemia, iron deficiency, and LBW, but 
no significant effect was observed on risk of preterm birth, gestational length, SGA, 
or birth length [17]. Evidence of the benefits of multiple micronutrient supplementa-
tion on birth and child health outcomes is inconsistent, with a recent review of 20 
randomized trials finding no significant benefits on mortality, growth at follow-up, 
head circumference, or cognitive function [18]. However, the largest of such trials to 
date, involving nearly 45,000 pregnancies from northwest Bangladesh, found slightly 
protective effects of antenatal and maternal postnatal micronutrient supplementation 
on stunting at birth, 1 month, and 3 months postpartum, but no effects on cognitive, 
language, or motor development [18,19]. Antenatal care guidelines from the World 
Health Organization issued in 2016 did not recommend micronutrient supplemen-
tation over iron and folic acid alone for improving maternal and perinatal health 
outcomes, but did identify the need for more research to identify potential benefits of 
individual nutrients and combinations of micronutrients [20].
Globally, nearly 15 million children are estimated to be born preterm and it is the 
leading cause of neonatal mortality, the second leading cause of death for children 
under 5, and an important cause of disability and cognitive impairment [21–23]. 
Numerous risk factors for preterm birth have been identified, including low or high 
maternal age, maternal undernutrition, micronutrient deficiencies, infections, diabe-
tes, and hypertension [16,23].
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Infants born small, or early, tend to stay small, although these effects appear to be 
stronger for the relationship between SGA and stunting than preterm. Infants born 
preterm have an approximately twofold greater risk of becoming stunted (OR 1.93, 
95% CI: 1.71, 2.18); those born SGA have a 2.43 (95% CI: 2.22, 2.66) greater risk; 
and those born SGA and preterm a have 4.51-fold greater risk (95% CI: 3.42, 5.93) 
compared with appropriate-for-gestational-age term infants. It is clear that address-
ing nutritional deficiencies and other risk factors for SGA and preterm birth during 
and entering pregnancy should be an essential part of stunting prevention [24].
THE NEXT 700 DAYS OF LIFE
The first day of life is a period of transition and a critical window of risk for the 
newborn. During this time, successful establishment of breastfeeding is essential, 
and challenging. Only 45% of the 140 million live-born newborns born each year 
are breastfed in the first year of life, and little improvement has been observed in this 
indicator over the past 15 years (Figure 1.4). In many countries, cultural practices 
of early newborn ritual feeding with sugar water, tea, honey, or animal milk are 
prevalent, and there is emerging evidence that these interfere with the provision of 
colostrum and delay the timely initiation of breastfeeding [25,26]. In a three-country 
study examining the timing of the initiation of breastfeeding and the risk of neonatal 
mortality, the risk of death was 41% higher in neonates who initiated breastfeeding 
at 2 to 23 hours, and 79% higher in infants initiating breastfeeding at 24 to 96 hours, 
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FIGURE 1.4 Infant and young child feeding practices on a global level. Age groups for 
denominators: Early introduction of breastfeeding, exclusive breastfeeding (0–5 months); 
introduced to solid, semisolid, or soft foods (6–8 months); minimum meal frequency, mini-
mum diet diversity, and minimum acceptable diet (6–23 months); and continued breastfeed-
ing at 1 year (12–15 months) and 2 years (20–23 months). Figures reflect UNICEF 2016 
global averages, largely from low- and middle-income countries, 2010–2016. (Data from 
United Nations Children’s Fund [UNICEF], From the first hour of life: Making the case for 
improved infant and young child feeding everywhere, New York: UNICEF, 2016.)
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the early initiation of breastfeeding influences the risk of mortality require more 
exploration, but may include greater consumption of colostrum (the first milk, which 
is rich in certain micronutrients and immune substances), warmth from contact with 
the mother, and strengthened gastrointestinal barrier integrity [27].
WHO recommends that all infants are exclusively breastfed for the first 
6  months  of  life, a practice defined as the exclusive consumption of breast milk, 
and medicines or vitamins/minerals as needed. Only 43% of infants were exclu-
sively breastfed in 2015 [28] (Figure 1.4). The same three-country study described 
earlier found that compared with exclusive breastfeeding, partial breastfeeding and 
no breastfeeding at 1 month were associated with a 1.8 and 10.9 times greater risk 
of mortality during the first 6 months of life [27]. Nearly two-thirds of children are 
transitioned to semisolid or soft foods by 6 to 8 months, but far fewer children are 
transitioned to diets in which they are fed with the frequency or diversity recom-
mended for healthy growth, or are breastfed well into the second year of life, as 
recommended by WHO and UNICEF (United Nations Children’s Fund) (Figure 1.4).
RISK FACTORS FOR CHILD STUNTING
A recent review consolidated data from 137 developing countries to examine risk 
factors for stunting among children 2 years of age [29]. The findings, illustrated in 
Figure 1.5, underscore the importance of the first 300 days in the etiology of stunting, 
and the need to develop and expand interventions that address the causes of preterm 
birth and intrauterine growth restriction in particular. Much research is currently 
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FIGURE 1.5 Number of stunting cases among children 2 years of age in 2011, attributable 
to risk factor clusters. (Reproduced from Danaei G, Andrews KG, Sudfeld CR et al., PLoS 
Med 2016; 13(11):e1002164. With permission.)
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ongoing to understand the extent to which factors, such as hygiene and sanitation and 
aflatoxins, influence stunting risk. Additionally, adolescent pregnancy, common in 
many countries in which stunting is most prevalent, is getting considerable attention 
as a risk factor for stunting [30].
PUBLIC HEALTH AND ECONOMIC IMPORTANCE 
OF NUTRITION AND THE FIRST 1,000 DAYS
From an epidemiological perspective, the 1,000 days is a critical window in terms 
of mortality risk and other health outcomes. Over 6 million children under the age 
of 5 die each year, primarily in low- and middle-income countries [27]. The epide-
miological burden of under-5 mortality is increasingly shifting to neonatal mortality: 
42% of under-5 deaths occurred during the neonatal period in 2013, compared with 
37% in 1990, suggesting that more attention needs to be paid to the factors that pre-
dispose children to early mortality [31].
The links between chronic undernutrition and child development have received 
greater attention over the past decade, building on early work that examined the effects 
of severe malnutrition in childhood on intelligence and school performance [29]. The 
first Lancet series on child development in developing countries identified several 
studies suggesting that term infants born with intrauterine growth restriction were 
associated with adverse developmental outcomes in the first several years of life, but 
identified a lack of studies that had outcomes followed up in later childhood [32]. More 
recently, meta-analyses have quantified the economic consequences of stunting and 
have estimated that early life growth faltering in low-income countries cost nearly 
70 million years of educational attainment per birth cohort, resulting in total economic 
costs of over $616 billion at purchasing power parity-adjusted exchange rates [33].
CONCLUSION
The first 1,000 days represent a life window when growth rates and neuroplasticity 
are at their peak and where nutritional deficiencies can exert their most devastating 
impacts. Ensuring that the nutritional needs of women, infants, and young children 
are met during this period can help avert child mortality and lifelong disease burden, 
maximize growth, and enable children to reach their cognitive and developmental 
potential, particularly when combined with psychosocial stimulation. While these 
impacts represent a strong epidemiological rationale for focusing interventions on 
this window, it is important to remember that neither growth nor brain development 
stops at 1,000 days, and that ensuring good nutrition through the lifecycle is likely to 
have the greatest absolute benefit in terms of health and other outcomes.
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What Is Normal Growth?
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Adequate nutrition during the early years of life is of paramount importance for growth, 
development, and long-term health through adulthood. It is during infancy and early 
childhood that irreversible faltering in linear growth and cognitive deficits occur [1,2]. 
Poor nutrition during this critical period contributes to significant morbidity and mortal-
ity [3]. Similarly, the increasing prevalence of childhood obesity worldwide is associ-
ated with an increased risk of unfavorable health outcomes later in life and decreased 
longevity [4]. Apart from contributing positively to child survival, the quality of infant 
and young child feeding is fundamental to achieving optimal growth and development.
Pediatricians and other health professionals rely largely on the assessment of chil-
dren’s growth status to determine whether infant and young child nutrition is ade-
quate. Growth charts are thus essential items in the pediatric toolkit for evaluating 
the degree to which physiological needs for growth and development are being met. 
However, the evaluation of child growth trajectories and the interventions designed 
to improve child health are highly dependent on the growth charts used.
In 2006, the World Health Organization (WHO) released new standards for assess-
ing the growth and development of children from birth to 5 years of age [5,6]. The 
standards were the product of a detailed process initiated in the early 1990s, which 
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involved various reviews of the uses of anthropometric references and alternative 
approaches to developing new tools to assess growth [7]. The WHO standards were 
developed to replace the National Center for Health Statistics (NCHS)/WHO inter-
national growth reference [8], the limitations of which have been described in detail 
elsewhere [9]. The purpose of this chapter is to describe the WHO Child Growth 
Standards, provide their background and rationale, detail how the charts were devel-
oped, and outline the main innovative aspects they offer. It also provides information 
on complementary charts for assessing the growth of fetuses, newborns by gesta-
tional age, preterm infants, and children over 5 years of age.
RATIONALE FOR DEVELOPING THE WORLD HEALTH 
ORGANIZATION CHILD GROWTH STANDARDS
The WHO standards date back to the early 1990s, when the WHO initiated a com-
prehensive review of the uses and interpretation of anthropometric references, and 
conducted an in-depth analysis of growth data from breastfed infants. This analysis 
showed that the growth pattern of healthy breastfed infants deviated to a signifi-
cant extent from the NCHS/WHO international reference [10]. The review group 
concluded from these and other related findings that the NCHS/WHO reference 
did not adequately describe the physiological growth of children, and that its use to 
monitor the health and nutrition of individual children or to derive estimates of child 
malnutrition in populations was flawed. In particular, the reference was inadequate 
for assessing the growth pattern of healthy breastfed infants, because it was based 
on predominantly formula-fed infants, as are most national growth charts in use 
today. The group recommended the development of new standards, adopting a novel 
approach that would describe how children should grow when free of disease and 
when their care follows healthy practices such as breastfeeding and nonsmoking [7]. 
This approach would permit the development of a standard, as opposed to a refer-
ence merely describing how children grew in a particular place and time. Although 
a standard and a reference both serve as a basis for comparison, each enables a dif-
ferent interpretation. Since a standard defines how children should grow, deviations 
from the pattern it describes are evidence of abnormal growth. A reference, on the 
other hand, does not provide as sound a basis for such value judgments, although in 
practice references often are mistakenly used as standards.
Following a resolution from the World Health Assembly endorsing these recom-
mendations (Resolution WHA47.5 on Infant and Young Child Nutrition, May 1994), 
the WHO Multicentre Growth Reference Study (MGRS) [11] was launched in 1997 
to collect primary growth data that would allow the construction of new growth 
charts consistent with “best” health practices.
DESIGN OF THE WHO MULTICENTRE GROWTH REFERENCE STUDY
The goal of the MGRS was to describe the growth of healthy children. Implemented 
between 1997 and 2003, the MGRS was a population-based study conducted in six 
countries from diverse geographical regions: Brazil, Ghana, India, Norway, Oman, 
and the United States [11]. The study combined a longitudinal follow-up from birth 
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to 24 months, with a cross-sectional component of children aged 18 to 71 months. In 
the longitudinal component, mothers and newborns were enrolled at birth and vis-
ited at home a total of 21 times (at weeks 1, 2, 4, and 6; monthly from 2 to 12 months; 
and bimonthly in the second year).
The study populations lived in socioeconomic conditions favorable to growth. The 
individual inclusion criteria were: no known health or environmental constraints to 
growth, mothers willing to follow MGRS feeding recommendations (i.e., exclusive or 
predominant breastfeeding for at least 4 months, the introduction of complementary 
foods by 6 months of age, and continued breastfeeding to at least 12 months of age); 
no maternal smoking before and after delivery; single term birth; and the absence of 
significant morbidity. Term low birth weight infants were not excluded. The eligibility 
criteria for the cross-sectional component were the same as those for the longitudinal 
component, with the exception of infant feeding practices. A minimum of 3 months of 
any type of breastfeeding was required for participants in the study’s cross-sectional 
component. Rigorously standardized methods of data collection and procedures for 
data management across sites yielded exceptionally high-quality data. A full descrip-
tion of the MGRS and its implementation in the six study sites is found elsewhere [11].
The length of the children was strikingly similar among the six sites (Figure 
2.1), with only about 3% of variability in length being due to intersite differences, as 
compared to 70% for individuals within sites [12]. The striking similarity in growth 
during early childhood across human populations means either a recent common ori-
gin as some suggest [13] or a strong selective advantage associated with the current 
























FIGURE 2.1 The mean length (centimeters) from birth through 2 years for each of the 
six study sites. (Reproduced from WHO Multicentre Growth Reference Study Group, Acta 
Paediatr 2006, (Suppl 450):56–65. With permission.)
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CONSTRUCTION OF THE WHO CHILD GROWTH STANDARDS
Of 1,743 mother–child dyads enrolled in the MGRS longitudinal sample, 882 complied 
fully with the study’s infant-feeding and nonsmoking criteria, and completed the follow-
up period of 24 months. The remaining mother–child dyads did not comply with the 
study criteria (n = 654), dropped out of the follow-up (n = 201), or experienced mor-
bidity which affected their growth (n = 6). The compliant sample (n = 882) was used 
to construct the WHO standards from birth to 2 years of age, combined with 6,669 
children from the cross-sectional sample from age 2 to 5 years [14]. Data from all sites 
were pooled to construct the standards [12]. The generation of the standards followed 
state-of-the-art statistical methodologies that are described in detail elsewhere [6].
Weight-for-age, length/height-for-age, weight-for-length/height, and body mass 
index-for-age percentile and z-score values were generated for boys and girls aged 
0 to 60 months and released in April 2006. The concordance between the smoothed 
curves and observed or empirical percentiles was excellent and free of bias at both 
the median and the edges, indicating that the resulting curves are a fair description of 
physiological growth of healthy children [6]. Detailed results of the MGRS study and 
the construction of the growth standards are available elsewhere [5,6]. The full set 
of tables and charts is presented on the WHO growth standards website (www.who 
.int/childgrowth/en), together with tools such as software and training materials that 
facilitate their application [15,16]. Figure 2.2 presents as an example the indicator of 
length/height-for-age, for boys aged 0 to 2 years (charts are available for different 
age groups). The length/height-based charts for the 0 to 5 years age group presents a 
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FIGURE 2.2 The length/height-for-age for boys aged 0 to 2 years (percentiles).
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disjunction of 0.7 cm at 24 months, which corresponds to the change from measuring 
recumbent length to standing height.
Standards for other anthropometric variables (i.e., head circumference, mid-
upper arm circumference, and triceps and subscapular skinfolds) were released in 
2007 [17], and growth velocity standards for weight, length, and head circumfer-
ence in 2009 [18,19]. The latter show striking differences compared to the U.S.-
based reference values for weight and length gains most commonly used prior to 
the release of the WHO standards. The main differences relate to the spread of the 




































































FIGURE 2.3 Three-month increments in length from birth to 24 months for WHO 
Standards and U.S.-based reference values for (a) boys and (b) girls. (Reproduced from de 
Onis M, Siyam A, Borghi E. et al., Pediatrics 2011, 128:e18–26. With permission.)
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WHO three-month length increments for boys and girls from birth to 24 months 
compared to the U.S.-based reference values [19]. The use of growth velocity has 
considerable potential for the early identification of abnormal growth and treatment 
responses. However, apart from the inherent complexities of interpreting growth 
velocity, the dearth of reliable reference values has been a major impediment to 
gaining a better understanding of how to use growth velocities in a way that is help-
ful to clinicians. The WHO growth velocity standards fill this gap by providing a 
biologically robust tool, which reflects age-specific changes in the rate of growth 
for a varied selection of measurement intervals to suit pediatric follow-up routines 
in different settings.
The WHO standards do not include sexes-combined charts, and present separate 
charts for boys and girls for all anthropometric indicators. There are significant sex 
differences in the attained growth of boys and girls that justify the need to use sepa-
rate charts. Figure 2.4 illustrates these differences for the indicator weight-for-age; 
the same applies to other growth indicators.
Last, windows of achievement for the six gross motor milestones collected in the 
MGRS (i.e., sitting without support, hands-and-knees crawling, standing with assis-
tance, walking with assistance, standing alone, and walking alone) are also available 
























FIGURE 2.4 Attained weight-for-age for boys and girls.
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INNOVATIVE ASPECTS OF THE WHO CHILD GROWTH STANDARDS
The WHO standards were derived from children who were raised in environ-
ments that minimized constraints to growth, such as poor diets and infection. In 
addition, their mothers followed healthy practices, such as breastfeeding their 
children and not smoking during and after pregnancy. The standards depict nor-
mal human growth under optimal environmental conditions, and can be used to 
assess children everywhere, regardless of ethnicity, socioeconomic status, and 
type of feeding.
Another key characteristic of the new standards is that they explicitly identify 
breastfeeding as the biological norm, and establish the breastfed child as the norma-
tive model for growth and development. As an advocacy tool for the protection and 
promotion of breastfeeding, the new standards have the potential to significantly 
strengthen health policies and public support for breastfeeding.
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FIGURE 2.5 Windows of motor development milestone achievement in months. 
(Reproduced from WHO Multicentre Growth Reference Study Group, Acta Paediatr 2006, 
(Suppl 450):86–95. With permission.)
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Third, the pooled sample from the six participating countries allowed the devel-
opment of a set of truly international growth standards, which underscore the 
fact that child populations grow similarly across the major regions of the world 
when their health and care needs are met. It also provides a tool that is timely and 
appropriate for the ethnic diversity seen within countries, and the evolution toward 
increasingly multiracial societies in the Americas and Europe, as elsewhere in the 
world.
Fourth, the wealth of data collected allowed not only the replacement of the 
current NCHS international references on attained growth (weight-for-age, length/
height-for-age, and weight-for-length/height), but also the development of new stan-
dards for triceps and subscapular skinfolds, head and arm circumferences, and body 
mass index. These innovative references are particularly useful for monitoring the 
increasing epidemic of childhood obesity.
Fifth, the study’s longitudinal nature also allowed the development of growth 
velocity standards. Pediatricians will not have to wait until children cross an attained 
growth threshold to make the diagnosis of undernutrition or overweight, since veloc-
ity standards will enable the early identification of children in the process of becom-
ing undernourished or overweight.
Last, the development of accompanying motor development reference data has 
provided a unique link between physical growth and motor development. Although, 
in the past, the WHO issued guidelines concerning attained physical growth, it has 
not previously made recommendations for assessing motor development.
IMPLICATIONS OF ADOPTING THE WHO CHILD GROWTH 
STANDARDS FOR PUBLIC HEALTH AND CLINICAL PRACTICE
The scrutiny that the WHO standards have undergone is without precedent in the 
history of developing and applying growth assessment tools. Governments set 
up committees to scrutinize the new standards before deciding to adopt them, 
and professional groups conducted thorough examinations of the standards. The 
detailed evaluation allowed the assessment of the impact of the new standards 
and document their robustness and benefits for child health programs. Since their 
release in 2006, the WHO growth standards have been widely implemented glob-
ally [21] in over 130 countries by September 2014 (Figure 2.6). Reasons for adop-
tion include: (1) the provision of a more reliable tool for assessing growth, which 
is consistent with the Global Strategy for Infant and Young Child Feeding; (2) the 
protection and promotion of breastfeeding; (3) the enablement of the monitoring 
of malnutrition’s double burden, stunting and overweight; (4) the promotion of 
healthy growth and protection of the right of children to reach their full genetic 
potential; and (5) the harmonization of national growth assessment systems. In 
adopting the WHO growth standards, countries have harmonized best practices in 
child growth assessment, and established the breastfed infant as the norm against 
which compliance with children’s right to achieve their full genetic growth poten-
tial is assessed.
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Detailed examination of the WHO growth standards by technical and scientific 
groups has provided a unique opportunity to validate their robustness and to improve 
understanding of their broad benefits:
• The WHO standards identify more children as being severely wasted [22]. 
Besides being more accurate in terms of the prediction of mortality risk 
[23–25], the use of the WHO standards results in shorter duration of treat-
ment, higher rates of recovery, fewer deaths, and reduced loss to follow-up 
or need for inpatient care [26].
• The WHO standards confirm the dissimilar growth patterns between 
breastfed and formula-fed infants, and provide an improved tool for cor-
rectly assessing the adequacy of growth in breastfed infants [27–29]. They 
thereby considerably reduce the risk of unnecessary supplementation or 
breastfeeding cessation, which are major sources of morbidity and mortal-
ity in poor hygiene settings.
• In addition to confirming the importance of the first 2 years of life as a 
window of opportunity for promoting growth, the WHO standards demon-
strate that intrauterine retardation in linear growth is more prevalent than 
previously thought [1], making a strong case for the need for interventions 
to start early in pregnancy and ideally before.
• Another important feature of the WHO standards is that they demon-
strate that undernutrition during the first 6 months of life is a consider-
ably  more  serious problem than previously detected [29,30], thereby 
reconciling  the  rates of growth faltering observed in young infants, and 







FIGURE 2.6 The implementation of the WHO Child Growth Standards in more than 300 
countries (by September 2014).
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• The WHO standards also improve early detection of excess weight gain 
among infants and young children [31,32], showing that obesity often begins 
in early childhood, which is also when measures to tackle this global time 
bomb should be put in place.
• Last but not least, the WHO standards are an important means of ensur-
ing the right of all children to be healthy, and to achieve their full physical 
and mental growth potential. They provide sound scientific evidence that, 
on average, young children everywhere experience similar growth patterns 
when their health and nutrition needs are met. For this reason, the WHO 
standards can be used to assess compliance with the UN Convention on the 
Rights of the Child, which recognizes the duties and obligations to children 
that cannot be met without attention to normal human development.
COMPLEMENTARY CHARTS FOR FETUSES, NEWBORNS 
BY GESTATIONAL AGE, PRETERM INFANTS, 
AND CHILDREN OLDER THAN 5 YEARS OF AGE
The WHO growth standards apply from birth to 5 years of age, and thus cannot be 
used to assess the growth of fetuses, newborns by gestational age, preterm infants, 
and children over 5 years of age. The recently completed International Fetal and 
Newborn Growth Consortium for the 21st Century (INTERGROWTH–21st) Project 
was designed to complement the WHO Child Growth Standards by providing com-
parable international standards for fetal growth from 9 weeks of gestation to birth 
and newborn size (weight, length, and head circumference) according to gestational 
age and sex [33].
Using a similar methodology and prescriptive approach to the MGRS [11], the 
eligibility criteria applied by INTERGROWTH–21st to select study populations and 
individual participants mirrored those used to construct the WHO Child Growth 
Standards (i.e., healthy populations seemingly free of disease, following current 
health recommendations, and living in environments highly unlikely to constrain 
growth) [34]. Implemented in eight countries several years after completion of the 
MGRS, the INTERGROWTH–21st project replicated the remarkable similarity in 
the linear growth of fetuses and newborns across study sites as that observed in the 
MGRS for children aged 0 to 60 months [12,35]. The results of the studies were also 
in strong agreement: The mean birth length for term newborns in INTERGROWTH–
21st was 49.4 ± 1.9 cm, compared to 49.5 ± 1.9 cm in the MGRS [35]. Both stud-
ies consequently demonstrate that human growth potential is universal for healthy 
populations from conception to at least 5 years of age, when health, environmental, 
and care needs are met.
This view raises the inevitable question: How is the similarity in growth possible 
given the enrolled populations’ distinct genetic backgrounds? It is true that tall parents 
tend to have tall children, and that short parents tend to have short children, but such 
expectations reflect interindividual rather than interpopulation variability. Moreover, 
recent studies of the genetics of height have identified about 200 genes associated 
with the genetic control of stature, explaining only approximately 10% of observed 
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variability [36], which is much less than the 40% to 80% expected from earlier stud-
ies completed before the availability of genomic approaches. The small proportion 
of variability explained by that large number of genes likely reflects the influences 
on linear growth by nutrition and other care and environmental variables, in ways 
that remain not fully understood. These considerations lead to the expectation that 
most variation in growth exists among individuals rather than among populations, 
an expectation borne out by both the WHO MGRS and the INTERGROWTH–21st 
Project.
International standards for fetal growth, newborn-size, and preterm infants from 
the INTERGROWTH–21st Project are available for routine clinical practice and 
public health uses [37,38].
Contrary to the broad international consensus about the utility of the WHO Child 
Growth Standards for assessing the growth of preschool children, far less is known 
about the growth and nutritional status of school-aged children and adolescents. 
Reasons for this lack of knowledge include the rapid changes in somatic growth, 
problems in dealing with variations in maturation, and difficulties in separating nor-
mal variations from those associated with health risks. Consequently, there is far 
less agreement with regard to which reference to use to assess the growth of school-
age children and adolescents. The release of the WHO Child Growth Standards for 
preschool children, and increasing public health concern over childhood obesity, 
stirred interest in developing appropriate growth curves for school-aged children and 
adolescents [39]. Some authors emphasize the use of contemporary, convenient (i.e., 
recent and logistically feasible) samples [40], while others feel it would be better to 
follow an approach analogous to the one used by the WHO in developing standards 
for preschool children, based on a prescriptive design [41].
A significant inherent problem when updating growth curves using contempo-
rary samples is that the resulting weight-based curves, such as the body mass index 
(BMI), are markedly skewed to the right, thereby redefining overweight and obesity 
as “normal” [40,42]. This progressive redefinition of overweight and obesity cutoffs 
due to the secular increase in the prevalence of these conditions results in a substan-
tial underestimation of the prevalence of childhood obesity [43].
In a recent Indian study [40], the 85th and 95th percentiles for BMI at 18 years 
are above 25 and 30, respectively. As the authors themselves acknowledge, using 
the 85th and 95th percentiles as cutoffs for defining overweight and obesity entails 
accepting higher BMI (overweight children) as “normal” at all ages. To overcome 
this flaw, the authors propose the use of the 75th percentile on the BMI curves as a 
cutoff for screening for overweight boys and girls. A key question is whether recom-
mending a lower percentile, such as the 75th percentile, as the cutoff for defining 
overweight is the appropriate way forward. The central purpose of growth charts is 
to provide sensible cutoffs to screen for growth problems. Lowering the proposed 
cutoffs for defining childhood overweight as updated growth curves become increas-
ingly skewed upward cannot be the solution. A better approach would be to construct 
growth curves using samples that have achieved expected linear growth, while still 
not being affected by excessive weight gain relative to linear growth.
The case made for using a national reference has traditionally been that it is more 
representative of a country’s children than any other reference could be. However, 
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given the child obesity epidemic, this no longer holds for either weight or BMI. As 
soon as a new reference is produced, it is out of date.
In order to complement the growth standards for children under 5 years of age, 
WHO developed a growth reference for school-aged children and adolescents, namely, 
the WHO Reference 2007 for School-Aged Children and Adolescents [44]. These 
curves are closely aligned with the WHO Child Growth Standards at 5 years and pro-
vide a suitable reference for the 5 to 19 years age group, for use in conjunction with the 
WHO Child Growth Standards from 0 to 5 years. The full set of tables and charts for 
height, weight, and BMI is available at www.who.int/growthref/en, and includes appli-
cation tools such as software for clinicians and public health specialists [45].
CONCLUSION
The WHO Child Growth Standards were derived from children who were raised in 
environments that minimized constraints to growth, such as poor diets and infection. 
In addition, their mothers followed healthy practices, such as breastfeeding their 
children and not smoking during and after pregnancy. The standards depict normal 
human growth under optimal environmental conditions and can be used to assess 
children everywhere, regardless of their ethnicity, socioeconomic status, or type of 
feeding. They also demonstrate that healthy children from around the world, who 
are raised in healthy environments and follow recommended feeding practices, have 
strikingly similar patterns of growth. The International Pediatric Association has 
officially endorsed the use of the WHO standards, describing them as “an effective 
tool for detecting both undernutrition and overweight and obesity” [46].
Early recognition of growth problems, such as growth faltering and excessive 
weight gain relative to linear growth, should become standard clinical practice via
• Routine collection of accurate weight and height measurements to enable 
monitoring of childhood growth
• Interpretation of anthropometric indices, such as height-for-age and BMI-
for-age, based on the WHO Child Growth Standards
• Early intervention, after changes on growth patterns (e.g., upward or down-
ward crossing of percentiles) have been observed, to provide parents and 
caregivers appropriate guidance and support
NOTES
The author is a staff member of the World Health Organization. The author alone is 
responsible for the views expressed in this publication and they do not necessarily 
represent the decisions, policy, or views of the World Health Organization.
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INTRODUCTION
The importance of nutrition before and during pregnancy for women’s health and 
fetal growth and development is well established, and the subject of other chapters in 
this book (see Chapters 4, 24, and 27).
The dietary requirements of pregnant women are higher to meet the needs of 
maternal tissue and plasma volume expansion, fetal growth, and preparation for 
lactation. To partially meet these needs, a number of normal cardiovascular, renal, 
endocrine, and metabolic changes during pregnancy improve the absorption and 
utilization of nutrients [1]. Even among healthy women with adequate nutritional 
status and reserves, these changes are insufficient to fully compensate for increased 
nutrient needs during pregnancy, and dietary requirements are therefore higher than 
those for nonpregnant women. Where women may not be able to meet their nutrient 
requirements from their daily dietary intake, a number of intervention programs 
exist, supported by recommendations from the World Health Organization (WHO) 
and national governments. The impact of such interventions is similarly covered in 
other chapters within this book.
In this chapter, we review nutrient requirements and recommended intakes during 
pregnancy, providing a brief biological justification for each. The first three sections 
focus on macronutrients, minerals, and vitamins, respectively. For each of these, we 
rely heavily on both published references (see Box 3.1) and, specifically, on Dietary 
Reference Intakes (DRIs; see Box 3.2). For each, we review the rationale, and pro-
vide an overview of current recommendations, including comments related to the 
strength of the evidence for these and any inconsistencies among diverse recom-
mendation values. In each section, we make only brief reference to specific situations 
during pregnancy that influence requirements and recommendations, specifically 
adolescent pregnancy, obesity, gestational diabetes, multiple pregnancies, short 
interpregnancy interval, and vegetarian diets, as most of these are the topics of other 
chapters in this book. The fourth section briefly presents a number of food items or 
components to be avoided during pregnancy, specifically heavy metals, caffeine, and 
alcohol and other intoxicants. The final section provides some summary comments, 
as well as potential areas for further research.
BOX 3.1 SOURCES
Primary sources for information on requirements and recommendations for 
nutrition and dietary intake during pregnancy:
• Institute of Medicine (IOM)—http://iom.nationalacademies.org
• World Health Organization (WHO)—http://www.who.int/nutrition
• Food and Agriculture Organization (FAO)—http://www.fao.org 
/nutrition/en
• International Federation of Gynecology and Obstetrics (FIGO)—
http://www.figo.org
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REQUIREMENTS AND RECOMMENDATIONS 
FOR MACRONUTRIENTS DURING PREGNANCY
EnErgy
During pregnancy, basal metabolic rate and energy expenditure increase, and addi-
tional energy is required for storage in expanding maternal and fetal tissue as well as 
the placenta. Multiple studies have estimated the energy costs of pregnancy by mea-
suring the increase in maternal basal metabolic rate and total energy expenditure. 
Assuming an average desirable gestational weight gain of 12 kg, it is estimated that 
between 76,048 and 76,652 additional kilocalories are required over the duration of 
a pregnancy, and that requirements progressively increase by trimester [1,3,4] (see 
Table 3.1).
Additional energy requirements are dependent on the expected weight gain of 
the mother, for which there are a number of determinants. Prepregnancy nutritional 
status (i.e., body mass index before pregnancy) is an important determinant of ideal 
weight gain. In 2009, the Institute of Medicine (IOM) updated weight gain recom-
mendations for women based on prepregnancy body mass index (BMI; kg/m2). 
Underweight women (BMI <18.5) are recommended to gain between 12.7 and 18.1 kg; 
normal weight women (BMI 18.5 to 24.9) between 11.3 and 15.9 kg; overweight 
women (BMI 24.9 to 29.9) between 6.8 and 11.3 kg; and obese women (BMI ≥30.0) 
between 5.0 and 9.1 kg. It is recommended that women of short stature (<157 cm) 
gain weight at the lower range for their prepregnancy BMI [1,3].
BOX 3.2 DIETARY REFERENCE INTAKES
The Dietary Reference Intakes (DRIs) are a set of reference values for inter-
preting the adequacy of dietary nutrient intakes [2].
• The Estimated Average Requirement (EAR) is the daily intake level 
that is estimated to meet the requirements of half of all healthy indi-
viduals in a population.
• The Recommended Dietary Allowance (RDA) is the daily intake 
level that is sufficient to meet the nutrient requirements of nearly all 
(97%–98%) healthy individuals.
• The Adequate Intake (AI) is used when there is insufficient evidence 
to establish an EAR from which a RDA can be based, and is the 
recommended average daily intake level based on observed or experi-
mentally determined estimates of nutrient intake among apparently 
healthy individuals, and is expected to meet or exceed the needs of 
most individuals in a population.
• The Upper Limit (UL) is the highest average daily intake of a nutrient 
that is likely to pose no risk of adverse health effects for nearly all 
persons in the general population.
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For adolescents who are pregnant, energy requirements are further elevated by 
continued growth and development. Although specific energy and/or weight gain 
requirements have not been developed for pregnant adolescents, two studies suggest 
that weight gains in the upper range of those listed for each BMI group would be 
most appropriate for pregnant adolescents [5]. Based on limited evidence for multiple 
pregnancies (i.e., ≥2 fetuses), the IOM [1] suggests the following gestational weight 
gain recommendations for women with twins: between 16.8 and 24.5 kg for normal 
weight woman, between 14.1 and 22.7 kg for overweight women, and between 11.3 
and 19.1 kg for obese women. Recommendations for underweight women with mul-
tiple pregnancies are still lacking.
Fat and Fatty acids
Fat is an important source of energy at all stages of life. Recommendations for fat 
intake are set as a proportion of total energy from fat and, at this time, there is no 
evidence to suggest that these should differ for pregnant women, compared to the 
general population. The IOM sets a recommended range of total energy from fat 
of 20% and 35% of daily total energy intake [2]. The International Federation of 
Gynecology and Obstetrics (FIGO) recommends slightly lower percentages, that is, 
between 15% and 30% [6].
Fatty acids can be categorized into two types: (1) nonessential fatty acids, which 
can be synthesized by the body, including saturated fatty acids and monounsaturated 
fatty acids; and (2) essential fatty acids, which cannot be synthesized by the body, 
and need to be provided by the diet, including polyunsaturated fatty acids, such as 
linoleic acid and α-linolenic acid. For saturated fatty acids and trans-fatty acids, rec-
ommendations for pregnant women are the same as for other adults; these nonessen-
tial fatty acids have been positively correlated with increased total and low-density 
TABLE 3.1
Additional Energy Requirements (kcal/day) during Pregnancy by Trimester 
(Assuming a Gestational Weight Gain of 12 kg)
Reference
FAO, 2001 Butte and King, 2005 IOM and NRC, 2009
1st trimester +69 +69 +0
2nd trimester +266 +265 +340
3rd trimester +496 +497 +452
Total pregnancy +76,530 +76,652 +76,048
Sources: Food and Agriculture Organization (FAO), Human energy requirements: Report of a joint FAO/
WHO/UNU Expert Consultation, Food and Nutrition Technical Report Series, Rome: Food and 
Agriculture Organization, 2001; Butte NF, King JC, Public Health Nutr 2005, 8(7A):1010–27; 
Institute of Medicine (IOM), National Research Council (NRC), Weight gain during pregnancy: 
Reexamining the guidelines, Rasmussen KM, Yaktine AL, eds., Washington, DC: National 
Academies Press, 2009.
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lipoprotein (LDL) cholesterol levels and an increased risk of coronary heart diseases 
[2,7], so their intake should be limited. There are no recommended daily intakes for 
other nonessential fatty acids, as they can be synthesized by the body.
Over the past decade, interest has been rising in omega-3 fatty acids, specifically 
docosahexaenoic acid (DHA), a fatty acid that is partly made by the body from 
α-linolenic acid. As this fatty acid can be synthesized in the body, it is not consid-
ered to be an essential fatty acid; however, conversion of α-linolenic acid to DHA 
is limited. Increased prenatal DHA intake has been associated with several posi-
tive cognitive and motor development outcomes in children [8], and supplementation 
with 150 to 1,200 mg DHA per day may prolong gestation, increase birth weight, 
and reduce the risk of preterm delivery [9]. Recommendations therefore suggest that 
the intake of polyunsaturated fatty acids should be maintained or increased during 
pregnancy. More precisely, based on estimated mean intakes of healthy pregnant 
women, the IOM recommends 13 g linoleic acid per day and 1.4 g α-linolenic acid 
per day. Moreover, the Perinatal Lipid Metabolism Research Project of the European 
Commission recommends at least 200 mg DHA per day for pregnant women [10]. 
The Health Minister of Canada does not recommend any DHA supplementation; 
however, it recommends that pregnant women consume at least 150 g of cooked fish 
per week [11].
We found no studies or documents that provided varying recommendations for 
fat or fatty acid intakes based on maternal nutritional status prepregnancy, or for 
adolescents. The diet of vegetarian and vegan women is generally low in saturated 
fats but is also very low to null in DHA. FIGO recommends that pregnant women 
increase their intake of α-linoleic acid (ALA) to compensate for the low intakes of 
DHA [6].
ProtEin
Due to adaptations in protein metabolism during pregnancy [12], the synthesis 
of protein in pregnant women is increased and protein is stored in the fetus, pla-
centa, and maternal tissues. Similar to fat, recommendations for protein intake are 
expressed as a percent of total energy for protein; the IOM recommends 10% to 35% 
of total energy from protein.
Many studies have examined protein requirements during pregnancy, based on 
estimations of the total amount of protein deposited and nitrogen balance stud-
ies. The IOM recommends no additional intake of protein for the first half of the 
pregnancy, as the metabolic adaptations are thought to compensate for increased 
needs. During the second half of the pregnancy, the IOM set the estimated average 
requirement (EAR) at 0.88 g/kg/day and the RDA at 1.1 g/kg/day. In 2007, a WHO/
Food and Agriculture Organization (FAO)/United Nations University (UNU) Expert 
Consultation concluded, based on the estimated efficiency of protein utilization and 
an addition gestational weight gain of 13.8 kg, that during the first, second, and third 
trimesters of pregnancy, an additional 1 g, 9 g, and 31 g protein per day are required, 
respectively [13]. Despite this higher need, caution should be taken in increasing 
intakes beyond recommendations. High protein supplements may have deleterious 
effects, such as increased risk of small for gestational age, and both the Cochrane 
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Review and the WHO Expert Consultation recommend against their use, and against 
increasing protein intakes greatly above the requirements [13,14].
Based on one large effectiveness study and one nitrogen balance study, it is esti-
mated that pregnant adolescent girls require slightly higher amounts of protein: 
1.5 g/kg/day [13]. The WHO Expert Consultation suggests that the recommended 
intakes for women pregnant with twins should be 50 g additional per day during the 
second and third trimesters. However, no currently published trial has investigated 
this question, and recommendations for multiple fetus pregnancies have not been 
developed [13]. In 2006, the IOM concluded that vegetarian and vegan women are 
more likely to consume insufficient amounts of certain essential amino acids, and 
are therefore at risk of suboptimal protein utilization and synthesis. Although cur-
rently limited evidence exists, vegetarian and vegan pregnant women should care-
fully ensure sufficient intakes in all essential amino acids, again avoiding the use of 
high protein supplements [2].
carbohydratEs
Carbohydrates are the primary source of energy for the cells of the pregnant women 
and the fetus. Glucose is the main source of energy for the brain, and the carbohy-
drate requirements of pregnant women are based on the estimated additional glu-
cose needed for fetal brain development. Carbohydrates can be classified by their 
glycemic index (GI). Diets rich in low GI carbohydrates have been proposed to help 
prevent obesity-associated diseases, such as type 2 diabetes and coronary heart dis-
ease [15]. Studies with pregnant women have shown that a low GI diet can, among 
other things, prevent excessive gestational weight gain, improve glucose tolerance 
and, in the extent to which low GI foods are more likely to be rich in micronutrients, 
increase their intakes [16].
As for the general population, the IOM recommends that, for pregnant women, 
carbohydrates should provide 45% to 65% of the total energy. The IOM set the EAR 
for pregnant women at 135 g/day and the RDA at 185 g/d, based on the amount of 
carbohydrate on the EAR for the women, plus the amount of glucose needed for the 
fetal brain. Due to limited evidence, there are currently no specific recommendations 
for carbohydrate intake for obese women. However, low GI diets have been shown 
to prevent excessive weight gain, as well as increase weight loss after delivery [17]. 
In women with gestational diabetes, a low GI diet has been associated with lower 
insulin use and lower postprandial glucose levels [18].
REQUIREMENTS AND RECOMMENDATIONS 
FOR MINERAL INTAKES DURING PREGNANCY
iron
Anemia remains one of the most common problems to affect women worldwide, and 
iron deficiency is among one of its many important causes. Anemia during pregnancy 
is associated with an increased risk of preterm birth, low birth weight, and reduced 
neonatal health, as well as reduced iron stores in the fetus [19]. The requirements in 
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iron rise progressively during pregnancy, especially during the second and third tri-
mesters when fetal growth is most rapid. Although iron absorption increases during 
pregnancy [20], iron intake is often insufficient, even in middle- and high-income 
populations [21]. The total amount of iron required for a normal pregnancy (for a 
women of 55 kg) is approximately 1,190 mg [20]. During the first trimester, the daily 
iron requirements increase by ~0.8 mg, during the second trimester they increase by 
between 4 and 5 mg, and during the third trimester by more than 6 mg [20]. Based 
on the estimated iron requirements of pregnancy, the IOM set the RDA for pregnant 
woman at 27 mg iron per day. The UL for iron is set at 45 mg iron per day.
As these levels of iron intake are not often reached by pregnant women, iron 
supplementation during pregnancy is implemented in countries where the prevalence 
of iron deficiency and anemia is high. Iron supplementation has been proven to be 
effective in preventing maternal iron deficiency and in reducing the risk of low birth 
weight, and the current WHO recommendations suggest 30 to 60 mg/day [22,23], 
together with folic acid (see “Folate” section, later). A short interpregnancy interval 
(i.e., <12 months) is associated with a higher risk of preterm birth, low birth weight, 
stillbirth, and neonatal death. A short interpregnancy interval is also associated with 
a higher risk of maternal iron deficiency and anemia; women could therefore benefit 
from higher iron intakes, although no specific recommendations have been devel-
oped [24].
The iron requirements of adolescent girls are high due to growth and menstrua-
tion and, during pregnancy, these are even further increased, putting pregnant ado-
lescent girls at a higher risk of iron deficiency and low body iron stores. Studies have 
shown that the supplementation of pregnant adolescent girls with iron at current 
recommendations (60 mg iron daily) is efficacious at improving and maintaining 
iron status [25].
The prevalence of iron deficiency anemia is 2.4 to 4 times higher in twin preg-
nancies than in singleton pregnancies. The suggested AI for twin pregnancies is 
30 mg iron daily. Specific recommendations for iron during multiple pregnancies 
have not been developed. Obese pregnant women are at a higher risk of being iron 
deficient due to reduced iron absorption induced by the rise in hepcidin [26]. Some 
evidence suggests that this could have a negative impact on the iron transfer to, and 
the iron status of, the fetus. How this may translate into specific higher recommen-
dations for iron during pregnancy in obese women has not been adequately studied 
[26]. Pregnant women with a vegetarian or vegan diet are at a higher risk of being 
iron deficient, because of the lower content and bioavailability of iron in vegetarian 
diets. The IOM recommends an iron intake that is 1.8 times higher for vegetarians, 
which corresponds to 48.6 mg iron per day instead of 27 mg per day for women with 
omnivorous diets [2].
Zinc
Zinc plays an important role in growth and development, and its effects during preg-
nancy have been extensively studied. Maternal zinc deficiency during pregnancy 
is associated with reduced fetal growth, low birth weight, and preterm labor and 
preeclampsia [27]. A Cochrane Review [28] has concluded that there is moderate 
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evidence that zinc supplementation (providing between 5 and 44 mg zinc per day) 
can reduce the risk of preterm birth, small for gestational age, and low birth weight. 
Findings for other pregnancy outcomes are mixed; possible reasons for the incon-
sistency of the findings are the lack of a reliable zinc status biomarker, small sample 
sizes, a variable start and duration of zinc supplementation, the presence of infec-
tions and other micronutrient deficiencies, and variable zinc absorption due to diet 
[29]. It is estimated that approximately 82% of the pregnant women in the world are 
zinc deficient [27].
Based on zinc absorption studies and estimated zinc accumulation in the fetus, 
the IOM estimated the EAR of pregnant women at 9.5 mg zinc per day and recom-
mends an RDA of 11 mg zinc per day. The IOM set the UL for zinc at 40 mg per day. 
Zinc is essential for growth and is therefore needed in especially high amounts by 
pregnant adolescent girls. The IOM estimated the EAR at 10.5 mg zinc per day and 
recommends an RDA of 12 mg zinc per day for pregnant adolescent girls. The UL 
is 34 mg zinc per day [2].
Vegetarian pregnant women typically consume and absorb lower amounts of zinc 
than nonvegetarian women. In addition to a lower zinc content, zinc bioavailability is 
lower in vegetarian diets due to the high content of dietary fiber and phytate, inhibi-
tors of zinc absorption. The IOM suggests that vegetarians should consume up to 
50% more zinc daily to account for this reduced bioavailability [2]. It is suggested 
that zinc transfer to the fetus could be impaired in obese women; evidence is limited, 
however [30].
iodinE
Iodine is essential for the thyroid functioning of the mother and the fetus, and iodine 
deficiency during pregnancy has serious consequences, especially for the fetus, such 
as pregnancy loss, infant mortality, and irreversible cognitive impairments in the 
child [31].
The recommendations for iodine intake during pregnancy vary between 200 and 
250 μg/day. The IOM recommends an RDA of 220 μg/day for pregnant women; the 
International Council for Control of Iodine Deficiency Disorders (ICCIDD) recom-
mends 250 μg/day [32]; and the European Food Safety Authority (EFSA) recom-
mends 200 μg/day [33]. The IOM advises on a UL of 1,100 μg/day. Obese women 
seem to be more likely to suffer from thyroid dysfunction during pregnancy [34]. 
However, the association between obesity and iodine requirements remains to be 
investigated.
calcium
During pregnancy, calcium is needed for the growth and development of fetal bones. 
Although the mechanism is not as yet fully understood, low calcium intakes have 
been associated with hypertension during pregnancy [35]. Calcium supplementation 
(≥1 g per day) during pregnancy has been shown to reduce the risk of preeclampsia, 
preterm birth, and neonatal death and morbidity [36].
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The IOM recommends 1 g calcium per day for pregnant women, based on bone 
mineral mass and on average intakes. Moreover, the WHO recommends the supple-
mentation of 1.5 to 2 g calcium per day in populations where calcium intakes are low 
[23,36]. The IOM set an UL at 2,500 mg calcium per day.
Pregnant adolescent girls need sufficient calcium to meet the needs of their own 
bone growth, as well as the growth of the fetus’s bones. The IOM recommends a 
daily intake of 1.3 g calcium for pregnant adolescent girls [2]. Bone metabolism 
differs between singleton and twin pregnancies, and requirements may be higher 
[37], but no specific recommendations for multiple pregnancies have been developed 
at this time. Calcium content and bioavailability is lower in vegetarian diets due to 
the high intakes in calcium absorption inhibitors (i.e., oxalic and phytic acids), and 
therefore recommended calcium intakes should be higher [2].
othEr minErals
Many other essential minerals exist with mixed strength in the evidence base that 
underpins recommendations specifically for requirements during pregnancy. The 
recommended intakes of copper, chromium, fluoride, magnesium, manganese, 
molybdenum, phosphorus, selenium and sodium chloride for pregnant women are 
shown in Table 3.2.
REQUIREMENTS AND RECOMMENDATIONS 
FOR VITAMIN INTAKES DURING PREGNANCY
Vitamin a
Vitamin A is essential for vision, gene expression, immune function, growth, repro-
duction, and embryonic development [38]. Maternal vitamin A deficiency increases 
the risk of maternal night blindness, maternal mortality, preterm birth, intrauterine 
growth restriction, low birth weight, and abnormal development of the fetus [6]. 
Vitamin A deficiency has also been shown to be associated with anemia and iron 
deficiency [38].
The requirements of pregnant women are estimated to be between 370 and 550 μg 
retinol activity equivalent (RAE) per day, and the recommended intake is 770 μg 
RAE/day [2]. The UL of vitamin A intake during pregnancy is 3,000 μg RAE/
day [2]. WHO recommends antenatal vitamin A supplementation in regions where 
the prevalence of vitamin A deficiency is high [39], as a means to reduce maternal 
night blindness, maternal anemia, and probably maternal infection. However, a high 
intake of preformed vitamin A (retinol) has been shown to be teratogenic, especially 
in early pregnancy [40], and women in countries where vitamin A deficiency is not 
common should avoid taking vitamin A supplements.
Vitamin A requirements for pregnant adolescents are estimated to be 530 μg RAE/
day; the recommended intake is set higher, at 750 μg RAE/day [2]. There is some sug-
gestion that women with gestational diabetes may be at greater risk of vitamin A defi-
ciency [41], although no specific recommendations to address this have been developed.
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TABLE 3.2
Recommended Intakes of Select Minerals for Pregnant Women
Mineral Recommendation Strength of Evidencea
Copper EAR: 800 μg/day
RDA: 1,000 μg/day
UL: 10,000 μg/day (8,000 μg/day for 
pregnant adolescents)
Moderate. Based on the results of 
nonpregnant women depletion/repletion 
studies and the estimated accumulation 
of copper in the fetus.
Chromium AI: 30 μg/day (29 μg/day for pregnant 
adolescents)
Low. AI based on the average intake of 
adult women and on the estimated body 
weight of pregnant women.
Fluoride AI: 3 mg/day
UL: 10 mg/day
Low. AI set at the same level as for 
nonpregnant women.
Magnesium EAR and RDA 19–30 years: 290 mg/
day and 350 mg/day
EAR and RDA 31–50 years: 300 mg/
day and 360 mg/day
EAR and RDA for adolescent girls: 
335 mg/day and 400 mg/day
UL: 350 mg/day
Moderate. Based on balance studies in 
nonpregnant women and estimated 
increase in lean mass in pregnant women.
Manganese AI: 2 mg/day
UL: 11 mg/day
Low. Based on the average intakes of 
nonpregnant women and modified for the 
average body weight of pregnant women.
Molybdenum EAR: 40 μg/day
RDA: 50 μg/day
UL: 2,000 μg/day (1,700 μg per day 
for pregnant adolescents)
Moderate. Based on balance studies and 
body weight.
Phosphorus EAR: 580 mg/day (1,055 mg/day for 
adolescent pregnancies)
RDA: 700 mg/day (1,250 mg/day for 
adolescent pregnancies)
UL: 3.5 g/day
Moderate. Based on studies of serum 
inorganic phosphate concentration 
studies.
Selenium EAR: 49 μg/day
RDA: 60 μg/day
UL: 400 μg/day
Moderate. Based on the maximization 
plasma glutathione peroxidase activity 
and the saturation of fetal selenoprotein.
Sodium 
chloride
AI: 1.5 g and 2.3 g/day
UL: 2.3 g and 3.6 g/day
Low. Based on the age-specific average 
intakes of nonpregnant women.
Source: Institute of Medicine (IOM), Dietary reference intakes: The essential guide to nutrient requirements, 
Otten JJ, Hellwig JP, Meyers LD, eds., Washington, DC: National Academy of Sciences, 2006.
a The strength of the evidence was assessed by the authors based to the extent possible on the GRADE 
system (https://www.essentialevidenceplus.com/).
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Vitamin d
Vitamin D not only plays a key role in calcium and phosphorus homeostasis and 
bone health, but also in immune function, growth, development, and blood pres-
sure. Vitamin D deficiency has been associated with, among others, increased risk 
of cardiovascular diseases, cancer, type 1 diabetes, and depression, also suggesting a 
prominent role in other processes [42]. During pregnancy, vitamin D deficiency has 
been associated with an increased risk of preeclampsia and gestational diabetes for 
the mother, and preterm birth, low birth weight, respiratory morbidity, rickets, and 
osteopenia for the child [6,43].
There is a considerable discrepancy among the existing recommendations for vita-
min D intake during pregnancy. The IOM recommends an RDA of 600 International 
Unit (IU) vitamin D per day [44]; the FIGO recommends a daily intake of ≥600 IU/day; 
and the Endocrine Society recommends a daily intake of ≥600 IU/day, and suggests 
that 1,500 to 2,000 IU/day might be needed [45]. However, animal studies suggest 
that high intakes of vitamin D could be teratogenic [43], and the IOM recommends 
a UL of 4,000 IU per day [44]. Obese pregnant women and women who develop 
gestational diabetes are at an increased risk of vitamin D deficiency [43], as are 
vegetarians due to average lower intakes of vitamin D [46], but no specific recom-
mendations exist.
FolatE
Folate functions as a coenzyme, and is essential for the nucleic and amino acid 
metabolisms as well as cell division and tissue growth [47]. Insufficient folic acid 
intake during the periconceptional period is associated with an increased risk of 
neural tube defects (NTDs) and other congenital malformations [48].
The requirements of women during pregnancy are estimated to be 520 μg dietary 
folate equivalents (DFE)/day; the RDA is 600 μg DFE/day [2]. It is widely rec-
ommended that pregnant women take 400 μg DFE supplements per day [2,6,23]. 
Because the neural tube closes very early in gestation, often before women realize 
that they are pregnant, it is also recommended that nonpregnant women, particularly 
those with a history of NTD, consume 400 μg of folic acid per day through supple-
ments and/or fortified foods [6]. The IOM set the UL for folic acid intake during 
pregnancy at 1,000 μg DFE/day. It has been suggested that obese women and women 
with diabetes may benefit from folic acid supplementation during pregnancy [6], but 
this has not been translated into specific recommendations.
Vitamin b12
Vitamin B12 plays a key role in blood formation and neurological function. Vitamin 
B12, along with folate, vitamin B6, choline, and methionine, are involved in homo-
cysteine metabolism and DNA methylation [2]. Vitamin B12 deficiency during preg-
nancy is associated with increased risk of spontaneous abortion, preeclampsia, 
preterm delivery, low birth weight, and NTDs [49].
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The IOM estimated that pregnant women’s vitamin B12 requirement is 2.2 μg/day, 
based on the amount needed to maintain normal hematological status and serum 
vitamin B12 levels, and the amount of vitamin B12 deposited in the fetus, and assum-
ing an absorption rate of 50%. The RDA for pregnant women is 2.6 μg vitamin B12 
per day. An observational study in India showed an association between vitamin B12 
deficiency and obesity, insulin resistance and gestational diabetes, suggesting that 
obese women might be at a higher risk of vitamin B12 deficiency [50]. As with all 
nutrients found primarily in animal source foods, vegetarian women are at a high 
risk of consuming insufficient amounts of vitamin B12.
othEr Vitamins
Recommendations specific to pregnant women exist for a number of additional 
vitamins; however, the evidence that substantiates these recommendations varies 
considerably. The recommended intakes of vitamin B6, riboflavin, thiamin, niacin, 
pantothenic acid, biotin, vitamin C, vitamin E, and vitamin K for pregnant women 
are shown in Table 3.3.
RECOMMENDATIONS FOR AVOIDANCE AND LIMITATION 
OF INTAKES DURING PREGNANCY
A number of substances consumed on their own, added to foods during processing, 
or entering the food chain through environmental contamination pose a health threat 
to pregnant women. Many of these are readily transported by the placenta and/or 
breast milk, with deleterious effects for the fetus/newborn.
toxic hEaVy mEtals, contaminants, and Food additiVEs
Toxic heavy metals may enter the food chain naturally, for example, where 
ground water is high in arsenic, or through environmental contamination. In par-
ticular, exposure to and intake of toxic heavy metals should be avoided during 
pregnancy, as they can cause serious negative effects on fetal growth and devel-
opment. Even low (<50 μg/L blood) exposure to arsenic has been shown to cause 
spontaneous abortion, stillbirth, low birth weight, and neonatal mortality [51]. 
Cadmium exposure has been associated with an increased risk of preterm birth 
and low birth weight [52]. Maximum levels during pregnancy have been defined 
for boron, lead, mercury, nickel, and vanadium (Table 3.4). Some studies suggest 
that the toxicity of heavy metals can be higher when micronutrient deficiencies 
are also present [53]. Strategies to limit the consumption of heavy metals during 
pregnancy have been implemented, including limiting the consumption of some 
types of fatty fish and shellfish prone to high levels of methylmercury, and the 
treatment of tube well water prior to consumption, where arsenic and other met-
als may be high.
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TABLE 3.3
Recommended Intakes of Select Vitamins for Pregnant Women
Mineral Recommendation Strength of Evidencea
Vitamin B6 EAR: 1.6 mg/day
RDA: 1.9 mg/day
UL: 100 mg/day (80 mg/day for 
adolescents)
Moderate. Based on plasma pyridoxal 
5-phosphate level.
Riboflavin EAR: 1.2 mg/day
RDA: 1.4 mg/day
Moderate. Based on age-specific requirements 
of nonpregnant women estimated from 
riboflavin excretion and blood values and 
erythrocyte glutathione reductase activity 
coefficient with additional amount from 
estimated increased energy utilization and 
growth needs during pregnancy.
Thiamin EAR: 1.2 mg/day
RDA: 1.4 mg/day
Moderate. Based on age-specific requirements 
of nonpregnant women estimated from 
depletion-repletion studies with additional 
amount from estimated increased energy 
utilization and growth needs during pregnancy.
Niacin EAR: 14 mg/day
RDA: 18 mg/day
UL: 35 mg/day (30 mg/day for 
adolescents)
Low. Based on age-specific requirements of 
nonpregnant women estimated from on urinary 
excretion of niacin metabolites with additional 
amount from estimated increased energy 
utilization and growth needs during pregnancy.
Pantothenic acid AI: 6 mg/day Low. Based on the mean intake of pregnant women.
Biotin AI: 30 μg/day Low. Extrapolated from concentration of biotin 
in human milk.
Vitamin C RDA: 85 mg/day (85 mg/day 
for adolescents)
UL: 2,000 mg/day (1,800 mg/
day for adolescents)
Moderate. Based on age-specific requirements of 
nonpregnant women estimated from neutrophil 
concentration studies with additional amount for 
the transfer of vitamin C to the fetus.
Vitamin E RDA: 15 mg/day
UL: 1,000 mg/day (800 mg/day 
for adolescents)
Low. Based on age-specific requirements of 
nonpregnant women estimated from in vitro 
studies and plasma concentration.
Vitamin K AI: 90 μg/day (75 μg/day for 
adolescents)
Low. Based on the median intake of adult 
women.
Source: Institute of Medicine (IOM), Dietary reference intakes: The essential guide to nutrient requirements, 
Otten JJ, Hellwig JP, Meyers LD, eds., Washington, DC: National Academy of Sciences, 2006.
a The strength of the evidence was assessed by the authors based to the extent possible on the GRADE 
system (https://www.essentialevidenceplus.com/).
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During pregnancy, foodborne infections and contamination should be avoided by 
reducing the consumption of raw or other potentially contaminated foods, and by 
ensuring that the foods are stored, washed, and prepared well [6]. Animal studies 
have shown that aflatoxin consumption is teratogenic [6], and human studies have 
associated exposure to aflatoxin with low birth weight newborns [57].
We did not find studies that specifically reported the potential adverse effects of 
pregnancy outcomes from the consumption of food additives, nor did we find any 
specific recommendations to limit their consumption at this time.
caFFEinE, alcohol, and othEr intoxicants
A Cochrane Review concluded that there is insufficient evidence to support that 
caffeine intake can have a negative or positive impact on pregnancy outcomes and 
fetal development [58]. However, the FIGO recommends limiting caffeine intake to 
200 mg per day on the basis that high maternal caffeine consumption has been asso-
ciated with fetal growth restriction.
The use of alcohol, tobacco, and other drugs should be avoided during pregnancy. 
Smoking during pregnancy is associated with spontaneous abortion, preterm birth, 
low birth weight, perinatal mortality, and impaired neurological and physical devel-
opment of the child [59]. Alcohol consumption during pregnancy, even when low and 
occasional, has been associated with spontaneous abortion, fetus malformations, and 
behavioral and neurological impairments [59]. Moreover, alcohol can interfere with 
the absorption of key nutrients [59].
CONCLUSION AND FUTURE DIRECTIONS FOR RESEARCH
Dietary requirements and the corresponding recommended nutrient intakes during 
pregnancy are well established and based on evidence for energy, protein, and many 
nutrients, such as iron, folic acid, and vitamin A. For others, such as specific fatty 
acids, including DHA, types of carbohydrates, specifically related to the glycemic 
index, and a number of vitamins and minerals including zinc and vitamin D, there 
are important evidence gaps. For others, such as sodium, the evidence to provide 
pregnancy-specific guidance is unclear.
TABLE 3.4
Maximum Levels of Heavy Metal Consumption during 
Pregnancy
Nutrient Maximum Level Reference
Boron 20 mg/day [2,54]
Lead 5 μg/dL (blood lead level) [55]
Mercury 1.3 μg methylmercury/kg/week [56]
Nickel 1 mg/day [2]
Vanadium 1.8 mg/day [54]
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Dietary intake recommendations are based on the assumption of maintenance 
in healthy populations, and there is still much to learn about the implications of 
diverse health conditions on dietary nutrient needs during pregnancy, for example, 
underweight and obesity [1,2]. Similarly, the consequences of micronutrient defi-
ciency for adverse pregnancy outcomes are well established, as is the potential of a 
number of interventions to improve pregnancy outcomes. Such interventions often 
provide supplements with a nutrient content at or above daily recommended intake 
amounts (e.g., iron folic acid supplementation during pregnancy). At the same time, 
there is some concern that high intakes of micronutrients may have deleterious 
effects, for example, vitamin A supplements in the absence of a deficiency, but the 
extent of other risks is not well established for other nutrients [2]. Improved meth-
ods of adequately assessing and balancing benefits and risks are needed. One such 
methodology, the Benefit-Risk Analysis for Foods (BRAFO) has been applied to a 
number of dietary interventions [60], but we found no studies at this time that use 
such methods to assess the balance of risks and benefits for nutrient intakes during 
pregnancy.
Similarly, there are considerable gaps in evidence related to additional nutrient 
requirements of specific subgroups, including adolescents and women with multiple 
pregnancies. Pregnant adolescents have increased nutrient requirements, not only 
for the fetus’s growth, but also for their own growth [6]. Although some research has 
been done on the requirements of adolescent girls with respect to certain nutrients, 
such as energy, protein, and iron, evidence for setting specific recommendations is 
lacking for many nutrients (e.g., zinc and magnesium) [2]. At the same time, in many 
countries, women are getting pregnant at an older age, and the use of fertility treat-
ments has become more common, resulting in a higher frequency of multiple preg-
nancies. However, specific recommendations for multiple pregnancies are lacking 
for most nutrients, such as proteins, iron, zinc, and calcium [2].
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Lactation is one of the most nutritionally demanding periods of a woman’s life, when 
her nutritional requirements increase beyond both prepregnant and pregnant levels 
in order to support newborn and infant growth and development, and to maintain 
her own metabolic needs. Infants double their weight in the first 4 to 6 months post­
partum, and the breast milk secreted in the first 4 months represents an amount of 
energy similar to the total energy cost of pregnancy [1]. Although the energy and 
nutrients stored during pregnancy are available to support milk production, there are 
undoubted increases in requirements for a broad range of nutrients during lactation. 
Most of these recommended intakes are based on our knowledge of the amount of 
milk produced during lactation, its energy and nutrient content, and the amount of 
maternal energy and nutrient reserves. Despite the increased nutrient demands of lac­
tation, women are remarkably resilient in their ability to produce breast milk of 
sufficient quantity and quality to support the growth of their infant, even when 
the mother is deprived of nutrients herself. During lactation, the mammary gland 
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Milk production may, therefore, have an impact on maternal body composition and 
nutritional status, and could impact negatively on any subsequent pregnancy, par­
ticularly if the interval between pregnancies is short. Pregnancies with short “recu­
perative intervals” (defined as the amount of time that the woman was not lactating 
prior to the next conception) may be particularly vulnerable to nutrient depletion. 
Yet reviews of the evidence, while highlighting weaknesses in the available stud­
ies, have found no clear evidence of a link between interpregnancy or recuperative 
interval and maternal anthropometric status, possibly due, in part, to changes in the 
hormonal regulation of nutrient partitioning between the mother and the fetus when 
a mother is malnourished [2,3].
Daily nutrient requirements during lactation are higher than requirements in preg­
nancy, and nutrient reference values are increased for a broad range of nutrients (Table 
4.1). The exact nature of many of these requirements is not well understood, and it is 
difficult to conclude whether breastfeeding women need to make significant changes 
to their diet. Factors such as the duration and intensity of lactation (whether the infant 
is breastfed exclusively or only partially) are likely to influence nutritional require­
ments, as an exclusively breastfeeding woman will have greater energy and nutrient 
needs (with the exception of iron, attributed to the potential protective effect of lac­
tational amenorrhea) than a woman who is partially breastfeeding [12]. Intensity of 
lactation has also been found to have an impact on the macronutrient content of breast 
milk. Recent research has found that the nutrient composition of the breast milk of 
exclusively breast feeding mothers is more calorific with a higher percentage fat con­
tent, and lower percentage protein and percentage carbohydrate content (percentages 
of total calorie content) than the milk of mixed feeding mothers [13].
In areas where micronutrient deficiency is prevalent, milk composition may be 
affected by marginal maternal deficiencies in fatty acids, iodine, and most vitamins. 
For most minerals, breast milk is more protected against variations in maternal 
nutrient intake and status by the mobilization of stores accrued during pregnancy 
(Table 4.2). Many minerals are transferred into milk by active transfer, rather than by 
passive diffusion, and this process compensates for variations in maternal mineral 
status.
ENERGY
The energy requirements of lactation are defined as “the level of energy intake from 
food that will balance the energy expenditure needed to maintain a body weight and 
body composition, a level of physical activity and breast milk production that are 
consistent with optimal health for the woman and her child” [14]. This definition 
implies that the energy required to produce an appropriate volume of milk must be 
added to the woman’s usual energy requirement, and assumes that she resumes her 
usual level of physical activity soon after giving birth [14]. Although some stud­
ies suggest that metabolic adaptations and reduced physical activity act to conserve 
energy during lactation, it is generally believed that resting metabolic rate and ther­
mogenesis are not significantly altered, and the savings gained from a sedentary 
lifestyle are unlikely to have much impact on availability of energy for lactation. 
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TABLE 4.1
United Kingdom, United States, and WHO/FAO Nutrient Reference Values 
during Lactation
UK DRV [4]—RNI U.S. DRI [5–9]—RDA WHO/FAO—[10]
Energy 2270 kcal (0–6 m)
↑a 330 kcal
↑ 550
Protein 56 g/d (0–4 m)
↑ 11




↑ 19.4 g/d (0–6 m)
↑ 12.5 g/d (6 m+)
Vitamin Ab 950 μg RE/d
↑ 350 μg RE/d
1200 μg RE/d 
(age 14–18 y)
↑ 500 μg RE/d
1300 μg RE/d 
(age 19–50 y)
↑ 600 μg RE/d
850 μg RE/d
↑ 350 μg RE/d






Vitamin E None set 19 mg/d
↑ 4 mg/d
None set
Vitamin K None set 75 μg/d (age 14–18 y)




Vitamin C 70 mg/d
↑ 30 mg/d
115 mg/d (age 14–18 y)
↑ 50 mg/d







↑ 0.6 mg/d (age 14–18 y)








↑ 0.4 mg/d (age 14–18 y)





16 mg/d (age 15–18 y)






Vitamin B6 1.2 mg
No increment
2.0 mg/d
↑ 0.8 mg/d (age 14–18 y)
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TABLE 4.1 (CONTINUED)
United Kingdom, United States, and WHO/FAO Nutrient Reference Values 
during Lactation
UK DRV [4]—RNI U.S. DRI [5–9]—RDA WHO/FAO—[10]
Biotin None set 35 μg/d (AI)
↑ 10 μg/d (age 14–18 y)
↑ 5 μg/d (age 19–50 y)
35 μg/d
↑ 5 μg/d
Choline None set 550 mg/d (AI)
↑ 150 mg/d (age 14–18 y)
↑ 125 mg/d (age 19–50 y)
None set
Calcium 1350 mg/d (age 15–18 y)
1250 mg/d (age 19–50 y)
↑ 550 mg/d
1300 mg/d (age 14­18 y)






during the growth spurt)
Iron 14.8 mg/d
No increment
10 mg/d (age 14–18 y)
↓ 5 mg/d
9 mg/d (age 19–50 y)
↓ 9 mg/d
10–30 mg/d depending on 
bioavailability of iron 
(a decrease of around 
50% of NPNL values)
Phosphoruse 990 mg/d
↑ 440 mg/d
1250 mg/d (age 14–18 y)
700 mg/d (age 19–50 y)
No increment
None set
Magnesium 350 mg/d (age 15–18 y)
320 mg/d (age 19–50 y)
↑ 50 mg/d
360 mg/d (age 14–18 y)
310 mg/d (age 19–30 y)




Zinc 13 mg/d (0–4 months)
↑ 6 mg/d
9.5 mg/d (4+ months)
↑ 2.5 mg/d
13 mg/d (age 14–18 y)




5.8–19 mg/d (0–3 m)
5.3–17.5 mg/d (3–6 m)
4.3–14.4 (7–12 m)
NPNL adolescents 
4.3–14.4 mg/d NPNL 
women 3.0–9.8 mg/d
Copper 1.3 μg/d (age 15–18 y)









35 μg/d (0–6 m)
↑ 9 μg/d














57Nutrient Requirements during Lactation
Therefore, the mother must increase her energy intake in order to meet the additional 
demand of lactation.
The energy requirements for lactation are high. Dewey [12] calculated that the 
average energy costs for milk production for an exclusively breastfeeding woman are 
595 kcal/day at 0 to 2 months postpartum and 670 kcal/day at 3 to 8 months postpartum. 
The energy needed to support this would be 440 to 515 kcal/day, allowing for 500 g of 
fat loss per month. The energy needs are lower for a partially breastfeeding woman, 
depending on the extent to which non–breast milk foods are consumed by her infant.
UK dietary reference values for energy during lactation increase by 330 kcal per 
day in the first 6 months [15], that is, a daily energy intake of 2,270 kcal. Thereafter, it 
is expected that the energy intake required to support breastfeeding will be modified 
by changes in maternal body composition and the breast milk intake of the infant. 
The World Health organization (WHO)/Food and Agriculture Organization of the 
United Nations (FAO) recommends an additional 505 kcal/day for well­ nourished 
women with adequate gestational weight gain, while undernourished women and 
those with insufficient gestational weight gain should increase their calorific intake 
by 675 kcal/day during the first semester of lactation [14] (see Table 4.1).
TABLE 4.1 (CONTINUED)
United Kingdom, United States, and WHO/FAO Nutrient Reference Values 
during Lactation
UK DRV [4]—RNI U.S. DRI [5–9]—RDA WHO/FAO—[10]
Manganese None set 2.6 mg/d (AI)
↑ 1.0 mg/d (age 14–18 y)
↑ 0.8 mg/d (age 19–50)
None set
Molybdenum None set 50 μg/d
↑ 7 μg/d (age 14–18 y)
↑ 5 μg/d (age 19–50)
None set
Abbreviations:  AI, adequate intake; DRI, dietary reference intakes; DRV, dietary reference value; RAE, reti­
nol activity equivalent; RDA, recommended dietary allowance; RE, retinol equivalent; RNI, 
recommended nutrient intake; NE, niacin equivalent; NPNL, nonpregnant, nonlactating.
a An upward­pointing arrow represents the amount of increase from nonpregnant, nonlactating levels. 
A downward­pointing arrow represents the amount of decrease from nonpregnant, nonlactating levels.
b As retinol activity equivalents (RAEs): 1 RAE = 1 μg retinol, 12 μg beta­carotene, 24 μg alpha­carotene, 
or 24 μg beta­cryptoxanthin. The RAE for dietary provitamin A carotenoids is twofold greater than the 
retinol equivalent, whereas the RAE for preformed vitamin A is the same as the retinol equivalent.
c The Scientific Advisory Committee on Nutrition (SACN) in the United Kingdom has recently proposed 
a Reference Nutrient Intake (RNI) for vitamin D of 10 μg/d for the UK population aged 4 years and 
over. This is the amount needed for 97.5% of the population to maintain a serum 25(OH)D concentra­
tion of 25 nmol/L when UVB sunshine exposure is minimal [11].
d As niacin equivalents: 1 mg of niacin = 60 mg tryptophan.
e RNI for phosphorus set to equal the RNI for calcium in millimoles (mmol). The increment for preg­
nancy therefore reflects the increment set for calcium.
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There is conflicting evidence about whether women who breastfeed their infants 
lose more weight postnatally than women who do not breastfeed. Systematic reviews 
seeking to explore the relationship between breastfeeding and postpartum weight 
change have highlighted a high degree of heterogeneity among studies, particu­
larly in relation to sample size, measurement time points, and in the classification 
of breastfeeding and postpartum weight change [16,17]. It has further been sug­
gested that the lack of a consistent relation between breastfeeding and a reduction 
in postpartum weight retention may have resulted from a combination of a pattern 
of breastfeeding that would not be expected to modify weight loss appreciably, low 
statistical power, or the poor quality of information about the intensity and dura­
tion of breastfeeding (or all three factors), as well as a complex association with 
prepregnancy body mass index (BMI) [18]. Despite these limitations, Neville and 
colleagues [17] found that of the five studies that were considered to be of high 
methodological quality, four studies demonstrated a positive association between 
breastfeeding and weight change, and in a pooled analysis of eleven studies, He 
et al. [16] found that breastfeeding for 3 to ≤6 months had a negative influence on 
postpartum weight retention, but had little effect after 6 months of breastfeeding. 
Baker et al. [18] calculated that, if women exclusively breastfed for 6 months as 
recommended, postpartum weight retention could be eliminated by that time in 
women with gestational weight gain values of approximately 12 kg, and that the 
possibility of major weight gain (≥5 kg) could be reduced in all but the heaviest 
women. Moreover, longitudinal studies have suggested breastfeeding may provide 
TABLE 4.2
Nutrients in Human Breast Milk Categorized According to Whether 
They Are Likely to Be Affected by Maternal Dietary Intake
Nutrients Present in Breast Milk 
at Generally Stable Concentrations
Nutrients for Which Material Intake Is Likely 
to Affect Breast Milk Composition
Polyunsaturated fatty acids (LA, ALA, ARA, DHA)
Total fat Trans fatty acids
Vitamin A (retinol and carotenes)
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long­term protection against postpartum weight retention among both normal 
weight [19] and obese women [20].
FATTY ACIDS
The major omega n­3 and n­6 long chain polyunsaturated fatty acid (LCPUFA) com­
ponents of breast milk are docosahexaenoic acid (DHA), alpha­linoleic acid (ALA), 
and arachidonic acid (ARA). DHA and ARA in particular play a major role in infant 
neurological development. Research has indicated that the DHA content of breast 
milk may be linked to a child’s optimal visual acuity development, neurodevelop­
ment, and subsequent IQ [21]. A study of breast milk DHA levels across 28 countries 
found a strong positive relationship between breast milk DHA and cognitive perfor­
mance, even when controlling for national wealth, investment in education and mac­
ronutrient intake [22]. Breast milk fatty acids may also contribute to the regulation 
of innate and adaptive immune responses later in childhood [23].
Although there is evidence that the fetus and infant are able to endogenously synthe­
size ARA and DHA, the synthesis is extremely low [24], making maternal LCPUFA 
supply critical during fetal and postnatal growth and development. The transfer of 
LCPUFA from mother to her infant during lactation is dependent largely upon mater­
nal status, and variations in breast milk fatty acid status across populations are evident. 
Whereas the proportion of breast milk saturated and monounsaturated fatty acids have 
been found to be relatively constant across a large number of countries, some of the 
PUFAs, especially DHA, have shown high variability with particularly low levels in low 
marine food­consuming populations [25,26]. Maternal body mass index and age have 
also been found to affect fatty acid levels in human milk [27]. Very premature infants are 
particularly vulnerable to low DHA levels at birth, as LCPUFA accretion occurs primar­
ily during the last trimester of pregnancy when maternal levels are high and growth and 
brain development are rapid. There is increasing evidence that optimizing LCPUFA pro­
vision postnatally may not only improve vision and neurodevelopment in very low birth 
weight and premature infants, but may also reduce the morbidity and mortality from 
diseases specific to premature infants, such as bronchopulmonary dysplasia, necrotizing 
enterocolitis, and retinopathy of prematurity [28].
Fish and seafood comprise the only food group that is a significant source of 
n­3 LCPUFA, which also offers a range of nutrients that are frequently underrep­
resented in habitual diets, including iodine, calcium, vitamin D, zinc, and iron [29]. 
Breast milk ALA levels tend to be better conserved than DHA, but DHA responds 
sensitively to dietary DHA and higher breast milk levels have been found in women 
consuming diets with high levels of fish intake [30]. LCPUFA levels in breast milk 
may be low when maternal fish intake is low and/or ALA intake is low and linoleic 
acid (LA) intake is high, as diets with very high levels of LA dramatically reduce 
conversion of ALA to DHA [31]. Food supplementation with DHA from midpreg­
nancy and throughout lactation has been shown to improve the DHA status of the 
mother and the amount of DHA present in her milk [32], resulting in higher DHA 
plasma concentrations in infants [33] and improved child neurodevelopment [34].
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PROTEIN
The protein content of milk varies according to the stage of lactation, with colostrum 
containing about 30 g/L and mature milk comprising 8 to 9 g/L, and whether the 
mother delivers at term: Preterm mothers’ milk contains significantly more protein 
than that of mothers who deliver at term. The protein in breast milk is composed 
of lactalbumin, casein, lactoferrin, and IgA. It is estimated that women require an 
additional 11 g protein/day over the first 6 months to meet this need. In high­income 
countries, most women consume protein well in excess of this amount and would not 
need to alter their intake when breastfeeding. Vegetarian women should ensure a diet 
containing adequate combinations of plant proteins to provide all essential amino 
acids in sufficient quantities.
Human milk contains many proteins that have been shown to be bioactive, includ­
ing lactoferrin, lysozyme, secretory IgA, haptocorrin, α­lactalbumin, and bile salt 
lipase. Their roles include enzymatic activities, enhancement of nutrient absorption, 
growth stimulation, modulation of the immune system, and defense against patho­
gens. Human milk proteins may be largely resistant to digestion in the gastrointes­
tinal tract, be partially digested into bioactive peptides, or be completely digested 
and utilized as a source of amino acids, and it is still not known to what extent their 
bioactivities are exerted in breastfed infants [35].
CARBOHYDRATE
Lactose, the primary carbohydrate in human milk and the second­largest component 
of milk (70 g/L) after water, does not seem to be influenced by fluctuations in maternal 
diet. Human milk oligosaccharides (HMOs) represent a significant fraction of breast 
milk, reaching concentrations of up to 20 g/L. HMOs are a family of structurally 
diverse unconjugated glycans that serve as a prebiotic substrate enabling enrichment of 
Bifidobacterium species in the infant gut. Lactate and short­chain fatty acids (SCFAs), 
the end products of bacterial fermentation of HMOs, can then be absorbed and used 
as an energy source. There is increasing evidence to suggest that HMOs are important 
antiadhesive antimicrobials, which serve as soluble decoy receptors; prevent patho­
gen attachment to infant mucosal surfaces; and lower the risk for viral, bacterial, and 
protozoan parasite infections. HMOs may also modulate epithelial and immune cell 
responses, reduce excessive mucosal leukocyte infiltration and activation, lower the 
risk of necrotizing enterocolitis, and provide the infant with sialic acid as a potentially 
essential nutrient for brain development and cognition [36]. HMOs have been found in 
the circulation of breastfed infants, indicating good correlation between infant plasma 
HMO concentrations and levels in the corresponding mother’s milk [37]. Differences 
in HMO composition in the mother’s milk has been associated with infant growth 
and body composition [38], protection against postnatal HIV transmission [39], and 
reduced mortality during breastfeeding in HIV­exposed children [40]. Although some 
intervention studies have evaluated the effects of perinatal administration of prebiotics 
to pregnant women and to infants after birth, giving conflicting results depending on 
the specific strains tested, the conditions of use, and the population group, even less 
is known about the potential impact of prebiotic administration during lactation [41].
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VITAMIN A
Vitamin A is needed for the growth and differentiation of cells and tissues and 
plays a key role in infant development. Vitamin A deficiency (VAD) is a major pub­
lic health problem in low­income countries, and it is estimated that 140 million to 
250 million children under the age of 5 years are affected globally. A lack of vitamin 
A is associated with a significant increased risk of illness and death from common 
childhood infections, such as measles and diarrhea, severe visual impairment and 
blindness. Breast milk is rich in vitamin A, derived mainly from maternal fat stores, 
and transported in the lipid fraction of milk as retinyl ester. Breastfed infants of 
women with adequate vitamin A status are generally protected from clinical VAD, 
as the amount of vitamin A transferred to the first 6 months of lactation is 60 times 
that which the fetus accumulates throughout gestation [42]. Breast milk vitamin A 
content is sensitive to maternal intake, and women with low intakes may be at risk 
of vitamin A deficiency, resulting from further depletion of their stores through 
breastfeeding. Although high doses of vitamin A should not be consumed during 
pregnancy to avoid teratogenesis, high­dose vitamin A supplementation of breast­
feeding women with low serum retinol levels has been shown to be an effective way 
of ensuring adequate supplies for the infant through colostrum and breast milk, and 
preventing deficiency in the infant [43,44].
B VITAMINS
The B vitamins are a broad class of water­soluble vitamins, which play important 
roles in cell metabolism. The recommended dietary intakes for several B vitamins 
are increased during lactation (i.e., thiamin, riboflavin, niacin, vitamin B6, vitamin 
B12, and folate). Breast milk concentrations of thiamin, riboflavin, and vitamins B6 
and B12 are strongly dependent on maternal dietary intake and status, and low mater­
nal intake/status can lead to the infant becoming deficient.
The two forms of thiamin present in breast milk are thiamin and thiamin mono­
phosphate (approximate ratio 30:70). The risk of thiamin depletion is increased where 
diets are high in refined or polished unfortified grains, and low in animal source 
foods and legumes. Thiamin deficiency (beriberi) is uncommon in high­income 
countries, where deficiency is more often associated with chronic alcoholism, HIV/
AIDS, or gastrointestinal conditions that impair vitamin absorption [45]. Infantile 
thiamin deficiency occurs mainly in infants who are breastfed by mothers with an 
inadequate intake of thiamin. There is evidence that infantile thiamin deficiency per­
sists in parts of Southeast Asia, such as Laos, Cambodia, and Burma, where it may 
be a major cause of infant mortality [46]. Trials have shown that thiamin fortification 
of food consumed through pregnancy and early lactation improves breast milk thia­
min concentrations, and has the potential to prevent infantile beriberi [47]. In 2003, 
several hundred Israeli infants were put at risk of thiamin deficiency after being fed a 
soy­based formula that was deficient in thiamin [48]. Approximately 20 infants were 
seriously affected, and 3 of them died. The long­term consequences of early thiamin 
deficiency included intellectual disability, motor abnormalities, severe epilepsy, and 
early kyphoscoliosis [49]. Some of the children with intellectual disability had been 
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considered “asymptomatic,” with no abnormal neurological symptoms during the 
thiamin deficiency period, suggesting that thiamin deficiency may exert its effects 
on the brain development of children without being detected [50].
Riboflavin is found mainly in animal source food and green vegetables, and so 
deficiency may be more common in populations whose diets are low in these food­
stuffs. Marginal riboflavin status has also been reported to be prevalent in low­milk 
consumers in industrialized countries [51]. A low maternal dietary take of riboflavin 
has been associated with congenital limb deficiency, cleft lip, and palate deformities, 
and congenital heart defects in their offspring [52,53]. Riboflavin deficiency in moth­
ers rapidly results in low breast milk concentrations of this vitamin, but supplemen­
tation of both the mother and infant can improve the status of the infant [45].
The predominant form of vitamin B6 in breast milk is pyridoxal (75%), and low 
breast milk concentrations have been associated with poor weight gain and linear 
growth, increased risk of seizure, and behavioral issues in early infancy, although 
evidence is limited [45]. The vitamin B6 intake of mothers is a strong predictor of 
infant status [54]. Maternal vitamin B6 supplementation results in a rapid increase 
in milk concentration of this vitamin. Associations between levels of vitamin B6 
in human breast milk and infant behavior have been suggested. A small study of 
Egyptian mothers reported that a low concentration of vitamin B6 in breast milk 
(<415 nmol/L) was associated with less consolability, inappropriate buildup to a 
crying state, and poorer response to aversive stimuli in their infants [55]. A sub­
sequent study, also carried out in Egyptian mother–infant pairs, reported a sig­
nificant relationship between maternal dietary quality during lactation and infant 
drowsiness, and this was linked to certain B­vitamin intakes (particularly vitamin 
B6, niacin, and riboflavin), and/or bioavailability of the nutrients [56]. A study in 
the United States of 25 lactating women whose vitamin B6 intake was greater than 
the group median had infants whose habituation and autonomic stability scores 
on the Brazelton Neonatal Assessment Scale were positively correlated with their 
breast milk vitamin B6 content [57]. All studies were small, however, and further 
work needs to be done to investigate whether these findings can be replicated in 
other contexts.
Neonates are thought to be at particular risk of vitamin B12 deficiency. Case 
studies have shown that breastfed infants born to vegetarian mothers or those with 
undiagnosed pernicious anemia may show clinical symptoms of vitamin B12 defi­
ciency within months of birth. Such symptoms include severe growth failure (length, 
weight, and head circumference); cerebral atrophy; and muscular, behavioral, and 
developmental problems [58]. Studies that have investigated the association between 
maternal vitamin B12 supplementation and infant growth and cognitive function 
have, however, been inconsistent [59]. Whereas supplementation of vitamin B12­
depleted lactating women results in only modest increments in breast milk levels 
[45], vitamin B12 supplementation throughout pregnancy and early lactation has been 
found to significantly increase the status of mothers and infants [60], suggesting that 
supplementation must start early in pregnancy, or before, if it is to impact on child 
outcomes. However, despite the relatively high prevalence of vitamin B12 deficiency 
and its deleterious effects on pregnant women and their infants, there is still no con­
sensus on the biochemical marker cutoff to correctly diagnose B12 deficiency, and 
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the optimal dose of B12 to normalize B12 status of mother–infant pairs in a deficient 
population is not yet known [61].
The predominant form of folate in human milk is 5­methyl tetrahydrofolate. 
Folate deficiency and depletion is thought to be widespread in both industrialized 
and nonindustrialized countries. Unlike many of the other B vitamins, concentra­
tions in human milk are maintained even when the mother is deficient in the vitamin, 
and there is no evidence that maternal supplementation with folate elicits beneficial 
effects on breast milk levels [62]. As a consequence of maintaining folate secretion 
in breast milk, women with low intakes will become more depleted as lactation pro­
gresses, and thus supplementation of the breastfeeding mother may be important for 
preserving maternal stores, which is particularly important for subsequent concep­
tion and pregnancy [45]. Steps to achieve folate sufficiency have included regulations 
for the mandatory fortification of wheat flour with folic acid. To date, 86 countries 
have legislation in place to mandate fortification of at least one industrially milled 
cereal grain, although in many cases these regulations have not been implemented 
[63]. Fortification of staple foodstuff with folic acid has reduced the number of births 
complicated by neural tube defects by up to 35% in the United States since folic acid 
fortification was mandated in 1998 [64].
VITAMIN C
Vitamin C is an essential water­soluble antioxidant vitamin and, in its role as a cofac­
tor for mixed function oxidases, it participates in the synthesis of various macromol­
ecules, including collagen and carnitine. Breast milk contains 30 to 80 mg/L vitamin C, 
and to compensate for the excretion of vitamin C into breast milk, dietary recom­
mendations advocate an increased intake of vitamin C during lactation. High­dose 
vitamin C supplementation (>200 mg/day) to the mother has not been found to result 
in higher breast milk concentrations in well­nourished women, but rather resulted in 
increased urinary excretion of vitamin C [65]. However, in women with low vitamin C 
status, breast milk concentrations can be doubled or tripled by taking vitamin C 
supplements, thereby improving the nutrient status of the breastfed infant [66]. No 
cases of infantile scurvy, characterized by hemorrhage around the connective tissue 
and bone, impaired bone development, listlessness, loss of appetite, and weight loss, 
have been reported in breastfed infants, even when maternal vitamin C intake is low. 
A higher breast milk vitamin C concentration, however, has been associated with 
a reduced risk of atopy in the infant [67]. After weaning, the vitamin C intake of 
infants declines significantly, but the potentially negative influences of low ascorbic 
acid intake in early life related to its antioxidant properties have yet to be evaluated.
VITAMIN D
Through its action in regulating calcium and phosphate absorption, vitamin D plays 
a vital role in the growth and development of bones. Infants, in particular, are at risk 
of vitamin D deficiency because of their relatively large vitamin D needs related to 
the high rate of skeletal growth [10]. Breast milk contains relatively small amounts 
of vitamin D that may not be sufficient to prevent vitamin D deficiency in exclusively 
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breastfed infants if sunlight exposure is limited [68]. Since several groups, such as 
the American Academy of Pediatrics, recommend that infants younger than 6 months 
should be kept out of direct sunlight and protected with clothing and hats, opportunities 
for vitamin D synthesis from sunlight may be further restricted. Pregnant women and 
newborn infants are recognized as populations at an increased risk of poor vitamin D 
status. Globally, 54% of pregnant women and 75% of newborns suffer from vitamin D 
deficiency (25(OH)D <50 nmol/L), and 18% of pregnant women and 29% of newborns 
suffer from severe vitamin D deficiency (25(OH)D concentration <25 nmol/L) [69].
During lactation, the efficiency of maternal dietary calcium absorption is 
increased to ensure adequate calcium content of breast milk. The metabolism of 
25(OH)D to 1,25(OH)2D is enhanced to meet this demand. However, because cir­
culating concentrations of 1,25(OH)2D are 500 to 1000 times less than 25(OH)D, 
the increased metabolism probably does not significantly alter the daily requirement 
for vitamin D [70]. Dietary guidelines recommend that pregnant and breastfeeding 
women should take 5 to 15 μg (200–600 IU) vitamin D per day (Table 4.1). Public 
health guidance in the United Kingdom highlights those at greatest risk of vitamin D 
deficiency, including women who are obese; have limited skin exposure to sunlight; 
or who are of South Asian, African, Caribbean, or Middle Eastern descent [71]. 
As there are few dietary sources of vitamin D available to meet this recommended 
target, vitamin D supplements should be taken. Supplementation with 10 μg/d (400 IU/
day), however, has been shown to have only a modest effect of maternal 25(OH)D 
levels, leading for calls to increase levels of supplementation in lactating women 
to at least 37.5 to 50 μg/d (1500–2000 IU/d) or 100 to 150 μg/d (4000– 6000 IU/d) 
if mothers choose not to give their infant a vitamin D supplement [70]. Studies have 
indicated that supplementation of healthy breastfeeding mothers with doses of 100 
to 160 μg/d vitamin D (4000–6400 IU/d) provides the breastfeeding infant with 
adequate levels of vitamin D, despite both mother and infant being limited in sun­
light exposure [72,73]. Maternal high­dose supplementation remains controversial, 
however, and research has shown that supplements administered directly to the 
infant during lactation can easily achieve vitamin D sufficiency. Several groups, such 
as the European Society for Pediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) and Health Canada, advocate that breastfed infants should receive an 
oral supplementation of 10 μg/d (400 IU/day) of vitamin D [74].
CALCIUM
Breastfeeding women typically lose calcium at a rate of 280 to 400 mg/day through 
their breast milk [75]. To meet this increased demand, the mother must mobilize cal­
cium from her own skeletal reserves. Physiologic adaptations, such as upregulation 
of intestinal calcium absorption and bone resorption, provide much of the calcium 
in breast milk (Figure 4.1). Once breastfeeding has ceased, bone density is fully 
restored over the subsequent 6 to 12 months [76]. Although the total duration of 
breastfeeding has not been found to have an adverse impact on bone mineral density 
in later life, short interpregnancy intervals (1 to 12 months) are associated with an 
increased risk of osteoporosis [77]. Several investigations of the effect of maternal 
dietary calcium intake on breast milk levels indicate that they may be independent. 
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A randomized controlled trial of pregnant and lactating women in The Gambia 
showed that, despite having low dietary intakes of calcium (300–400 mg/d) and low 
breast milk concentrations, calcium supplements had no significant benefit in terms 
of breast milk concentration [78].
The calcium requirements of adolescents are elevated as a result of intensive bone 
and muscular development, and most adolescents worldwide fail to achieve recom­
mended calcium intakes [79]. There is some concern, therefore, that adolescent moth­
ers with low calcium intakes may not achieve normal peak bone mass as a consequence 
of lactation­induced bone loss. Although there is evidence that adolescents experience 
bone mineral density loss during lactation, this effect has been shown to be transient, 
with subsequent repletion of bone mineral density once breastfeeding is ceased [80]. 
Evidence remains limited, however, and adolescent mothers are advised to maintain or 
increase their dietary intake to recommended levels (1300 mg/d) while breastfeeding 
to ensure that their growth needs are met and that peak bone mass is achieved [81].
IRON
Iron deficiency is the most common micronutrient deficiency globally, and young 
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FIGURE 4.1 The contrast of calcium homeostasis in human pregnancy and lactation, com­
pared with nonpregnant, nonlactating levels. The thickness of arrows indicates a relative 
increase or decrease with respect to the normal nonpregnant state. The serum (total) calcium 
is decreased during pregnancy, while the ionized calcium remains normal during both preg­
nancy and lactation. (Reproduced from Kovacs CS, Endocrinol Metab Clin North Am 2011, 
40(4):795–826. With permission.)
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growth. Controversy exists regarding the adequacy of exclusive breastfeeding for 
6 months in maintaining optimum iron status in term babies. The ESPGHAN 
Committee on Nutrition recently reviewed the evidence for iron requirements in 
early childhood and concluded that there is no convincing evidence that iron sup­
plements should be provided to normal­birth weight, exclusively breastfed infants 
during the first 6 months of life in populations with a low prevalence of iron defi­
ciency anemia (IDA) among 6 month olds [82]. After this time, many infants exhaust 
their iron stores and require a secondary dietary iron supply in the form of iron­rich 
complementary foods. In low­resource settings, however, where newborn iron stores 
may be suboptimal and there is reduced access to iron­rich foods, it has been sug­
gested that breastfeeding mothers may need to be supplemented with iron to ensure 
the hematological status of the infant is not compromised, particularly in low­birth­
weight infants [83], but evidence is limited. Several studies have found no correlation 
between the levels of iron in breast milk and maternal iron status, and some have 
demonstrated that exclusively breastfed infants of both anemic and nonanemic moth­
ers in resource­poor areas do not develop iron deficiency or iron deficiency anemia 
by 6 months of age [84]. The WHO recommends delayed umbilical cord clamping 
(not earlier than one minute after birth) for the prevention of iron deficiency anemia 
in infants [85].
IODINE
The iodine concentration of human breast milk varies markedly as a function of 
the iodine intake of the population, and depends on the iodine levels in local soil, 
seafood consumption, and the availability and use of iodized salt. An average con­
sumption of 750 mL breast milk per day would provide an intake of iodine of about 
60 μg/day in Europe and 120 μg/day in the United States, which, in some areas, falls 
short of the WHO recommendation of 90 μg iodine/day from birth [10]. For women 
with marginal iodine status, the demands of lactation can precipitate clinical and 
biochemical symptoms including increased thyroid volume, altered thyroid hormone 
levels, and impaired mental function [86,87].
Thyroidal iodine turnover rate is more rapid in infants [88] so adequate breast 
milk iodine levels are particularly important for neurodevelopment in breastfed 
infants. A 33% increase in iodine intake is needed to accommodate the changes in 
maternal thyroid metabolism to support lactation and to supply sufficient iodine for 
milk to meet the needs for growth and development of the infant [10]. The levels 
recommended to ensure that pregnant and lactating women do not suffer from iodine 
deficiency postpartum are listed in Table 4.1.
Although substantial progress has been made over the recent decades through 
programs of universal salt iodization, iodine deficiency remains a significant health 
problem worldwide, and affects both industrialized and developing nations [89]. 
Evidence suggests that pregnant and lactating women may be at risk of iodine defi­
ciency where universal salt iodization is not fully implemented. The WHO and 
UNICEF (United Nations Children’s Fund) recommend iodine supplementation 
for pregnant and lactating women in countries where less than 20% of households 
have access to iodized salt, until the salt iodization program is scaled up. Countries 
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in which household access to iodized salt ranges from 20% and 90% should make 
efforts to accelerate salt iodization programs or assess the feasibility of increasing 
iodine intake in the form of a supplement or other iodine­fortified foods by the most 
susceptible groups [90].
ZINC
Zinc is vital for infant development, and an adequate supply of zinc is essential for 
mammary gland function and for milk synthesis and secretion. The level of zinc in 
colostrum is 17 times higher than in maternal blood but declines rapidly in breast 
milk during the first 3 months postpartum [91]. A number of studies of lactating 
women with marginal zinc status have revealed that homeostatic mechanisms can 
compensate for low maternal dietary zinc intakes. The proportion of dietary zinc 
absorbed in such women has been shown to increase by over 70%, compared to 
nonlactating women or preconception values [92]. Nevertheless, the adequacy of 
breast milk zinc for optimal infant growth and development is likely to depend on 
the amount of infant zinc reserves at birth; more research is needed to elucidate this 
[93,94].
COPPER AND SELENIUM
Copper and selenium are essential trace minerals, and the requirements for both are 
increased during lactation. Copper has a number of biochemical roles, most nota­
bly as a cofactor for enzymes that regulate various physiologic pathways such as 
energy production, iron metabolism, connective tissue maturation, and neurotrans­
mission. Selenium is a component of selenoproteins that act as antioxidant enzymes 
and regulate thyroid hormone metabolism and immune function. The copper content 
of human milk is highest during early lactation, and declines as lactation progresses, 
averaging approximately 250 μg/L in the first 6 months. Maternal intake of copper 
has little effect on breast milk concentrations or infant status [95]. The selenium 
content of breast milk also decreases over the course of lactation but, unlike copper, 
is influenced by maternal status.
CONCLUSION
Although dietary requirements for many nutrients are increased during lactation, 
the requisite levels of intake are likely to be met within the normal diets of well­
nourished women. Other factors, such as the mother’s nutritional stores, reductions 
in physical activity, and metabolic adaptation, all combine to provide a buffer to 
protect the breastfed infant against suboptimal nutrient intake. There is evidence, 
however, that the secretion of certain nutrients into breast milk is rapidly or sub­
stantially reduced by maternal depletion. Such nutrients include vitamin A, thi­
amin, riboflavin, vitamin B6, vitamin B12, vitamin D, selenium, and iodine. The 
concentrations of nutrients less sensitive to maternal depletion (folate, calcium, 
iron, copper, and zinc) may be adequate and maintained through lactation, but low 
maternal intakes are likely to deplete mothers’ reserves as lactation progresses. 
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The  nutritional status  of pregnant women and women of childbearing age, par­
ticularly in resource­poor settings, is therefore of critical importance. Multiple­
micronutrient supplementation of mothers during pregnancy and lactation may be 
an important intervention to improve nutrient concentrations in breast milk [96]. 
The magnitude of the effect of supplementation of pregnant and breastfeeding 
mothers on their breast milk composition, however, has been highly variable, per­
haps due in part to methodological issues such as differences in the dose of the sup­
plement and the timing of sample collection, as many nutrients exhibit considerable 
kinetic variation in their secretion into milk following consumption. In addition, 
education is important in order to change cultural taboos and practices that impair 
maternal and infant status, most notably maternal perinatal and/or postpartum food 
avoidance. Optimal infant and young child feeding practices, which include the 
early introduction of breastfeeding, exclusive and continued breastfeeding, and 
good hygiene and sanitation (including the use of clean water and the introduction 
of safe and appropriate complementary feeding from 6 months of age), should all be 
promoted to ensure that the health­promoting properties of breast milk are provided 
to the infant to sustain optimal health.
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NUTRITION CONSIDERATIONS FOR YOUNG 
INFANTS (0–6 MONTHS)
Infancy is the period of the life cycle with the highest growth rate, and thus meeting 
energy and nutrient needs is critical to ensure optimal development. Infants have 
comparatively high needs for most nutrients relative to body size. Moreover, com-
pared with older children, very young infants have immature digestive, absorptive, 
and renal capacities. Therefore, human milk, with low renal solute load and compo-
sitional factors that facilitate nutrient absorption, is the ideal sole source of nutrition 
for healthy, term infants from birth through approximately 6 months of age. Besides 
promoting optimal growth, human milk contains many bioactive components, such 
as anti-infectious and anti-inflammatory agents, growth factors, and prebiotics [1].
Mature human milk remains relatively stable in composition during lactation, 
although longitudinal declines occur in protein content and some micronutrients. 
The exact mechanisms for such physiologic changes are not yet characterized but, 
teleologically, such changes are concurrent with the gradually reduced rate of infant 
growth, and serve to spare the demands on maternal nutrition. Other aspects of milk 
composition are more variable, for example, lipid content, which varies over the 
course of both a feed and a day.
The overall macronutrient content of human milk is well characterized, but recent 
research emphasizes numerous distinctive features within this traditional framework 
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that contribute to its uniquely beneficial aspects for the young infant. The main car-
bohydrate in human milk is lactose; mature, term human milk has an average lactose 
concentration of ~70 g/L, which gradually increases over time as protein concentra-
tion declines. Besides lactose, multiple oligosaccharides are found in human milk, 
and exert potent prebiotic effects and protective immunomodulatory functions, such 
as mediating leukocyte adhesion and activation [2]. Recent investigations have high-
lighted the importance of stage of lactation, maternal phenotype, and environmental 
factors with regard to diversity in the oligosaccharide profile of human milk [3]. 
These differences, in turn, have been associated with infant outcomes. For exam-
ple, an increase in lacto-N-fucopentaose is associated with a decrease of fat mass 
in 6-month-old breastfed infants [4]. Total protein in mature, term human milk is 
approximately 10 g/L and is whey protein-dominant. Of this, α-lactalbumin, which 
is high in tryptophan and cysteine, accounts for 41% of whey and 28% of total pro-
tein in human milk [5]. In addition to containing high quantities of essential amino 
acids, α-lactalbumin is found to have protective effects against common pathogens 
such as Escherichia coli [6]. Other whey proteins, such as lactoferrin and secre-
tory IgA, are also present in human milk, and exert unique functions, including 
facilitating iron absorption and boosting the innate immune system, respectively 
[7,8]. Lipids in human milk are high in palmitic and oleic acids [1], and also con-
tain essential fatty acids such as long-chain polyunsaturated fatty acids (LCPUFA), 
which are important components of cell membranes and of cell-signaling pathways, 
and make up a large proportion of brain tissue. The highest variability of human 
milk composition is found with regard to the lipid composition, which is dependent 
on a number of maternal factors, such as diet, age, body mass index (BMI), and the 
stage of lactation. In particular, the fatty acid composition of human milk, including 
the proportions of omega-6 and omega-3 fatty acids, reflects maternal diet and fatty 
acid status. The ratio of omega-6 to omega-3 fatty acids in human milk, which has 
been observed to differ between normal weight and obese women, may influence 
the rate and quality of infant adipogenesis [9]. Overall, it is virtually impossible to 
define a “standard” lipid composition of human milk. The quantity of lipid also var-
ies; a range of 10 to 50 g/L in human milk has been reported [10]. Correspondingly, 
this variability in the lipid content of human milk results in variable energy den-
sity, which has been proposed to contribute to infants’ satiety and self-regulation of 
energy intake. Generally, lipids are assumed to provide approximately 50% of the 
energy content of human milk.
The micronutrient content of human milk may also vary by maternal diet and 
nutritional status; this is true especially for water-soluble vitamins, with the excep-
tion of folate. Recent reports suggest that concentrations may vary substantially 
[11]. Concentrations of fat-soluble vitamins also can be affected by maternal intake. 
Vitamin D is generally low in human milk relative to infants’ needs, especially 
for mothers with limited sun exposure [12], for whom prenatal transfer to the fetus 
would likely also have been modest. However, a recent trial of high dose vitamin D 
supplementation to mothers demonstrated its capacity to sufficiently increase the 
level to meet estimated infant needs [13]. In contrast to vitamins, the concentra-
tions of most macro- and trace minerals in human milk are independent of mater-
nal dietary intake; iodine and selenium are exceptions. The concentration of iron is 
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consistently low (0.3–0.5 mg/L), which fosters healthy bacterial colonization of the 
newborn’s intestine, and thus is one of the nonspecific protective factors of human 
milk. In contrast to iron, the zinc content of human milk (~4 mg/L) is initially quite 
high relative to the infant’s requirements, but sharply and steadily declines over the 
early months postpartum; by 6 months, typical concentration is <1.0 mg/L. Calcium 
concentrations follow a similar but less dramatic pattern, with a postpartum decline 
of ~15% from birth to 6 months. Term infants are born with an endowment of iron 
that is typically adequate for the first approximately 6 months of life [14], which 
also coincides with the time when the amount of zinc provided by milk alone also 
becomes marginally adequate [15,16]. These considerations thus impact the timing 
and quality of complementary feeding.
When human milk is not available, an alternative human milk substitute, ideally 
one which is modified specifically for infants, should be recommended [17]. This 
poses an important challenge in low-resource settings, where the expense of com-
mercial infant formulas is typically prohibitive and the availability of clean water is 
often problematic. Unmodified bovine milk is unsuitable for young human infants, 
primarily because of the high protein content, which is 3 times the concentration 
of human milk, as well as the overall high mineral content. These factors result 
in a high renal solute load and can lead to dehydration due to the young infant’s 
limited ability to concentrate the urine. Commercial infant formulas, with a lower 
and modified protein content, are considered a safe alternative when human milk is 
unavailable and if clean water and sanitation can be ensured. Most standard com-
mercial infant formulas are produced with bovine milk concentrates and bovine 
whey protein extracts, and tend to have a higher protein content than human milk. 
Despite higher total protein content, infant formulas still have less than half of the 
α-lactalbumin found in human milk. Efforts are being made to promote a lower 
protein infant formula while increasing α-lactalbumin and certain essential amino 
acids, such as tryptophan, which is rich in human milk. Attention to the impact 
of intact bovine milk protein on atopic disease has increased in recent years, with 
results from randomized trials supporting a lower rate of atopic disease from for-
mulas with partially or extensively hydrolyzed protein [18]. Although bioactive 
components discovered in human milk, including prebiotics (e.g., oligosaccharides), 
are also added to some infant formulas, it is impossible to completely reproduce 
the unique features of human milk (e.g., secretory IgA) or to replicate the enor-
mous public health benefits that derive from breastfeeding. Indeed, the challenge to 
health care providers and policy makers is to actively protect, promote, and support 
breastfeeding in all settings. This includes initiation of nursing within the first 30 to 
60 minutes after birth (the “golden hour”) and exclusive breastfeeding through the 
critical early months of life when enteric colonization is established and influences 
the developing innate immune response.
NUTRITION CONSIDERATIONS FOR OLDER INFANTS 
AND TODDLERS (6–24 MONTHS)
Complementary feeding, the inclusion of other foods and liquids besides human milk 
or infant formula, generally starts around 6 months of age and continues to 24 months 
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of age. This ~18-month interval accounts for a substantial portion of the “1,000 days,” 
and represents a critical window for disease prevention and long-term health. The 
best time to introduce complementary foods to infants is still being debated [19], par-
ticularly in high-resource settings in which concern about ingestion of contaminated 
foods and liquids is low. Very few randomized controlled trials have been conducted 
to specifically address this question, but the importance of context and consider-
ations of risks versus benefits clearly merit discussion. Regardless of the setting, the 
most recent systematic review identified less morbidity from gastrointestinal infec-
tion in infants who were exclusively breastfed for 6 months, compared to those who 
were partially breastfed by 3 to 4 months [19]. No deficits in growth or effects on 
risk of allergy development were identified with 6 months of exclusive breastfeeding. 
The review also found that, in low-resource settings, where newborn iron stores may 
be low, exclusive breastfeeding for 6 months (without iron supplementation) may be 
associated with compromised hematologic status [20]. Data for the optimal timing 
of initiating complementary feeding in infants who are exclusively formula-fed are 
even more limited, but generally suggest no difference in growth or micronutrient 
status when comparing introduction of complementary foods at 3 to 4 months versus 
6 months. Exclusive breastfeeding without complementary foods beyond 6 months 
increases the risk of micronutrient deficiencies (especially iron and zinc) and of 
atopic disease. Complementary foods are generally introduced gradually to accom-
modate the infant’s oral-motor skill development and acceptance of new flavors and 
food consistencies. However, the evidence base for strict adherence to a prescribed 
order of food introduction is limited, since the gastrointestinal tract is considered to 
be essentially mature by approximately 5 months of age.
Breastfed and formula-fed infants have different dependence on complementary 
foods to meet nutrient needs. The most notable difference is for micronutrients, due 
to the generous fortification levels in all standard infant formulas, which result in a 
minimal risk of micronutrient deficiencies and make the choice of specific comple-
mentary foods less critical. In contrast, exclusively breastfed infants will need either 
to consume iron- and zinc-rich complementary foods (e.g., meats or fortified foods) 
or to receive supplements to supply these two micronutrients. Without additional 
iron intake starting at approximately 6 months, the risk for iron deficiency progres-
sively increases. Iron deficiency is the most common nutritional deficiency in breast-
fed infants [21]. Zinc deficiency is also very common in older infants and toddlers. 
Many traditional complementary foods are low in both iron and zinc, as described 
later, and bioavailability from cereal-based foods is limited. Additionally, in low-
resource settings, other factors, such as chronic inflammation and environmental 
enteric dysfunction, may interfere with iron absorption due to the stimulation of 
hepcidin, which blocks the release of iron from the basal surface of the enterocyte 
into the circulation. Similarly, zinc absorption may also be impaired in older infants 
who bear a high inflammatory burden [16].
The order of complementary food introduction in Western settings is often not 
specified but, traditionally, the order is fortified cereal, fruits, vegetables, and meats. 
The recommendation for iron-fortified infant cereal as the first food recognizes the 
need for iron. However, absorption from the iron fortificant in the cereal is quite low; 
furthermore, many infant cereals are not routinely fortified with zinc. On the other 
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hand, animal-flesh sources of complementary foods are generally considered good 
sources of both iron and zinc with a more favorable bioavailability. From an evolu-
tionary perspective, red meat (premasticated) and other animal source foods may 
have been more readily available to infants as complementary foods when humans 
relied on hunting and fishing as their primary means of getting food, and before the 
agricultural revolution. This dietary pattern, an early reliance on inclusion of animal 
 source foods, is most consistent with the nutrients in human milk that become limit-
ing for the older infant and toddler. In contrast, the modern day complementary diet 
is largely cereal based; not only does this generally provide lower concentrations 
of iron and zinc, but it also means that such foods also contain many inhibitors of 
absorption, such as phytates and polyphenols [22].
Consumption of meat also increases protein intake, for which caution has been 
raised with regard to potential accelerated weight gain and risk of obesity later in 
life. As discussed later, high protein intake from infant formula and dairy foods has 
been associated with early rapid weight and fat gain during infancy, and with higher 
BMI at school age [23–25]. Consumption of meat, on the other hand, may not have 
the same weight-gain-accelerating effect in infants and young children, possibly 
because of the different amino acid profile between meat and dairy protein, although 
research is limited. Some current guidelines for complementary feeding do not rec-
ommend against the use of meats as early complementary foods, but there is often no 
emphasis on introducing them as an important source of protein and micronutrients, 
especially for breastfed infants. The World Health Organization (WHO) has been 
more explicit about this, particularly in low-resource settings, where fortified com-
plementary foods are often not available: “Meat, poultry, fish or eggs should be eaten 
daily, or as often as possible” [26]. The new recommendations for complementary 
feeding by the European Society for Paediatric Gastroenterology, Hepatology, and 
Nutrition (ESPGHAN) Committee on Nutrition also emphasized the importance of 
red meat, especially between 6 and 12 months, primarily due to its high iron and 
zinc content [19].
With regard to promoting positive feeding behaviors in older infants and toddlers, 
“responsive feeding” is recommended. Caregivers are encouraged to follow infant 
cues of hunger and satiety, rather than being overly prescriptive in urging the infant 
to consume “expected” volumes, which can result in either the infant’s resistance to 
eating or excessive intakes. Both restrictive and permissive feeding styles can lead 
to poor regulation of energy intake and result in overconsumption of energy [27], 
which increases the risk of being overweight. Breastfed infants have also been found 
to have better satiety regulation than formula-fed infants, and formula-fed infants 
tend to consume more energy in general [28]. In a study of cereal versus meat-based 
complementary feeding for 9- to 10-month-old breastfed infants, strikingly different 
macronutrient distributions and total energy intakes from complementary foods in 
the two groups resulted in the adjustment of breast milk intake accordingly, and vir-
tually identical total daily energy intake [29]. When introducing new foods to infants, 
initial refusal of new foods is common. Studies have demonstrated that repeated 
exposure improves the acceptance of new foods in infants, including pureed meats 
[30]. Offering a variety of healthy foods is also important to provide adequate nutri-
tion and build a healthy eating pattern. Breastfed infants have been shown to be more 
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likely to accept a new food than formula-fed infants [31], possibly due to exposure to 
a greater variety of flavors via human milk, which may increase the acceptance of 
foods with similar flavors during the complementary feeding period [32].
CONTEMPORARY HEALTH ISSUES RELATED 
TO COMPLEMENTARY FEEDING PRACTICES
The following subsections will address atopic disease and the risk of obesity, health 
problems of great public health significance in resource-rich environments and of 
emerging relevance in settings undergoing the nutrition transition. The last sec-
tion highlights current understanding of the relationship between nutrients, feeding 
choices, and neurodevelopment.
Complementary Feeding and allergy prevention
In Westernized settings, complementary foods have traditionally been introduced 
one food and one food group at a time with the rationale that allergies/intolerance 
can be more readily identified. The evidence base for this practice is limited, how-
ever, and the pattern is not generally followed in low-resource settings, where fam-
ily foods are typically offered to older infants. Food allergy occurs in up to 12% of 
American children and adults, and rates have been steadily increasing over the last 
two decades.
Infants are at the highest risk of developing food allergies, due in part to immature 
gastrointestinal function and the developing immune system, as well as to genetic 
predisposition. Contrary to past recommendations to delay introduction of allergenic 
foods such as peanuts and eggs, infants at risk of developing food allergies should not 
delay the consumption of such foods. The American Academy of Allergy, Asthma 
& Immunology recommends introducing highly allergenic complementary foods 
between 4 and 6 months of age once a few typical foods have been fed and tolerated. 
Emerging evidence suggests that delaying the introduction of allergenic foods may 
actually increase the risk of allergic reactions [18]. For example, the “Learning Early 
About Peanut” allergy (LEAP) study found that infants with a high risk of peanut 
allergies consuming a peanut-butter mush between 4 and 11 months of age were 80% 
less likely to develop a peanut allergy by age 5, compared with high-risk infants who 
were not exposed to peanuts early in life [33].
obesity risk and protein intake
Young children who are obese have a higher likelihood of becoming obese adults 
[34]. Evidence-based consensus holds that the first 2 years of life are critical in 
obesity “programming,” and that obesity prevention should be implemented early 
in life [35]. Given the current childhood obesity rates in the United States and 
other Westernized settings [36], a better understanding of potentially modifiable risk 
factors underpinning excessive weight and adiposity gain early in life is urgently 
needed. Multiple observational studies [37–39] have reported greater weight gain in 
 formula-fed infants compared with breastfed infants. As described earlier, standard 
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bovine-milk-based formula has a higher protein content than human milk and the 
difference in protein intakes has been considered a key contributor to the greater 
weight gain in formula-fed infants. This speculation has been strongly supported by 
a large-scale randomized controlled trial [23] by the European Childhood Obesity 
Group to examine how protein quantity relates to infant growth, using isocaloric 
infant formula with high- or low-protein content from birth to 24 months. The results 
showed that linear growth (length-for-age z-scores, LAZ) did not differ between 
groups during the intervention, whereas the weight-for-length z-scores (WLZ) of 
infants in the high-protein formula group were on average 0.20-z higher than those 
of the low-protein formula group at 24 months. The high-protein formula group also 
had a higher adiposity at 24 months [24]. Overall, the current literature suggests that 
consuming more protein, particularly dairy protein, increases WLZ and adiposity 
early in life, and may contribute to later obesity development.
The physiologic mechanisms underlying the relation between protein quantity 
and increased obesity risk are not clear. Insulin-like growth factor I (IGF-1) has been 
proposed to be the key mediator [23], since high protein intake is associated with 
high circulating IGF-1. However, findings are inconclusive [29,40]. Another potential 
mechanism may be driven by protein source, for example, through branched chain 
amino acids (BCAA), which tend to be higher in milk-derived protein compared 
to meats. Emerging metabolomics studies report associations of adult obesity and 
insulin resistance with BCAA and their degradation products, short-chain acylcar-
nitines [41]. Another proposed critical variable is the specific amino acid glutamate, 
which is considered a key regulator of appetite and energy intake [42]. Thus, current 
research findings reflect the complexity of interactions between protein intake (both 
quantity and quality), weight gain, adiposity, and later obesity risk.
Although the mechanism is not clear, emerging consensus for infant feeding rec-
ommendations in Westernized settings is to reduce protein intake to no more than 
15% of total energy [19]. A caution regarding such a recommendation is that it does 
not distinguish between sources of protein (e.g., meats versus dairy versus plant-
based sources), or between breastfed and formula-fed infants. This proposed guid-
ance does not necessarily have equal relevance to settings in which breastfeeding 
predominates. As described earlier, meat can be an important dietary component 
to avoid micronutrient deficiencies in breastfed infants, and there is no evidence for 
its contribution to excessive weight gain. However, research that directly compares 
protein sources is limited and an area of active investigation.
neuroCognitive development and early nutrition
Critical brain development occurs during the first 24 months of postnatal life. Brain 
and peripheral nervous tissues are especially sensitive to nutrient inadequacies, and 
suboptimal nutrition during this critical phase may lead to irreversible deficits in 
neurodevelopment. The developing brain clearly demonstrates plasticity, but the 
effects of nutritional insults, and their persistence, depend on the timing, duration, 
and severity of deficiencies and other risk factors. Before complementary foods 
are introduced, human milk is considered the ideal source of nutrition for brain 
development. Multiple studies have demonstrated that breastfed infants have better 
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cognitive function than formula-fed infants, likely due to the difference in nutrient 
composition between human milk and infant formula, and the potentially greater 
mother–infant interactions with breastfeeding [43]. For the older infant, many of the 
micronutrients that are critical for brain development are found primarily, or in some 
cases exclusively, in animal source foods, especially flesh foods. Key nutrients to be 
discussed in this section in relation to brain development include LCPUFA, iron, 
zinc, iodine, choline, and vitamin B12, which are either highly variable or commonly 
present the risk of deficiency.
Sixty percent of brain matter is lipid, including long-chain polyunsaturated fatty 
acids, with docosahexaenoic acid (DHA) and arachidonic acid (AA) being the most 
abundant fatty acids in the brain, the content of which continues to increase in the 
brain from birth to approximately 2 years of age [44]. DHA is essential for neuro-
genesis, as it is a structural component of cell membrane phospholipids, especially 
in the central nervous system [45]. Synthesis of DHA from α-linolenic acid occurs at 
a relatively low rate in young infants, and the primary source of DHA should be the 
diet. DHA content in human milk is dependent on maternal diet and is highly vari-
able. When complementary feeding starts, omega-3-rich seafood, such as salmon, 
is a good source of dietary DHA, but this is not a typical food choice. Studies in 
Westernized settings investigating the effect of adding DHA to infants’ diet on neu-
rodevelopment early in life have not demonstrated a clear benefit in term infants 
[46,47]; stronger positive effects of DHA-enriched formulas have been observed for 
preterm infants. Potential confounding factors include sex, dose, duration, and cog-
nitive assessment methods. One long-term follow-up study found that the benefits of 
LCPUFA may not be evident until 3 to 5 years of age [48].
The three most relevant micronutrient deficiencies to brain development are iron, 
zinc, and iodine. Iron is involved in numerous cellular processes in the brain, includ-
ing myelination, and also serves as a cofactor for serotonin and catecholamines bio-
synthesis. As discussed earlier, human milk is uniformly low in iron and infants rely 
on prenatal iron stores, the transfer of the erythrocytes from delayed cord clamping at 
birth, and iron-rich complementary foods or supplementation. Despite the fortification 
of infant and many toddler foods in the United States, a significant number of chil-
dren still develop iron deficiency or iron deficiency anemia, partially because of poor 
absorption from iron-fortified foods [49]. Multiple observational studies comparing 
infants and toddlers with and without iron deficiency have shown that iron deficiency, 
even without anemia, is associated with significantly lower scores of mental develop-
ment, such as information processing and social-emotional development, in otherwise 
healthy term infants [50]. These impacts can be long term. A 19-year follow-up of 
term infants with iron deficiency in late infancy showed persisting motor differences, 
more grade repetition, anxiety/depression, social problems, and inattention in ado-
lescence [51]. These adverse effects can be prevented if iron is supplemented before 
iron deficiency becomes severe or chronic [52]. Maternal diabetes and obesity are 
associated with low iron status in the offspring, and may be an important contributor 
to development of iron deficiency in Westernized settings where diabetes and obesity 
rates are high. In low-resource settings, chronic inflammation likely stimulates hep-
cidin, an anti-inflammatory hormone that inhibits iron absorption. Zinc is essential 
for neurogenesis, neuronal migration, and synaptogenesis, and plays an important 
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role in neurotransmission and subsequent neuropsychological behavior. Zinc defi-
ciency early in life may result in poorer learning, memory, and attention. After about 
6 months of age, infant and toddler reliance on zinc-rich complementary foods to 
meet their relatively high needs places them at risk of developing at least mild zinc 
deficiency, particularly in settings where the zinc in foods may be poorly absorbed. 
Controlled trials of zinc supplementation on developmental outcomes, however, have 
had more mixed results. The role of iodine in brain development is through thyroid 
hormone synthesis. Iodine is routinely added to salt and widely available in both high- 
and low-resource settings; thus, iodine deficiency is not as common as iron and zinc 
deficiencies. However, iodine is one of the nutrients in human milk that reflects mater-
nal status. Low iodine concentrations in human milk have been observed in regions 
with a high prevalence of goiter, and prevalence of cretinism has been reported in 5% 
to 15% of breastfed infants in such regions.
Choline is also considered a critical nutrient for brain and neurodevelopment. 
Choline is the precursor of the neurotransmitter acetylcholine and is also the major 
source of methyl groups in the diet. Human milk is rich in choline, and infant formu-
las are also typically fortified with choline. Animal source foods, such as liver and 
eggs, are excellent sources of dietary choline. Choline deficiencies are not common 
in infants and young children with a balanced diet, but the prevalence of deficiency 
is unknown in low-resource settings where access to animal source foods is limited.
Vitamin B12 is an enzyme cofactor in the formation of myelination. Deficiency 
of B12 can cause brain myelination impairment and affect neural development in 
infants. Because the vitamin B12 content in breast milk is substantially affected by 
maternal status, B12 deficiency can be caused by maternal lack of animal source 
foods intake, including meat and dairy. In addition, infants born to vegan mothers or 
mothers who have limited access to animal source foods are at risk for inadequate 
B12 stores at birth [11].
The human brain is composed of multiple regions, each with unique developmen-
tal processes. The hippocampus, for example, which is critical for special memory 
and navigation, begins its peak growth at approximately 32 weeks gestation and 
growth continues to at least 18 months. However, the frontal cortex, which controls 
complex processing behaviors (e.g., attention), has a much more protracted develop-
mental trajectory. Thus, understanding the timing of the developmental trajectories 
is critical for assessing the impact of nutrient deficiencies. If a certain deficiency 
occurs during the time when the need for that nutrient is high, impairment is more 
likely to occur. The timing in five key neurodevelopmental domains and their rela-
tion with nutrient needs have recently been summarized [53].
CONCLUSION
The biology of the young infant is influenced by fetal exposures, but the post-
natal period exemplifies an additional window of critical programming potential 
with long-term impact. The robust but dynamic composition of human milk pro-
vides nutritional and immunologic advantages to the young infant, while mitigating 
nutritional demands for the mother over time. The macronutrient profile of human 
milk includes a distinctive protein and amino acid composition, which provides 
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immunologic benefits and optimizes growth and brain development; an array of oli-
gosaccharides that modify infectious disease susceptibility; and lipid composition 
that enhances neurodevelopment and may influence the quality of infant weight gain. 
Likewise, the micronutrient composition of human milk is relatively robust and is 
dynamically tailored to meet the infant’s changing nutritional needs through the 
critical early postnatal months. While human milk substitutes continue to be modi-
fied to better align with the beneficial matrix of human milk, many gaps remain.
The importance of high-quality complementary foods for the older infant and 
toddler is evident, as choices have clear impact on the nutritional adequacy of the 
complete diet. Attaining optimal intakes of several critical micronutrients is strongly 
dependent on high-quality complementary foods, which should include animal 
source foods and/or fortified products. Dietary exposures during the complementary 
feeding period, which comprises two-thirds of the 1,000 day window, are likely to 
affect long-term outcomes, including the risk of atopic disease, later obesity and met-
abolic health, and, perhaps most important, optimal neurodevelopment. As under-
standing of these critical biological underpinnings continues to emerge, the need 
for rigorous research as well as targeted programs and policies to support this most 
vulnerable time of the life cycle cannot be overstated.
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THE HORMONES OF LACTATION: ACTIONS 
AND PATTERNS OF SECRETION
Lactation, the physiological condition during which milk is produced for the purpose 
of providing nutrition to the offspring, features numerous anatomical, cellular, physi-
ological, and behavioral adaptations, which affect the central nervous system as well as 
the mammary gland. Traditionally, lactation comprise of the sequential phases of lacto-
genesis I, the onset of milk synthesis without secretion during late pregnancy; lactogen-
esis II, the onset of active milk secretion shortly after parturition; and lactogenesis III 
(galactopoiesis), the maintenance of lactation [1–3]. Milk ejection, or letdown, refers to 
the process by which milk is removed from the mammary gland during lactation by the 
nursing offspring [1,2,4]. All aspects of lactation are influenced by multiple, interacting 
endocrine and paracrine messengers, including ovarian and adrenal steroids and insulin 
[1,2]. However, prolactin (PRL), released from the anterior pituitary gland and critical for 
milk synthesis and secretion, and oxytocin (OT), released from the posterior pituitary 
and required for milk ejection, are arguably the most important hormonal regulators of 
lactation, and their patterns of secretion, physiological actions and neuroendocrine regu-
lation will be the focus of this review. Table 6.1 shows some actions of these and other 
hormones, which are exerted within the mammary gland and important for lactation.
The release of both PRL and OT during lactation is elicited through neuroen-
docrine reflex arcs that are initiated by suckling and, likely, other sensory stimuli 
TABLE 6.1
Actions of Hormones in Lactogenesis
Hormone Effects in Mammary Gland
Estradiol Stimulation of ductal developmenta
Inhibition of milk secretiona
Stimulation of PRL gene expression
Stimulation of OT gene expressiona
Progesterone Stimulation of ductal developmenta
Inhibition of milk secretiona
Stimulation of lactose synthesisa
Inhibition of OT gene expressiona
Cortisol Stimulation of casein gene expression
Stimulation of PRL receptor expression
Prolactin Stimulation of milk proteins gene expression
Stimulation of milk lipid synthetic enzymes gene expression
Stimulation of progestin receptor gene expression
Oxytocin Stimulation of myoepithelial cell contractions
Notes: OT, oxytocin; PRL, prolactin.
a Effects exerted during pregnancy.
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from the offspring, and that engage complex ascending pathways into the neuroendo-
crine hypothalamus. These processes have been investigated in highly sophisticated 
animal models for many years and are the subject of detailed reviews [5–10], yet 
our understanding of these processes remains incomplete. This chapter provides an 
overview of our current knowledge of the mechanisms that mediate these neuro-
endocrine reflexes. Although the vast majority of the experimental data have been 
obtained from studies in animals, it seems highly likely that the regulation of lacta-
tion in humans will follow similar principles.
Actions of ProlActin (Prl)
PRL participates in multiple aspects of lactation, both in the mammary gland and in 
the central nervous system [2,3,9,11]. PRL is secreted from the lactotrophs (or mam-
motrophs) of the anterior pituitary gland, and also from a population that secretes 
both PRL and growth hormone (somatomammotrophs) [8]. The chemistry of PRL 
has been thoroughly reviewed elsewhere [12]. Briefly, native PRL is a protein of 
approximately 23,000 molecular weight, but PRL also circulates in a number of 
isoforms, for example, as phosphorylated or glycosylated monomers, as well as in 
multimeric species, modifications that can influence biological activity [8].
The actions of PRL in the mammary gland to promote lactogenesis have likewise 
been reviewed extensively and are reasonably well understood [1,2,9,12]. The PRL 
receptor is a member of the cytokine superfamily. The binding of PRL occurs in a 
stepwise fashion across two PRL receptor monomers, which then promotes their 
dimerization and initiates signal transduction, mediated predominantly via Janus 
kinase-signal transducer and activator of transcription proteins, which are coupled 
to gene expression [9,12]. Mammary gland genes that are regulated by PRL encode 
most milk proteins, as well as enzymes that are involved in synthesis of other milk 
constituents (e.g., lipids) (Table 6.1). A current concept is that PRL, along with cor-
tisol, supports the onset of lactogenesis II when progesterone, which inhibits milk 
secretion, falls after parturition and also is essential in maintaining lactation [2,3]. 
PRL also gains access to the brain and exerts multiple actions that support lactation, 
such as the initiation of maternal behavior, the stimulation of food intake, and, pos-
sibly, facilitatory effects on OT secretion [11].
Actions of oxytocin (ot)
Although its actions are largely limited to the stimulation of milk ejection, OT, a nine-
amino acid peptide released from the brain, is no less essential for a successful lactation, 
in as much as milk ejections are totally absent in mice bearing a deletion of the OT 
gene [13]. Stimulation of OT receptors increases the contractions of myoepithelial cells 
that are present on the surface of the alveoli and ducts of the mammary gland, with the 
increase in intramammary pressure thereby forcing milk to the nipple [4]. OT receptor 
structure, signal transduction pathways, and effects within the mammary gland to affect 
milk letdown have been authoritatively reviewed by Arrowsmith and Wray [14] and 
Burbach et al. [6]. Acting within the central nervous system as a central neurotransmitter, 
OT is importantly involved in the induction and regulation of maternal behavior [1,15].
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DifferentiAl PAtterns of Prl AnD ot releAse in resPonse to suckling
Animal Studies
Although both PRL and OT are released in a reflexive way by the sensory stimulation 
from the suckling offspring, the patterns of release of these two hormones are quite 
distinct. When female rats are suckled by their offspring after a period of separation 
(the separation–reunion paradigm), plasma concentrations of PRL begin to increase 
almost immediately, reach peak levels by 10 to 15 minutes, and exhibit irregular 
pulses, with peaks and troughs superimposed on the elevated baseline [4,16,17]. In 
contrast, the release of OT from the neurohypophysis may be delayed for a consider-
able period of time in lactating rats [16,18], although this latency is not seen in other 
species, including humans. OT release in response to suckling is pulsatile in all spe-
cies examined, including humans, but in a pattern distinct from that described for 
PRL. Thus, the blood levels of OT during suckling are not elevated from baseline, 
but remain generally low and exhibit intermittent, abrupt increases of release that 
occur at approximately 5 to 10 minute intervals, last only several minutes, and then 
return to baseline [10,17,18]. During each secretory episode, a bolus of OT is deliv-
ered to the mammary gland, resulting in the increase in intramammary pressure and 
milk ejection [4,6,16]. Milk is thus available to the offspring only intermittently as a 
result of this pulsatile pattern of OT release.
Studies in Humans
Although not studied as extensively, the release of PRL and OT in lactating women 
exhibits a number of similarities to common animal models, such as the rat. For 
example, most studies show that PRL levels increase quickly and remain elevated 
throughout the period of suckling in women [1,19–21], and there is evidence of pulsa-
tility as well [20,22]. Of considerable interest, the release of PRL in lactating women 
appears to be specifically linked to the suckling stimulus, as PRL is not increased 
prior to the onset of nursing (e.g., from visual or olfactory cues), or in response to 
tactile, non-suckling stimulation of the breast [1,20,21].
In nursing women, OT release in response to suckling begins quickly and exhib-
its a pulsatile pattern very much like that seen in animal models, that is, transient 
increases of OT release at intervals, followed by a return to baseline [20–23]. An 
important experimental consideration is that blood sampling must be sufficiently fre-
quent in order to detect such pulsatility in women, which may account for the failure 
of some studies, which used more infrequent blood sampling protocols to observe 
OT pulses [1]. In contrast to PRL, OT is often released in lactating women prior to 
suckling and in response to tactile stimulation [19–21].
The neuroendocrine controls over lactation are prepared during pregnancy, par-
ticularly in late pregnancy, under the influence of ovarian hormones [7]. As noted 
in Table 6.1, estradiol and progesterone exert important effects during pregnancy to 
ready the mammary gland anatomically and physiologically, yet both also inhibit 
milk secretion, most likely to conserve the supply until needed following parturition. 
Indeed, the fall in progesterone following delivery of the placenta has been identi-
fied as a key event in the initiation of lactogenesis II in experimental animals and 
humans, with PRL and cortisol exerting stimulatory influences at this time [1–3]. 
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The fall in progesterone is also important for the upregulation of OT gene expression 
in the hypothalamus [7]. Estradiol, in addition to stimulating PRL gene expression 
[8], at the same time inhibits milk production, an effect that also has a clinical impact 
on the choice of contraception during lactation.
NEUROENDOCRINE CONTROL OF PRL AND OT SECRETION
The general consistencies in the patterns of PRL and OT release across animal mod-
els and humans support the view that the neuroendocrine mechanisms identified in 
animal studies are likely to be very similar in humans, so that the wealth of mecha-
nistic data obtained from animal models can likely provide insights into the physi-
ological processes that occur in lactating women. However, it is important to keep in 
mind the obvious caveat that definitive mechanistic studies in lactating women are 
not going to be forthcoming. The next sections review the neural mechanisms that 
mediate suckling-induced PRL and OT release, with descriptions of the separate 
neuroendocrine control systems that regulate each hormone and the mechanisms 
that mediate their release in response to suckling during lactation.
the suckling-ActivAteD Afferent PAthwAy 
to the neuroenDocrine hyPothAlAmus
It has long been a goal of neuroendocrinologists to identify the neural pathways 
activated by suckling, which ultimately generate the distinct patterns of PRL and OT 
secretion described earlier. The following discussion briefly summarizes the results 
of numerous investigations; for more detail, the reader is referred to recent detailed 
summaries of this literature [5–7,10]. Sensory information from mechanoreceptors 
in the mammary glands is conveyed by the mammary nerves into the dorsal horn 
of the spinal cord and ascends ipsilaterally in the spino-cervical tract into the cau-
dal medulla. From this level, most suckling-activated fibers cross the midline, and 
eventually reach the border between the mesencephalon and diencephalon. However, 
along the way, numerous connections are made with neurons in various nuclei of 
the brainstem, which, in turn, also contribute their processes to the ascending sys-
tem. The exact routes taken by the nerve fibers of the afferent pathway from the 
mesencephalic– diencephalic border into the hypothalamic OT and PRL regulatory 
centers are not known with much certainty, at present.
neuroenDocrine regulAtion of Prl secretion in lActAtion
The secretion of protein hormones from the anterior pituitary gland, a true endo-
crine secretory tissue, is governed by the central nervous system, but not through 
direct neural connections. Rather, clusters of neurons in the hypothalamus and basal 
forebrain express chemical messengers, which are released from nerve terminals 
in response to action potentials into the primary capillary plexus in the median 
eminence at the base of the hypothalamus. These hypophysiotropic hormones (also 
known as releasing factors or hormones) travel through the long portal veins into 
the anterior pituitary, and exert either stimulatory or inhibitory effects on specific 
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anterior pituitary cell types. In the case of PRL, inhibitory and excitatory hypophy-
siotropic hormones exist [7,8].
tuberoinfunDibulAr DoPAmine
The predominant mode of hypothalamic regulation over PRL secretion is tonically 
inhibitory and is accomplished by dopamine (DA), in this case acting as a hypophy-
siotropic hormone rather than a neurotransmitter. The hypothalamic DA systems 
that act in this manner have been described extensively ([11,24]; see Figure 4 in 
Freeman et al. [8]). The major DA cell group regulating PRL is located in the arcuate 
nucleus of the medial-basal hypothalamus and is referred to as the tuberoinfundibu-
lar dopamine (TIDA) system. The axons of these cells project to the external zones 
of the median eminence in proximity to the portal capillaries.
The administration of pharmacological agents that inhibit DA synthesis, deplete 
dopamine, or block the D2 subtype of DA receptor, which is the predominant subtype 
present on lactotrophs, rapidly increases PRL secretion in animals; conversely, DA 
receptor agonists, especially those specific to the D2 receptor, decrease PRL release in 
response to physiologic stimuli, including suckling [8]. That the TIDA system exerts 
these effects in humans is strongly supported by abundant evidence that D2 antagonists 
used clinically (e.g., typical and atypical neuroleptics for treatment of psychosis and 
bipolar disorder) routinely elevate PRL, and several, such as metaclopramide and dom-
peridone, have also been investigated for clinical utility as “galactogues,” that is, stimu-
lants of milk production in women experiencing difficulties in breast feeding [1,25–27]. 
Conversely, D2 agonists, such as bromocriptine and cabergoline, are commonly used to 
lower PRL hypersecretion from prolactinomas of the anterior pituitary gland [25,26].
There is strong evidence from animal studies that this tonic inhibitory control 
exerted by DA over the lactotroph is removed as an obligatory step before PRL can 
be secreted in response to physiologic stimuli, including suckling during lactation 
[8,11]. For example, suckling or a suckling-mimetic stimulus, such as mammary 
nerve stimulation, reduces the release of DA from the TIDA system into the por-
tal vasculature, as measured with various experimental techniques, including direct 
measurement of DA in portal blood [7,8,24,28]. Moreover, the evidence indicates 
that such a reduction in DA release itself constitutes a stimulus for an increase in 
PRL secretion; this has been demonstrated not only by the previously mentioned 
pharmacological studies with DA antagonists, but also in in vitro preparations, for 
example, in cultured anterior pituitary cell preparations, in which an increase in PRL 
release is observed following the removal of DA after a period of exposure [28].
thyrotroPin-releAsing hormone
PRL secretion in response to suckling also requires a stimulatory hypophysiotropic 
influence, and the tripeptide thyrotropin-releasing hormone (TRH), which also stimu-
lates thyroid-stimulating hormone, appears to fulfill this role, at least in some species. 
TRH-immunopositive neurons are found in several hypothalamic regions, most nota-
bly in the parvicellular (small cell) regions of the paraventricular nucleus of the hypo-
thalamus [29]. TRH is highly effective in physiological concentrations in stimulating 
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PRL secretion from anterior pituitary cells and PRL-secreting pituitary tumor cell 
lines [8]. Administration of TRH to lactating women also results in an increase of 
PRL secretion [1,30], strongly suggestive of a physiological role of this peptide in 
humans. Further, the suckling-mimetic stimulus of mammary nerve stimulation pro-
duces a significant increase in TRH concentrations in hypophyseal portal blood, and 
inhibition of TRH action via immunoneutralization prevents suckling-induced PRL 
release in rats [7,8]. Moreover, DA withdrawal, as described earlier during suckling, 
enhances the ability of TRH to stimulate PRL secretion [4,28]. Hence, our current 
concept is that suckling activates a dynamic interplay of hypophysiotropic regulation 
that involves DA withdrawal from and TRH stimulation of the lactotroph as the criti-
cal hypophysiotropic mechanism governing PRL secretion in response to suckling.
“uPstreAm” regulAtion over ProlActin: centrAl neurotrAnsmitters
This dual hypophysiotropic control represents the final output of the central ner-
vous system in mediating suckling-induced PRL release, but what neural systems 
are activated by suckling, connect with these neuroendocrine systems, and effect the 
withdrawal of DA and activation of TRH release? Pharmacological approaches have 
provided evidence in animals and humans that strongly suggests important stimula-
tory actions of serotonin (5-hydroxytryptamine, or 5-HT) and opioid peptides.
Pharmacological studies indicate a generally excitatory action of 5-HT on PRL secre-
tion in different physiological conditions [8,31], an effect also observed in humans [32]. 
Pharmacological disruption of serotonergic transmission inhibits suckling-induced PRL 
release in animals, implying an obligatory role for this system [7,31]. Serotonin neurons 
originating in the midbrain innervate the hypothalamic nuclei containing the TIDA sys-
tem and TRH neurons, and these serotonergic cells are likely activated by the suckling 
stimulus as a component of the suckling-activated ascending pathway [7,31]. Moreover, 
evidence suggests that, when activated, the serotonin system concomitantly inhibits 
TIDA activity and stimulates TRH neurons [7,8,31], thereby setting in motion the critical 
hypophysiotropic mechanism for suckling-induced PRL release discussed earlier.
Opioid drugs, such as morphine, and the endogenous peptides, ß-endorphin, the 
enkephalins, and the dynorphins, the receptors of which are stimulated by opioid 
drugs, also stimulate PRL secretion in animals and humans [1,7,8,31,33]. Suggesting 
an obligatory role of opioid peptides during lactation, administration of the opioid 
receptor antagonist naloxone can inhibit suckling-induced PRL release in rats [31,34]. 
On the other hand, naloxone treatment failed to inhibit PRL release in lactating women 
evoked by stimulation of the nipples by breast pump [35], so that an obligatory role 
in the mechanism of suckling-induced PRL release in humans is much less certain.
Interactions of opioids with the TIDA system have been addressed in many ani-
mal studies and, as might be expected, opioid peptides and agonists decrease TIDA 
neuronal activity, thereby diminishing DA release [34]. An opioid–serotonin interac-
tion also seems plausible, and it seems reasonable to propose that one or more endog-
enous opioid systems contribute to the physiological process of suckling-induced 
PRL release via (1) suppression of the TIDA inhibitory system, and (2) enhancement 
of excitatory serotonergic activity [7,31]. Figure 6.1 presents an overall mechanism 
for suckling-induced PRL secretion that incorporates these mechanisms.
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neuroenDocrine regulAtion of ot secretion in lActAtion
The major focus of investigations on OT secretion during lactation has been on the 
complex neurophysiological mechanisms responsible for generating the episodic, 
pulsatile pattern of OT release described earlier, a pattern which occurs only dur-
ing lactation and parturition, and not in response to other physiological stimuli, 
and which is also different from that seen with PRL (see earlier). Because OT 
release results from OT neuronal activity, it is critical to understand the process 
by which OT neurons largely remain at baseline levels of activity, despite the con-
tinual presence of the suckling stimulus, but are interrupted at varying intervals 
by a dramatic increase in neuronal activity that lasts only a few seconds, resulting 
in a brief pulse of OT release into the systemic vasculature, followed by a return 
to baseline. Out of necessity, these investigations have been performed in animal mod-


















FIGURE 6.1 Basic mechanisms of suckling-induced prolactin secretion during lactation. 
Serotonin (5-HT) neurons in the mesencephalon are activated by the suckling stimulus and 
reduce the tonic inhibitory influence over PRL secretion exerted by the hypophysiotropic tuber-
oinfundibular dopamine (TIDA) system present in the arcuate nucleus of the hypothalamus 
(ARC), likely through a link with endogenous opioid peptides (EOP). Concomitantly, the 5-HT 
system activates the release of the stimulatory hypophysiotropic hormone thyrotropin- releasing 
hormone (TRH) neurons present in the hypothalamic paraventricular nucleus (PVN). AP, ante-
rior pituitary; DHsc, dorsal horn of the spinal cord; ME, median eminence.
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AnAtomy of the ot neuroenDocrine system
The neuroanatomical organization of the OT neuroendocrine system is well estab-
lished ([5]; see also Figure 3 in Armstrong [36] and Figure 5 in Crowley and Armstrong 
[18]). Briefly, OT is synthesized by large (magnocellular) neurons in the hypotha-
lamic paraventricular (PVN) and supraoptic (SON) nuclei, and in several nearby 
“accessory” clusters of neurons, and is transported in vesicles down the axons that 
project into the neurohypophysis, in reality an outgrowth of the brain rather than a 
true endocrine organ. OT is released into the circulation via the classic process of 
calcium-dependent neuronal exocytosis, in response to invasion of the nerve termi-
nals by action potentials that are generated in the cell bodies [10].
the milk ejection reflex: neuronAl mechAnisms
Underlying the episodic pattern of systemic OT release is the intermittent burst-
ing behavior of magnocellular OT neurons in response to suckling (“milk ejection 
bursts”), which has been extensively studied in sophisticated electrophysiological 
experiments in lactating animals [5,6,10,37]. As observed in the separation–reunion 
paradigm in rats, the onset of suckling typically does not immediately change the 
irregular, baseline pattern of OT neuronal firing. However, after a variable latent 
period, and approximately 15 to 20 seconds before each milk ejection, a brief and 
explosive increase in the firing rate of the OT neurons occurs, lasting 2 to 4 seconds, 
followed by a short period of inhibition and then a return to irregular baseline activ-
ity (see Figure 1 in Crowley and Armstrong [18] and Figure 8 in Wakerley [10]). 
These milk ejection bursts recur at intervals of 5 to 10 minutes throughout the period 
of suckling. Further, during these events, it appears that virtually the entire mag-
nocellular OT population on both sides of the brain fires bursts of action potentials 
in a coordinated manner in order to deliver each bolus pulse of OT to the systemic 
circulation and from there to the mammary gland [10,37]. Given the similar pattern 
of pulsatile OT secretion in lactating women, there is every reason to believe that this 
milk ejection burst mechanism also occurs in humans.
However, the mechanisms by which (1) the continuous suckling stimulus gener-
ates intermittent bursting behavior of magnocellular OT neurons, and (2) this burst-
ing activity becomes coordinated and synchronized across the entire population in 
diverse hypothalamic nuclei both remain to be determined. A common view is that 
suckling initially activates mechanisms that promote local excitatory interactions 
among OT neurons within each PVN and SON, progressively leading to more coor-
dination among these cells in their firing patterns. As increasing numbers of OT 
neurons are recruited into this coordinated firing, eventually the entire population 
explodes with a burst of action potentials that last for a few seconds, followed by 
a brief period of inhibition, before the process begins anew [5,7,10]. However, to 
accomplish this, there must not only be excitatory interactions among OT neurons 
within a nucleus, but also intercommunications between the multiple neurosecretory 
nuclei to mediate activation of the entire population. Some of the mechanisms that 
may participate in this complex process are discussed next, and the reader is referred 
to several recent, more detailed reviews [5–7,10].
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NEUROTRANSMITTERS: GLUTAMATE, NOREPINEPHRINE, 
AND γ-AMINOBUTYRIC ACID
Multidisciplinary studies indicate that glutamate (Glu) and norepinephrine (NE) are 
critical excitatory neurotransmitters for suckling-induced OT release [7]. OT neurons 
receive a dense innervation from local glutamatergic neurons adjacent to the magno-
cellular nuclei [38] and from noradrenergic neurons in the lower brainstem [18]; both 
systems are components of the suckling-activated ascending afferent pathway [7,18]. 
Agonists at the AMPA receptor for Glu and α-1 receptor for NE stimulate OT release, 
while antagonists at these respective receptors inhibit suckling-induced OT release 
[39–41], thus providing strong evidence that these systems are critically involved in 
the neural mechanism mediating the suckling-induced OT neuroendocrine reflex. 
Further, intrahypothalamic Glu systems appear to be particularly important in gener-
ating the burst-type of firing pattern in OT neurons during lactation [38]. On the other 
hand, γ-aminobutyric acid (GABA), also released from local hypothalamic neurons 
near the magnocellular nuclei, inhibits OT neuronal firing, and has been proposed to 
be important in shaping the burst pattern of OT neuronal activity [42].
intrAnucleAr releAse of ot
An important neurochemical signal for the generation of the milk ejection burst in OT 
neurons involves an action of OT itself. In addition to being released into the systemic 
circulation, OT is also released within the magnocellular nuclei, mainly from dendrites, 
in response to suckling, and such “intranuclear release” is critical in promoting the milk 
ejection bursts of neuronal firing [5,7,10,43,44]. For example, OT activates OT neurons 
but, more specifically, increases the frequency and amplitude of milk ejection bursts 
in response to suckling [45]; further, because central administration of an OT receptor 
antagonist inhibits both intranuclear and systemic OT release, it is proposed that OT acts 
in a positive feedback manner to increase its own intranuclear release, which, in turn, 
ultimately leads to the milk ejection burst and release into the systemic circulation [44].
These and other experiments have led to the hypothesis [5,10,43] that, prior to the 
onset of milk ejection bursts, suckling may initially stimulate the release of OT within 
the magnocellular nuclei, most likely in response to NE and Glu [7,39]. As suckling 
continues, the intranuclear release of OT progressively increases and, acting on OT 
receptors on the same neuron and/or on adjacent OT neurons, intranuclear OT exerts 
multiple neurochemical effects that progressively excite and coordinate the firing of OT 
neurons, until the entire population unites in firing the brief milk ejection burst [5,43].
synchronizAtion mechAnisms
Whereas local mechanisms such as those described earlier can account for the coor-
dinated activation of OT neurons within a single PVN or SON (i.e., intranuclear 
synchronization), how can we explain the synchronized activation of the entire 
OT neurosecretory population during the milk ejection burst, involving OT neu-
rons residing in multiple nuclei and on both sides of the brain (internuclear syn-
chronization)? This question cannot be answered definitively at present, but there is 
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anatomical and electrophysiological evidence for local interconnections between, for 
example, the PVN and SON [38], which could propagate excitation from one magno-
cellular nucleus to the other ipsilaterally. In addition, interconnections exist between 
the two SONs and between the two PVNs [5,7], which could account for the contra-
lateral spread of excitation. It may also be the case that these local interconnections 
among the magnocellular nuclei could relay synchronizing signals that originate in 
more distal structures. For example, investigators have identified neurons in the ven-
tromedial medulla that are activated by suckling and that project bilaterally to both 
the PVN and SON [46]. Other regions put forth as synchronization “centers” include 
the mammillary bodies [47]. Figure 6.2 presents a mechanism for suckling-induced 














PVN (OT) SON (OT)
FIGURE 6.2 Basic mechanisms of suckling-induced oxytocin secretion during lactation. 
Ascending systems from the brainstem activated by suckling include noradrenergic neurons 
(NE), which stimulate activity of OT neurons in the paraventricular (PVN) and supraoptic 
(SON) nuclei of the hypothalamus. Intrahypothalamic glutamate (Glu) and γ-aminobutyric 
acid (GABA) neurons also provide important excitatory and inhibitory inputs, respectively, 
and OT released within the magnocellular nuclei exerts critical facilitatory actions on OT 
neuronal firing and coordination of firing. Arrows represent local and extrinsic mechanisms 
for synchronization of the entire OT population to produce a brief milk ejection burst of fir-
ing. Withdrawal of glial elements may also promote an excitatory neurochemical microenvi-
ronment. DHsc, dorsal horn of the spinal cord; OT, oxytocin.
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gliAl PlAsticity in the mAgnocellulAr nuclei AnD neurohyPoPhysis
An additional mechanism that may facilitate the milk ejection burst involves a remod-
eling of the anatomical relationships between astroglial cells and OT neurons in the 
magnocellular nuclei [5,48,49]. To summarize this work briefly, during lactation, and 
dependent upon the continual presence of the suckling stimulus, astroglial processes 
surround magnocellular OT neurons retract, thereby permitting close somatic apposi-
tions between OT neurons, and also increasing the incidence of “double synapses” 
(i.e., presynaptic nerve terminals that contact multiple OT neurons postsynaptically). 
Interestingly, many of these double synapses are glutamatergic and noradrenergic 
[49], which provide the major excitatory drives to OT neurons in response to suckling 
(see earlier). Intranuclear release of OT may also promote this plasticity in the glial-
neuronal interactions in the magnocellular nuclei [49]. While the precise mechanisms 
and physiological significance of these morphological changes remain to be conclu-
sively determined, it is attractive to hypothesize that they could enhance the actions 
of excitatory neurotransmitters to create a stimulatory neurochemical microenviron-
ment affecting multiple OT neurons, which might then facilitate coordinated activity 
among OT neurons within each magnocellular nucleus. OT-containing nerve termi-
nals in the neurohypophysis are also enclosed by glial cells, which separate them from 
the capillaries; these glia are also withdrawn from the neurosecretory endings during 
parturition and lactation, increasing access of released OT to the capillaries [50].
ENDOCRINE DYSFUNCTION AND LACTATION
Although detailed information on pathophysiologic mechanisms is generally not 
available, lactation may be compromised or complicated in women with endo-
crine disease, perhaps as a result of disruptions in intermediary metabolism, and 
the supply of nutrients to the mammary gland [1]. For example, both hypo- and 
hyperthyroidism can impair lactation, as can all forms of diabetes mellitus. On the 
other hand, there is suggestive evidence in humans that the metabolic adaptations 
of lactation can lower insulin requirements and even serve a metabolically “protec-
tive” function in women with diabetes mellitus [1]. Polycystic ovarian syndrome, a 
complex, poorly understood neuroendocrine disorder, also complicates pregnancy 
and lactation, perhaps via alterations in steroid receptor function [1]. As previously 
noted, both estradiol and progesterone can inhibit milk production, which is likely 
to be important during pregnancy, but can have clinical significance in the context 
of choice of contraceptives during lactation. Generally, combined oral contracep-
tives have been avoided from concerns over the estrogenic component, in favor of 
progestin-only contraceptives, which are usually initiated only after lactation has 
been established to avoid any inhibition by progestin.
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7 Thyroid Function 
and Growth
The Mechanisms of Iodine
Jessica Farebrother and Fabian Rohner
CONSEQUENCES OF SUBOPTIMAL IODINE STATUS 
DURING THE FIRST 1,000 DAYS
Iodine deficiency used to be highly prevalent in many parts of the world until salt 
iodization programs and other prevention strategies were implemented and scaled 
up, beginning in the 1980s in most countries [1]. Great progress toward reducing 
iodine deficiency and its consequences has been achieved since; however, large num-
bers of people continue to be affected [2,3].
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In particular, the fetus and the neonate are important at-risk groups, both with 
regard to physiological needs and supply from the mother, and because of the pro-
found negative effects that iodine deficiency can have during perinatal development 
[4,5]. During pregnancy and lactation, maternal iodine requirements are increased 
to supply the fetus, neonate, and, later, infant, and iodine stores (if available at the 
onset of pregnancy) can become rapidly depleted if the pregnant or lactating woman 
does not consume sufficient dietary iodine [6–9]. Iodine requirements during these 
life stages are thus higher than for the general population.
Figure 7.1 summarizes the consequences of iodine deficiency during the first 
1,000 days, along with a judgment of the quality of evidence for each effect and each 
early life stage. All effects presented are child-related and do not include adverse 
effects on pregnant or lactating women. Upward arrows indicate an improvement of 
the situation. For example, an upward arrow indicates less child cretinism if iodine 
is provided during pregnancy. These effects are usually stronger when intervening in 
populations that are severely iodine deficient, but, to some extent, they also apply in 
situations of moderate deficiency.
In summary, there is strong evidence as to the negative consequences of suboptimal 
iodine status during the first 1,000 days, such as reduced cognition, cretinism, and 
lower birth weight, as outlined in several recent reviews. Whereas Bougma et al. [10] 
concluded that iodine deficiency has an important association with the mental devel-
opment in children under 5 years, Zimmermann [11] concluded that iodine supple-
mentation at varying levels before or during early pregnancy among women living in 
moderate to severely iodine-deficient areas eliminates cretinism, increases cognitive 
development in young children, increases birth weight, and reduces infant mortality. 
Life Stage of Intervention





















FIGURE 7.1 The effect of iodine interventions on known consequences of iodine deficiency 
during the 1,000 day window, by outcome and quality of evidence. Quality of evidence 
rating criteria: insufficient literature, only individual studies that are somewhat unclear or 
conflicting; low, small number of studies, but mostly consistent findings; medium, existing 
meta-analyses or systematic reviews, but somewhat conflicting findings; high, existing meta-
analyses or systematic reviews, with mostly consistent findings. Outcomes reported for cre-
tinism [10], cognition [10–12], birth weight [10,12], growth [13], perinatal and infant mortality 
[10], and abortion/stillbirth [14]. NA, not applicable (intervention–outcome combination not 
applicable for this life stage). 1Graded medium level despite only a few studies available. 
Studies showed consistent and clear improvements and thus, for ethical reasons, intervention 
studies to further corroborate findings are no longer feasible. 2Iodine supplements were given 
to neonate directly, not via maternal breast milk.
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Similarly, Gunnarsdottir and Dahl [12] suggest that an improved prenatal iodine sta-
tus is associated with improvements in cognitive function for infants and toddlers to 
18 months. In contrast, there is little evidence on the effect of iodine status, or iodine 
supplementation or fortification on infant and child growth outcomes [13]. However, 
as seen in the reviews discussed above, in the case of iodine there are clear positive 
effects of correcting iodine status on infant morbidities, likely due to the underlying 
mechanisms of action of iodine in the body. Iodine plays an essential role in the syn-
thesis of thyroid hormones; these hormones are required for many metabolic reactions 
essential to growth and development such as protein synthesis, and bone turnover and 
regulation, which will be discussed in more detail later in the chapter.
Given the paucity of available evidence about the effect of iodine deficiency on 
growth as an outcome measure, the objective of this chapter is to elucidate the under-
lying mechanisms linking iodine nutrition to growth during the life stages of the first 
1,000 days.
IODINE METABOLISM AND THE THYROID HORMONES
The only known function of iodine in the human body is in the synthesis of thyroid 
hormones, of which it is a key component. This makes iodine an essential nutri-
ent. The thyroid hormones T4 and T3 are hereafter collectively referred to as “thy-
roid hormones” (TH). The functions of TH in the human body are many-fold; those 
directly involved with somatic growth and development are discussed later in the 
section “Iodine Metabolism and Thyroid Hormones during the First 1,000 Days.”
The thyroid prohormone 3,5,3′,5′-L-tetraiodothyronine (thyroxine, T4) and its 
biologically active counterpart 3,5,3′-L-triiodothyronine (T3) are small, biphenolic 
compounds produced by the thyroid gland in a process that is rate-limited by iodine 
availability. Very little T3 is secreted by the thyroid gland itself, as T3 is principally 
formed in the peripheral tissues by the deiodination of circulating T4 [15]. Iodine 
comprises 65% and 59% of T4 and T3, respectively [16]. They are structurally iden-
tical, with the exception of one less iodine at the 5′ position on the outer ring of T3.
Figure 7.2 provides a visual overview of the following sections of this chapter and 
will be referred to frequently.
IodIne Uptake from the GUt
After ingestion, iodine uptake into the bloodstream is facilitated by the sodium/iodine 
(Na/I) symporter (NIS), found on the apical surface of enterocytes in the stomach and 
duodenum [17], as shown in Figure 7.2. Uptake is autoregulated; with increasing con-
centrations of iodine in the gut, a regulatory mechanism is initiated that downregu-
lates the genetic expression and, thus, production and activity of the NIS [17]. Iodine 
circulates in the blood in three forms: (1) inorganic iodide; (2) as TH bound to carrier 
proteins; and (3) to a very small extent, as part of free TH [15]. Thyroid hormones 
are released by the thyroid gland, which is a highly vascularized organ with a unique 
structure of thyroid cells surrounding a colloid. The main constituent of the colloid is 
thyroglobulin (Tg), a thyroid-specific, large molecular weight glycoprotein that pro-
vides the structure for thyroid hormone synthesis and iodine storage [5].













































FIGURE 7.2 Overview of the role of iodine and its role in the human body, with a particular 
focus on the first 1,000 days. Iodine taken up via the stomach/duodenum is used for the produc-
tion of TH by the thyroid gland. TH are secreted into the blood circulation, where they join 
free circulating iodine. TH act on almost all cells and tissues in the body to influence cellular 
metabolism and growth mechanisms as described later in the chapter. They do this in conjunc-
tion with GH and IGFs, which promote growth and cell survival for almost every cell in the 
body. During pregnancy, TH and free circulating iodine move from the maternal circulation 
through the placenta to the fetus where they promote growth and development, in particular 
an accelerated myelination of nerves in the brain and central nervous system. After birth, free 
circulating iodine, provided by the mother via breast milk, is critical for the continued develop-
ment of neonate and infant. Any superfluous TH and free circulating iodine not removed by 
the placenta or mammary gland are eliminated via the liver or kidney respectively. Some free 
iodine is also lost in sweat. Feedback mechanisms maintain homeostasis in blood hormone levels. 
GH, growth hormone; GHRH, growth hormone releasing hormone; HPT-axis, hypothalamus-
pituitary-thyroid axis; I–, Iodine; IGFs, insulin-like growth factors; NIS, sodium/iodine (Na/I) 
symporter; T3, 3,5,3′-L-triiodothyronine; T4, thyroid pro-hormone 3,5,3′,5′-L-tetraiodothyronine 
(thyroxine); TH, thyroid hormones; TRHs, thyroid-releasing hormones; TSHs, thyroid- stimulating 
hormones. (Reproduced with permission from Sabine Douxchamps.)
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metabolIsm of IodIne: the formatIon 
and CellUlar Uptake of thyroId hormones
Iodine metabolism and TH synthesis are regulated via intricate interactions between 
the hypothalamus, pituitary, and thyroid glands, which together form the hypothalamus-
pituitary-thyroid axis (HPT) (see Figure 7.2).
The synthesis of TH starts in the hypothalamus, where thyrotropin-releasing hor-
mones (TRHs) stimulate both the synthesis and release of thyroid-stimulating hormones 
(TSHs). TSHs have the same α-subunit structure as other glycoprotein hormones syn-
thesized by the pituitary. Its β-subunit provides receptor-binding specificity and binds 
to TSH receptors at the thyroid cell surface. This initiates a cascade of reactions in the 
thyroid, resulting in the synthesis of TH, which are subsequently released into the blood-
stream. Upon release into the circulation, TH are bound noncovalently to carrier proteins, 
mainly to thyroxine-binding globulin (75%) but also albumin (10%) and transthyretin 
(15%) [16,18]. TH are taken up from the blood into target tissues by active transport to a 
concentration of approximately 10 times that of the circulation [15]. Circulating TH exert 
a negative feedback effect to control the release of TSH from the pituitary gland and 
on the activity of the TRH-stimulating neurons in the hypothalamus. In this way, similar 
to the autoregulation of iodine uptake, TH regulate their own synthesis (Figure 7.2).
Once inside the cell, TH bind to a nuclear TH receptor to elicit a response. TH 
receptors are found throughout the body, including the liver, kidney, heart, skeletal 
muscle, brain, pituitary gland, adipose tissue [16], and bone [19], but not in the adult 
brain, spleen, testes, uterus, or thyroid gland itself. Additionally, TH can act via non-
genomic mechanisms [20], or other indirect mechanisms through their influence on 
other endocrine systems such as the growth hormone and insulin-like growth factor 
axis (IGF-axis; see Figure 7.2).
IodIne exCretIon
Circulating inorganic iodide is removed from the bloodstream for excretion by the 
kidney [16]. Renal uptake occurs by passive diffusion and is relatively constant at 
85% to 90% of daily iodine intake under conditions of sufficiency [21]. There is 
no mechanism by which the body can reduce renal excretion to retain iodine [21]. 
Iodine circulating as TH is excreted hepatically through conjugation via sulfotrans-
ferase or glucuronyl-transferase. The conjugates are eliminated in the bile, and the 
iodine is excreted in feces along with any other iodine not absorbed from the gut 
[15,22]. Iodine is also lost in sweat, which may be an important factor to consider 
in hot environments, since these losses can contribute to a depletion of iodine stores 
[23]. This may be particularly pronounced in infants due to the high surface-area-to-
body-mass ratio (see Figure 7.2).
IODINE METABOLISM AND THYROID HORMONES 
DURING THE FIRST 1,000 DAYS
In addition to renal and hepatic iodine excretion, both the placenta and mam-
mary gland remove iodine and TH from the mother for the support of growth and 
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development of the fetus and infant, as shown in Figure 7.2. In particular, the transfer 
of maternal TH is important in the early stages of pregnancy until the fetal thyroid is 
functional and can make use of the transplacental transfer of iodine, which is the only 
source of iodine for the fetus during gestation, for fetal TH production. Similarly, 
during exclusive breastfeeding as recommended by the World Health Organization 
(WHO) until 6 months of age [24], the iodine in breast milk must sustain the needs 
of the infant (Figure 7.2), despite the wide variations in breast milk iodine concentra-
tion corresponding to the mother’s intake [25].
preGnanCy and the fetUs
Pregnancy induces several major changes in thyroid function and iodine metabo-
lism. Maternal requirements are increased in pregnancy due to an increased iodine 
demand, and a higher than usual iodine clearance rate, as described later. The con-
centration of TH in utero regulates fetal growth, development, and viability via a 
number of factors, as discussed later. Formation of the fetal thyroid does not occur 
until about week 12 of gestation, and it is not capable of iodine organification until 
around week 20 [26]. At this point, the fetal thyroid can produce and secrete TH 
under the control of the HPT axis and, although it is fully functional at birth [27], 
during gestation the fetus is reliant on maternal TH and, later in pregnancy, iodine 
from the maternal circulation. At the start of gestation, therefore, maternal T4 crosses 
the placenta in small amounts [27]. To reflect this, in the first trimester maternal T4 
production is increased by about 50% to ensure that the fetus has adequate T4 for 
local deiodination to the active TH, T3, for correct cerebral development [28]. An 
increase in circulating estrogen inhibits the breakdown of thyroid-binding globulin, 
maintaining higher levels of total circulating TH [26,29]. Transiently during preg-
nancy, there is a trend toward a reduction in free circulating TH, which stimulates 
a rise in TSH that in turn stimulates the synthesis of TH to maintain homeostasis in 
levels of unbound TH in the bloodstream [26,30]. Additional iodine is needed for the 
increase in TH synthesis; to compensate for this, iodine uptake and the use of mater-
nal iodine stores are increased. Additionally, human chorionic gonadotropin, which 
shares the same α-subunit as TSHs and is produced in the first days of pregnancy, can 
also bind to TSH receptors on the maternal thyroid cells and stimulate TH synthesis 
[30]. Once the fetal thyroid function is established and is capable of organification of 
iodine from week 20, fetal iodine supply is met entirely from maternal intake [30].
From early pregnancy, there is a 30% to 50% increase in maternal glomerular 
filtration rate and a corresponding increase in renal blood flow, leading to a greater 
loss of iodine that persists until the end of the pregnancy [26,30]. To compensate, 
the thyroid gland increases iodine uptake [31]. In iodine-replete regions, women 
will typically have between 10 and 20 mg of iodine stored in their thyroid gland, 
and if iodine intake remains sufficient during gestation, the increased demands can 
be met [26]. However, if the mother’s own thyroidal iodine stores are depleted at 
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the start of gestation and her intake during pregnancy does not compensate for the 
higher need, then the risks of the effects of iodine deficiency on both mother and 
child are increased [31].
the neonate and the Infant
Though infants are born with a functioning thyroid gland, they have only scant 
iodine stores at birth. The average iodine content of the thyroid gland of a neonate 
is 50 to 100 μg [32], compared to 15 to 20 mg in iodine-sufficient adults [16]. Yet, 
in terms of iodine requirements per kilogram body weight, infants have the highest 
relative requirements for iodine of any life stage group [33]. There are significant 
changes in thyroid physiology and circulating TH concentrations after birth. There 
is a distinctly high turnover of T4 in infants relative to that of adults: Turnover is 
estimated to be about 5 to 6 μg/kg/day for infants under 3 years, compared to 1.5 μg/
kg/day in adults [34].
In the neonate and young infant, excluding infants who receive formula milk 
(which is usually iodized), the main source of external iodine is breast milk. 
Breastfeeding is recommended until 2 years of age [24]. The milk must therefore 
contain adequate levels of iodine to ensure continued growth and development until 
the infant can obtain adequate iodine from food sources and iodized salt. A number 
of factors can influence breast milk iodine concentration: maternal iodine status, 
recent maternal iodine intake, duration of lactation, and maternal fluid intake [35]. 
In iodine-sufficient populations where the mother has had adequate intakes of iodine 
during pregnancy, breast milk iodine concentrations are considered adequate to meet 
the needs of neonates and young infants [29]. The mammary gland is able to con-
centrate iodine at levels 20 to 50 times higher than in plasma [36] due to the upregu-
lated expression of NIS in breast alveoli during lactation [37]. About 20% of iodine 
in breast milk is present as organic iodine, including a small amount of TH, which 
are considered insufficient for neonatal and infant TH requirements, particularly 
because, via oral ingestion, the TH are likely to be destroyed during digestion [38]. 
The remaining 80% of the iodine present in breast milk is in the form of free iodide 
from the maternal bloodstream. This should cover the deficit in iodine requirement, 
provided that the mother’s dietary iodine intake is adequate [29], and in which case, 
breast milk is considered sufficient to fulfill the iodine requirements of the breastfed 
infant.
IodIne reqUIrements dUrInG the fIrst 1,000 days
To reflect the increased nutritional needs to support normal fetal, neonatal, and infant 
growth and development, the daily recommended iodine intakes for pregnant and 
lactating women are increased. The iodine requirements for these groups, women of 
reproductive age, and infants are summarized in Table 7.1 [39,40].
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IODINE, THYROID HORMONES, AND GROWTH 
DURING THE FIRST 1,000 DAYS
An adequate and continued supply of iodine is needed throughout life for the synthe-
sis of TH, yet, as outlined earlier, the first 1,000 days are of particular importance. 
Iodine supplementation of mothers during pregnancy, and directly to infants, has 
been shown to improve infant survival [10,41], and, if undertaken before or during 
pregnancy, maternal iodine supplementation [10,42,43], or an adequate iodine sta-
tus [44,45], has been positively associated with birth weight [10,42–45] and infant 
growth at 6 months [46]. Furthermore, recent analyses by Krämer et al. (2016) 
suggest a positive association between the absence of iodized salt availability at 
household level and low birth weight [47]. Additionally, they observed significant 
associations between household iodized salt availability and growth indicators (e.g., 
stunting, wasting, and underweight); however, the association was only positive 
for infants over 5 months of age, probably due to breastfeeding practices, although 
some benefit via maternal milk is proposed [47]. In toddlers, Neumann and Harrison 
(1994) reported that household availability of iodized salt use in Kenya was related 
to improvements in height [48] and, in toddlers and older infants, the use of iodized 
salt has been associated with increased weight-for-age z-scores and mid-upper-arm 
circumference in some countries in Asia [49].
During fetal development and the neonatal period, TH are responsible for a mul-
titude of effects that include accelerated myelination in the brain, and improved 
TABLE 7.1
Iodine Intake Recommendations for Individuals during the First 1,000-Day 
Window
World Health Organization Institute of Medicine
Population Group RNI (μg/day) Population Group RDA (μg/day)
Women and 
children >12 years
150 Women and children ≥14 
years
150
Children 0–5 years 90 Infants 0–12 monthsa 110–130
Children 1–8 years 90
Pregnant 250 Pregnant 220
Lactating 250 Lactating 290
Source: Data from Institute of Medicine, Academy of Sciences, USA, Dietary reference intakes for vita-
min A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, 
nickel, silicon, vanadium and zinc, Washington DC: National Academy Press, 2001; and World 
Health Organization, United Nations Children’s Fund, International Council for the Control of 
Iodine Deficiency Disorders, Assessment of iodine deficiency disorders and monitoring their 
elimination: A guide for programme managers, 3rd ed., Geneva: World Health Organization, 
2007.
Notes: RNI, Recommended Nutrient Intake; RDA, Recommended Dietary Allowance.
a Adequate intake.
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central nervous system cell migration, differentiation, and maturation [50,51] (see 
Figure 7.2). TH also promote the growth and maturation of the peripheral tissues 
and skeleton, and they raise the basal metabolic rate [16], which provides energy for 
growth (see Figure 7.2). Indeed, TH may be the best surrogate biochemical markers 
for healthy fetal development [28,52].
The actions of TH in target tissues are mediated by thyroid hormone receptors 
that regulate the transcription of target genes, which can induce pathways that stimu-
late or inhibit protein synthesis [16]. However, the numerous effects of TH integral 
to human growth are not limited to TH and TH receptor interactions: Nongenomic 
functions of TH have also been identified. Such effects do not require gene tran-
scription or protein synthesis, and can have a rapid onset [20]. Furthermore, and 
importantly, TH can also indirectly affect growth via other hormonal axes, the most 
consequent of which involves human growth hormone (GH). Both TH and GH are 
essential for normal growth and development [53]: Thyroid function and growth 
mechanisms are intertwined in a complex relationship; neither can be considered 
without the other, and iodine plays a central and fundamental role.
The impact of TH on growth mechanisms is discussed next. A detailed and fully 
comprehensive discussion on growth mechanisms above those directly implicated 
with thyroid function is beyond the scope herein. For further in-depth reading, addi-
tional publications are suggested at the end of this chapter.
effeCts of thyroId hormones on the reprodUCtIve system
Although not directly a growth mechanism, the ability to reproduce successfully is 
the primary determinant of the viability of a new life. Normal reproductive physi-
ology in both women and men is dependent on having normal levels of TH, and 
evidence points to the association between reproductive complications or failure and 
TH levels. This association is mainly based upon the interrelationship between the 
HPT axis and the hypothalamic-pituitary-gonadal axis, which controls the release of 
sex steroid hormones, as both axes influence each other.
Abnormal amounts of TH can cause problems with sperm morphology and motil-
ity and induce erectile dysfunction [54]. In women, reproductive problems due to 
incorrect TH levels may impact menstruation, oocyte quality, and endometrial thick-
ness [54]. In both sexes, TH abnormalities cause changes in sex hormone-binding 
globulin and sex steroids.
effeCts of thyroId hormones on mUsCle, CellUlar enerGy 
tUrnover, and GlUCose metabolIsm
Skeletal muscle is a principal target of TH signaling, and TH regulate the expression 
of a broad range of genes with key roles in skeletal muscle development, homeo-
stasis, function, and metabolism [55]. TH transporter proteins and deiodination 
enzymes that are required for TH binding and the conversion of the inactive T4 to 
the active metabolite T3 are expressed in skeletal muscle tissue [55], and provide the 
means to control TH uptake and activation. Starting with early embryonic develop-
ment of the trunk and limbs, the development of fetal skeletal muscle is dependent 
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upon TH, a process that continues postnatally with the transition from fetal muscle 
fiber phenotypes to adult phenotypes [55]. Furthermore, muscle is one of the major 
tissues involved in glucose uptake, and TH can control glucose uptake both from the 
gut and also by skeletal muscle, thereby influencing the overall glucose homeostasis 
of the body. This is particularly important since the fetus is highly reliant upon glu-
cose, not only for energy but also as a precursor for biochemical reactions promoting 
tissue growth.
TH are unique in their ability to affect the resting metabolic rate [20], primar-
ily through their actions on skeletal muscle both at rest and while active. The 
sodium/potassium (Na+/K+) adenosine triphosphatase (ATP) pump, responsible 
for the maintenance of the resting cellular membrane potential, is a direct target 
gene for T3. The ability of TH to regulate energy utilization is closely linked to 
effects on the function of mitochondria, which provide about 90% of intracel-
lular energy in the form of ATP [56], and actions can also be via nongenomic 
influences of TH directly on mitochondria [20]. TH can also increase the number 
of mitochondria in a cell [57], thereby increasing the capacity to generate ATP. 
These factors influence fetal growth and metabolism, and hypothyroid fetuses 
will obtain less ATP, and therefore have less energy available for growth of non-
essential tissues [27].
Last, TH have an important role to play in the survival of the neonate at birth. 
After delivery, the neonate must expend ATP to maintain the extrauterine body tem-
perature, which requires the generation of more heat than while in the protective 
environment of the uterus. Activation of this thermogenesis in brown adipose tissue 
is reliant on T3 [27,55].
effeCts of thyroId hormones on the CardIovasCUlar system
TH are critical regulators of cardiac development during fetal and postnatal life. 
Cardiac functions, such as heart rate, cardiac output, and contraction force, are 
linked to TH. In the fetus, TH are responsible for the maturation of the cardiovascu-
lar system adaptation of the heart at birth, when the ventricles switch from pumping 
in parallel to pumping in series [27].
effeCts of thyroId hormones on skeletal bone 
development and maIntenanCe
The dependence of bone maturation, growth, and development on thyroid func-
tion is well recognized [19,58], and the association between myxedematous cretin-
ism and short stature is confirmed [59]. A euthyroid state is essential for normal 
skeletal development. Thyroid hormone receptors (THRs) have been identified in 
bone cells (osteoblasts, osteoclasts) and cartilage cells (chondrocytes) [19,58], and 
TH have been shown to accelerate osteoblastic differentiation [60]. In response to 
TH, bone cells stop proliferating and develop differentiated functions including 
production of growth factors, cytokines, prostaglandins, and structural proteins 
[60]. Osteoblasts are stimulated directly by T3 and, indirectly, via the action of 
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T3 on growth factors, such as insulin-like growth factor-1 (see next section) [61]. 
Furthermore, TSH receptors, expressed predominantly on thyroid cells, have also 
been identified in bone, suggesting that TSH may have a direct effect on bone and 
cartilage itself [62].
effeCts of thyroId hormones on Growth hormones 
and InsUlIn-lIke Growth faCtors
The human growth hormone (GH) is the most abundant hormone secreted from the 
anterior pituitary. It is secreted in response to a stimulus on the anterior pituitary by 
growth hormone releasing hormone, which itself is secreted from the hypothalamus. 
GH is essential for normal growth and development, and exerts its effects on almost 
all tissues in the body. TH promotes GH synthesis and secretion from the pituitary, 
and has a permissive effect on the anabolic and metabolic effects of GH. In turn, GH 
also affects TH activity: GH depresses the secretion of TSH from the pituitary, 
which in turn will dampen the cascade of reactions initiated by TSH to produce TH.
The main function of GH is to promote the synthesis and secretion of IGFs, which 
mediate the effects of GH. IGFs cause cell growth and multiplication by increasing 
the uptake of amino acids into the cell, thereby promoting protein synthesis. GH 
acts on muscle, cartilage, bone, and other tissues and, indirectly, on the liver, to 
promote IGF secretion. IGFs circulate in the plasma in complexes with structurally 
related binding proteins, called IGF-binding proteins. IGF-binding protein-3 is the 
most common and has the highest binding affinity for IGF-1, binding approximately 
95% of the growth factor [63].
Via IGFs, GH promotes accelerated protein growth, an increase in cell size, an 
increase in cell mitosis, and a corresponding increase in cell number. It promotes the 
specific differentiation of certain types of cells, for example, bone growth cells and 
early muscle cells. In infants and children, in whom the bone has not yet reached its 
adult length, GH increases the growth rate of the skeleton and skeletal muscles.
GH stimulates the increased deposition of proteins around the body, yet the most 
visible effect is on somatic growth, the stimulation of growth of the skeletal frame. 
This impact on skeletal growth occurs as a result of multiple effects on bone, includ-
ing (1) an increased deposition of protein by chondrocytic and osteogenic cells that 
cause bone growth; (2) an increased rate of reproduction of these cells; and (3) the 
specific effect of converting chondrocytes into osteogenic cells, thus causing specific 
deposition of new bone.
Indeed, the growth-promoting actions of GH and IGF-1 are critical for growth 
during early life: IGFs are widely expressed in fetal tissues and have major influ-
ences on fetal growth [27,53], and in neonates and infants, where a deficiency of GH 
is established by 6 months of age, growth failure may result in stunted growth of up 
to 3 or 4 standard deviations below the mean [53].
An adequate iodine status and euthyroid state can thereby promote growth, 
through the promotion of the secretion of GH. The secretion of GH, IGF-1, and 
IGFBP-3 is dependent on thyroid function, both directly and indirectly via the effects 
of TH on pituitary secretion [63].
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CONCLUSION
Iodine is an essential micronutrient for optimal health, being the principal compo-
nent of thyroid hormones. Thyroid hormones are implicated in nearly all cells in the 
body, and control a vast array of biochemical reactions. During the first 1,000 days, 
iodine and thyroid hormones are indispensable for the viability of the developing 
fetus and for perinatal survival, including brain formation and cognitive develop-
ment, and thereafter for the growth and ongoing development of the child.
Whereas the biological mechanisms are well characterized for iodine to have 
a clear impact on growth processes and growth outcomes, measurable effects of 
thyroid hormones on growth are principally seen in situations of severe or moder-
ate deficiency. In situations of mild iodine deficiency, where the body’s regulatory 
mechanisms are better prepared to maintain homeostasis, we may be unlikely to see 
a measureable impact on growth. That said, there is a distinct lack of literature on 
the effects of iodine status, or supplementation or fortification strategies, on infant 
and child growth outcomes [13]. The available data are mainly cross-sectional, 
which are limited in scope since they make assumptions that current iodine status 
is reflective of past status, and may not control for socioeconomic confounders [63]. 
The little evidence from iodine intervention strategies on growth is of low qual-
ity: There are few randomized controlled trials, and those conducted have generally 
been underpowered to study growth outcomes [13,64,65]. Furthermore, growth as an 
outcome is difficult to measure in single nutrient nutritional studies, since the factors 
impacting growth are vast and spread beyond the reach of a single nutrient or even 
nutrition alone, and studies need to be of sufficient duration to detect a measureable 
difference. There is a clear need for well-designed, long-term controlled trials with 
adequate sample sizes to appropriately assess the impact of iodine status on growth 
outcomes.
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The year 2016 marks the 25th anniversary of the seminal Medical Research Council 
(MRC) randomized trial that conclusively demonstrated a marked protection against 
the recurrence of a neural tube defect (NTD) affected pregnancy among previously 
affected mothers by the simple prophylactic treatment of folic acid supplements in the 
periconceptional period [1]. This trial and a contemporaneous Hungarian trial [2] that 
assessed the efficacy of multivitamins containing folic acid on the first occurrence 
of an NTD were the culmination of a decade of prior research, primarily led by the 
work of Professor Smithells in Leeds, United Kingdom. Smithells’s work strongly 
suggested that women entering pregnancy with deficiency or inadequate status of 
specific micronutrients might be predisposed to these congenital defects, and that 
multivitamin supplements, taken before and during the first trimester of pregnancy, 
might be protective. The work resolved well-established epidemiologic data on the 
prevalence and patterns of occurrence of NTDs suggesting that maternal nutrition 
was an important factor. In the 25 years since these seminal trials, many countries 
worldwide have introduced mandatory folic acid food fortification programs to reduce 
NTD occurrence; other countries have limited their official involvement to public 
health recommendations and promoting increased awareness of the benefits of folic 
acid. The fortification programs have had more success, but the worldwide preva-
lence of NTDs is still documented at more than 300,000 births per year, with great 
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variation in prevalence from region to region and an unclear extent of underreporting 
[3]. Moreover, efforts to understand the molecular nature of the effect of folic acid in 
preventing NTDs have had little success, despite intense research.
CLINICAL FEATURES AND EPIDEMIOLOGY
NTDs are the largest group of anomalies of the central nervous system and are 
among the most significant congenital causes of morbidity and mortality in infants 
worldwide [3–5]. They occur when the embryonic neural plate fails to fuse and form 
a closed structure, known as the neural tube. Primary neural tube closure is an early 
developmental event that produces the prototype of the spinal column and brain in 
the fetus and is completed in the human embryo between days 21 and 28 of gestation. 
The fusion of the neural plate is thought to progress at multiple sites simultaneously, 
and NTDs occur when the process malfunctions in any respect [6–8]. Incomplete 
closure gives rise to lesions of different types and severity, depending on the portion 






























FIGURE 8.1 Neural tube defects: The left panel shows cross-sectional diagrams of embry-
onic neural tube development, (a) during neural tube closure and (b) after closure. Panel (c) 
shows the clinical features of the main types of neural tube defects. The central diagram 
shows a dorsal view of the embryo with dotted lines referring to the cross-sections in the 
left panel. (Reproduced from Botto LD, Moore CA, Khoury MJ et al., N Engl J Med 1999, 
341(20):1509–19. With permission.)
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is a complete failure to commence fusion, is craniorachischisis, a rare form of NTD 
occurring in less than 5% of cases.
The two most common forms of lesion are anencephaly (affecting the cranium 
and involving some 40% of all NTD cases) and spina bifida (affecting the spi-
nal cord and including several open spinal dysraphisms such as myelomeningocele 
and myelocele), which comprise about 50% of all NTD cases. Other rarer forms, 
including encephalocele and iniencephalocele, make up the remaining proportion 
of cases [3]. Severely affected cases may include combinations of these lesions. As 
might be expected, the position and the extent of the lesion are the main factors in 
determining the medical management and long-term prognosis. Anencephaly is a 
lethal disorder. Spina bifida is not intrinsically lethal, but the position and extent of 
the lesion dictates severity. Most surviving individuals require intensive medical 
intervention and lifelong care. There is some evidence that at least part of the dam-
age evident at birth in children born with open spina bifida is caused by infiltration 
of amniotic fluid over the course of the pregnancy. Newly developed methods to 
repair the lesion in utero offer the possibility of improved quality of life for children 
with myelomeningocele [9]. Several other forms of NTD result from malformations 
occurring somewhat later in development and are termed secondary or postneuru-
lation defects. They are generally not considered to have the same causative back-
ground as primary neural tube defects, and it is not known whether folic acid can 
protect against their occurrence.
Worldwide, the birth prevalence of NTDs is reported to be between 6 and 60 cases 
per 10,000 births [5], but there are wide geographic variations in prevalence. In low-
income countries, NTDs have been estimated to account for up to 29% of neonatal 
deaths due to visible congenital abnormalities [10]. A recent systematic study found 
prevalence rates between 0.3 and 199.4 per 10,000 births across different regions, but 
reported great difficulty in obtaining accurate estimates, particularly in low-income 
countries [3].
ENVIRONMENTAL AND GENETIC INFLUENCES
It has been accepted for many years that NTDs have a multifactorial etiology, 
containing both environmental and genetic influences, and probably requiring an 
interaction of both elements for the defect to occur. The influence of environmental 
factors is shown in several ways. In addition to variations in the underlying rates 
across geographic and ethnic groups, changing trends over time have been well doc-
umented. Variations with season, social class, and food availability (e.g., increased 
incidence during periods of economic and wartime nutritional deprivation) have 
been described [10–12]. Of particular note is a significant decline in the prevalence 
of NTDs over some 40 years of monitoring in developed countries, most noticeably 
in areas with historically high rates, and occurring mainly prior to the introduc-
tion of food fortification practices [13–15]. Although the reason for this decline is 
not understood, improved nutrition is probably an important consideration. Better 
prenatal detection and increased use of screening programs to terminate affected 
pregnancies have also contributed significantly to the decline in the number of live-
born cases in most developed countries.
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The evidence of a genetic component is strongly demonstrated in familial recur-
rence patterns, which are at least 10 times the general occurrence risk [11,16]. There 
are also higher rates in females (particularly for anencephaly) and there are well-
recognized Mendelian syndromes that feature an NTD as part of the defect [7,11]. 
The underlying genetic component can also be observed in prevalence differences 
among some ethnic groups compared with others. For example, data from the United 
States indicate that Hispanic women have a higher susceptibility than non-Hispanic 
whites, with black non-Hispanic women having the lowest risk [17]. Studies from 
other parts of the world also show lower observed rates among African populations 
and highest in some Chinese provinces [3]. Finally, the importance of genetic factors 
is clearly demonstrated by the generation of more than 240 laboratory mouse strains 
exhibiting NTDs [8,18]. Despite these known environmental and genetic influences, 
it must be said that most NTDs are isolated events.
FOLIC ACID AS A PROTECTIVE AGENT
EvidEncE from intErvEntion trials
The past 25 years has seen extensive literature on the role of folic acid in the pre-
vention of NTDs, but the possible involvement of micronutrients and particularly 
folic acid in protection against these devastating defects had been suggested since 
the 1960s (reviewed by Molloy et al. [19]). Smithells et al. [20] suggested the pos-
sibility of a micronutrient deficiency in women who had previously had an NTD-
affected pregnancy. In a series of intervention trials conducted in the early 1970s, 
they tested the hypothesis that preconceptional vitamin supplementation would pre-
vent these defects [21]. The amount of folic acid delivered to women in the treatment 
group was 360 μg/day in multivitamin supplement tablets (Pregnavite Forte F). The 
control group consisted of women who chose not to take the multivitamins or who 
were already pregnant at the time of the intervention. The results were striking and 
showed highly protective effects in the treatment group, but because the interven-
tion was not randomized, the level of evidence was considered low. There followed 
a heated debate on the need for a more scientifically rigorous randomized controlled 
trial [22–24]. This culminated in two seminal trials. The UK MRC trial [1] tested the 
risk of NTD recurrence in women who had previously delivered an affected infant. 
Because of the known familial aggregation of the defect, these women were at high 
risk and one might say that they were implicitly considered to be genetically sus-
ceptible. The second trial, conducted in Hungary [2], tested the first occurrence in a 
pregnancy and therefore was aimed at an unbiased population of women. Both trials 
demonstrated conclusively that supplements containing folic acid were highly pro-
tective in preventing NTDs. Several features of the trials are worth noting. The MRC 
trial used a high folic acid dose (4 mg/day), and the research design was to investi-
gate the effects of folic acid alone, a combination of other vitamins plus folic acid, a 
combination of other vitamins without folic acid, and a placebo control. There were 
a total of 1,195 completed pregnancies in the trial, with 27 recorded NTDs, of which 
6 were in the groups that took folic acid and 21 were in the two other groups. The 
calculated relative risk for taking folic acid was 0.28 (95% CI: 0.12, 0.71) indicating 
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that 72% of recurrences could be prevented by folic acid. An important point guid-
ing future research was that the multivitamin combination, which had no protective 
effect on its own, included vitamin B6 and B2 but did not include vitamin B12. The 
Hungarian trial had just two treatment arms: one with multivitamins that contained 
folic acid at a lower dose of 800 μg/day and a multimineral preparation considered 
to function as a virtual placebo. There were no NTDs from 2,104 pregnancies in the 
multivitamin-treated group but 6 from 2,052 pregnancies in the multimineral group. 
The study demonstrated a similarly striking effect to the MRC trial but was notably 
different in design because it showed that multivitamins containing folic acid could 
prevent NTDs, but it did not show that folic acid was the active agent. Interestingly 
vitamin B12 was also included in the list of multivitamins in this trial.
In relation to the dose of folic acid that would be protective, several smaller ran-
domized intervention trials [4], a large (n = 247,831) nonrandomized trial in China 
[25], and the trials carried out by Smithells’s group in Leeds all demonstrated sig-
nificant protection with doses as low as 400 μg/day. The efficacy of 400 μg/day was 
also supported by several observational studies, most of which found a significant 
protective effect of maternal periconceptional use of vitamin supplements contain-
ing between 400 and 800 μg/day folic acid. The totality of evidence after the ran-
domized trials created a dilemma for public health authorities. Since NTDs are rare 
events in reproduction, most women would be regarded as at low risk for having 
an NTD-affected pregnancy (see earlier discussion of prevalence rates). A woman’s 
genetic susceptibility becomes evident after she has an NTD-affected pregnancy and 
she is then regarded as high-risk for having another affected pregnancy. In develop-
ing public health guidelines for primary prevention of NTDs, recommending that 
high-risk women take 4 mg/day folic acid was a straightforward decision for public 
health authorities. However, experts agreed that the folic acid doses in both the MRC 
and Hungarian trials were too high to recommend for use in low-risk women. The 
additional information from the other studies above was considered in the public 
health guidelines for primary prevention of NTDs in low-risk women. Within 5 years 
of the randomized trials, guidelines were published by many countries worldwide 
and by the World Health Organization (WHO) [26–28]. For low-risk women, the 
guidelines state that all women capable of becoming pregnant (the wording varies in 
this respect) should consume 400 μg/day folic acid, in addition to their usual dietary 
intake of folate, which in most developed countries approximates 200 μg/day.
In recent years, there have been calls to recommend higher doses for specific sub-
groups of women who may have a moderately higher risk of having an NTD-affected 
pregnancy [29]. These include women who are obese or have diabetes, both of which 
conditions are associated with approximately double the risk of having an NTD-
affected pregnancy compared to the general population of women [30–32]. The inten-
tion of these revisions is to improve health and ensure maximum protection against 
NTDs, but the evidence for changing the original recommendations is low, since it is 
not clear that these risk factors are folate responsive. It must also be said that no dose-
finding studies have ever been carried out in relation to folic acid and NTDs (such 
studies could not now be ethically approved), and so the minimal requirement for 
folic acid to prevent NTDs is not known but, as discussed later, is likely to be depen-
dent on the underlying folate status of individual women as they enter pregnancy.
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Primary PrEvEntion Pitfalls and oPPortunitiEs
The goal of primary prevention is to prevent the development of an NTD in utero, 
either as a first occurrence or as a recurrence. In the case of NTDs, although the 
finding that folic acid was protective was hailed as an important medical advance, 
a major obstacle to successful primary prevention has been the very early timing 
of neural tube closure in pregnancy, when many women are unaware that they are 
pregnant. Thus for optimum efficacy, folic acid supplements need to be taken prior 
to becoming pregnant. Even after 25 years of knowledge by public health authori-
ties, campaigns to encourage women to take folic acid supplements remain unsuc-
cessful [33–36]. Moreover, numerous studies show sociodemographic differences 
with respect to a woman’s knowledge and use of folic acid, with those in lower 
socioeconomic groups, who were historically known to be most at risk of having an 
NTD-affected pregnancy, being least likely to know the benefits of folic acid supple-
mentation or take folic acid supplements prior to becoming pregnant.
Because many women do not plan their pregnancies and do not understand the 
benefit of periconceptional folic acid supplement use, fortification of flour or grain 
products that are consumed by all sectors of the population was initially established 
in the United States and Canada, and is now mandated in approximately 80 coun-
tries worldwide. These programs of mandatory fortification have been successful 
in reducing the prevalence of NTDs [17,37]. Fortification is not mandated in most 
countries in Europe, Africa, or Asia [27,38], but a number of countries allow vol-
untary food fortification with folic acid, including many European states and New 
Zealand. Although this has been effective in raising the general folate status of the 
populations involved, as documented in several studies across Europe [39,40], the 
lack of reduction in the prevalence of NTDs across Europe over the past 2 decades 
strongly suggests that such commerce-driven strategies are not adequately effective 
in improving the folate status of women of child-bearing age [41]. A recent system-
atic review concluded that spina bifida is significantly more common in areas of the 
world without mandatory fortification, regardless of population type [38].
At this point, after nearly 20 years of mandatory fortification in the United States 
and Canada, the decline in NTD rates in the United States has leveled off at a total 
prevalence for anencephaly and spina bifida of approximately 7 per 10,000 births 
[17]. Other observational data from several population-based studies give some indi-
cation there is a limit to the reduction achievable by folic acid fortification [42,43] 
and that the threshold of NTD occurrence below which folic acid is not effective is 
in the region of 6 or 7 per 10,000 pregnancies [37,43]. This is in line with data from 
the MRC trial, indicating that not all NTDs are folic acid responsive.
MECHANISM OF FOLIC ACID PROTECTIVE EFFECT
matErnal Blood folatE status and nEural tuBE dEfEcts
In parallel with the intervention studies carried out over some 20 years from 
1976, other biological evidence was also accumulating that implicated low mater-
nal folate status as an important factor. Several authors reported lower total folate 
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concentrations in serum or red blood cells of women during or after an NTD-affected 
pregnancy, although other studies showed no effect, and a limitation of all was low 
sample size, as expected since an NTD-affected pregnancy is a rare event. For this 
reason, Kirke et al. in Dublin, Ireland, a traditionally high-risk area, collected blood 
samples at an average gestation of 15 weeks from over 56,000 women over a 4-year 
period to assemble a large enough sample of bloods from women who were under-
going an NTD-affected pregnancy (reviewed by Molloy et al. [19]). Then, in a nested 
case control study from this large pregnancy cohort, consisting of 84 women who 
were carrying NTD-affected fetuses and 247 nonaffected women, they found sig-
nificantly lower concentrations of plasma and red blood cell (RBC) folate in NTD-
affected women [44]. In a follow-up risk analysis of the data, the group reported an 
approximate eightfold higher risk for NTDs among women with early pregnancy 
RBC folate concentrations below 340 nmol/l, compared with those who had RBC 
folate above 906 nmol/l [45]. Although it has never been possible to replicate this 
sample size with RBC folate measurements in early pregnancy, the hypothesis was 
recently tested in an in silico Bayesian analysis by amalgamating data from two 
large Chinese population studies; one, a folic acid dose response study in which RBC 
folate was measured after different folic acid supplement interventions [46] and the 
other a folic acid intervention trial in which the prevalence of NTDs was monitored 
in an ethnically identical population of women [25]. Amazingly, the Bayesian cal-
culations resulted in risks that were almost identical to the Dublin study [47]. This 
strengthened the evidence that women should aim to enter pregnancy with an RBC 
folate concentration above 906 nmol/L in order to be optimally protected against an 
NTD. This work has recently led to new WHO guidelines on optimal folate status 
for protection against NTDs [48]. Two points are noteworthy. First, was the observa-
tion in both studies of increased risk among women with low folate status but who 
would not be described as clinically folate deficient. Second, was the presence of a 
continuous relationship between folate status and risk reduction, apparently even 
beyond RBC concentrations of 906 nmol/l. The findings argue against a mechanism 
of simple folate deficiency and support a mechanism whereby an inadequate nutri-
tional status exacerbates an underlying genetic susceptibility leading occasionally 
to an NTD, as would be predicted for a condition caused by a low-penetrance gene-
nutrient interaction.
molEcular and GEnEtic considErations
The complex processes involved during embryonic neural tube closure have been 
the subjects of ongoing research for decades. It is known that the progression of 
closure is highly orchestrated at the molecular level and involves multiple processes, 
including cell proliferation and differentiation plus cell apoptotic events, all of which 
involve complex genetic expression and regulatory activities [7,8,18]. Despite these 
advances, there is little understanding of what developmental mechanisms are folate 
sensitive. The unexplained effect of folic acid on neural tube closure is all the more 
extraordinary when one considers that other important processes occurring during 
early embryonic life, such as the development of the lip and palate, appear not to be 
so unequivocally sensitive to folic acid treatment.
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Folic acid is not a biologically active vitamin. It is the stable, commercially avail-
able precursor of the B-vitamin folate but it can be readily converted within the 
enteral cells and liver to the biologically active molecule, tetrahydrofolate (THF). 
THF plays a central role in one-carbon metabolism of the cell. One-carbon units 
(more precisely formyl, methylene, and methyl groups) are essential components of 
nucleotides and an extensive variety of methylated cell components that are critical 
to cell signaling, gene expression, and other functions that ensure optimum perfor-
mance of the living organism. THF accepts one-carbon units from small, simple 
molecules, such as the amino acids serine and glycine and the organic acid formate. 
These THF derivatives can then donate one-carbon units to other molecules (Figure 
8.2). The two most important elements of folate metabolism are as follows. First, 
THF donates one-carbon groups in the de novo synthesis of purines and the pyrimi-
dine, thymidine. This means that folate metabolism is needed for DNA synthesis 
and is an essential nutritional factor in situations that involve extensive and rapid 
cellular proliferation, as is the case in early fetal development. Second, the deriva-
tive methyl-THF is used to regenerate the amino acid methionine from its precur-
sor homocysteine (Figure 8.2). Of note, the enzyme responsible for this reaction 
(methionine synthase) requires cobalamin (vitamin B12). In a sequence of enzymatic 
steps, termed the methylation cycle, the newly synthesized methionine is used to 
produce S-adenosylmethionine, the universal donor of methyl groups for numerous 
biological reactions, including the methylation of DNA, an important mechanism of 
gene silencing, and the methylation of histone proteins that confer epigenetic control 
over gene expression. Transfer of the methyl group to its final destination, results 
in a molecule of S-adenosylhomocysteine, which is converted to homocysteine and 
recycled back to methionine. In this way, the provision of methyl groups, derived 
ultimately from folate metabolism, is a crucial factor involved in the choreography of 
gene activation and silencing activities required by the developing cell. Such control 
would be expected to play an important role in the molecular stages through which 
the developing embryo must progress during the fashioning of the neural tube.
Because folate metabolism is involved in so many fundamental cellular pro-
cesses, it is easy to see the difficulty in identifying any single reaction or series of 
steps that might be the key to understanding the mechanism that fails and causes an 
NTD. Nevertheless, in the wake of the randomized trials, the likely involvement of a 
gene–folate interaction in the pathogenesis of NTDs prompted researchers to study 
common genetic variation in candidate genes that are linked to folate metabolism as 
the most productive way to approach the problem of identifying a folate-responsive 
mechanism. Such an approach was not trivial, when one considers the dozens of rel-
evant gene products such as membrane receptors, folate transporters, and handling 
proteins, as well as enzymes involved in the interconversion of THF derivatives and 
the movement of one-carbon units, and so forth. However, in 1995 an important poly-
morphism (677C>T) in the folate pathway gene methylenetetrahydrofolate reductase 
(MTHFR) was discovered [49]. MTHFR is an important checkpoint enzyme in the 
folate metabolic pathway because it catalyzes the essentially irreversible conversion 
of 5,10-methyleneTHF to 5-methylTHF and thereby channels one-carbon units away 
from purine and pyrimidine synthesis and into the provision of methyl groups for 
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have the rarer TT genotype tend to have lower serum and RBC folate concentra-
tions, suggesting an increased requirement for folate [50]. The polymorphism was 
the first to be examined in relation to NTDs and remains more thoroughly explored 
than other folate enzymes in relation to NTDs, showing an approximate twofold risk 
in mothers and in cases themselves, calculated to be about 12% of the population 
attributable risk [51,52]. This relatively moderate effect emphasized the need to find 
other factors. Candidate polymorphism analysis very quickly led to the broader task 
of candidate gene analysis, where all of the common variability in a gene is evalu-
ated for association with risk. However, despite a considerable body of research on 
candidate genes in folate pathways, other than the MTHFR gene, which confers 
at most a moderately increased risk, there has been little success in uncovering a 
genetic cause for NTDs that is based on common genetic variability in folate candi-
date genes [19,53,54].
A major limitation of candidate gene analysis is that the list of candidates that 
can be produced is limited by our knowledge of the molecular pathways. More 
unfocused methods, such as genome-wide associated studies (GWAS) apply a broad 
unbiased approach to searching for common genetic variation. Such an analysis has 
not yet been applied to the study of NTDs. Other approaches, such as exome sequenc-
ing, aim to find rare and de novo mutations that may confer risk [55]. The lack of suc-
cess in discovering risk factors at the genetic level has also prompted researchers to 
consider the possibility that changes in epigenetic patterns rather than genetic factors 
may be an important feature of neural tube closure. Since folate metabolism is essen-
tial for DNA and histone methylations, it might be expected that low maternal folate 
status could cause an inadequate supply of methyl groups leading to changes at the 
chromatin level and altered transcriptional activity during mammalian development 
[56]. A recent study found altered methylation patterns in a study of ten spina bifida 
cases and six controls [57]. These types of studies are still in their infancy but give an 
example of the directions being taken to understand the basis of folic acid responsive 
NTDs. The tools and expertise to carry out such analysis of the human genome and 
methylome are beginning to be more widely available, and it will soon be possible 
to explore a broader architecture of the genome and epigenome in relation to these 
defects. Whether such explorations will provide a breakthrough in our understand-
ing of the genetic factors causing susceptibility to NTDs is unknown.
othEr intEractinG nutriEnts
Finally, it is important to include some comment on the role of vitamin B12, because 
of the requirement for cobalamin in providing folate derived methyl groups for 
methionine synthesis. There are no trials demonstrating that vitamin B12 can prevent 
NTDs, but several studies have found evidence of low or altered vitamin B12 status 
in maternal blood or amniotic fluid during and after an NTD-affected pregnancy 
[58,59]. Furthermore, genes in vitamin B12 metabolizing proteins have emerged as 
significant risk factors for NTDs [60]. No evidence of a role for vitamin B6 has been 
found, although several steps in folate metabolism require pyridoxal phosphate. 
Smithells’s group reported low blood riboflavin and vitamin C concentrations in 
women during NTD-affected pregnancies, but as noted earlier, none of these had 
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an effect in the randomized trials. Anecdotally, the Hungarian trial, which included 
vitamin B12 in the treatment group, reported no cases of NTD in that group. This 
could be due to chance, but it is also possible that folic acid plus vitamin B12 reduced 
the risk to an even lower level than that seen in the MRC study. It is also possible 
that the importance of this vitamin to NTD prevention may be much greater in low-
income countries where vitamin B12 deficiency is widespread.
CONCLUSION
There are many unsolved questions in relation to the mechanism of folic acid protec-
tion against NTDs, despite a quarter century of intense research. The multifactorial 
nature of the defect is probably the biggest obstacle to research efforts. Intervention 
trials indicate that folate is the most important environmental factor, but the contri-
bution of the interacting nutrient vitamin B12 cannot be ignored. It is important to 
note that a proportion of NTDs are not responsive to folic acid. Certain toxins such 
as fumonisin, hyperthermia during early pregnancy, use of antifolate medicines such 
as some antiepileptic drugs, obesity, and diabetes are all maternal risk factors for 
having an NTD-affected birth. It is not clear if increasing folic acid supplement use 
can moderate the increased risk that is associated with conditions such as obesity 
and diabetes. The ongoing surge of progress in genomic and epigenomic research 
will soon give us much deeper knowledge of gene structure and control, but until 
this is linked to the equally complex tapestry of our nutritional environment, a true 
understanding of the nature of NTDs is unlikely to emerge.
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9 Cleft Lip and Palate
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and Katherine Kula
NORMAL EMBRYOLOGICAL FACE STRUCTURE DEVELOPMENT
Early in the fourth week intrauterine, five primordial swellings, consisting of neural 
crest derived mesenchyme, appear around the stomodeum and are mainly respon-
sible for face development (Figure 9.1). The process starts with the appearance of the 
nasal placodes on the inferior aspect of the frontonasal process. Proliferation of the 
ectomesenchyme on both sides of each placode results in the formation of the lateral 
and medial nasal processes, and the formation of the depression representing the 
primitive nostril, or “nasal pit.” As the two maxillary processes enlarge, they fuse 
medially with the medial nasal processes to form the upper lip. The failure of one 
or both of the maxillary processes to fuse with the medial nasal processes leads to a 
unilateral or bilateral cleft of the lip, respectively [1–4].
Development of the palate begins at the end of the fifth week. The primary palate 
is then formed by the fusion of the medial nasal processes to form the intermaxillary 
segment. This segment is responsible for the formation of the premaxilla, which is 
the triangular bony piece that will support the maxillary incisor teeth. The second-
ary palate is the primordia of the hard and soft palate posterior to the premaxilla, 
and is formed from the maxillary processes of the first branchial arches [3,4]. Two 
lateral palatine processes develop from the internal aspects of both maxillary pro-
cesses, initially in a vertical position on each side of the developing tongue. With the 
development and growth of the mandible, the tongue moves inferiorly, allowing the 
palatine processes to move horizontally and grow toward each other. By the end of 
the eighth week, fusion occurs between the two palatine processes or shelves, and 
also with the primary palate and nasal septum. The process of palate formation is 
completed by the twelfth week. Bone develops in the anterior region, forming the 
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hard palate, and the posterior part develops as the muscular soft palate. Defective 
fusion of the palatine processes results in a cleft palate [1–4].
EPIDEMIOLOGY OF CLEFT LIP AND PALATE (CLP)
Incidence reports estimate about 1 per 2,500 births for cleft lip and palate (CLP), 
and about 1 per 1,500 births for cleft palate (CP) alone. Cleft lip (CL) and CP occur 
together in about 45% of cases, with about 30% being only CP and about 25% being 
isolated CL. CLP occurs more frequently in males, while CP is more predominant 
in females. Approximately 50% of CL patients also have CP, which is considered to 
be a secondary effect resulting from the abnormal fusion of facial prominences that 
precedes palate development [5,6]. The majority of CLP (about 70%) are classified 
as nonsyndromic, while the rest are considered to be syndromic cases, where cleft-
ing occurs as part of a range of chromosomal anomalies, or either teratogenic or 
Mendelian syndromes. Unilateral clefts are more prevalent than bilateral clefts, and 
left-sided unilateral clefts are more common than right-sided clefts [6,7].
The prevalence of CLP in general shows large variations among different popu-
lations, with high rates reported in Asians, moderate rates among Caucasians, and 
low rates among African populations. Reports indicate a risk of 14 per 10,000 births 
in Asians, 10 per 10,000 births in Caucasians, and 4 per 10,000 births in African 
Americans. In addition to genetic association, the wide variation in reported data 
was suggested to be due, in part, to methodological problems, such as selection bias 
and underreporting associated with using different data sources [8–10]. Data from 
some regions depends on investigating hospital records and birth certificates, rather 
than large population data registries. Some reports only included live births, whereas 
others included stillborn and aborted fetuses. Data was sometimes based on iso-







FIGURE 9.1 Structures contributing to the face formation.
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abnormalities or syndromes. There were also differences in the classification system 
used in each report. It is thus considered to be difficult to draw definite conclusions 
from these figures; effective comparisons as well as accurate descriptive epidemio-
logical data are unlikely to be possible with the existence of all these variations 
[10,11].
CLP ETIOLOGY AND ASSOCIATED RISK FACTORS
CLP is etiologically heterogeneous, with complex genetic and environmental inter-
actions. It is essential to distinguish between isolated nonsyndromic cases and those 
clefts associated with particular syndromes, as both are considered etiologically dis-
tinct. More than 350 specific genetic syndromes are identified as being associated 
with CLP [12,13]. Advances in segregation analysis, genetic linkage, and associa-
tion studies, as well as twin studies, have made it possible to identify major genetic 
factors related to clefts [12–14]. Three classes of genes are suggested to play a role 
in the susceptibility to clefting: (1) genes involved in the process of palate devel-
opment, specifically the transforming growth factors alpha and beta (TGFα, TGFβ 2, 
TGFβ 3); (2) genes identified in transgenic animal models with clefts, such as the 
Msx1, Msx2, Gabrb3, and Ap-2 genes; and (3) genes involved in certain biologi-
cal activities that are linked to CLP pathogenesis, such as xenobiotic metabolism 
(CYP1A1, glutathione S-transferase μ1 [GSTM1], N-acetyltransferase [NAT2]), and 
nutrient metabolism (methylene tetrahydrofolate reductase [MTHFR], retinoic acid 
receptor [RAR-α], and folate receptor [FOLR1]). Candidate gene studies on CLP 
cases associated with Van der Woude (VWS) syndrome have also provided strong 
evidence for the involvement of the interferon regulatory factor 6 (IRF6) gene in cleft 
development. VWS is an autosomal dominant disorder that is considered to be the 
most important model for isolated CLP [15–17].
Several environmental factors have also been implicated in the CLP etiology, 
such as maternal smoking and alcohol consumption, dietary vitamins and folate defi-
ciency, medications during pregnancy, infections, and other environmental triggers. 
These environmental components are suggested to be modulators for the genetic 
elements [18–20]. The most extensively studied teratogen linked to CLP is maternal 
tobacco and cigarette smoking. Studies have indicated that maternal smoking is a cen-
tral covariate in clefting, and that it doubles the frequency of cleft development when 
compared to nonsmoking mothers [19,20]. The genes glutathione S-transferase-θ1 
(GSTT1) and nitric oxide synthase 3 (NOS3), which are both major players in met-
abolic detoxification pathways, were confirmed to be directly linked to maternal 
smoking and the susceptibility to the development of clefts [3].
Maternal alcohol consumption has also been suggested as a risk factor; however, most 
reports indicate that evidence linking alcohol to cleft development is yet to be confirmed 
[21]. Other teratogens that are linked to increased risk of clefts via ingestion during preg-
nancy include anticonvulsant medications, specifically phenytoin, corticosteroids, thalid-
omide, and benzodiazepines, or pesticides, such as dioxin. Maternal use of phenytoin has 
been associated with a tenfold increase in the incidence of CL [21,22]. Some nutritional 
factors, such as folate, play a critical role in neural tube formation. Folate deficiency 
was recognized as being potentially responsible for several congenital malformations, 
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including CLP. Several investigators suggested that folate deficiency is associated with 
an increased risk of CLP development through a common mechanism that interferes 
with normal embryonic development. Other reports supported the beneficial effects of 
periconceptional folic acid supplementation in reducing this risk [23,24].
CLASSIFICATION OF CLP
Although many systems have been offered to classify CLP, none of them has been 
considered to be either comprehensive or universally accepted. The simple numeri-
cal method of classification proposed by Veau is widely used, and categorizes clefts 
into four groups: I, clefts of the soft palate; II, clefts of the soft and hard palate; III, 
complete unilateral clefts of the lip and palate; and IV, complete bilateral clefts of 
the lip and palate. More complex classification systems were developed later, but 
Veau classification has remained popular because it is simple and easy to use [25,26].
Several embryologically based and more comprehensive classification systems 
and codes have also been suggested in the literature, and later on have been sub-
jected to further modifications and revisions, albeit without general agreement. They 
mainly divide the groups into clefts of the lip, alveolus, and palate, where the palate 
is identified as either the primary or secondary palate. Failure to apply a standard-
ized, comparable, and internationally accepted classification has always presented 
a barrier to collecting accurate epidemiological data, and to efforts to plan proper 
preventive and public health services for cleft patients [6,27,28].
A CL can be either unilateral or bilateral, and can be isolated or associated with 
CP. CP cases demonstrate a wide range of severity. The defect can be as minimal as a 
“bifid uvula,” in which the uvula is affected by a median cleft without any clinical con-
sequences, it can involve the soft palate alone, or the hard and soft palates (Figures 9.2 
and 9.3). CLP may be associated with other major congenital anomalies, such as mal-
formations of the upper and lower limbs or the vertebral column, mental retardation, or 
congenital heart disease [29–32]. In addition, clefting occurs in a subset of more than 
350 syndromes. Examples of the syndromes and chromosomal abnormalities most 
frequently associated with CLP include trisomy 13, trisomy 18, Meckel syndrome, 
Treacher Collins syndrome, VWS, Pierre Robin syndrome, Crouzon syndrome, Apert 
Normal Unilateral cleft lip Bilateral cleft lip
FIGURE 9.2 (From left) A normal lip, unilateral, and bilateral cleft lip.
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syndrome, Stickler syndrome, fetal alcohol syndrome, Turner syndrome, Down syn-
drome, cri-du-chat syndrome, amniotic band anomalad, velocardiofacial syndrome, 
Wolf-Hirschhorn syndrome, and Fryns syndrome [29–32].
DIAGNOSIS AND PREVENTION
Advances in molecular technology, and the identification of genes’ environmental 
interactions associated with cleft development, has allowed for hypothesis testing for 
prevention. Preventive measures include efforts toward avoiding maternal smoking 
and alcohol exposure, as well as anticonvulsants and other risk-related medications 
[33]. Genetic counseling is likely to be significant in terms of primary prevention. 
Reports have indicated that the molecular identification of mutations in certain 
genes, such as Msx1 and VWS, might deliver valuable information on the expected 
risk. Maternal supplementation, in particular with folic acid and other important 
micronutrients, such as zinc and vitamin B6, is recommended for prevention of clefts 
and other birth anomalies in newborns [8,28,33].
The prenatal detection of CLP, as well as any other genetic abnormalities, provides 
parents with a chance to plan adequate counseling and neonatal care. Counseling should 
provide information on the possible associated risks, anticipated treatment plans and 
surgical protocols, and the overall prognosis of each case [34,35]. Antenatal ultrasound 
is currently considered to be a routine procedure of prenatal care and is reported to be 
an efficient diagnostic tool for the detection of CLP. Diagnosis of facial cleft anomalies 
can be identified as early as the 12th week intrauterine. Abnormal ultrasound find-
ings that indicate possible clefting should be considered to be a forewarning of the pos-
sibility of other serious associated defects, which could be ruled out via karyotyping 
and amniocentesis. Reports have indicated that about 25% of neonates diagnosed with 
CLP have other associated malformations, syndromes, or trisomies [35–37].
TREATMENT AND MANAGEMENT
CLP is considered to be a debilitating condition associated with significant feed-
ing, hearing, speech, and psychological problems. Affected children suffer from 
multiple aesthetic and functional impairments. Feeding difficulties due to problems 
with the oral seal, for example, start very early in life and can greatly affect the 




FIGURE 9.3 The ventral view of the palate in “normal,” and cleft lip and palate-affected 
individuals.
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nutritional status of the child [38]. Other complications, such as hearing problems 
and nasal regurgitation, and speech and dental problems, may lead to negative social 
and psychological burdens for both the child and the parents. Management of a CLP 
case is challenging and ideally requires a multidisciplinary approach. The process 
starts from birth and may continue into adulthood, and involves cooperation between 
different health professionals including, but not limited to, a pediatrician, plastic 
surgeon, otolaryngologist, pediatric dentist, psychologist, speech pathologist, social 
worker, and orthodontist [39–41].
Surgical management is generally required, and it involves multiple primary and 
secondary surgeries, which may start in infancy and continue throughout childhood. 
Surgeries reconstruct the lip and palate, and improve esthetic appearance and func-
tions, including swallowing, speech, and breathing. The specific nature and timing 
of the surgical procedures vary considerably, depending on the treatment protocol 
set by the therapeutic team and the severity of the defect. Primary lip closure is usu-
ally indicated early during the first months after birth, followed by a palatoplasty, the 
procedure used for palatal repair, later in life [42–45]. Autogenous bone grafts, pros-
thetic appliances, and orthognathic procedures may be required at certain points to 
ensure better functional and esthetic results according to the treatment plan. Social 
and psychological care is also indicated, to assist the parents in dealing with the con-
dition. Other forms of treatment such as dental, hearing, and speech therapy, should 
be provided throughout the whole treatment process. Genetic counseling is highly 
recommended. Reports have indicated that the risk of clefting, in isolated CLP cases, 
in a sibling of an affected child is 3% to 5%; this increases to about 10% to 20% if any 
first-degree relative or other family member is also affected. The risk is significantly 
higher in syndromic cases [42–45].
CONCLUSION
CLP is a common human birth defect of complex etiology including multiple 
genetic and environmental factors. Complete understanding of causes and asso-
ciated risk factors requires extensive research through epidemiological, animal 
models, and genetics studies. It is only possible for a CLP patient to receive the 
essential care and support that help ensure better living conditions with the sup-
port of a multidisciplinary approach from a dedicated team of professionals from 
various fields.
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10 Obesity and 
Gestational Diabetes
Maria Farren and Michael J. Turner
INTRODUCTION
Maternal obesity in early pregnancy is an important risk factor for gestational dia-
betes mellitus (GDM) [1]. Epidemiological studies show that both conditions are 
prevalent and at an increasing rate worldwide, and they are associated with increased 
fetomaternal complications. They carry lifelong consequences for both the mother 
and her offspring, and thus place heavy demands on health care resources [1–3]. 
Authors of a meta-analysis concluded that GDM was increased twofold in women 
with mild obesity, fourfold in women with moderate obesity, and eightfold in women 
with severe obesity [1], as compared with women with a normal body mass index 
(BMI). There is little consensus internationally about the diagnosis and subsequent 
management of GDM, which results in wide variations in obstetric care in countries 
throughout the world [4,5]. Whereas much of the debate around GDM is focused 
on the screening tests used and the diagnostic criteria involved, until recently little 
attention has been given to the importance of preanalytical glucose sample handling 
and the subsequent effect this has on diagnostic accuracy [6]. This has the potential 
to revolutionize our approach to GDM in the future.
DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS
GDM may be defined as any degree of glucose intolerance with onset or first recogni-
tion during pregnancy [7]. This includes women with type 2 diabetes mellitus (T2DM) 
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who present for the first time during pregnancy. Other experts define women with 
GDM as those with onset or first diagnosis during pregnancy who return to nor-
moglycemia postnatally [8,9]. The original laboratory criteria used for diagnosis of 
GDM were based on oral glucose tolerance test (OGTT) values, which determined 
the risk of developing T2DM in a nonpregnant population and were not based on any 
increased pregnancy risk to the woman or her offspring [10].
The findings of the Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) 
study, which was a large, international multicenter study of 25,000 women, led to 
recommendations that revised the diagnostic thresholds for diagnosis of GDM. In 
2010, the World Health Organization (WHO) convened an international group of 
experts to review recommendations for the diagnosis of GDM in light of the findings 
of the HAPO study [9]. This panel recognized that the existing recommendations 
published in 1999 were not evidence based. A systematic review was undertaken, 
focused on studies that looked at short-term pregnancy outcomes and perinatal 
outcomes. Potential long-term benefits were not evaluated. The review considered 
the effects on pregnancy, when both the International Association of Diabetes and 
Pregnancy Study Groups (IADPSG) and the WHO criteria (which had different 
diagnostic cutoffs) were used. GDM was associated with an increased risk ratio (RR) 
of large for gestational age (LGA) (RR 1.73 of IADPSG, RR 1.53 for WHO) and with 
an increased risk of preeclampsia (RR 1.71 for IADPSG, RR 1.69 for WHO). The 
evidence for an increased risk of caesarean section (CS) and shoulder dystocia with 
GDM was weaker. It was predicted that adopting the IADPSG criteria would reduce 
LGA and preeclampsia by 0.32% and 0.12%, respectively, and would have no effect 
on CS rates.
Following the convening of this expert panel three important recommendations 
were made by the WHO:
 1. Hyperglycemia detected at any time during pregnancy must be classified as 
either:
 a. Diabetes mellitus in pregnancy (DMIP)
 b. Gestational diabetes mellitus
 2. DMIP should be diagnosed by the 2006 WHO criteria for diabetes if one or 
more of the following criteria are met:
 a. Fasting plasma glucose ≥11.1 mmol/L (200 mg/dL)
 b. Three-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) following a 75 g 
oral glucose load
 c. Random plasma glucose ≥11.1 mmol/L (200 mg/dL) in the presence of 
diabetes symptoms
 3. GDM diagnosed in pregnancy should be based on the following:
 a. Fasting plasma glucose of 5.1–6.9 mmol/L (92–125 mg/dL)
 b. One-hour post 75 g oral glucose load ≥10.0 mmol/L (180 mg/dL)
 c. Two-hour post 75 g oral glucose load 8.5–11.0 mmol/L (153–199 mg/dL)
In the interest of consensus, WHO decided to adopt the IADPSG criteria for the 
diagnosis of GDM. Screening for GDM in pregnancy, however, continues to vary 
worldwide [5]. In Europe, women are selectively screened based on a host of risk 
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factors including BMI, a family history of diabetes mellitus (DM), ethnicity, previ-
ous history of GDM, macrosomia (≥4.5 kg) or stillbirth, or metabolic issues such as 
polycystic ovarian syndrome (PCOS) [11]. There is, however, variation in the test 
used for diagnosis. The IADPSG recommends a one-step 75 g 2-hour oral glucose 
tolerance test (OGTT) between 24 and 28 weeks gestation, with additional consid-
eration given to screening women who are at high risk of T2DM based on a fast-
ing or random glucose at the first antenatal visit. In the United States, Canada, and 
Australia, however, the American College of Obstetrics and Gynecology recom-
mends a universal approach, where all women are screened using a 50 g one-hour 
oral glucose challenge test (OGCT) between 24 and 28 weeks gestation [12].
The result of such disparity is reflected in the wide variety of reported prevalence 
of GDM. Within the United States, the prevalence varies from 1% to 26% [3]. A large 
review of European centers identified 32 different estimates of prevalence of GDM. 
In over half the studies (n = 17), the prevalence was between 2% and 6%, with the 
remainder varying between 7% and 25% [5]. Regional variation was observed in that 
the Northern and Atlantic seaboard regions of Europe mostly had a prevalence rate 
below 4%, while many areas of Southern Europe and the Mediterranean seaboard 
exceeded 6%. Of note, most of the previously reported European studies used a 100 g 
OGTT.
The type of OGTT used is only one factor accounting for the wide variety in 
the prevalence of GDM. The criteria used, the gestational age at which women 
are screened, the ethnicity of the population, the obesity levels of the population 
screened, and even whether the screening is universal or selective further compli-
cates the issue of diagnosis. Moreover, many women with an abnormal OGTT do 
not have a postnatal OGTT to determine if they remain glucose intolerant, making it 
difficult to determine whether they have GDM or T2DM [13].
The way in which the samples of maternal glucose are handled as a subject until 
now has received scant attention. The importance of glycolysis postsampling in the 
accurate measurement of plasma glucose level is well established [14]. Blood glu-
cose  levels fall proportionate to time, in particular when the time from sampling 
to analysis exceeds 90 minutes [15,16]. The HAPO study attempted to standardize 
research conditions across all 15 centers with special attention being paid to how the 
samples were handled and analyzing maternal glucose centrally [17]. Subsequently, 
in 2011 the American Diabetes Association (ADA) recommended stricter guidelines 
for laboratory standards when diagnosing diabetes mellitus. It is recommended that, 
when using fluoride tubes to prevent glycolysis, “one should place the sample tube 
immediately in an ice-water slurry, and plasma should be separated from the cells 
within 30 mins” [18]. Although most laboratory scientists understand this, there is a 
paucity of information on the implementation of these strict conditions when screen-
ing women within the maternity services internationally. The impact of implement-
ing such conditions was demonstrated in a prospective observational study in our 
hospital in 2014 [6]. Obese women were recruited after accurate measurement of 
BMI. One group of 24 women had a fasting glucose test in early pregnancy, while 
a second group of 24 women had an oral glucose tolerance test between 24 and 
28 weeks gestation. In both groups paired glucose samples were taken. One sam-
ple was handled under customary conditions (i.e., not placed on ice for transfer), 
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while the other sample was handled under strict research conditions (i.e., on ice with 
immediate analysis). The current WHO diagnostic criteria were used [9]. In the first 
cohort of women who had fasting glucose in early pregnancy, the result was abnor-
mal in 29% of samples analyzed under hospital conditions, as compared to 67% of 
samples analyzed under strict, fast-tracked research conditions (P < 0.01). In the sec-
ond cohort of women, who had an OGTT in the second trimester, the fasting glucose 
was abnormal in 17% of samples analyzed under customary conditions, as compared 
to 54% of samples under research conditions (P < 0.001). These results highlight 
an important aspect of the diagnosis of GDM. Unless strict laboratory standards 
are implemented, we could potentially be underdiagnosing GDM. This finding may 
explain the poor reproducibility of OGTTs reported in the literature [4,19,20].
THE HYPERGLYCEMIA AND ADVERSE PREGNANCY OUTCOME 
(HAPO) STUDY AND GESTATIONAL DIABETES MELLITUS
The HAPO study examined the relationship between mild hyperglycemia in the 
third trimester using a 75 g OGTT and pregnancy outcomes in a multicenter, mul-
ticultural, heterogeneous, ethnically diverse cohort of 25,000 women. The primary 
outcomes were birth weight (BW) >90th percentile, primary CS, neonatal hypogly-
cemia and cord C-peptide, which reflects fetal hyperinsulinemia, >90th percentile. 
A number of observations can be made about this study. There was a wide variation 
in the primary outcome and the incidence of GDM across the 15 field centers. The 
incidence of GDM ranged from 9% to 25%. The cause for such variation remains 
uncertain but is possibly attributable to obesity levels among the study population. 
The primary outcome of CS was 18%, with a variation of 8% to 24%. There was no 
distinction between elective and emergency CS, and there was no analysis by parity. 
Neonatal hypoglycemia ranged from 0.3% to 6% between centers. However, this 
was not based on the measurement of neonatal glucose in all cases but was based on 
recording in medical charts.
The IADPSG Consensus Panel, established after publication of the HAPO study, 
recommended that OGTTs be performed between 24 and 28 weeks gestation [21]. 
The HAPO study was intended to exclude women with overt DM [22]. However, the 
panel also noted that women with preexisting or overt T2DM might not be diagnosed 
until they actually become pregnant and this issue become more prominent as obe-
sity rates continue to rise. It further recommended early testing of populations with 
a high prevalence of T2DM.
When establishing increased risk with mild hyperglycemia, the IADPSG con-
cluded that the predefined value for this odds ratio (OR) at the threshold relative to the 
mean should be 1.75 for the fasting, 1-hour and 2-hour plasma glucose of the cohort. 
Within the HAPO cohort, approximately 2% were unblinded due to severe hypergly-
cemia [23]. When the remaining cohort was considered, the diagnosis of GDM was 
made on the fasting glucose in 8% of cases, the 1-hour glucose in an additional 5%, 
and the 2-hour glucose in 2% [21]. A further prospective observational study carried 
out in our hospital examined the role of the fasting, 1-hour and 2-hour tests in the 
OGTT [24]. Paired samples were taken from 155 women. One sample of the pair was 
handled under normal hospital conditions (i.e., not on ice), whereas a second sample 
149Obesity and Gestational Diabetes
was immediately put on ice and underwent fast-tracked analysis. Again, the rates of 
diagnosis were higher in the samples collected under research conditions, but it was 
also concluded that, based on the IADPSG criteria for diagnosis, GDM could be 
diagnosed on the fasting sample in 86% of cases, and on the 1-hour sample in the 
remaining 14% of cases. The 2-hour sample was not required for the diagnosis of 
GDM. This could potentially eliminate the need for the 2-hour OGTT, which would 
make the test more time efficient and tolerable for women and hospital staff alike.
The subsequent response following HAPO remains controversial. The OR of 1.75 
was chosen arbitrarily and the reproducibility of IADPSG criteria is unknown [19]. 
When we consider the HAPO findings, we must also consider what we now know 
about preanalytical sample handling. In the future, it may not be necessary for women 
to undergo a 2-hour OGTT. It also may not be necessary for women with GDM to 
receive the intensive fetal and maternal monitoring previously received by women with 
GM, and which should continue to be received by women with T1DM and T2DM.
CATEGORIZATION OF MATERNAL OBESITY
We have already considered in detail the challenges of accurately diagnosing GDM, 
but must also consider the categorization of maternal obesity [25]. A diagnosis of 
obesity is usually made based on the WHO categorization of BMI, which is a sur-
rogate measure for adiposity and does not provide information on the distribution of 
adiposity. It also does not reflect the possibility that there is variation in adiposity in 
different ethnic groups at the same BMI measurement [26]. This may explain why 
GDM is more common in certain ethnic groups.
Most epidemiological studies base the calculation of BMI on weight and height 
that is self-reported, which leads to 22% of women being assigned to the wrong BMI 
category and the diagnosis of obesity being missed in 5% [27]. A Canadian study of 
2,667 women demonstrated the pitfalls of self-reported height and weight. Women 
in this study were being screened for T2DM outside of pregnancy, and self-reported 
both height and weight. This led to an exaggerated risk in obese women because 
women who were mildly obese reported themselves in the overweight and not the 
obese category [28].
The impact of accurate diagnosis of obesity is particularly important in countries 
where obesity is an indication for selective screening for GDM. Many studies use 
prepregnancy self-reported weight, which is unreliable [29]. Other studies use the 
weight and BMI calculated at the first antenatal visit. This calls into question the 
optimum timing of the calculation of BMI. Ideally, recording of BMI should take 
place before 18 weeks gestation [4]. Therefore, if the first antenatal visit takes place 
after 18 weeks, this measurement may not be accurate.
There is little information on the prevalence of obesity in pregnancy, unlike the 
well-documented rise in obesity in the nonpregnant adult population in developed 
countries [30]. In our hospital, based on accurate measurement of height and weight, 
17% of women booking for antenatal care are obese and 1 in 50 are morbidly obese 
with a BMI ≥39.9 kg/m2 [31].
In an analysis in the United States between 2004 and 2006, which only included 
seven states, 21% of women were obese with a prevalence of GDM of 4% [32]. 
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The prevalence of GDM in normal-weight women was approximately 2%, but was 
5% in overweight women, approximately 6% in women with mild obesity, and 12% 
in women with moderate or severe obesity. However, it is worth noting that these 
rates were based on self-reported prepregnancy weight. It is not clear what popu-
lation was screened and how. However, this does highlight the close relationship 
between increasing obesity and GDM.
In a study of white European women in our hospital, 547 women were selectively 
screened using the 100 g OGTT [33]. Compared with overweight women, women 
with mild obesity were not more likely to have an abnormal OGTT, but women 
with moderate and severe obesity were more likely to have an abnormal result (P = 
0.008). Nearly one in four women in this study with moderate or severe obesity had 
an abnormal OGTT. The risk of abnormal OGTT increased at the 90th percentile for 
BMI, which was 33 kg/m2 and not the standard cutoff for obesity of >29.9.0 kg/m2.
In another study of women with moderate to severe obesity, 100 women were 
offered screening before 20 weeks gestation, and if results were normal, the OGTT 
was repeated at 28 weeks gestation [34]. Prior to 20 weeks gestation, 88 women were 
screened, of whom approximately 21% had an abnormal OGTT. Of these 88 women, 
11% had an abnormal early OGTT, and 10% had an abnormal OGTT at 28 weeks. 
This suggests that obese women diagnosed with GDM may have impaired glucose in 
early pregnancy and calls into question the optimum gestation at which we should be 
screening. Screening should be performed early and, if negative, should be repeated 
at between 24 and 28 weeks gestation. This is to ensure that GDM is not missed or 
diagnosis delayed. The clinical outcomes of treating GDM in early pregnancy are 
not known, and may depend on BMI levels and gestational weight gain before the 
diagnosis [35].
MATERNAL OBESITY AND GESTATIONAL DIABETES MELLITUS
The relationship between maternal BMI and hyperglycemia is poorly characterized 
because BMI has not been calculated accurately in early pregnancy and the defini-
tion of GDM has varied over time and between studies. There is uncertainty around 
the role of inflammatory biomarkers in the interplay between obesity and GDM. It 
is difficult to ascertain if inflammation in obese women contributes to the develop-
ment of GDM or whether abnormal inflammatory biomarkers reflect an epidemio-
logical association [36]. There is also uncertainty around the role of hyperglycemia 
in programming intrauterine fetal growth development and whether other metabolic 
abnormalities such as hypertriglyceridemia may be of greater importance [37].
It was previously thought that increasing obesity levels may lead to an increase 
in the rate of fetal macrosomia. However, there is no evidence at present to suggest 
an increasing fetal macrosomia rate in developed countries, despite rising rates of 
obesity and GDM [38].
THE HAPO STUDY AND MATERNAL OBESITY
A secondary analysis of the HAPO study specifically focused on the association 
between maternal obesity, GDM, and adverse pregnancy outcome. This found that 
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both GDM and obesity were independently associated with adverse outcomes such 
as CS, birth weight, and birth injury [39]. However, it is worth noting that the diagno-
sis of obesity was not made until the time of the OGTT, at between 24 and 32 weeks 
gestation, and that the categorization for obesity was based on BMI ≥33 kg/m2, the 
90th percentile for BMI in the study above and not the WHO standard of 29.9 kg/m2 
[7]. To allow for weight gain during pregnancy, the recategorization of BMI at OGTT 
was based on prepregnancy BMI and gestational age at the time of testing. This, 
however, assumed weight gain in pregnancy to be linear and did not consider the 
wide variation in timing of the OGTT.
When we consider the outcomes, the OR for the different statistical models found 
that the associations with GDM were consistently stronger than the associations with 
obesity at the OGTT. There was no association between obesity alone with shoulder 
dystocia/birth injury despite obesity alone having an OR of 1.7 (95% CI: 1.5, 2.0) for 
BW >90th percentile. This was shown in a previous meta-analysis that showed no 
relationship between obesity and shoulder dystocia [30].
Following the findings of HAPO, obese women were recommended to follow the 
Institute of Medicine guidelines with regard to gestational weight gain. This included 
all obese women, both those with and without GDM. However, it is worth noting 
that obese women already gain less weight in pregnancy than nonobese women. 
Therefore, weight management interventions during pregnancy in obese women with 
GDM may not lead to improved clinical outcomes [29].
THE RISKS AND BENEFITS OF SCREENING 
FOR GESTATIONAL DIABETES MELLITUS
The debate continues about the risks and benefits of screening for GDM and the 
optimum management once the diagnosis is made [22,40]. While there is consensus 
that women with a BMI ≥29.9 kg/m2 should be screened, in certain ethnic groups, 
the diagnosis of obesity should perhaps be made at a lower BMI [33].
One of the disadvantages of screening, however, is that it may lead to further 
testing, ultrasound examinations, and medical interventions, such as the induction of 
labor and CS. We must also be mindful that ultrasound examination of fetal growth 
is more technically challenging in the obese woman [41]. This can lead to potential 
overdiagnosis of fetal macrosomia and subsequent unnecessary intervention. For 
example, induction of labor in the obese woman is more likely to be unsuccessful, 
resulting in an increase in emergency CS. It is also important to note that obese 
women are more likely to need CS, even in the absence of GDM [42]. The increase 
in CS rates in obese women with GDM may become a self-fulfilling prophecy, and 
result in more adverse outcomes due the risk associated with this cohort.
A meta-analysis in 2009 quantified the risk of developing T2DM in women 
diagnosed with GDM [43]. This included 20 studies involving 675,455 women. 
Compared to women who did not have GDM, women with GDM had an increased 
risk for T2DM (RR of 7.4) [43]. The diagnosis of GDM was not standardized, and 
the duration of the follow-up varied. However, the authors concluded that GDM 
was a low-cost screening test of T2DM. This raises the possibility that initiating 
cardioprotective interventions in obese women with GDM may reduce their risk of 
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cardiovascular disease, and its complications in later life. The ADA now recom-
mends annual testing for women in the prediabetes range and testing every 3 years 
for women with GDM [11].
CONCLUSION
Based on the implementation of the HAPO findings and subsequent research, the 
number of women diagnosed with GDM will double, and one in three pregnan-
cies in obese women may be complicated with GDM. This may further increase 
should the strict handling of glucose samples be implemented. The strength of the 
relationship between maternal obesity and GDM remains uncertain. What interven-
tions, either prepregnancy or in the antenatal period, may lead to improved clinical 
outcomes for the woman and her baby also remain to be determined.
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11 Nutrition and 
Hypertensive Disorders 
of Pregnancy
Antonia W. Shand and Tim J. Green
INTRODUCTION
Hypertensive disorders of pregnancy (HDP) affect 4% to 9% of women and are 
among the leading causes of maternal and perinatal morbidity and mortality world-
wide [1]. In low-income countries where maternal mortality is high, HDP-related 
maternal death ranges from 9% of deaths in Asia and Africa to 26% in South 
America. In high-income countries where maternal mortality rates are lower and 
effective diagnosis and treatment are available, HDP still account for 16% of mater-
nal deaths [2]. The burden of maternal morbidity, perinatal morbidity and mortal-
ity, and costs to health care systems are even higher. There has been considerable 
interest in identifying modifiable risk factors, such as nutritional and lifestyle factors 
that might reduce the burden of HDP. Nutrition interventions, such as dietary modi-
fication and micronutrient supplementation, have been explored in relation to HDP 
risk and, given that obesity is associated with an increased risk of HDP, lifestyle 
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interventions have also been investigated. In this chapter, following an overview of 
HDP and its pathogenesis, we examine the evidence relating to nutrition and HDP, 
and try to elucidate some of the mechanisms by which nutrition may influence HDP.
DEFINITION, TREATMENT, AND OUTCOME
HDP include preeclampsia (PE), gestational hypertension, PE superimposed on 
preexisting (chronic) hypertension, and chronic hypertension. Although there are 
several classification systems, PE generally refers to the onset of hypertension with 
either proteinuria and/or end organ dysfunction in a previously normotensive woman 
[3]. PE can be categorized as early (<34 weeks gestation) or late (≥34 weeks ges-
tation) onset, depending on when it first develops. Gestational hypertension is the 
development of hypertension in a pregnant woman after 20 weeks gestation, without 
the presence of protein in the urine or other signs of PE. Hypertension in pregnancy 
is defined as a systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure 
of ≥90 mmHg. Overall, HDP affects 3.6% to 9.1% of all pregnancies, with PE affect-
ing 1.4% to 5% of pregnancies; however, early-onset PE affects only 0.3% to 0.7% 
of pregnancies [1,4].
Maternal morbidity from PE may be significant, including stroke, renal failure, 
eclampsia (seizures), or pulmonary edema [4]. In addition, perinatal and infant mor-
bidity may result from iatrogenic or spontaneous preterm birth (<37 weeks gesta-
tion), and may lead to chronic lung disease, cerebral palsy, and neurodevelopmental 
disability [5]. An emerging concept is that PE may have several subtypes by gesta-
tion, resulting in varying degrees of intrauterine growth restriction, maternal hyper-
tension, and maternal organ system involvement [6].
Treatment for PE is delivery of the fetus. When PE occurs preterm (<37 weeks 
gestation), the risks and benefits of delivery in terms of fetal, neonatal, and mater-
nal outcomes must be evaluated [7]. Optimal antenatal treatment may include the 
provision of antenatal steroids for fetal lung maturation, transfer to an appropriate 
hospital for birth, magnesium sulfate for fetal and/or maternal neuroprotection, and 
expectant care or delivery, depending on the severity of PE and gestational age. 
Antihypertensive treatment is recommended for severe hypertension (BP ≥160/110) 
to reduce the risk of stroke. However, guidelines for less severe hypertension vary 
in terms of the medications recommended and the blood pressure targets utilized. It 
is recommended that women with gestational hypertension be observed for features 
of PE <37 weeks, with the consideration of delivery at term, despite a low risk of 
adverse outcomes [3,7].
PATHOPHYSIOLOGY OF HYPERTENSIVE 
DISORDERS OF PREGNANCY
PE is a multisystem syndrome with multifactorial causation. Reduced uterine perfu-
sion and/or certain disease states (e.g., metabolic, immune, and cardiovascular) are 
associated with the maternal and placental abnormalities. In addition, there may be 
a genetic component predisposing women to the development of PE and influenc-
ing its severity [8]. It is proposed that PE is a two-stage disorder (see Figure 11.1), 





































































































































































































































































































































































































































































































































































































































































































































































158 The Biology of the First 1,000 Days
with abnormal placentation leading to a maternal inflammatory response [9]. First, 
defective trophoblast invasion during early implantation may contribute to the 
release of vasoactive agents and subsequent remodeling of the uterine spiral arter-
ies. This ultimately presents as defective uteroplacental blood circulation and pla-
cental ischemia. The second stage is a maternal systemic inflammatory response 
and maternal endothelial dysfunction. This results in the manifestation of clinical 
features, such as hypertension, proteinuria, cerebrovascular effects, and hepatic dys-
function, which may occur sometime later in pregnancy [8]. Interestingly, women 
with HDP are at greater risk of of cardiovascular disease in later life, the incidence 
of which is associated with the severity and gestation of onset in pregnancy, and the 
severity of intrauterine growth restriction [10].
The placental features of PE include a smaller placenta, excessive syncytial knots, 
infarcts covering more than 10% of the placental area, decidual vasculopathy includ-
ing unconverted spiral arterioles, fibrinoid necrosis, atheroma, thrombosis of the 
uteroplacental vessels, the absence of intermediate villi (distal villous hypoplasia), 
and placental erythroblastosis [11]. These changes are thought to occur as a result 
of reduced perfusion or hypoxia of the maternal–fetal interface leading to oxidative 
stress, which can be detected long before signs of PE appear [9,11].
RISK FACTORS FOR HYPERTENSIVE DISORDERS OF PREGNANCY
Maternal, placental, and fetal mechanisms associated with inflammation, immune 
responses, and metabolism may have a role in the development of HDP, and these 
may be influenced by nutrition. Risk factors for HDP include obesity, diabetes, pre-
vious hypertensive disorders, polycystic ovarian syndrome, multiple pregnancy, first 
pregnancy, later gestation, ethnicity, extremes of maternal age, renal disease, the 
presence of antiphospholipid antibodies, prolonged interpregnancy interval, assisted 
reproductive technologies, a family history of PE, and a new partner [7].
There is a substantial amount of evidence to suggest that many foods, nutrients, 
and nonnutrient food components modulate both acute and chronic inflammation. 
However, the mechanisms underlying the association between maternal nutrition 
and HDP are unknown, with genetic, inflammatory, hormonal, metabolic, and vas-
cular changes proposed [8,12].
OBSERVATIONAL STUDIES OF DIETARY PATTERNS 
AND HYPERTENSIVE DISORDERS OF PREGNANCY
A systematic review and meta-analysis of observational studies has reported an 
association between HDP and several dietary factors [13] (Table 11.1). Women who 
had low calcium intake from their diet, lower magnesium intake, and higher energy 
intake were more likely to be diagnosed with HDP. The few studies on diet included 
in the meta-analysis suggest a trend toward a beneficial effect of diets high in vegeta-
bles and fruit on PE risk. In a prospective cohort study, prepregnancy fruit intake also 
increased the chance of an uncomplicated pregnancy outcome [14]. In a population-
based study of Australian women, a protective dose response was observed between 
HDP risk and prepregnancy consumption of a Mediterranean-style dietary pattern, 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































161Nutrition and Hypertensive Disorders of Pregnancy
characterized by vegetables, legumes, nuts, tofu, rice, pasta, rye bread, red wine, 
and fish [26]. The authors found a 42% lower risk of HDP in women in the highest 
quartile of Mediterranean-style diet intake compared to women in the lowest quar-
tile. This was similar to findings from a Norwegian study, which found that women 
with a diet high in vegetables, plant foods, and vegetable oils had a lower risk of PE 
[27]. This may be attributable to specific flavonoids that affect inflammation [28]. 
It has been proposed that unresolved chronic inflammation is a cause of a range of 
chronic diseases, and that diet may have anti-inflammatory and proinflammatory 
components. However, the mechanisms by which diet influences HDP risk has not 
been well studied.
OBESITY
Obesity, defined as a body mass index greater than 30 kg/m2, has been identified as a 
major risk factor for the development of HDP. Obesity not only increases the risk of 
entering pregnancy with high blood pressure, but it also independently increases the 
risk of PE. Obesity rates are rising not only in Western countries such as the United 
States, where 50% of pregnant women are overweight or obese (BMI ≥25 kg/m2), but 
also in middle-income countries, such as India and China. Rates of PE have risen in 
tandem with rising rates of obesity. The degree of obesity and risk of PE is a graded 
relationship, where with a normal BMI (18.5–24.9 kg/m2) the risk is 3%, rising to 
13% in the superobese (BMI ≥50 kg/m2) [29].
Obesity is a risk factor for a number of other adverse pregnancy outcomes, 
including gestational diabetes, macrosomia, birth trauma, preterm birth, fetal 
anomalies, and stillbirth. Excessive weight gain during pregnancy has also been 
associated with an increased risk of PE [30]. This is, in part, why the Institute of 
Medicine recommends weight gain in pregnancy based on prepregnancy weight, 
with obese and overweight women recommended to gain less weight than normal 
weight women [31].
The mechanisms by which obesity leads to adverse pregnancy outcomes as 
well as chronic diseases are likely to be similar. Obesity can lead to a proin-
flammatory state with elevated cytokine levels, possibly making these women 
more susceptible to PE. Body mass index is also associated with the activation 
of inflammatory pathways in the placenta. It has been suggested that increased 
related metabolic factors alter uteroplacental vascular remodeling leading to pla-
cental ischemia, which in turn leads to exaggerated release of soluble placental 
factors, such as anti-angiogenic sFlt-1 and proinflammatory TNF-α and AT1-AA. 
Obesity can lead to an exaggerated response to placental factors, ultimately lead-
ing to reduced renal excretory function and hypertension. Obesity also increases 
the risk of type 2 diabetes mellitus and gestational diabetes, both of which are 
associated with HDP; women with poor glycemic control are at even higher risk 
[32]. Hyperglycemia may lead to oxidative stress and inflammation via nitric 
oxide (NO) pathways, thereby reducing NO concentrations and causing impair-
ments in vasodilation [33].
A number of clinical trials have examined the effect of dietary and lifestyle 
interventions to promote appropriate weight gain in both obese and normal weight 
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pregnant women, with and without gestational diabetes mellitus. Overall, the use 
of mainly dietary interventions, including energy-restricted or cholesterol-lowering 
diets, healthy dietary advice provided by a trained nutritionist, and the use of food 
diaries, was found to be associated with a 33% reduced risk of PE compared to con-
trols (RR 0.67, 95% CI: 0.53, 0.85; 6 studies, n = 2,695 women). However, there was 
no reduction in the risk of PE with mixed interventions that included diet, physical 
activity, and lifestyle (RR 0.93, 95% CI: 0.66, 1.32; 6 studies, n = 1,438 women) [15]. 
Subsequent to this meta-analysis, in the largest study to date, Dodd et al. [16] ran-
domized 2,252 women with a BMI ≥25 kg/m2 between 10 and 20 weeks of gestation 
to either dietary and lifestyle intervention or standard care. In this trial, they found 
no difference in rates of hypertension (RR 1.05, 95% CI: 0.81, 1.38) or PE (RR 1.03, 
95% CI: 0.71, 1.47) between the intervention and control groups. However, it should 
be noted that the intervention did not result in a lower gestational weight gain com-
pared to the control (9.39 kg versus 9.44 kg). Likewise, the UPBEAT trial random-
ized 1,555 obese pregnant women with a mean BMI of 36 kg/m2 to diet and activity 
or usual care, and found no difference in the rates of hypertensive disorders (RR 1.00, 
95% CI: 0.59, 1.69) [17]. Thus, the effects of intervention to prevent excess weight 
gain on pregnancy outcomes such as HDP still remain to be determined. Currently, 
the World Health Organization (WHO) recommends that all women receive coun-
seling about healthy eating and keeping physically active during pregnancy to stay 
healthy and to prevent excessive weight gain during pregnancy [34].
CALCIUM
The idea that calcium could reduce HDP came from Mayan Indians, who have a low 
incidence of PE and a high calcium intake due to their practice of soaking corn, a 
dietary staple, in lime (calcium oxide or calcium hydroxide) prior to cooking. A recent 
meta-analysis reported that women with the lowest quintile of dietary calcium intake 
were more likely to be diagnosed with HDP than women with the highest quintile 
of calcium intake (gestational hypertension, adjusted OR 0.63, 95% CI: 0.41, 0.97 
and, overall, HDP adjusted OR 0.76, 95% CI: 0.57, 1.01; 5 studies, n = 2,203 women) 
[13]. A subsequent meta-analysis reported a significant reduction in the risk of PE 
with calcium supplementation (RR 0.45, 95% CI: 0.31, 0.65; 13 studies, n = 15,730 
women). In particular, the effect was greatest for women with low calcium diets (RR 
0.36, 95% CI: 0.20, 0.65; 8 studies, n = 10,678 women) and women at high risk of 
PE (RR 0.22, 95% CI: 0.12, 0.42; 5 studies, n = 587 women) [18]. Calcium supple-
mentation was also associated with a lower rate of gestational hypertension, with or 
without proteinuria (RR 0.65, 95% CI: 0.53, 0.81; 12 studies, n = 15,470 women). 
Again, a larger effect size was seen in areas with low background dietary calcium 
and in women already at a high risk of PE. Based largely on these meta-analyses, 
the WHO has issued guidelines recommending that women in areas where calcium 
intake is low take 1.5 to 2.0 g of oral elemental calcium daily to reduce the risk of PE. 
Calcium intake is typically low in areas where the main dietary source of calcium is 
grains. The WHO guidelines also emphasize the need for pregnant women at risk of 
gestational hypertension to take calcium supplements [34].
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The mechanism for how calcium influences vessel contractility and how supple-
mentation decreases HDP and PE is unknown. Low dietary calcium intake may lead 
to lower serum calcium and, in response, increased parathyroid hormone that may 
lead to higher levels of intracellular free calcium. Increased parathyroid hormone 
has been shown to be associated with raised blood pressure and has vasoconstrictive 
properties. Higher intracellular free calcium levels result in smooth muscle contrac-
tility and vasoconstriction. Other pathways, including the renin-angiotensin system, 
or antiangiogenic factors may play a role in PE [35].
VITAMIN D
Vitamin D deficiency, assessed by measuring 25-hydroxyvitamin D (25OHD) con-
centration, is common among pregnant women, with a prevalence of over 80% 
in some countries [36]. Because humans normally synthesize vitamin D through 
their skin by the action of ultraviolet (UV) light, populations of women who live 
at extremes of latitudes or “cover up” for religious or cultural regions tend to be at 
greatest risk. Low 25OHD during pregnancy has been associated with an increased 
risk of HDP in some but not all observational studies [37]. There have been at least 
five meta-analyses of the association of maternal vitamin D deficiency and risk 
of PE producing very different odds ratios, ranging from 0.78 to 2.11 [38]. The 
meta-analyses differed in their inclusion criteria, used different cutoffs for 25OHD 
to define deficiency, and often reported significant between-study heterogeneity. 
Several more studies have been published on the association between 25OHD and 
PE since the latest meta-analyses, and a number of studies are ongoing.
Vitamin D deficiency impairs calcium absorption and may increase HDP risk 
through similar mechanisms to having a low calcium diet. Vitamin D deficiency 
may also lead to immune dysfunction, abnormal angiogenesis, excessive inflamma-
tion, and hypertension, conditions that are involved in the pathogenesis of PE. In PE, 
high proinflammatory and low anti-inflammatory cytokine concentrations have been 
reported compared to normal pregnancies. Vitamin D receptors are located in the 
placenta, and it is possible that vitamin D deficiency promotes a cytokine profile that 
leads to placental dysfunction and PE [39].
Unfortunately, there have been few randomized trials evaluating vitamin D sup-
plementation and PE risk, and those conducted have often used a combination of 
calcium and vitamin D. The most recent meta-analysis includes data from two trials 
involving 219 women, and suggests that women who received vitamin D supple-
ments may have a lower risk of PE than those receiving no intervention or placebo 
(8.9% versus 15.5%; RR 0.52, 95% CI: 0.25, 1.05) [19]. However, the studies were 
very small, and the rate of PE in these studies was very high, limiting the generaliz-
ability of the findings. The meta-analysis also reported that women who received a 
combination of vitamin D and calcium supplementation had a reduced risk of PE 
compared to controls (5% versus 9%, RR 0.50, 95% CI: 0.32, 0.80; 3 studies, n = 
1,114 women) but an increased risk of preterm birth (RR 1.57, 95% CI: 1.02, 2.43) 
[19]. Conversely, a reduction of preterm birth has been reported in the meta-analysis 
of calcium supplementation with or without vitamin D [34]. These findings suggest 
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the need to determine the independent effects of vitamin D and calcium on HDP and 
other pregnancy outcomes.
At present, there is insufficient evidence to recommend vitamin D supplementa-
tion for PE prevention. Whether vitamin D supplementation will reduce the risk of 
HDP requires well-designed randomized control trials. Careful consideration needs 
to be given to study design, dose of vitamin D, and population.
ANTIOXIDANT NUTRIENTS
Vitamins E and C, as well as selenium, have antioxidant roles in the body. As oxidative 
stress is a known cause of endothelial dysfunction, it has been proposed that lower 
antioxidant levels may predispose women to PE. A recent study found an association 
between midpregnancy antioxidant nutrients and early onset PE [40]. This included 
the ratio of α-tocopherol:cholesterol, retinol, and lutein; however, the sources, such 
as diet or supplement use, were not measured.
Although earlier studies showed promise, the most recent meta-analyses have 
shown no effect of vitamin C or vitamin E supplementation on the risk of PE. There 
was no difference in the rate of PE in women with vitamin C supplementation (with or 
without other vitamins, including vitamin E) compared to placebo or no control (RR 
0.92, 95% CI: 0.80, 1.05; 16 studies, n = 21,956 women) [20]. In the meta-analysis, 
there was no difference in the risk of PE in women with vitamin E supplementation 
(with or without other vitamins, including vitamin C) compared to placebo or no 
control (RR 0.91, 95% CI: 0.79, 1.06; 14 studies, n = 20,878 women) [21]. Therefore, 
vitamin C and E supplementation is not recommended in pregnancy.
An association with selenium deficiency and PE has been found [41]; however, 
there is limited data to support the benefits of selenium supplementation in prevent-
ing HDP. One randomized study, which included 230 primiparous women, found no 
difference in PE rates in women treated with selenium supplementation compared to 
controls. However, given the small number of subjects, the trial was underpowered 
for this outcome [42].
FOLATE
A number of studies have reported an association between folate deficiency and 
observed biomarkers in women at risk of PE. However, there is limited data from 
prospective studies as to whether folate supplementation reduces the risk of HDP 
[43]. A recent prospective cohort study found an association between folate supple-
mentation or multivitamins containing folic acid and a reduction in PE in high-risk 
women (OR 0.17, 95% CI: 0.03, 0.95) [44]. However, a meta-analysis of observational 
studies and randomized studies found no difference in outcomes with folic acid or 
multivitamin containing folic acid [43]. A large multicountry randomized trial con-
ducted among high-risk women (n = 3,656) comparing 4000 μg/d folate versus pla-
cebo has just been completed and is expected to be published in the next year [45].
Folate may exert a protective effect through its role in modifying DNA and influ-
ence on DNA methylation. Elevated homocysteine concentrations, which can be 
lowered by taking folate and certain other B vitamins, have been associated with 
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higher rates of PE in numerous studies. Homocysteine might contribute to the 
placental vasoconstriction and ischemia of PE by increasing collagen deposition in 
arteries leading to vascular thickening, promoting apoptosis in umbilical vein endo-
thelial cells and smooth muscle cells, increasing proinflammatory cytokines within 
blood vessels, and downregulating glutathione peroxidase, thus reducing nitric oxide, 
a major vasodilator.
SALT (SODIUM)
Dietary salt is a well-established risk factor for hypertensive disorders, and a reduc-
tion in salt intake can reduce blood pressure in some people [46]. Excess salt can 
cause the kidneys to retain water, increasing plasma volume, and thereby increasing 
blood pressure. Two trials, both conducted in the Netherlands, compared dietary 
advice to reduce salt intake versus the continuation of a normal diet: one study 
included women with hypertension (diastolic blood pressure >85 mmHg), and the 
other only included healthy women. Neither study, nor the meta-analysis of the two 
studies, showed a significant benefit of sodium restriction on PE risk (RR 1.11, 95% 
CI: 0.46, 2.66; 2 studies, n = 603 women) [22]. At present, salt restriction is not 
recommended in pregnancy, even for women at high risk of PE. The role of sodium 
restriction in the general population for the prevention of cardiovascular disease also 
remains uncertain [47].
ZINC
Zinc is a trace metal with a wide range of metabolic functions. Observational studies of 
serum zinc levels and PE have found conflicting information, with some studies find-
ing an association between low serum zinc levels and HDP, and other studies reporting 
no association [48]. The mechanisms for this association between zinc and PE are not 
entirely understood; however, it is thought that zinc may alleviate oxidative stress by 
increasing antioxidants, or by serving as a cofactor or substrate for the activation of 
antioxidant enzymes. However, a meta-analysis of 21 randomized studies found no dif-
ference in any maternal outcomes including HDP, with zinc supplementation in preg-
nancy compared to controls, although there was a small reduction in the rate of preterm 
birth (RR 0.86, 95% CI: 0.76, 0.97; 16 studies, n = 7,637 women) [23]. Therefore, zinc 
supplementation is not recommended for PE prevention.
MAGNESIUM
Magnesium is an essential mineral that is required for nucleic acid and protein syn-
thesis, body temperature control, and maintenance of nerve and muscle cell electri-
cal potentials. Magnesium occurs naturally in many foods, and studies have shown 
that many women, especially those from disadvantaged populations, have intakes 
that are lower than recommended. Intravenous magnesium sulfate supplementation 
is the first-line anticonvulsant of choice in the prevention and treatment of eclampsia 
and has been used for this purpose for many years [49]. However, the mechanism of 
action, optimal dosing regimen, and pharmacokinetic properties remain unknown. 
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The use of intravenous magnesium sulfate gave rise to the idea that magnesium sul-
fate supplementation in pregnancy might reduce the risk of HDP. In a systematic 
review and meta-analysis of studies, oral magnesium supplementation in pregnancy 
compared to no magnesium or placebo was associated with no significant difference 
in PE (RR 0.87; 95% CI: 0.58, 1.32; 3 studies, n = 1,042 women), perinatal mortality, 
or small-for-gestational age fetuses. Therefore, oral magnesium supplementation is 
not recommended in pregnancy [24].
MARINE OILS
Greenland Inuit have lower rates of HDP than other populations, ascribed to their 
intake of marine oil, which contains high amounts of long-chain omega-3 fatty 
acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) [49]. 
Omega-3 fatty acids have been shown to give rise to cytokines, which have anti-
inflammatory properties. In contrast, omega-6 fatty acids, such as arachidonic acid, 
which predominate in most Western diets, give rise to cytokines that have proin-
flammatory effects and promote vasoconstriction. PE and gestational hypertension 
are associated with vasoconstriction and endothelial damage. Both DHA and EPA 
compete with the thromboxane A2 precursor, arachidonic acid, and downregulate 
these responses.
In the most recent systematic review of studies of marine oils and HDP, there 
was no difference in either the rate of high blood pressure during pregnancy or the 
incidence of PE in women treated with marine oils compared to controls (RR 0.93, 
95% CI: 0.66, 1.32; 6 studies, n = 2,304 women) [15]. Most of these studies were 
completed in women with previous pregnancy complications, usually gestational 
hypertension. One exception was a study that randomized 2,399 low-risk pregnant 
women with singleton pregnancies to DHA-enriched fish oil (800 mg) or placebo 
from midpregnancy. However, they also found no difference in the rate of gestational 
hypertension (RR 0.97, 95% CI: 0.74, 1.27) or PE (RR 0.87, 95% CI: 0.60, 1.25) in 
the women treated with fish oil compared to placebo [50].
CONCLUSION AND FURTHER RESEARCH
The mechanisms by which diet and/or dietary supplementation influence HDP are 
not well understood. Currently, it appears that calcium supplementation in women 
with a low calcium diet reduces the risk of HDP. A diet high in vegetables and fruit 
also appears to increase the odds of an uncomplicated pregnancy outcome; however, 
analyzing diet separately to other lifestyle considerations is difficult. Prepregnancy 
weight loss and glycemic control in women with diabetes mellitus have evidence for 
benefit. Further studies are needed to assess the effect of vitamin D, with or with-
out calcium, and folate supplementation in pregnancy. Further studies would benefit 
from standardized definitions of HDP, and describing risk factors for HDP, includ-
ing maternal and family history, blood pressure, body mass index, uterine artery 
Doppler studies, and biomarkers. Ideally, future intervention studies should enroll 
women either prepregnancy or very early in pregnancy, when placentation occurs; 
however, this comes with logistic issues.
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INTRODUCTION
The first 1,000 days, a period that spans from conception until 2 years of age, is 
a critical period of life. Optimal growth and development during this sensitive 
period is central to neonatal health and, ultimately, health throughout the lifespan. 
Furthermore, growth is dependent upon several elements, including maternal, fetal, 
placental, and environmental factors. However, in unfavorable prenatal conditions, it 
is hypothesized that permanent growth restriction and adult disease risk can occur [1].
This chapter will focus on the biology of the postnatal consequences of low birth 
weight (LBW) and small for gestational age (SGA). Related to these consequences is 
intrauterine growth restriction (IUGR), a prenatal observation of growth restriction 
proven either by a documented reduced fetal growth velocity and/or by the presence 
of specific causes such as fetal infection, compromised placental blood flow, or toxic 
effects. However, a child born SGA or LBW might have not suffered IUGR, and a 
baby born after a short span of IUGR might not be SGA or LBW.
LOW BIRTH WEIGHT
Historically, from the 1920s to the 1950s the terms low birth weight and premature 
were used synonymously in literature [2]. In 1950, the World Health Organization 
(WHO) Expert Group on Prematurity declared that an infant of birth weight under 
5.5 pounds (~2,500 grams) should be termed premature [3]. However, epidemiologi-
cal studies in the 1950s and 1960s made it evident that not all babies born small are 
premature, and not all premature babies are small. Recognizing this difference, in 
1961 the WHO Expert Committee on Maternal and Child Health recommended that 
the two terms be used distinctly, and that the concept of prematurity in the definition 
should give way to that of LBW [4].
LBW is defined as a neonate who weighs <2,500 grams regardless of gestational age 
(until 1976, the WHO defined this as less than or equal to 2,500 grams) [5]. Birth weight 
BOX 12.1 KEY DEFINITIONS
Small for gestational age (SGA)—An infant who weighs <10th percen-
tile of the birth weight for gestational age, gender-specific reference 
population.
Low birth weight (LBW)—An infant who weighs <2,500 grams regard-
less of gestational age.
Intrauterine growth restriction (IUGR)—A prenatal condition in which 
a fetus’s estimated weight is below the recommended gender-specific 
weight for gestational age.
Preterm—Preterm is referred to as birth before 37 completed weeks of 
gestation or fewer than 259 days since the first day of a woman’s last 
menstrual period.
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is directly determined by the period of gestation and the rate of fetal growth [6]. Thus, 
LBW can be a consequence of being born too early (preterm) or too small (SGA). SGA 
is not always a consequence of a pathology and includes two groups: those who have 
achieved their growth potential but are constitutionally small, and those who experience 
growth restriction and do not achieve their genetic potential. Thus, the LBW group can 
include preterm neonates, at-term SGA neonates, and the preterm SGA neonates.
Figure 12.1 demonstrates that newborns who are at the expected weight (whether 
preterm or full term) are referred to as appropriate for gestational age (AGA), while 
those who are lower than expected weight for gestation (whether preterm or full term) 
are SGA. LBW can include both AGA and SGA, depending upon gestational age.
SMALL FOR GESTATIONAL AGE
There is no general consensus on the definition of SGA, thus several definitions exist. 
To measure SGA, gestational dating, precise measurements of weight and length at 
birth, and reference population data are key factors to consider. SGA children can be 
born either full term or premature. It is also important to note that being born SGA 
is neither indicative nor synonymous with IUGR, and vice versa, but an overlap can 
occur. The two most common definitions of SGA include [7]: (1) the birth weight 
for gestational age, sex specific, single/twin curve, where the 10th percentile of the 
curve should be used to classify SGA; and (2) the birth weight and/or length is less 
than two standard deviations below the mean for the neonate’s gestational age, based 
on a reference population.
More recently, a multicountry project titled “INTERGROWTH–21st” aimed to 
develop international standards regarding sex-specific fetal (over 33 weeks gestational 
age), newborn, and postnatal growth (see Figure 12.2). Although highly robust and 










FIGURE 12.1 The relationship of birth weight and gestational age for classification of 
LBW and SGA. (Reproduced from Black RE, Victora CG, Walker SP et al., Lancet 2013, 
382:427–51. With permission.)
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THE BURDEN OF LOW BIRTH WEIGHT
According to the latest Global Nutrition Report, in 2014, globally 15% of infants were 
born LBW, or 20 million births per year [9]. Importantly, LBW is also an important pop-
ulation health indicator, as it occurs with greater prevalence in vulnerable populations. 
Estimates of LBW in low- and middle-income regions include 28% in South Asia, 13% 
in sub-Saharan Africa, and 9% in Latin America (see Table 12.1); however, intracountry 
variation exists. It is also worth noting that data on LBW remains limited or unreliable, 
as many deliveries occur in homes or small health clinics and are not reported in official 




































FIGURE 12.2 The INTERGROWTH–21st birth weight for gestational age stan-
dard. (Reproduced from Houk CP, Lee PA, Int J Pediatr Endocrinol 2012, 2012:11. With 
permission.)
TABLE 12.1
Percent of Infants Born Low Birth Weight
Region
Percent (%) of Infants Born 
Low Birth Weight
Percent (%) of Infants Not 
Weighed at Birth
Sub-Saharan Africa 13 54
Eastern and Southern Africa 11 46
West and Central Africa 14 60
Middle East and North Africa – –
South Asia 28 66
East Asia and Pacific 6 22
Latin America and Caribbean 9 10
Source: Adapted from UNICEF global databases, 2014, based on Multiple Indicator Cluster Surveys 
(MICS), Demographic and Health Surveys (DHS) and other nationally representative surveys, 
2009–2013 (for % not weighted is 2008–2012), with the exception of India and Indonesia.
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THE BURDEN OF SMALL FOR GESTATIONAL AGE
The prevalence and incidence of morbidity and mortality is often estimated to under-
stand the impact of SGA and LBW worldwide. However, due to the lack of agree-
ment on an SGA definition, there are no accurate estimates of SGA burden. In 2010, 
an estimated 32.4 million infants were born SGA in low- and middle-income coun-
tries (LMICs). Of these, 19 million were born at term, and 10.6 million were born 
both full term and LBW [11].
RISK FACTORS FOR LOW BIRTH WEIGHT (PRETERM 
AND/OR SMALL FOR GESTATIONAL AGE)
One of the earliest and most detailed reviews on the etiology of LBW, published in 
1987, identified and classified 43 determinants of LBW [5]. The etiology and risk 
factors associated with LBW include those that contribute to preterm births and to 
impaired fetal growth (SGA). However, it is difficult to separate these risk factors as 
many remain common to both, and thus will be discussed together. Notably, nearly 
40% of SGA do not have an identifiable cause. Of the 60% with known etiology, 
approximately 50% are a consequence of maternal factors, 5% a result of fetal fac-
tors, and 5% involve placental abnormalities [12].
The risk factors can be categorized into maternal, paternal, and fetal-related [1,13]:
• Maternal—Physiological and social factors (maternal height, ethnicity, low 
socioeconomic status, young or advanced maternal age, short interpreg-
nancy intervals, poor maternal nutrition [low maternal body mass index, 
undernutrition, micronutrient deficiencies]), lifestyle factors (smoking, 
excess alcohol consumption, drug abuse, stress, excessive physical work), 
and inadequate antenatal care
• Maternal mental health—Depression, domestic violence
• Multiple pregnancy
• Preeclampsia
• Chronic medical illness—Diabetes, hypertension, anemia, asthma, 
thyroid disease, renal disease
• Infections—Urinary tract infection, malaria, bacterial vagino-
sis, HIV, syphilis, Listeria monocytogenes, group B streptococcus, 
chorioamnionitis
• Uterine factors—Bicornuate uterus, incompetent cervix
• Uteroplacental factors—Insufficient uteroplacental perfusion, placenta 
previa, abruptio placentae
• Paternal-related factors—Paternal height or race
• Fetal-related factors—Gender (more common in males), congenital mal-
formations, chromosomal abnormalities, inborn errors of metabolism, con-
genital infections
In addition to these factors, there are some circumstances that increase a 
predisposition to preterm births, including premature rupture of membranes, fetal 
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distress, polyhydramnios, iatrogenic, trauma, and provider- initiated (induction of 
labor or elective caesarean for maternal or fetal indications).
THE ETIOLOGY OF INFANTS OF LOW BIRTH WEIGHT 
AND SMALL FOR GESTATIONAL AGE IN THE 
CONTEXT OF THE FIRST 1,000 DAYS
It is apparent from the risk factors mentioned that the etiology of LBW is multifacto-
rial and complex, including both nutritional and nonnutritional elements. Moreover, 
the factors leading to LBW vary with different geographies and economies. Whereas 
nearly half of all LBW infants born in high-income countries are preterm, most 
LBW infants in LMIC are SGA and have been affected by IUGR.
Nutrition is the most influential environmental factor for fetal development. In 
fact, the prevalent underlying factors accountable for SGA in LMIC are nutrition-
related, namely, poor weight gain in pregnancy, low preconception body mass index 
(BMI), and chronic maternal undernutrition (maternal short stature). It has been 
estimated that more than 50% of all LBW in LMIC can be attributed to poor mater-
nal nutrition preconceptionally and early pregnancy [14]. Following recognition of 
the key role of maternal and fetal nutrition as causes of LBW, the World Health 
Assembly adopted the prevalence of LBW births as a nutrition indicator with a target 
of 30% reduction in prevalence by 2025 [15,16].
Thus, nutrition during the first 270 days of the 1,000 days is the key to healthy 
pregnancy outcomes. However, acknowledging the increasing importance of pre-
conception nutrition, experts are now advocating a life-course approach for women’s 
nutrition, rather than one focused solely on pregnancies.
MATERNAL WEIGHT GAIN DURING PREGNANCY
Of the nutrition-related factors, poor maternal weight gain during pregnancy has 
the strongest association with SGA. The WHO and FAO recommend that dietary 
intake during pregnancy should provide energy sufficient for “the full-term delivery 
of a healthy newborn baby of adequate size and appropriate body composition by 
a woman whose weight, body composition and physical activity level are consis-
tent with long-term good health and well-being.” Energy needs during pregnancy 
are increased to provide for growth of the fetus, placenta, and maternal tissues; the 
increased metabolic demands of pregnancy; maintaining maternal weight, body 
composition, and physical activity throughout pregnancy; and adequate energy 
stores for lactation.
BMI is an index for weight-for-height; the maternal prepregnancy BMI is used 
to assess maternal nutritional status. Recommended weight gain for each woman 
from preconception to delivery is based on her preconception BMI. For example, if a 
woman is underweight (BMI <18.5) she should gain between 12.5 and 18 kg during 
the pregnancy. Women who are overweight or obese preconception need not gain as 
much weight during pregnancy (Table 12.2).
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Adequate weight gain is critical for optimal maternal (e.g., preventing maternal 
morbidity and mortality) and fetal outcomes (e.g., adequate growth and develop-
ment). Maternal BMI, nutritional stores, diet, and placental blood flow determine the 
availability of nutrients to the fetus, which in turn influences fetal maturation and 
weight gain. Although a mother’s body has improved utilization of nutrients during 
pregnancy, these changes might not be sufficient if her prenatal nutritional status or 
her diet during pregnancy is inadequate [17]. An inadequate supply of nutrients has 
a restrictive effect on fetal growth, leading to SGA and LBW [18].
Poor diet during pregnancy, as well as a lack of micronutrient supplementation, 
can lead to micronutrient deficiencies. Anemia (a low hemoglobin concentration) is 
prevalent among women in LMIC, where an estimated 40% prevalence among non-
pregnant and 49% among pregnant women [19]. Anemia may be a cause of iron or 
other micronutrient deficiency, although it has many other genetic and nonnutritional 
causes. Anemia in pregnancy has been associated with an increased risk of maternal 
mortality and fetal growth restriction. It has been hypothesized that periconceptional 
anemia may influence hormone physiology, and that it may adversely affect fetal 
growth [20]. Maternal vitamin D deficiency, especially in early pregnancy, has also 
been shown to increase the risk of preterm birth and SGA [21]. Recent evidence 
suggests that preconceptional and periconceptional intake of multiple micronutrient 
supplements reduces the risk of LBW, SGA, and stillbirths to a greater extent than 
iron, with or without folic acid [22]. This indicates the importance of multiple micro-
nutrients in the maternal diet for fetal growth and development [23].
MATERNAL BODY MASS INDEX
Maternal nutrition is generally a consequence of the interplay of many factors, including 
socioeconomic status, adequate nutrition, cultural norms, heavy labor, multiple pregnan-
cies, and frequent infection. Preconception body mass index (BMI) is a strong predictor 
of pregnancy outcomes and neonatal birth weight. A low BMI (<18.5) is associated with 
TABLE 12.2
Recommended Weight Gain in Pregnancy Based on Prepregnancy 
Body Mass Index
Prepregnancy BMI (kg/m2) Total Weight Gain (kg)
Underweight: BMI <18.5 12.5–18 kg
Normal weight: BMI 18.5–24.9 11.5–16 kg
Overweight: BMI 25–29.9 7–11.5 kg
Obese: BMI ≥30.0 5–9 kg
Source: Adapted from the Institute of Medicine, Weight gain during pregnancy: Reexamining 
the guidelines, Washington, DC: National Academies Press, 2009.
Note: BMI, body mass index.
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a higher risk of preterm delivery; an even greater association is with neonatal weight 
outcomes and a higher risk of LBW and SGA.
The mechanism behind the association could be due to a direct consequence of 
poor nutrition and fewer available calories leading to fetal growth restriction [24]. 
However, other pathways, such as undernutrition leading to immune deficiency 
and infections, or physical labor leading to low BMI, could also explain poor fetal 
outcomes. Moreover, as discussed, maternal micronutrient status is critical for 
fetal growth and development. Preconception iron deficiency is associated with a 
fivefold increase in the risk of fetal growth restriction and a sevenfold increase in 
LBW [25].
MATERNAL SHORT STATURE
Maternal short stature, often a consequence of chronic undernutrition, has been 
shown to have a strong relationship with preterm birth, LBW, and SGA. In the mid-
1990s, the WHO Collaborative Study of Maternal Anthropometry and Pregnancy 
Outcomes described a significant association of maternal short stature with LBW, 
SGA, and preterm birth [24]. More recently, in 2015, the Child Health Epidemiology 
Reference Group SGA/Preterm Birth Working Group published a meta-analysis in 
LMIC, in which they reported that nearly 6.5 million SGA and preterm births from 
these regions may be associated with low maternal height. According to the report, 
5.5 million term SGA (18.6% of the global total), 550,800 preterm AGA (5.0% of 
the global total), and 458,000 preterm SGA (16.5% of the global total) births may be 
associated with maternal short stature. In turn, SGA infants are at a higher risk of 
stunted linear growth; 20% of stunting is attributable to fetal growth restriction [26].
Thus, many infants are born undernourished and underweight because their 
mothers are undernourished and underweight (Figure 12.3) [27]. This negative cycle 
underscores the importance of optimal nutrition for girls and women. Moreover, 
nearly 16 million women aged 15 to 19 years give birth annually [28], and these ado-
lescent pregnancies are associated with increased maternal morbidity and mortality, 
Child growth failure
Small adult woman




FIGURE 12.3 The intergenerational cycle of undernutrition. (Reproduced from World 
Food Programme, WFP Bangladesh: Nutrition strategy 2012–2016, Rome: World Food 
Programme, 2012. With permission.)
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as well as preterm and LBW. In these young pregnancies, both mother and growing 
fetus are competing for nutrients, leading to a higher risk of poor outcomes.
MATERNAL CHRONIC DISEASES
Maternal hypertension and diabetes increase the risk of SGA infants. There is some 
evidence to suggest that prepregnancy hypertension and preeclampsia impair placen-
tal functioning, increasing the risk of poor nutrient and oxygen transfer to the fetus 
and, consequently, growth restriction (see Chapter 11 for more details). In terms 
of prepregnancy diabetes, as well as gestational diabetes, maternal hyperglycemia 
likely impacts the production of various placental proteins. These placental proteins 
affect placental metabolism, growth, and development [29].
MATERNAL COMMUNICABLE DISEASES
Maternal communicable diseases are another important risk factor, especially in 
LMIC, where infections can chronically affect maternal nutritional status and fur-
ther expose fetuses to unfavorable growth environments [1]. Specifically, pregnant 
mothers infected with Plasmodium falciparum or Plasmodium vivax malaria are at 
increased risk of delivering an infant LBW, SGA, or both [30].
ENVIRONMENTAL FACTORS
Studies on urban air pollution, as well as tobacco smoke (firsthand and secondhand) 
have been well studied in relation to fetal outcomes, including growth and neurotoxic 
effects. Smoking during pregnancy has been adversely associated with reduced birth 
weight, with maternal smoking doubling the risk of having a LBW, SGA, and/or 
preterm infant. Secondhand tobacco smoke exposure has also been linked with these 
consequences, as well as with prenatal mortality.
In regards to air pollution or particulate matter, microscopic chemicals emitted 
from power plants, industries, and vehicles are easily inhaled by pregnant moth-
ers, which can subsequently cause growth complications and other adverse maternal 
health consequences, such as deficiencies in lung function. In fact, as the third tri-
mester is the most prolific period of growth, particulate matter has been positively 
associated with poor outcomes, such as growth restriction and LBW infants, most 
often when there is exposure within the third trimester window [31].
OUTCOMES OF LOW BIRTH WEIGHT 
AND SMALL FOR GESTATIONAL AGE
Short-term ConSequenCeS
The association between LBW and SGA and increased risk of mortality is well 
documented. Several studies have demonstrated a greater relative risk for neonatal 
(1–28 days) and postneonatal (29–365 days) mortality associated with SGA, as com-
pared to AGA [11]. The highest risk is for infants born preterm SGA relative to term 
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AGA. Moreover, over 50% of SGA babies, although not LBW, are still at double the 
risk of neonatal mortality than term AGA infants [32]. It is also estimated that 50% 
of unexplained stillbirths may be related to undiagnosed IUGR [33].
Many of the metabolic, hematological, and immunological disturbances associ-
ated with LBW and SGA could account for this high mortality risk, as indicated 
below:
• Metabolic—Hyperglycemia, hypoglycemia, hypocalcemia, hypothermia, 
late metabolic acidosis
• Hematological—Polycythemia (hyperviscosity)
• Immunological—Reduced immune response (reduced lymphocyte count, 
reduced immunoglobulin levels, increased risk of infection)
Moreover, preterm infants can suffer from many other complications in addi-
tion to the above disturbances. Preterm babies often have multisystem issues affect-
ing their respiratory, gastrointestinal, cardiovascular, and central nervous systems. 
Respiratory distress syndrome, neonatal pneumonia, congenital heart defects, hyper-
bilirubinemia, intraventricular hemorrhage, and infections are some of the most 
common issues affecting preterm neonates.
IntermedIate ConSequenCeS
Linear Growth
Nearly all stunting occurs in the first 1,000 days after conception, and is most influ-
enced by maternal and fetal nutrition. Maternal stunting puts infants at risk of being 
born SGA. In turn, SGA is one of the strongest predictors for childhood stunting. It 
has been estimated that nearly 20% of childhood stunting could be a consequence 
of being born SGA. Interestingly, being SGA carries a higher risk of stunting than 
being born preterm [11].
Neurodevelopmental
In the intermediate, there is consistent evidence for the association of SGA with 
impaired cognitive and motor development in early childhood (up to 36 months of 
age). Lower cognitive scores, poorer problem-solving abilities, and reduced activ-
ity have frequently been reported in infants and young children born SGA [34,35]. 
Further, several studies have identified a lasting adverse influence of LBW and SGA 
on IQ and academic achievement at school age and even during middle and late 
adolescence [1,36]. Behavioral problems, such as apathy and irritability, have been 
reported more frequently in SGA children, especially at preschool age. Substantial 
evidence also suggests an association of stunting with poor motor and cognitive 
development.
The underlying biology behind these neurodevelopmental consequences in infants 
born SGA is not fully understood. Cerebral cortex thinning and reduced cortical 
gray matter have been reported in very low birth weight and SGA births, suggesting 
that fetal growth restriction can affect brain development.
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Long-term ConSequenCeS
The pathophysiological changes occurring in LBW and SGA babies puts them at risk 
of adverse health outcomes in the long term, which includes increased risk factors 
for chronic disease (e.g., obesity, hypertension, reduced glucose tolerance, increased 
insulin resistance, and dyslipidemia) and a higher incidence of noncommunicable 
diseases (e.g., type 2 diabetes, cardiovascular disease, and chronic lung and kidney 
disease).
THE DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE
The developmental origins of health and disease (DOHaD) hypothesis, originally 
described in 1989, proposed that an association existed between LBW and the risk of 
developing coronary heart disease later in life. Further studies suggested that prena-
tal and early postnatal undernutrition had permanent effects on the body’s structure 
and function, predisposing it to chronic disease in adult life, and demonstrating the 
phenomenon of developmental plasticity and epigenetics.
The well-known Dutch famine studies demonstrated that individuals who had 
prenatal exposure to this 1944–1945 famine, especially those in the first trimester 
of pregnancy, were more likely to suffer from obesity, diabetes, and cardiovascu-
lar disease. Interestingly, in some cases, this was true even for infants not born 
LBW [37].
Evidence suggests that the fetus adapts to a limited supply of nutrients in utero by 
undergoing structural and physiological changes, such as the redistribution of blood 
flow to vital organs, alteration in the production of growth-influencing hormones, 
and changes in the glucose-insulin metabolism [33]. This forms the basis of the sug-
gested “fetal programming” phenomenon. Some suggest that epigenetic changes 
inducing long-term alterations in gene expressions may be one of the mechanisms 
contributing to this “programming.”
Although associated with short-term gains [38], rapid catch-up growth in LBW 
infants, leading to relatively quick weight gain in childhood, is linked to an increased 
risk of chronic disease in adults [33]. Though they possess reduced body fat mass, 
SGA children have been shown to have greater visceral adiposity and more cen-
tralized distribution of fat mass [39]. The fetal development process of adiposity is 
regarded as one of the factors influencing the increased insulin resistance associated 
with SGA infants in their adulthood [40].
However, although the pathophysiology for impaired renal and lung outcomes 
seen in SGA infants is not fully understood, it is postulated from the literature that 
fetal nutrient restriction influences the number of renal nephrons and the glomerular 
filtration rate, as well as the lung acinar and alveoli development [33].
STUNTING AND HUMAN CAPITAL
Height achieved in the first 1,000 days has been recognized as a good predictor 
of human capital [38]. Nearly 10% of children born SGA do not achieve catch-up 
growth after the first 1,000 days and remain stunted. Moreover, SGA children have 
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presented with earlier starts to puberty and a short pubertal growth spurt, which fur-
ther contributes to a shorter adult height. Stunting is associated with a loss of devel-
opmental potential, due to its adverse influence on cognitive function and economic 
yield at a population level.
INTERVENTIONS
In the presence of an SGA fetus during pregnancy, timely diagnosis of SGA, fol-
lowed by optimal monitoring and surveillance, is important. Simple ultrasound 
as well as more modern techniques such as umbilical artery doppler, cardioto-
cography, and the assessment of amniotic fluid can be used for monitoring [41]. 
Diagnosis and monitoring is vital for the subsequent appropriate management and 
delivery of the SGA fetus. However, the prevention of SGA is of prime importance. 
Optimum nutrition, timely and effective antenatal care, improved management of 
high-risk pregnancies, and interventions targeting the underlying determinants of 
undernutrition are all pivotal for promoting optimal fetal development and pre-
venting SGA.
A recent review of interventions across the continuum of care, and their effect 
on neonatal outcomes, identified key actions that have a significant effect in pre-
venting SGA. These include multiple-micronutrient supplementation, balanced 
energy protein supplementation, intermittent preventive treatment for malaria 
in pregnancy, insecticide-treated bed nets, and antiplatelet medications for pre-
eclampsia [42]. Furthermore, a previous review recognized antiplatelet agents 
and multiple-micronutrient supplementation as the most effective interventions 
for preventing SGA, and noted that they were appropriate to use by all preg-
nant women [43]. For high-risk pregnancies, the same review identified antiplate-
lets <16 weeks, cessation of smoking, and progesterone therapy as being most 
effective.
the ImportanCe of preConCeptIon Care and InterventIonS
Preconception care, as defined by the WHO, is the “provision of preventive, 
promotive or curative health and social interventions before conception occurs” 
[44]. It can be provided to both men and women; however, adolescent girls and 
women are especially vulnerable, and thus often the focus of these interventions. 
Preconception care for these groups is vital for the promotion of a healthy preg-
nancy, and the prevention of adverse fetal outcomes, including LBW. Research has 
recognized the association between maternal underweight and an increased risk of 
SGA [45], underscoring the significance of preconception interventions that address 
risk factors for maternal undernutrition [46]. Shorter interpregnancy intervals are 
associated with an increased risk of preterm and LBW [47]. A strong need exists 
for steps promoting optimum nutrition, family planning, and appropriate inter-
pregnancy intervals. Moreover, the prevention of early and adolescent pregnancies 
is integral to the prevention of undernutrition in pregnant women [48]. On the other 
hand, childbearing past the age of 35 years is also associated with increased odds 
of LBW. More specifically, preconception folic acid supplementation has been 
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shown to reduce the risk of SGA (<5th percentile) probably through epigenetic 
mechanisms [49].
mICronutrIent SuppLementatIon In pregnanCy
With the nutritional needs of both the mother and child being the greatest in the 
first 1,000 days, there has been significant research into the impact of supplemen-
tation. The 2016 WHO antenatal guidelines recommends routine iron and folic 
acid supplementation in pregnancy, where the dosage of iron is dependent upon the 
 population-level prevalence of anemia [50]. The WHO is not currently recommend-
ing multiple-micronutrient supplementation during pregnancy [50]; however, over 
the past decade, a multiple-micronutrient supplement, UNIMMAP, has emerged as 
a means to cost-effectively combat other maternal micronutrient deficiencies during 
pregnancy and is being distributed in some countries. The UNIMMAP supplement 
contains vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic 
acid, vitamin C, vitamin D, vitamin E, copper, selenium, and iodine, as well as 30 mg 
of iron and 15 mg of zinc.
According to a recent Cochrane Review [22], women who took UNIMMAP, com-
pared to an iron supplement with or without folic acid, had a reduced risk of SGA 
infants (RR 0.90, 95% CI: 0.83, 0.97), LBW infants (RR 0.88, 95% CI: 0.85, 0.91), 
and stillbirths (RR 0.91, 95% CI: 0.85, 0.98). There were no differences found in 
preterm births, miscarriage, and anemia in the third trimester. These findings and 
previous reviews support the guidance to replace iron with folic acid supplements 
with multiple micronutrient supplements in pregnant mothers [51,52].
BaLanCed energy and proteIn SuppLementatIon
As mentioned, undernourishment in pregnancy increases the risk of adverse fetal 
outcomes. Gestational weight gain has been associated with increased birth weight 
and fewer SGA babies. To promote maternal weight gain, evidence indicates that 
balanced energy and protein supplementation increases mean birth weight and 
reduces the risk of stillbirths by 40% and SGA babies by 21%. However, findings 
regarding the reduction of preterm and LBW are inconclusive. Currently, there is no 
recommendation to increase energy and protein intake during pregnancy; however, 
guidance on appropriate weight gain has been well established [53,54].
CeSSatIon of SmokIng and envIronmentaL InterventIonS
Tobacco smoking remains one of the few preventable factors associated with infants 
born preterm and/or LBW. Interventions regarding the promotion of smoking ces-
sation include psychosocial interventions, pharmacological aids, and nicotine 
replacement therapy (NRT). There is only evidence to suggest that psychosocial 
interventions are associated with an increased proportion of women quitting smok-
ing in late pregnancy, and subsequently reducing preterm and LBW infants [55,56]. 
Further studies are required to understand the impact of pharmacological and NRT 
interventions, as current reviews are inconclusive.
184 The Biology of the First 1,000 Days
maLarIa preventIon
In moderate- to high-transmission settings, P. falciparum and P. vivax infection 
leading to placental parasitaemia and maternal anemia, can both contribute to LBW 
and SGA. The prevention and treatment of malaria is a priority intervention of the 
WHO in these areas. The use of insecticide-treated bed nets, intermittent preventive 
treatment of malaria with sulfadoxine-pyrimethamine (IPTp-SP), and appropriate 
case management are the components of this three-pronged approach. Three or more 
doses of IPTp-SP have been associated with higher mean birth weights and an esti-
mated relative risk reduction for LBW by 20% [57]. Other reviews have estimated 
a 37% decrease in the risk of LBW infants in unprotected women (in their first or 
second pregnancy) as a result of IPTp-SP use [1]. Moreover, insecticide-treated bed 
nets have been associated with a 23% risk reduction for LBW.
CONCLUSION AND RECOMMENDATIONS
In conclusion, there has been significant progress in the delineation of risk factors, etio-
logical pathways, and the consequences of SGA and LBW babies. In fact, the associa-
tion between LBW, including SGA, and coronary heart disease and stroke in later life 
has been recognized. However, quite a few limitations exist in current data and research.
First and foremost, clarification and consistency around the use of SGA and 
IUGR definitions are necessary in order to observe accurate estimates of incidence 
and prevalence, as well as to understand the effectiveness and efficaciousness of 
interventions. Secondary to this is that, although maternal nutrition interventions 
that include general dietary advice are central in terms of reducing the risk of SGA, 
there is little hope of success unless the underlying determinants of undernutrition, 
including illiteracy, poverty, and the empowerment of women, are addressed.
Although several interventions that address fetal growth restriction and SGA have 
been identified, further research is needed to study the associated impact of these 
measures on maternal health and pregnancy outcomes [43]. Future research should 
particularly focus on the association between prepregnancy BMI and fetal growth 
restriction, as well as the relationship of maternal micronutrient deficiencies and 
poor fetal weight [58]. Finally, further studies should be conducted on the underlying 
mechanism of the long-term effects of IUGR and SGA on neurodevelopmental and 
metabolic outcomes [36].
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INTRODUCTION
Children can be underweight because they have a low weight in relation to their height 
and/or because they are short in relation to their age. Waterlow introduced the term 
wasted for children with a low weight-for-height (WFH), and stunted for those who 
have a low height-for-age [1]. Children suffering from acute food shortage become 
wasted as they lose weight, but their height remains constant, and wasting is often 
considered as reflecting an episode of acute malnutrition (AM). In contrast, stunting 
is regarded as a more chronic form of malnutrition. Although wasting can also be 
chronic, and linear growth stops in the case of AM, AM is often defined by wasting, 
more specifically by a WFH <–2 z-score of the World Health Organization (WHO) 
growth standard [2]. Moderate acute malnutrition (MAM) is defined by a z-score 
between –2 and –3, and severe acute malnutrition (SAM) is defined by a WFH <-3 
z-score or a mid-upper arm circumference (MUAC) <115 mm (in children aged 6 to 
60 months) or the presence of nutritional edema [3]. The MUAC-based definition of 
SAM was introduced to include children with a low MUAC, because these children 
are at high risk of death [4]. In programs that aim to prevent malnutrition-associated 
mortality, MAM is also often defined by a MUAC between 115 and 125 mm [5]. The 
cutoffs for MAM and SAM are convenient for establishing programs, but there is no 
abrupt change of the pathophysiology or of the associated risk around these cutoffs, 
and there is a continuum between SAM and MAM.
Current estimates suggest that, globally, there are approximately 51 million wasted 
children defined by a WFH <–2. Of these, 19 million are severely wasted (WFH 
<–3), leading to approximately 540,000 deaths per year [6]. These estimates are 
based on prevalence data, whereas incidence would be needed to assess the number 
of deaths related to acute malnutrition. In addition, these estimates do not include 
children with a MUAC <115 mm with a WFH >–3, nor those with edema who have 
a high risk of death. The numbers of children affected every year by SAM and the 
associated mortality are, presumably, considerably higher.
PATHOPHYSIOLOGY
Children with AM have a history of insufficient energy and nutrient intakes com-
pared to their needs. This can be due either to poor access to a nutrient-dense diet 
and/or inflammation (usually due to infections), which can induce anorexia and fur-
ther increase nutritional needs. The organism adapts to this insufficient energy and 
nutrient intake by consuming its own tissues, mainly fat and muscle, which results 
in changes in body composition. The organism also adapts to the insufficient energy 
and nutrient by decreasing its energy and nutrient expenditure via a reduction in the 
activity of different organs, which impairs their function.
Changes in Body Composition
The weight deficit observed in malnourished affects tissues and organs in different 
ways [7]. Animal models show that the brain weight is relatively conserved com-
pared to the thymus, heart, and kidneys, but that it is fat and muscle that are reduced 
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the most in relation to body weight [8]. This decrease in fat and muscle can largely 
be explained by metabolic adjustments that take place when energy intake is insuf-
ficient [9]. In some children, these changes in body composition are associated with 
edema.
Decrease in Fat Mass
In well-nourished subjects, energy needs are largely provided by the metabolism of 
carbohydrate and fat, mainly carbohydrate following a meal, and then fat after a few 
hours of fasting. This switch between these two main fuels is due to a decrease of 
insulin secretion and to an increase of glucagon following the decrease of blood glu-
cose concentration. This switch to fat as the main fuel is needed, as body carbohy-
drate reserves in the liver and muscle are limited and exhausted after a few hours of 
fasting [9]. In contrast, fat stores are usually large enough to maintain metabolism for 
several weeks. The brain, however, usually only consumes glucose as fuel, so a mini-
mum must be synthesized by gluconeogenesis, either from glucogenic amino acids 
derived from muscle or from the glycerol derived from triglycerides. This process is 
set to a minimum after a few days, as the brain and other organs adapt and start using 
ketone bodies, produced during fat catabolism as fuel instead of carbohydrates. This 
switch to fat as the main fuel occurs much faster in children than in adults, presum-
ably as the brain, the major glucose-consuming organ, is proportionally larger in 
children. Body fat seems to be the main factor limiting survival in malnourished 
children in the absence of infections [10]. Leptin, which is a marker of fat mass, is 
associated with survival in children treated for SAM [11]. In addition to its role as 
fuel, fat may also influence survival through its action on the immune system [12].
Decrease of Muscle Mass
Muscle is the main storage site of amino acids in the body and, when protein intake 
is insufficient to sustain metabolism, these amino acids are released, leading to a 
decrease in muscle mass. The release of amino acids is the result of the activation 
of ubiquitin-proteasome pathway, which are also activated in numerous conditions 
leading to muscle mass depletion, including trauma, diabetes, uremia, hyperadreno-
cortisolism, hyperthyroidism, immobilization, and sepsis [13]. In the event of infec-
tion, muscle breakdown can be accelerated by the need to synthesize acute phase 
proteins, which have a high content of aromatic amino acids. The synthesis of these 
acute phase proteins, which can account for up to 30% of total protein synthesis, 
requires a high level of protein catabolism, mainly from muscle [14].
Muscle, like all other lean tissues, contains a wide range of nutrients, which are 
essential for metabolism and are not stored in specific organs. Anorexia can occur 
during malnutrition, leading to lean tissue catabolism and the release of these nutri-
ents, making them available for metabolism [15]. This may also contribute to muscle 
mass depletion.
Muscle mass has been shown to be linked with survival in a variety of clinical 
conditions in adults, including infections, cancer, and cirrhosis [16]. Epidemiological 
studies suggest that it is linked to survival in children as well [17], but this link 
may depend on the presence of infections associated with malnutrition as, in their 
absence, fat appears to be more important [18]. The critical role of muscle mass in 
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making children more vulnerable to malnutrition is made likely by its low value in 
relation to body mass compared to adults [16].
The Presence of Edema
Edema is due to an expansion of the interstitial compartment, that is, of the extracel-
lular water outside the vascular system. The association of edema with malnutrition 
has been known since biblical times, but only attracted the attention of clinicians 
after the publication of works by Cecily Williams, who introduced the term kwashi-
orkor to medical literature [19].
Edematous malnutrition is associated with a fatty liver, skin lesions, and apathy. 
To date, its pathophysiology is poorly understood, with none of the explanations 
proposed so far adequately explaining its clinical characteristics.
Possible Mechanisms of Edema
Protein deficiency was initially proposed because the protein intake of children 
with kwashiorkor was lower than what was then recommended for healthy children. 
The frequently decreased serum albumin levels in edematous malnutrition were 
attributed to insufficient protein intake, leading to decreased albumin synthesis, a 
decrease in plasma oncotic pressure, and edema. In this interpretation, a fatty liver 
was attributed to an insufficient synthesis of the lipoproteins needed to export fat 
from the liver [7].
However, all of the steps of this causal link were to be challenged. Protein 
requirements have been reestimated at lower levels, and the difference between 
intake and estimated requirements is not clear. A comparison of the diet of malnour-
ished children with and without edema failed to show a lower protein intake in those 
who develop edema compared to healthy controls [20]. Albumin is an acute phase 
protein, which is influenced not only by protein intake but also by the presence of 
infection, and its relation with protein intake is not clear. The link between plasma 
albumin and edema remains debated [21,22].
Oxidative stress has been proposed as a possible cause of edema, based on the 
observation that circulating glutathione concentrations are low in edematous malnu-
trition [23]. As a result of infections or of the action of toxins, some malnourished 
children do not have the capacity to respond adequately to the associated oxidative 
stress. This may lead to membrane damage as a result of lipid oxidation or to changes 
in sulfated complex carbohydrates, which are present in the interstitial tissue, lead-
ing to edema [22]. This hypothesis is supported by consistent reports that edematous 
malnutrition is associated with increased oxidative stress [24,25]. Consistent with 
this hypothesis, supplementation of edematous children with glutathione or the anti-
oxidant alpha-lipoic acid has a favorable effect on the clinical outcome of kwashior-
kor [26]. It is not clear, however, whether oxidative stress is a cause or a consequence 
of edematous malnutrition. Several elements are not consistent with the primary role 
of oxidative stress as a cause of edema. Children infected with HIV, an infection 
associated with a high level of oxidative stress, more frequently have a nonedematous 
form of severe malnutrition [27]. There is no association between polymorphic vari-
ation in a series of redox enzyme genes associated with the response to an oxidative 
stress (catalase, superoxide dismutases, epoxide hydrolases, quinone oxidoreductase, 
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and NADPH oxidase), and the presence of edema in children with SAM [28]. An 
attempt to prevent kwashiorkor via supplementation with an antioxidant including 
vitamins, minerals, and N-acetyl cysteine, which stimulates glutathione synthesis, 
did not show any effect [29].
One possible role of the gut microbiota, which plays an important role in the 
metabolism and immune response of the host, has been suggested by a study of 
twins in Malawi, only one of whom developed edematous malnutrition (discordant 
pairs). The twin with edematous malnutrition had an immature gut microbiota com-
pared to that of the healthy twin, and this microbiota induced weight loss when 
transplanted to germ-free mice receiving a suboptimal diet [30]. However, another 
study did show that nonedematous SAM children have lower gut microbiota diver-
sity compared to edematous SAM children, but no clear compositional differences 
were identified [31].
Changes in Body FunCtions
In parallel with the change in body composition, the organism adapts to malnutri-
tion by reducing the activity of virtually all of its body functions [7]. These changes 
have mainly been described in children suffering from SAM, but they also occur to 
a lesser extent in children with MAM.
Physical Activity
Malnourished children have reduced physical activity. This has been documented in 
children with SAM with accelerometers [32], but also with more moderate degrees 
of wasting, stunting, and anemia [33]. This reduction in physical activity can be 
regarded as an immediate adaptation to low energy intake, but the resulting decreased 
exploration of the environment may negatively affect cognitive development [34].
Sodium Pump Activity
The sodium pump maintains the concentrations of sodium and potassium in intra- 
and extracellular spaces. It expels sodium from the cells in exchange for potas-
sium. This process is energy demanding and represents about 25% of the energy 
expenditure of the whole body at rest. The activity of the sodium pump is reduced 
in nonedematous malnutrition but is increased in edematous malnutrition, pre-
sumably to compensate for the increased cell membrane permeability to electro-
lyte [35]. The reduction of the sodium pump activity and membrane leakage are 
likely to explain the high sodium levels and low potassium levels observed within 
cells obtained from biopsies, and also the loss of total body potassium commonly 
observed in malnutrition, as potassium not entering the cells has to be excreted in 
the kidney [7].
Protein Metabolism
Early reports suggested that protein turnover slowed in children with SAM  [36]. 
Later studies suggested, however, that a reduction of protein breakdown only occurred 
in children with edematous malnutrition and was maintained in a nonedematous 
form of malnutrition [37]. Protein breakdown, on the other hand, is increased in the 
196 The Biology of the First 1,000 Days
presence of infection, which is also associated with an increased synthesis of acute 
phase proteins [14].
Renal Function
The kidney is one of the most energy-demanding organs, and its functions are reduced 
in malnutrition [38], demonstrated by a decreased capacity to concentrate or dilute 
urine, to excrete an acidic load, or to excrete excess sodium. This has implications 
for treatment, as these changes make children more vulnerable not only to dehydra-
tion but also to fluid overload in the event of aggressive rehydration.
Cardiac Function
There is a reduction of cardiac output in relation to body surface area, which is 
related to both a decreased heart rate and a decreased stroke volume. It is not clear 
whether this reduced function is due to a reduction of cardiac mass and volume, or to 
adaptation to a reduced demand [7]. Elevated levels of cardiac troponin in children 
with SAM suggest, however, that heart function is impaired by malnutrition, at least 
in its severe form [39]. This may explain the excess of deaths observed in SAM chil-
dren receiving diets with a high sodium content [40].
NUTRITIONAL REQUIREMENTS OF CHILDREN 
WITH ACUTE MALNUTRITION
Children’s nutritional requirements have two components: a maintenance compo-
nent, which is needed to sustain metabolism, and a growth component, needed to 
synthesize new tissues. In malnourished children, the reestablishment of normal 
nutrient concentrations in different tissues for correcting preexisting deficiencies 
represents a third component.
In the first days of treatment, if the child has associated complications, especially 
infections, the priority is to treat these complications, and no attempt is made to pro-
mote weight gain. At this stage, requirements correspond to maintenance require-
ments and, for some nutrients, to the correction of associated deficiencies. During 
the recovery phase, growth (catch-up) can be 10 to 15 times faster than that of a 
well-nourished child of the same age. Nutritional requirements for growth are then 
increased in the same proportions. Nutrient requirements for maintenance and for 
growth vary in different proportions in relation to weight gain for energy, and for 
different nutrients. They also depend on the nature of the weight gain, mainly on the 
balance between lean and fat tissue.
energy requirements
Requirements for Maintenance
Basal energy requirements in SAM children are influenced by two opposing fac-
tors. First, observed changes in body composition increase the proportion of organs, 
which have a high energy requirement per weight unit, such as the brain, heart, or 
kidneys. This tends to increase the energy requirements in relation to body weight. 
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On the other hand, most energy-demanding functions slow down as part of the adap-
tation to lower energy intakes, which tends to lower energy requirements. Studies 
describe a wide range of basal energy expenditure, ranging from 75 to 103 kcal/kg/
day [7], slightly higher compared to about 75 kcal/kg in healthy children [41].
Requirements for Growth
The energy required for growth depends on the type of tissue being laid down [42]. 
Fat contains 9 kcal/g; about 10% extra is needed to incorporate each gram of fat into 
tissue, so that the total cost of 1 g of fat tissue deposited is about 10 kcal. Lean tissue 
consists of approximately 80% water and 20% protein. Protein contains 4 kcal/g, but 
the energy efficiency of protein deposition is only 50%, which means that for each 
gram of protein being deposited, about 8 kcal is needed. Hence, to deposit 1 g of lean 
tissue, which contains about 0.2 g of protein, 1.6 kcal is needed.
Total Energy Requirements
The total energy requirement (Etot) is the sum of energy needed for energy mainte-
nance (Em) and for weight gain. This can be expressed as follows:
 








where Fg is the fat gain and Lg is the lean tissue gain.
Total energy requirements increase rapidly with weight gain; during rapid catch-
up, energy requirements approach twice the value of well-nourished children of the 
same age (Table 13.1).
TABLE 13.1
Energy Requirements in Relation to Weight Gain
Total Energy Requirements (kcal/kg/day)
Nature of Deposited 
Tissue 40% Lean, 60% Fat 50% Lean, 50% Fat 60% Lean, 40% Fat
Weight gain (g/kg/day)
0 80 80 80
1 87 86 85
2 93 92 90
5 113 109 105
10 146 138 129
15 179 166 154
Note: The maintenance requirements were estimated at 80 kcal/kg/day.
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protein requirements
Protein requirements also have two components: the basal requirement to maintain 
protein metabolism in the absence of weight gain, and a growth component, corre-
sponding to the quantity of protein being deposited in new tissues.
Requirements for Maintenance
Maintenance requirements in protein are similar in children with SAM, as compared 
to well-nourished children and adults, at approximately 0.7 g/kg/day [7].
Requirements for Growth
Fat tissue contains only small amounts of proteins, and the effect of fat tissue depo-
sition on protein requirements is negligible. Lean tissue contains about 0.2 g of 
protein per gram of tissue, but a higher amount is needed, as the amino acid profile 
of dietary protein is not identical to the proteins being laid down, and the efficiency 
of protein synthesis is also imperfect. An overall efficiency of 70% is a reasonable 
assumption [42].
Total Protein Requirements
The total protein requirement (Ptot) of a child recovering from SAM is the sum of 
requirements for maintenance and for growth:
 Ptot (g/kg/day) (g/kg/day) (Lg (g/kg/day)= + ×0 70. 0.2)/ .0 70
where Lg is the lean tissue gain.
Protein requirements can be expressed as a percentage of energy in relation 
to weight gain and the nature of tissue deposition using the preceding equation. 

































% Lean tissue 
FIGURE 13.1 Protein requirements (% energy) in relation to weight gain and the percentage 
of lean tissue in weight gain. Energy maintenance estimated at 80 kcal/kg/day.
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deposited during growth. It shows that protein represent about 3% of the energy 
requirement, in the absence of weight gain, and go up to nearly 9% when weight gain 
is very high. This percentage also increases with the proportion of lean tissue being 
laid down during growth.
These estimates are based on several approximations with regard to basal protein 
and energy requirements, and the efficiency of growth, but a change of parameters in 
the preceding equations shows that the proportion of energy that should be provided 
by protein is around 3% in children when weight gain is just maintained. During 
catch-up growth, protein requirements increase but never to more than 10% to 12% 
of energy. These estimates are to be compared with the diet currently recommended 
by World Health Organization at the beginning of treatment (F-75), of which pro-
tein provides 5% of total energy [43], and with the protein content of ready-to-use 
therapeutic foods (RUTF) used during the catch-up phase, which should be between 
10% and 12% of total energy [44]. Of note, these protein requirements are calculated 
based on the quantity of proteins needed for synthesis of new tissues, and these esti-
mates do not take into account the possible effects of protein quantity and quality on 
growth regulation and height gain [45]. The actual requirements for optimal height 
recovery may actually be higher.
Protein Quality
Children require essential amino acids to maintain their metabolism and synthesize 
new tissues. The proportion of essential amino acids needed for growth is higher 
than what is needed for maintenance (Table 13.2) [46].
Total amino acid requirement is the sum of amino acid needed for maintenance 
and for growth. Table 13.3 shows the effect of different rates of weight gain on the 
amino acid profile needed to cover both maintenance and growth requirements. As 
the proportion of essential amino acids needed for new tissue synthesis is higher than 
that for maintenance, the proportions of these essential amino acids increases with 
TABLE 13.2
Amino Acid Pattern Needed for Maintenance of New Tissues Synthesized 
during Growth
His Ile Leu Lys SAA AAA Thr Trp Val
Tissue amino acid 
pattern 
(mg/g protein)




15 30 59 45 22 38 23 6 39
Source: Data from Food and Agriculture Organization of the United Nations (FAO), Dietary protein 
quality evaluation in human nutrition: Report of an FAO expert consultation, 31 March–2 April, 
2011, Auckland, New Zealand, Rome: FAO, 2013.
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weight gain. So, in children with catch-up growth, the quantity of essential amino 
acid needed for new synthesis is higher than that for “normal” children.
mineral and Vitamins
All forms of AM are associated with different degrees of mineral and vitamin defi-
ciencies [7]. Mineral and vitamin requirements for children with AM were estimated 
based on the requirements of well-nourished children, adjusted to correct preexisting 
deficiencies and an increased rate of weight gain.
Potassium requirements are increased to correct a low tissue concentration, which 
can be due to low dietary intake, to the effect of repeated episodes of diarrhea, and 
to increased renal excretion. During the catch-up growth phase, the requirements 
associated with synthesis of lean tissues are also increased. Studies suggest that chil-
dren with SAM require between 4 and 8 mEq/Kg/day of potassium. Magnesium 
deficiency is also very common, and its correction is needed to correct the associ-
ated potassium deficiency [7]. Zinc is needed for lean tissue synthesis and, if the 
amounts provided during catch-up growth are insufficient, excess fat is deposited 
during catch-up growth [47].
Iron requirements are mainly related to growth, and the requirement for main-
tenance is negligible in the absence of pathological blood loss. Children with SAM 
often have an excess of body iron at the beginning of their treatment, and the levels 
of these stores, assessed by ferritin plasma concentrations, are associated with an 
increased mortality [48]. Although this association between ferritin concentration and 
mortality can be partly explained by infections, iron is not given during the first few 
days of treatment in children with complicated SAM. During catch-up growth, how-
ever, iron requirements increase and may be higher than those for normal children.
TABLE 13.3
Amino Acid Scoring Pattern (mg/g Protein) for Well-Nourished Children 
Aged 6–36 Months, and for Recovering Malnourished Children with 
Different Rates of Weight Gain
His Ile Leu Lys SAA AAA Thr Trp Val
Well-Nourished Children Aged 6–36 Months
20 32 66 57 27 52 31 8 43
Malnourished Children during Recovery with a Weight Gain of
5 g/kg/day 22 33 68 61 29 58 34 9 45
10 g/kg/day 24 34 71 65 31 63 37 10 46
15 g/kg/day 25 34 72 67 32 66 38 11 47
Note: It was assumed that these children gained 50% of fat and 50% of lean tissue. The efficiency of 
protein synthesis was assumed to be 58%, as in the Food and Agriculture Organization of the 
United Nations (FAO), Dietary protein quality evaluation in human nutrition: Report of an FAO 
expert consultation, 31 March–2 April, 2011, Auckland, New Zealand, Rome: FAO, 2013.
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PREVENTION AND TREATMENT OF ACUTE MALNUTRITION
preVention
Prevention should be based on ensuring access to an adequate nutrient-dense diet, 
and preventing and treating infections, the latter being beyond the scope of this chap-
ter. Ensuring an adequate diet should rely first on the promotion of exclusive breast-
feeding for the first 6 months. Before this age, in poor settings, the introduction of 
other foods, beyond the risk of exposing the child to pathogens, always results in 
a decrease in the nutrient density of the diet. Beyond 6 months, it is necessary to 
introduce complementary feeding, following the WHO guiding principles [49]. The 
use of food supplements as a substantial part of protein and energy requirements is 
only needed to prevent AM in situations of food insecurity. Mineral and vitamin 
supplementation, or the use of foods fortified with problem nutrients (such as zinc, 
iron, and vitamin A), however, are often required to ensure the nutritional adequacy 
of the diet [49]. The nutrients most likely to be missing in the diet, and which should 
be provided by supplements or fortified foods, should be determined by analyzing 
locally available foods and local food habits [50].
treatment
Severe Acute Malnutrition
Treatment of SAM is described in detail in national protocols that have been devel-
oped over the past 10 years and adapted to the local situation [51]. Uncomplicated 
forms, the most frequent, should be treated in the community, while only compli-
cated forms should be referred to inpatient treatment.
Uncomplicated Forms
Children with uncomplicated forms of malnutrition, with good appetite and without 
clinical signs of infection, mainly need an energy- and nutrient-dense diet. The need 
for antibiotics is being debated and seems to depend on the context [52].
A diet high in energy and nutrients is difficult to achieve by combining local foods 
[53], and WHO and the United Nations Children’s Fund (UNICEF) recommend the 
use of RUTF for these children [44]. RUTF provides 10% to 12% of its energy from 
protein, which, as discussed earlier, is sufficient to promote rapid weight gain. At 
least half of total protein should be derived from milk products [44]. Attempts to 
replace milk with plant proteins have demonstrated mixed results [54], possibly 
because a high proportion of essential amino acids is needed for rapid weight gain. 
Other factors, such as the presence of antinutrients associated with plant proteins 
(e.g., soy or beans), may also be involved [55].
High-fat diets are energy dense and facilitate the intake of the high quantities 
of energy needed to sustain rapid catch-up growth. RUTF provides 45% to 60% of 
its energy from fat. This should be compared with the energy content of the tissue 
being deposited: Assuming that the proportion is 50% fat and 50% lean tissue (with 
about 20% of proteins), the energy being deposited in 1 g of tissue is 4.5 kcal for fat 
and 0.4 kcal for proteins, corresponding, respectively, to 92% and 8% of the energy 
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content of new tissues. These proportions of the fat and protein of new tissues and 
the corresponding energy requirements for growth are comparable to those observed 
during the first 3 months of life, when the child is breastfed, and receives about half 
of its energy from fat.
Initially, minerals and vitamins were given separately from the food and dosed 
in relation to weight, as was done for drugs. Minerals and vitamins were later incor-
porated into the F-100 rehabilitation diet in the 1999 WHO manual on management 
of SAM [43], following the common practice of feeding nonbreastfed children with 
infant formulas fortified with minerals and vitamins. An advantage of this approach 
is that children with the most rapid growth, with the highest requirements, have the 
highest intake of different vitamins and minerals. The formulation of RUTF was 
derived from the previously developed F-100 formula, with the addition of iron. The 
risk–benefit balance seems in favor of adding iron for children receiving RUTF who 
have rapid growth and very high iron requirements.
Compared to standard infant formulas, the nutrient density of RUTF differs 
mainly in terms of its higher potassium, magnesium, vitamin A, zinc, iron, and cop-
per content (Table 13.4). These nutrients are specifically needed for children with 
SAM. Copper is also needed, as the high level of zinc provided to these children may 
result in copper deficiency.
TABLE 13.4
Comparison of the Content in Selected Nutrients of Ready-to-Use 




Min Max Min Max
Vitamin A (μg retinol equivalent/100 kcal) 145 205 60 180
Vitamin D (μg/100 kcal) 2.8 3.7 1 2.5
Vitamin E (mg/100 kcal) 3.7 NA 0.5 NA
Sodium (mg/100 kcal) NA 54 20 60
Potassium (mg/100 kcal) 205 260 60 180
Magnesium (mg/100 kcal) 15 26 5 NA
Iron (mg/100 kcal) 1.8 2.6 0.45 NA
Zinc (mg/100 kcal) 2 2.6 0.5 NA
Copper (μg/100 kcal) 260 340 35 NA
Selenium (μg/100 kcal) 3.7 7.5 1 NA
Linoleic acid (mg/100 kcal) 330 1111 300 NA
α-Linolenic acid (mg/100 kcal) 33 280 50 NA
Notes: Only nutrients that are markedly different between RUTF and the Codex standard for infant for-
mula are shown in the table. Units were converted to facilitate the comparison with the Codex 
standard. NA, not available; RUTF, ready-to-use therapeutic food.
a RUTF nutrient composition is adapted from the World Health Organization, Community-based man-
agement of severe acute malnutrition, Geneva: World Health Organization, 2007.
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Current RUTF specifications for essential fatty acids are very close to those of 
the Codex Alimentarius for infant formulas. Recent data suggest, however, that they 
may need revision, as children treated with current RUTF fail to maintain their sta-
tus in long-chain polyunsaturated fatty acids, especially DHA; this is possibly as 
a result of too high levels of linoleic acid in RUTF with peanut butter as the major 
ingredient [56].
Complicated Forms
In complicated SAM, associated infections should be treated first. Asymptomatic 
infections are often present, particularly in children with anorexia, and antibiotics 
should be routinely given to these children. Until these infections are under con-
trol, children should receive just enough energy and nutrients to maintain their body 
weight and restore body functions. This is achieved by giving the low protein, low 
energy F-75 diet recommended by the WHO [43]. F-75 is fortified with all nutrients 
likely to be needed to correct deficiencies in concentrations similar to F-100. There 
is no added iron in F-75, as iron stores are often very high before treatment. Once 
their appetite is back to normal, these children should be treated as outpatients, as 
children with uncomplicated forms of SAM, and should receive RUTF.
Moderate Acute Malnutrition
The management of MAM relies on the same principle of giving a diet adequate to 
sustain rapid growth. Achieving a rapid weight gain, however, is less important than 
for children with SAM, and adequate weight gain allowing for catch-up growth can 
be achieved using local foods in situations where nutrient dense foods are available 
and accessible. Nutrient supplements can also be provided but, in this case, these 
should be given in addition to family foods, with the objective of providing only 
those nutrients missing in local foods. These supplements should provide less energy 
than those for SAM children, but should be more nutrient dense. Their desirable 
composition has been described in detail elsewhere [57].
CONCLUSION
AM affects millions of children globally and is associated with increased mortality. 
Prevention relies on providing a diet with nutrient-rich foods and in prevention of 
infections, and will remain difficult in poor populations with limited access to food 
and who are living in unhygienic conditions. Management of AM, however, espe-
cially in its severe form, has been greatly improved and simplified in recent years. 
SAM should be considered a public health priority, as it affects large numbers of 
affected children, is associated with a high risk of death, is easy to detect, and has an 
effective, affordable treatment.
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14 Management of Acute 
Malnutrition in Infants 
under 6 Months of Age
Marko Kerac and Marie McGrath
INTRODUCTION
Both acute malnutrition and nutrition (breastfeeding) in infants under 6 months of age 
(infants <6 months) are important global health issues and have received much interna-
tional attention over the years. However, it is only recently that the two in  combination—
the management of acute malnutrition in infants <6 months (MAMI)—have been 
examined [1]. This chapter outlines the background epidemiology, why acute mal-
nutrition in this age group matters, key challenges around infant <6 months mal-
nutrition, current assessment and treatment strategies, and, finally, directions for 
the future. Readers should look to other chapters of this book for added detail, as 
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MAMI has numerous links and synergies with other areas of malnutrition, with 
many opportunities to benefit both short- and long-term health.
EPIDEMIOLOGY OF A “FORGOTTEN PROBLEM”
For several decades, it was widely assumed that acute malnutrition in infants 
<6 months was a minor individual-level issue, rather than a significant public health 
problem. The logical fallacy went like this: Since breastfeeding is associated with 
good nutritional status, and since infants <6 months should be breastfed, poor nutri-
tion among infants <6 months must therefore be rare, assuming it only occurs where 
infants are not breastfed or perhaps where there is early introduction of comple-
mentary foods. This was even expressed by authoritative sources, such as the World 
Health Organization (WHO) “Field Guide to Nutritional Assessment,” which stated 
that “children under six months of age … are often still breast-fed and therefore 
satisfactorily nourished” [2]. Combined with the greater practical difficulties of 
conducting anthropometric measurements in young infants [3,4], this presupposi-
tion meant that infants <6 months were often omitted from nutrition surveys and 
surveillance activities [5,6]. As with any problem that is not being actively looked 
for, acute malnutrition in this age group was often simply overlooked. Specifically, 
the following factors were overlooked:
• Rates of breastfeeding are almost universally suboptimal [7].
• Despite being the cornerstone of good infant nutrition, breastfeeding is not 
100% protective from nutrition-related problems.
• Nutritional status is dependent on many factors, not just good quality 
dietary intake [8]. Especially in young infants, there are a large number and 
variety of health problems that can adversely impact on nutrition. These can 
be challenging to diagnose and treat, even in high-income, well-resourced 
settings.
In 2010, in response to questions about infants <6 months by field-based practitio-
ners, a report on MAMI [1] and a subsequent research paper [9] aimed to test previ-
ous assumptions and quantify the problem as an essential first step toward properly 
understanding this. An extrapolation of demographic and health survey data from 
21 “high burden” low- and middle-income countries found an important burden of 
disease (Table 14.1). Other observations and issues arising from Table 14.1 include:
• Wasted infants <6 months constitute an important proportion of all wasted 
children aged <60 months. This is an argument for program planners and 
managers needing to take this group seriously and make provisions for their 
care.
• The 2006 WHO Child Growth Standards (WHO-GS; see Chapter 2 for 
more detail) really are the gold standard of good growth, setting the bar 
quite high. Using WHO-GS rather than the previous dominant National 
Center for Health Statistics (NCHS) growth standards thus results in more 
infants <6 months being recognized as “wasted.”
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• This also challenges some prior assumptions that, since the WHO-GS were 
based on breastfed infants, they “will result in fewer breastfed babies diag-
nosed as growing poorly” [10,11].
• Figures for edematous malnutrition are not available. The table thus under-
estimates the total burden of disease of acute malnutrition and severe 
acute malnutrition (SAM; edematous malnutrition being part of that case 
definition) [12]. That said, anecdotal reports suggest that kwashiorkor is 
uncommon in this age group and that, if bilateral pitting edema is observed, 
another cause is more likely [13,14].
WHY MALNUTRITION MATTERS FOR INFANTS 
UNDER 6 MONTHS OF AGE
Short term
In the short term, mortality is the most serious risk faced by acutely malnourished 
infants <6 months. Acute malnutrition has a widely recognized, well-described high 
case fatality rate [15–17], but infants are at particular risk. Reasons include physi-
ological and immunological immaturity, which make them more vulnerable in the first 
place and more likely to suffer severe adverse consequences. In one recent meta-analy-
sis that compared infants <6 months with children 6–60 months in the same treatment 
programs, the infants’ risk of death was significantly greater (risk ratio 1.30, 95% CI: 
1.09, 1.56; P< 0.01) [18]. Although biologically not unexpected, a key question is how 
much of this excess mortality can be avoided with improved or alternative treatment.
Long term
The longer-term effect—and why infant <6 months malnutrition is a key topic in this 
book—is the increasing recognition that early-life nutritional exposures have clinically 
TABLE 14.1
Global Epidemiology of Wasting in Infants under 6 Months of Age
All Infants and 
Children (0 to 60 
Months), n = 556 
Million
Infants <6 Months 
(WHO Growth 
Standards), n = 56 
Million
Infants <6 Months 
(NCHS Growth 
References), n = 56 
Million
Total wasting (millions), 
weight-for-length z-score <–2
58 8.5 3.0
Moderate wasting (millions), 
WLZ ≥–2 to <–3
38 4.7 2.2
Severe wasting (millions), 
WLZ <–3
20 3.8 0.8
Source: Adapted from Kerac M, Blencowe H, Grijalva-Eternod C et al., Arch Dis Child 2011, 
96(11):1008–13.
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significant long-term “programming” effects on adult health and well being [19,20]. 
Although the best-known work focuses on exposures during prenatal life [21,22], the 
window of developmental plasticity (and hence the opportunity to make a positive dif-
ference) extends well beyond birth. Optimizing infant nutrition has a major role to play 
in reducing the current epidemic of noncommunicable disease [23,24]. Acute malnutri-
tion represents an especially severe nutritional “insult” with a high likelihood of corre-
spondingly severe long-term noncommunicable disease (NCD)-related risks [25]. There 
is a great need for interventions to help infants not only “survive” episodes of malnutri-
tion but also to ultimately “thrive.”
THE CHALLENGES OF ACUTE MALNUTRITION IN INFANTS 
UNDER 6 MONTHS OF AGE
MAMI currently lags behind great successes in treating older malnourished children 
[26]. This can be explained by the numerous challenges related to their needs and 
care.
A Period of rAPid mAturAtion
Infants <6 months are not simply mini-children; the period represents a major transi-
tion from neonatal life, and the beginnings of independence from their mother’s milk 
as the sole source of nutrition.
• Rapid physical and physiological maturation means that a 1-month-old, for 
example, is very different from a 4-month-old, even though only 3 months 
separate them in time. What is appropriate for some is not appropriate for 
all, for example, although exclusive breastfeeding is the target diet for all 
infants <6 months, some acute malnutrition treatment programs report 
a pragmatic decision to introduce early complementary feeds for those 
close to 6 months [1].
• There is also a spectrum of development that impacts on care, with some 
infants maturing faster or slower than most others.
Staff who are skilled and experienced enough to successfully manage these subtle-
ties of approach are often in short supply in settings where malnutrition is common. 
Any benefits of precisely age-tailored or developmentally tailored treatments thus 
need to be balanced against the added complexities that these impose on programs; 
guidelines that are too complex are likely to be poorly implemented in everyday 
practice. There is also a risk of mixed-messaging regarding feeding practices spill-
ing over to the general population.
unique dietAry needS
Malnourished infants <6 months cannot be treated with simple top-up supplementary 
or therapeutic feeds, as can older malnourished children. Their target diet is exclu-
sive breastfeeding. Even where the mother is around, establishing or reestablishing 
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effective exclusive breastfeeding (the mainstay of treatment) is not always straight-
forward [27–29]. It can require lots of time spent with well-trained, highly skilled 
support workers. Treatment is thus focused on software (skilled feeding support) 
rather than hardware (products such as ready-to-use therapeutic food). This often 
makes this less tangible and, thereby, often also less attractive as an investment for 
policy makers and program managers.
mAny And ComPLex underLying CAuSeS
Rather than a diagnosis in its own right, acute malnutrition is often seen as a symp-
tom of another problem. Only if the underlying cause is properly addressed can the 
malnutrition be definitively treated. Because the range of causes is greater in young 
infants (if left untreated, more severe cases can be fatal), assessment and treatment 
is more complex and, again, more resources are needed.
The underlying cause of infant malnutrition can include several contributing 
factors.
Reduced Nutrient Intake
• An insufficient quantity and/or quality of food offered. This can be due to a 
variety of social/cultural/economic factors. The child might be an orphan, 
with no wet nurse or a family unable to safely supply a sufficient quality/
quantity of breast milk substitute, or the mother may be working, so is not 
available to breastfeed sufficiently (this can eventually result in secondary 
lactation failure).
  Although few conditions directly affect the maternal milk supply, many 
can reduce the frequency/duration of breastfeeding and thus cause second-
ary lactation failure. It is vital to properly understand the physiology of 
breastfeeding. More suckling will stimulate more breast milk production; 
if suckling is reduced for any reason, the breast milk supply will eventually 
be reduced.
• An anatomical/structural problem. For example, cleft palate, which can 
affect attachment (feeding suction) and allow milk to enter nasal passages, 
causing choking.
• A functional problem. For example, poor attachment to the breast due to 
poor technique; poor suckling or swallowing in prematurity, or cerebral 
palsy.
• Feed aversion. If an infant is in pain or discomfort when feeding (e.g., in 
severe reflux or where an anxious carer tries to force-feed), she or he can 
develop an aversion to feeds, and may try to spit out or otherwise refuse feeds.
Reduced Nutrient Absorption
• Malabsorption. This can happen in a variety of conditions (e.g., chronic diar-
rhea, environmental enteric dysfunction, celiac disease, and cystic fibrosis).
Increased Nutrient Loss
• Vomiting (e.g., severe gastroesophageal reflux or pyloric stenosis).
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Increased or Impaired Nutrient Utilization
• Infections
• Acute (e.g., diarrhea, urinary tract infection)
• Chronic (e.g., HIV, TB)
• Congenital disease (e.g., congenital heart disease)
• Metabolic disorders
The frequency and severity of the underlying problem varies. Breastfeeding 
attachment problems are, for instance, relatively common; they may not always have 
major effects on nutritional status, but can be easily and rapidly rectified with skilled 
support. Congenital metabolic disorders are rare, but can be fatal and difficult to 
manage, even in resource-rich environments.
It is also vital to note the timing of the nutritional insult; some infants will be 
small because they were of low birth weight, but are now growing well and “catching 
up” postnatally. Others will be experiencing postnatal problems.
ASSESSING INFANTS UNDER 6 MONTHS OF AGE
Definitions of acute malnutrition in infants <6 months mirror those in older chil-
dren, focusing on anthropometry (Table 14.2). This is combined with their clinical 
status (mainly the presence/absence of integrated management of childhood illness 
[IMCI] danger signs) to distinguish between complicated acute malnutrition (i.e., 
sick, clinically high-risk infants requiring more intensive, specialized care available 
in inpatient facilities) and uncomplicated malnutrition (i.e., clinically stable infants, 
suitable for outpatient care).
This current case definition has numerous limitations. Refining it is considered 
to be one of the most urgent future priorities to improve care [30], especially since 
mislabeling an infant with malnutrition carries serious risks, notably that a breast-
feeding mother inappropriately introduces formula feeding, with the consequent 
risks of infection from unsafe water and contaminated bottles/feeding utensils. This 
TABLE 14.2
Anthropometric Case Definitions of Acute Malnutrition in Infants 
under 6 Months of Age
Term Defined By
Acute malnutrition (AM) SAM + MAM
Moderate acute malnutrition (MAM) Weight-for-length ≥–3 to <–2 z-scores 
Severe acute malnutrition (SAM) Weight-for-length <–3 z-scores and/or nutritional 
edema (kwashiorkor)
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contrasts with the situation for older children, for whom a sensitive (rather than spe-
cific) case definition is perfectly acceptable, since the risks of a short period of top-up 
therapeutic or supplementary food are minimal, hence the benefit–risk balance of 
intervention is favorable [11].
Other difficulties for infants <6 months include:
• Weight-for-length is especially hard to measure in younger infants. Past 
studies and a recent review highlight poor reliability [3,4,31].
• Weight-for-length cannot be calculated at all for shorter infants (<45 cm), 
since the lookup tables do not extend below this level. For these, clinical 
assessment is carried out.
• There is currently no agreed mid-upper arm circumference (MUAC)-based 
case definition, as there is for older children. This is a major gap, since 
MUAC enables quick, effective case finding and is key to the achievement 
of high coverage by treatment programs [32]. Promising MUAC-based stud-
ies do exist, but need replicating in additional settings in order for global 
policy to change [33].
• Infant <6 months malnutrition is special (and thus especially challenging to 
manage), in that it is critically dependent on the mother. Her prenatal and 
postnatal nutrition and physical/mental health affect the nutritional status 
and growth of her infant [34]. Assessing the mother–infant dyad, rather 
than the infant alone, should be common practice.
• A single anthropometric measurement is difficult to interpret, but sequen-
tial growth monitoring-type measures are often not available. Some infants 
with low weight-for-length will catch up and become “normal” without 
intervention. Conversely, other infants can be nutritionally vulnerable and 
not gaining/losing weight, even if their current weight-for-length measure-
ment is still in the “normal” range.
The recent 2013 WHO Guidelines on Managing Acute Malnutrition also note 
that “infants who have been identified to have poor weight gain and who have not 
responded to nutrition counselling and support should be admitted for further inves-
tigation and treatment” [35].
Recognizing the more complex nature of infant <6 months malnutrition, and thus 
the need for more comprehensive assessment, an IMCI-style assessment checklist 
has recently been developed (Figure 14.1). This is an attempt to translate the WHO 
2013 technical guidelines into an operational handbook for use by field-level health 
care workers [35]. It also aims to harmonize the WHO malnutrition [35] and IMCI 
guidelines [36]. Using the IMCI “traffic light” approach (red = urgent problem; yel-
low = problem but suitable for community-level care; green = no acute problem), it 
leads the user through key areas, including anthropometry, feeding practice, clinical 
condition, and maternal well-being. This includes the mother’s physical, mental, and 
nutritional health.
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MANAGING ACUTELY MALNOURISHED INFANTS 
UNDER 6 MONTHS OF AGE
For many years, normative guidance recommended inpatient care for all acutely 
malnourished infants <6 months [1]. This is still the case in almost all national 
acute malnutrition guidelines [1]. A major international-level development in the 
latest 2013 WHO Guidelines on Severe Acute Malnutrition [35] was the intro-
duction of community-based care for infants <6 months with “uncomplicated” 
SAM. This brought their classification and management in line with that of older 
children [26].
Key principles that guide management include:
• Early identification of malnourished and nutritionally vulnerable infants in 
the community, and at any health-related contact point (e.g., when attending 
for immunizations, or when seeking clinic or hospital treatment for an acute 
or chronic illness).
• Early treatment in the community wherever possible (uncomplicated cases).
• Early referral and treatment of sick infants (complicated cases).
• Breastfeeding support to restore effective exclusive breastfeeding wherever 
possible.
• Careful use of breast milk substitutes for nonbreastfed infants, if wet- 
nursing or banked breast milk is not available.
• General medical care for any underlying problems.
• All severely malnourished infants, including those with uncomplicated 
diseases, should receive a course of broad-spectrum antibiotics (oral if 
possible, parenteral if needed).
• Other conditions (e.g., HIV, sepsis, surgical problems, or disability) 
should be dealt with as needed.
• Follow-up on infants postdischarge in the community.
• Targeted support to the mother that considers her nutritional, physical, and 
mental condition.
• Considering and engaging with the broader household and community and 
societal influences on the mother–infant dyad that may affect feeding and/
or care practices.
inPAtient mAnAgement [37]
The cornerstone of inpatient care is supplementary suckling. This aims to restore 
exclusive breastfeeding, and involves taping a small nasogastric tube onto the 
breast, with the tip adjacent to the nipple. Supplementary milk (infant formula, F-75 
therapeutic milk, or diluted F-100 therapeutic milk—there is no hard evidence as 
to which of these is best) [36] is given via the tube. Crucially, however, the infant is 
placed on the breast, and attempts to suckle at the same time, thereby stimulating 
breast milk production. As the quantity of breast milk supply begins to increase, 
the quantity of supplementary milk can be decreased and, eventually, stopped 
entirely. A galactagogue (e.g., metoclopramide) can be given to aid this process. 
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Although supplementary sucking can be a great success in centers with experience, 
success rates vary [1] and depend on many factors, including motivation, breast-
feeding views, practicalities, understanding, and perceptions of hospital-based 
medicine [27].
The management of nonbreastfed infants is not well catered for in terms of guid-
ance, and creates huge practical challenges in resource-poor settings. It begins by 
feeding infants with the same supplementary milks (infant formula, F-75, or diluted 
F-100) to get them back to their normal weight. The biggest difficulty then comes 
in terms of what to do longer term. Identifying a wet nurse is a priority when cul-
turally acceptable and available. Where wet nursing is not viable, infant formula is 
necessary for infants <6 months; nutritional indication for infant formula in children 
6 months to 2 years depend on the complementary foods available, in particular 
animal source foods [38]. Where infant formula is not a viable option, a 5-month-old 
nonbreastfed infant recovering from malnutrition might start early complementary 
feeds based on skilled assessment as part of a pragmatic care approach, but a 2- or 
3-month-old needs a longer term appropriate breast milk substitute, which, in many 
settings, may not be affordable or available, and requires a package of support ser-
vices, including water, sanitation, and hygiene (WASH), and access to nutrition and 
health monitoring. The risks of relapse and of chronic undernutrition in these infants 
are high. More evidence is needed as to what works for this especially vulnerable 
group of infants and their carers.
outPAtient mAnAgement
The WHO 2013 guidance recommends the following for the outpatient care of infant 
<6 months with severe acute malnutrition [35]:
• “Counselling and support for optimal infant and young child feeding, 
based on general recommendations for feeding infants and young children, 
including for low birth weight infants,
• Weekly weight monitoring to observe changes,
• Referral into inpatient care if the infant does not gain weight, or loses 
weight, and
• Assessment of the physical and mental health status of mothers or caregiv-
ers with appropriate treatment and support provided.”
Since these are all low-risk interventions, it is appropriate to extend the same 
approach to infants with moderate acute malnutrition and even those who are nutri-
tionally vulnerable but do not (yet) have weight-for-length <–2 z-scores. Again, the 
C-MAMI tool brings together and reformats guidance that has been successful 
in other settings for other infant populations. Figure 14.2 is an example from the 
C-MAMI tool of how to identify and address poor attachment, which is a common 
problem.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































218 The Biology of the First 1,000 Days
FUTURE DIRECTIONS
Most WHO recommendations for managing infants <6 months are “strong” recom-
mendations [35]. It is vital, however, to acknowledge that the underlying evidence is 
“low quality” [39]. This represents a problem but also an opportunity to rapidly move 
things forward for this vulnerable group.
In a recent research prioritization exercise [30], the three top-ranked research 
questions were
 1. How should infant <6 months SAM be defined? As discussed, there are seri-
ous problems with the current anthropometry weight-for-length focused case 
definition of acute malnutrition in infants <6 months. The need for a refined 
and improved case definition offers a great opportunity to embrace more 
holistic terms of reference, assessing infants and their mothers and their 
social/home environments. Only thus can their problems be understood, and 
truly effective care packages planned and put in place for each individual.
 2. What are/is the key opportunities/timing when infant SAM management can 
be incorporated with other health care programs? MAMI offers an opportu-
nity to connect numerous emergency and development programs and stake-
holders across many sectors. Rather than being a narrow vertical program, it 
has to ensure links with other health and social programs, so that every occa-
sion where there is contact with an infant provides an opportunity for identify-
ing those who are nutritionally vulnerable and supporting/treating them.
 3. What are the priority components of a package of care for outpatient treat-
ment of infant <6 months SAM? MAMI requires interventions at many lev-
els, from individual case management to societal level interventions, such 
as social protection/maternity pay.
CONCLUSION
MAMI is a new and rapidly evolving area. Although much progress has been made, 
much still needs to take place. The 2013 WHO guidelines on infant <6 months are 
a major step forward, but still need to be translated into country-level guidelines 
and, most important, to front-line clinical settings. Despite the many challenges and 
difficulties, addressing MAMI offers an opportunity to escape from siloed nutrition 
thinking and programming. Strengthening the early identification and management 
of nutritionally vulnerable infants has to go past nutrition and involve other sectors, 
especially reproductive health, neonatal health, and WASH; has to include the nutri-
tion and health of mothers and, within that, adolescents; and has to innovate and look 
to development programming for management strategies.
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Chronic malnutrition refers to a process of suboptimal nutrition, which is the result of 
nutrient needs not being met and/or suffering from disease or infection, which con-
tinues over a prolonged period of time. Undernutrition has several short- and longer-
term consequences due to the effects of accumulated nutritional deficits on growth, 
health, and development, including higher morbidity and mortality, increased risk of 
noncommunicable diseases, poorer school performance, and lower income earning 
potential due to suboptimal cognitive and physical development early in life.
The main indicator of chronic malnutrition at the population level is the preva-
lence of stunting, or shortness for age, among children under 5 years old, which is 
assessed by comparing length (0–23 months) or height (24 months and older) to that 
of a reference population of the same age and sex [1].
However, although the prevalence of low length/height-for-age is the key indica-
tor of the extent to which young children in a population are affected by chronic mal-
nutrition, shortness is just one consequence of prolonged undernutrition. Stunting is 
related to an increased risk of morbidity and mortality, poorer school performance, 
lower income earning potential as an adult, and an increased risk of noncommuni-
cable diseases later in life, because it indicates inadequate nutrition during a critical 
phase of development, that is, the first 1,000 days (from conception until the sec-
ond birthday) [2–6]. In addition to linear growth, inadequate nutrition during this 
period also affects epigenetic programming during fetal life [7], brain growth and 
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development, the performance of the immune system, and factors that increase the 
risk of noncommunicable disease later in life [2–6].
A child whose nutrient intake does not meet his or her needs over a prolonged 
period of time will become stunted and also suffer from micronutrient deficiencies. 
This underlies the relationship between stunting and the increased risk of morbidity 
and mortality, as well as suboptimal brain development. Thus, stunting is an indica-
tor of vulnerability and suboptimal development, especially at the population level.
Measures for the prevention of chronic malnutrition should target all of those who 
are at risk. This may be the entire population in the window of the first 1,000 days 
in areas where stunting prevalence is high (e.g., above 40%), or it may be a subgroup 
of the population amongst whom prevalence is high (e.g., in a specific geographic 
area or in households with a low socioeconomic status). The prevention of chronic 
malnutrition requires the improvement of both diets and health of groups implicated 
throughout the 1,000 days window, pregnant and lactating women, and children 
under 24 months of age. It should also be ensured that women of reproductive age, 
including adolescent girls, have a good nutritional status, do not start their reproduc-
tive life until they are themselves fully grown and developed (i.e., 19 years of age 
or older), and that their pregnancies are well spaced (i.e., do not occur too closely 
together).
Improvements of both diets and health can occur during the economic develop-
ment of a country. However, the extent to which this occurs, and who benefits, varies, 
and specific targeted efforts may be required to ensure that those who most need the 
improvements are not left behind. The same applies to populations of countries that 
experience little economic development or face a difficult period (e.g., an economic 
crisis, or an emergency), during which those individuals passing through this critical 
1,000 days window should be protected against undernutrition. In order to sustain 
improvements to diet and health, the underlying and basic causes of  malnutrition 
such as access to recourses and economic and political climate should also be 
improved, requiring action by sectors that have not traditionally focused on nutrition.
This chapter reviews the causes of and approaches to prevent chronic malnutrition.
PREVALENCE OF STUNTING, AND TARGETS 
AND COMMITMENTS FOR ITS REDUCTION
In 2016, approximately 23% of the world’s children under 5 years old were stunted, 
coming to around 155 million children [8]. This percentage was considerably higher 
in the past, that is, approximately 40% in 1990, 33% in 2000, and 27% in 2010 [1]. 
Thus, the proportion of the world’s population that today suffers the consequences of 
chronic malnutrition during early childhood is around 35%, or more than 2.5 billion 
people. This is comparable to the number of people who are estimated to suffer from 
micronutrient deficiencies and is also close to the number suffering from overweight 
or obesity. It is important to note that these forms of malnutrition can occur simulta-
neously in one individual, that is, most often stunting and micronutrient deficiencies 
during childhood, and overweight or obesity accompanied by micronutrient deficien-
cies during adulthood, but sometimes these three can even occur simultaneously 
during childhood [9].
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In 2012, the World Health Assembly (WHA) set a target of 40% for the reduction 
of stunting between 2010 and 2025, which is equivalent to an annual, year-on-year, 
reduction of around 3%, and applies to all countries [10]. Thus, a country with 30% 
stunting in 2010 should reduce prevalence to 18% or less by 2025, and a country with 
45% in 2010 should reduce prevalence to 27% or less by 2025.
Preventing malnutrition is also a key component of the Sustainable Development 
Goals (SDGs) [11]. SDG2, Zero Hunger, aims to end hunger, achieve food secu-
rity and improved nutrition, and promote sustainable agriculture. It includes the fol-
lowing nutrition targets for 2030: “End hunger and ensure access by all people in 
particular the poor and people in vulnerable situations, including infants, to safe, 
nutritious, and sufficient food all year round; end all forms of malnutrition,” includ-
ing achieving by 2025, the WHA targets on stunting and wasting in children under 
5 years of age, and addressing the nutritional needs of adolescent girls, pregnant and 
lactating women, and older persons [11].
The Scaling Up Nutrition (SUN) Movement [12] was formed in 2010 to work 
together across constituents and sectors to improve nutrition. Governments of 
countries that have joined the SUN Movement are in the lead, and organizations 
at national as well as global levels are organized in networks for civil society, the 
United Nations (UN), donors, businesses, and researchers to work in a collective 
manner to improve nutrition. The UN established the Zero Hunger Challenge in 
2012 [13], prior to the establishment of the SDGs, to galvanize action focused on 
improving food and nutrition.
CAUSES OF CHRONIC MALNUTRITION
Direct causes of undernutrition can include an inadequate intake of required nutri-
ents, illness, and infection. Nutrient requirements are diverse and high during the 
first 1,000 days, relative to energy requirements, and are therefore challenging to 
meet (see Chapters 3 to 5 for further details). Illness increases nutrient needs, and it 
can cause anorexia, which decreases food intake, and also increases losses of cer-
tain nutrients, such as vitamin A [14]. Furthermore, inflammation and subclinical 
infection, such as environmental enteropathic dysfunction (EED), also interfere with 
nutrient absorption and utilization and, hence, also contribute to malnutrition [15]. 
The underlying causes of undernutrition lead to the direct causes of undernutrition, 
and include food insecurity, poor hygiene, water and sanitation, limited curative and 
preventive health services as well as inadequate caring practices. These underlying 
causes are in turn affected by a country’s economic situation, governance, climate, 
and gender roles.
In addition, intrauterine growth retardation (IUGR), which results in the small for 
gestational age births, which underlie 20% of stunting in low- and middle-income 
countries [16], is caused by poor maternal nutrition and health. This cannot com-
pletely be addressed by good nutrition and health during the start of the 1,000 days 
window, that is, during pregnancy. Factors that should be modified prior to preg-
nancy include the age of the mother (i.e., child bearing should start after adoles-
cence) and pregnancies need to be well spaced (at least 24 months between delivery 
and the start of the next pregnancy). Girls should be well nourished in order to not 
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have short stature and/or poor nutritional status as they become pregnant themselves. 
In order to ensure adequate nutrition at the time of conception, women of reproduc-
tive age need to be well nourished in general.
RELATIONSHIP BETWEEN CHRONIC AND ACUTE MALNUTRITION
The increased vulnerability to morbidity among children who suffer from chronic 
malnutrition, whether they are yet classified as stunted or not, also increases the risk 
of acute malnutrition, which is measured by low weight-for-height or small mid-
upper arm circumference, and is generally caused by weight loss [17]. Morbidity 
leads to weight loss, reduced appetite and, hence, reduced food consumption, lower 
absorption, and increased utilization and also loss of nutrients. The reverse, that is, 
morbidity and acute malnutrition leading to chronic malnutrition, is not necessarily 
true, but frequent and/or longer lasting periods may add up and, as such, contribute 
to chronic malnutrition, especially when the in-between periods of recovery are too 
short and do not allow for accumulated nutrient deficits to be caught up on.
STUNTING SHOULD PROMPT PREVENTIVE ACTION 
AT POPULATION LEVEL
As mentioned earlier, stunting is a population-level indicator of vulnerability and 
suboptimal development. Acute malnutrition, on the other hand, is an indicator of an 
increased risk of (further) morbidity and mortality at an individual level, based upon 
which the individual can be treated to recover from acute malnutrition (i.e., gaining 
weight by rebuilding lean tissue and fat storage) and any concurrent illness.
As a population-level indicator, stunting should prompt actions to ensure that 
nutrient needs are met, and disease and poor birth outcomes are prevented, espe-
cially among individuals in the period of the 1,000 days (i.e., pregnant and lactating 
women and children under 2 years of age).
Furthermore, because of the increased risk of morbidity and mortality, a high 
level of stunting among a population that is exposed to an adverse situation, such as 
an increased risk of illness in the rainy season (e.g., malaria or diarrhea), crowded 
conditions with higher infection pressure due to an emergency or refugee situation, 
or increased food insecurity and, hence, reduced dietary quality, should also prompt 
specific actions to prevent illness. Such actions should focus both on health (e.g., 
immunization, adequate water and sanitation facilities, and hygiene practices) and 
ensuring the consumption of a nutritious diet, including an adequate micronutrient 
intake to support the immune system. This can be in the form of supplements (e.g., 
vitamin A and zinc, in particular), home fortificants, or fortified foods for the general 
population and special fortified foods for nutritionally vulnerable groups.
There are three reasons why stunting is not diagnosed and treated at an individual 
level, but needs to be prevented at population level. First, a child is diagnosed as 
stunted when his or her length is lower than that of 2.25% of the reference popula-
tion (two standard deviations below the median, or –2 z-scores), and it takes time for 
that growth deficit to accumulate. Some children may already be below that cutoff at 
birth due to intrauterine growth restriction, which results in a small for gestational 
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age birth (a birth weight that is below that of 10% of the reference population for that 
gestational age) [18]. For other children, growth is slower than that of the reference 
population, due to which they gradually deviate more and more from the reference 
curve. In some populations, stunting prevalence is already 20% to 25% at the age of 
6 months, whereas in others it mainly develops between the ages of 6 and 18 months. 
In all countries, the prevalence of stunting increases until the age of 24 months, 
after which it stabilizes. Thus, the process of growth faltering until the point that the 
child’s length (or height) has fallen below –2 z-scores of that of the reference popula-
tion and the child is classified as stunted is gradual. While it is ongoing, however, 
the child is already at a disadvantage due to unmet nutrient needs and, hence, at an 
increased risk of morbidity and mortality, and of not achieving his or her full poten-
tial in terms of growth and development.
Second, while catching up on height after the age of 2 years is biologically pos-
sible, many of the other consequences of undernutrition during the first 1,000 days, 
such as suboptimal brain growth and development, and the consequences of intra-
uterine growth retardation in terms of increased risk of noncommunicable disease 
cannot be undone or “repaired.” The increased risk of morbidity and mortality is 
also current, and it should be prevented at the moment it occurs while the child may 
be in the process of becoming stunted. In addition, it is very important to note that 
moving from below the –2 z-score to above that cutoff may not necessarily indicate 
that the child is catching up on linear growth, as the accumulated deficit compared to 
the median height of the reference population may still be increasing [19].
The third reason is that it is not only stunted children (i.e., those who fall below 
the –2 z-score cutoff) who are not developing to their full potential. Where stunting 
prevalence is high, the distribution of the whole population is shifted toward the left 
(see Figure 15.1). Thus, children who have a z-score of, for example, –1 may also be 











FIGURE 15.1 The distribution of height-for-age z-scores of a stunted and a normal 
population.
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well below their own potential and would thus benefit from population-level inter-
ventions for the prevention of chronic malnutrition. These three reasons basically 
indicate that
• Stunting is just one indicator of chronic malnutrition, at a population level.
• Ongoing exposure to undernutrition, which is known as “chronic malnutri-
tion,” has both immediate and longer-term consequences.
• It is important to prevent undernutrition throughout the period when the 
risk is highest (i.e., the 1,000 days period), because of the immediate as well 
as the irreversible consequences.
• Indicators of success in preventing undernutrition are not limited to the 
reduction of stunting, but also include reductions of morbidity and micro-
nutrient deficiencies, and intermediate indicators such as improved dietary 
diversity, a lower incidence of adolescent pregnancies, and some of which 
can occur without a simultaneous measurable change of stunting.
NUTRIENT REQUIREMENTS DURING THE FIRST 1,000 DAYS
Nutrient requirements need to be met in order to prevent undernutrition. During the 
first 1,000 days, these needs are high in comparison to energy needs due to the rapid 
growth of the fetus, infant, and young child. For example, a child aged 6 to 8 months 
needs 9 times as much iron and 4 times as much zinc per 100 kcal of complementary 
food, as that required by an adult man per 100 kcal of his diet [20].
Recommended Nutrient Intakes (RNI) [21] or Recommended Dietary Allowances 
(RDA) [22] have been set for individual nutrients and for specific age, sex, and physi-
ological status (e.g., pregnant or breastfeeding) groups. These recommended intakes 
are for normal, healthy individuals, and are set at a level that would meet or exceed 
the needs of 97.5% of the specific group. The Estimated Average Requirement (EAR) 
is the level at which the needs of 50% of the population would be met or exceeded, 
which for most nutrients is at a level of approximately 70% of the RNI. For nutrients 
and age groups for which an RNI or EAR has not been established, which is par-
ticularly the case for young children, an Adequate Intake (AI) has been set, which is 
based on the actual intakes of apparently healthy individuals [22].
In order to meet the recommended intakes of some 40 nutrients, a diverse diet 
needs to be consumed, because no single food contains all required nutrients. Such 
a diet must include plant-source foods (i.e., staple foods, vegetables, and fruits), 
animal source foods (i.e., eggs, fish, dairy, and meat), as well as fortified foods (e.g., 
iodized salt and flour fortified with folic acid) [23–25]. Consuming a diet that meets 
not only energy and protein needs, which can be fulfilled with quite a basic diet, but 
also the needs of vitamins, minerals, essential fatty acids, essential amino acids, and 
other nutrients is more challenging and costs more, as it needs to be more diverse 
[26,27].
Certain subgroups of individuals have higher needs than the rest of their popu-
lation group, including individuals who suffer from undernutrition (e.g., moderate 
acute malnutrition), infants born small for gestational age, people with  micronutrient 
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deficiencies, and people with chronic infections. Precise nutrient requirements under 
these circumstances are not known, but it is likely, for example, that children who 
suffer frequent episodes of illness have needs that are somewhere between those 
of normal, healthy children and children with moderate acute malnutrition [28]. In 
addition, it is likely that nutrient needs vary between days and between periods with 
less or more bodily growth [29].
At an individual level, these varying nutrient needs are difficult to take into 
account, except during nutritional treatment, such as for severe acute malnutrition. 
At a population level, they are important to take into account when setting targets 
for nutrient intake that aim to prevent deficiencies, where it is important to ensure 
that the recommended intake is met, including by individuals with the lowest intakes 
from their current diet. This means that the population distribution of intake needs to 
be shifted to be above the EAR, while not exceeding the tolerable upper limit of the 
intake of individual nutrients by far, and for a prolonged period of time [22,30–32].
PREVENTING CHRONIC MALNUTRITION: APPROACHING IT 
FROM A CONCEPTUAL AND EVIDENCE-BASED POINT OF VIEW
Any intervention to prevent chronic malnutrition should aim to achieve an adequate 
nutrient intake, prevent disease, and ensure healthy, well-spaced, nonadolescent 
pregnancies. Conceptually, this may sound straightforward. However, realizing 
this at a population level, in a specific context, in a way that complements existing 
diets, health services, and hygiene measures; is accepted and well-practiced by the 
intended target group and its caretakers; and is cost-effective (i.e., achieves the most 
at the lowest cost) is very challenging.
As far as achieving optimal nutrient intake is concerned, improvements to food 
intake can be achieved in two ways that can complement each other: (1) people can 
be encouraged to make better food choices, including ensuring optimal breastfeeding 
practices and consuming a diverse diet that includes a range of foods from different 
food groups; and (2) people can be provided with specific nutritious food comple-
ments to add to their existing diet. Systematic reviews have assessed the impact 
of both approaches, and it has been concluded that nutrition education about good 
complementary feeding can reduce stunting and improve height-for-age z-scores 
(HAZ) in food-secure contexts and that nutrition education in combination with food 
supplements reduces stunting and improves HAZ in food-insecure contexts [33,34].
This makes sense. Where people can afford to make better choices and more 
nutritious foods are available to choose from, their diet can improve. This also 
underlies the relationship seen across countries between the level of a country’s gross 
domestic product (GDP) and stunting prevalence. For every 10% higher the GDP is, 
the stunting prevalence is, on average, approximately 6% lower [35]. A higher GDP 
not only indicates greater purchasing power but also a more developed food system 
that results in greater access to a diverse diet, including animal source foods and 
processed foods for specific target groups, as well as a range of other factors that 
can improve nutrition and health. Where and for whom purchasing power remains 
relatively low, specific assistance may be required to enable improvements of dietary 
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intake toward greater diversity and inclusion of more animal source and fortified 
foods in order to meet nutrient requirements.
Where specific assistance is required to improve nutrient intake, the aim is to do 
so most efficiently (i.e., by making the most difference at the lowest cost), including 
with the smallest possible modification of the daily diet. This often means that a spe-
cial nutritious, fortified food is selected to complement the diet of children aged 6 to 
23 months, because these are more cost-effective in terms of meeting nutrient needs, 
as compared to a combination of locally available fresh foods. A young child’s need 
for iron, zinc, and often also calcium are particularly difficult to meet without forti-
fication [20,25,36].
Income support, in the form of cash or vouchers for purchasing food, is another 
way to improve access to food, but the extent to which it improves nutrient intake of 
specific individuals in the household depends on what foods can be purchased, how 
much purchasing power is increased (i.e., how much cash is provided), and what 
choices are made by the consumer. The main difference is that cash is targeted at 
poor households and is likely to benefit most of its members in several ways, whereas 
a specific nutritious food for a specific individual is very targeted, can be well tai-
lored to specific nutrient needs, and costs less. In fact, to make social safety nets 
more nutrition sensitive, the inclusion of specific nutritious foods for certain target 
groups can be recommended [37]. This approach is similar to that of the Women, 
Infants, and Children (WIC) program in the United States [38].
The impact that the distribution of a special nutritious food will have on the desired 
outcome (i.e., reduction of undernutrition) depends on several factors, including [39]:
• Its specific composition, that is, which nutrients it contains and in what 
amounts
• Its actual intake, that is, what quantity is consumed and how frequently, 
which depends on actual distribution and communication/marketing mes-
sages, as well as acceptance and understanding by caretakers
• The difference that it makes to total nutrient intake, that is, where the nutri-
ent intake gap is greater, and when it is consumed in addition to (rather than 
as a replacement for) the existing diet, the impact is likely to be larger
For these reasons, the magnitude of impact that a particular food type, of a well-
defined composition, can have varies by context, as it depends on the difference 
that it can make in terms of closing the nutrient intake gap, whether consumption 
is as intended and whether it adds, rather than replaces, existing nutrient intake. 
Therefore, systematic reviews that assess the magnitude of the impact of particu-
lar types of commodities for reducing undernutrition based on studies conducted in 
different contexts and with commodities of somewhat different composition are of 
limited value, as these studies have very low external validity (i.e., their findings may 
not apply to other settings).
When the aim is to improve nutrient intake substantially among the targeted pop-
ulation, rather than selecting a commodity based on evidence of impact from other 
contexts, the choice should be guided by knowledge of the local context with regard 
to the likely magnitude and characteristics of the nutrient intake gap, and local food 
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preferences and practices, as well as manufacturing possibilities, costs, and pos-
sible distribution mechanisms, including whether certain consumers can be reached 
through market channels and others through public sector distribution (e.g., health, 
social protection, and community outreach). Box 15.1 lists the types of considerations 
that are important for selecting suitable food(s) for improving the nutrient intake of 
specific target groups, in a context where specific nutritional assistance is required.
When an approach has been chosen and is gradually being rolled out, it is impor-
tant to monitor the acceptability and actual intake of the commodities, as well as 
concurrent changes to the existing diet. Nutrition surveillance is a good way to moni-
tor programs in context [40].
PREVENTING CHRONIC MALNUTRITION: APPROACHING 
IT FROM A PRACTICAL, CONTEXT-SPECIFIC, POINT 
OF VIEW—“FILLING THE NUTRIENT GAP”
Considering that meeting nutrient requirements is a prerequisite for preventing 
undernutrition, that many factors affect whether nutrient intake targets are being 
met, that we mostly have proxy indicators for the extent to which nutrient needs are 
being met, and that approaches for improving nutrient intake need to be specific to 
their target group and context, the design of context-specific approaches for preven-
tion of undernutrition should start with a thorough situation analysis.
BOX 15.1 CONSIDERATIONS WHEN SELECTING FOOD-
BASED INTERVENTIONS TO IMPROVE NUTRIENT INTAKE
When selecting a food-based intervention to improve nutrient intake from the 
diet in a specific context, which can range from providing specific nutritious 
foods to certain target groups or increasing their availability in markets to 
recommending dietary changes possibly accompanied by homestead food pro-
duction or other food security interventions, it is important to consider
• Quantitatively the magnitude of the difference that needs to be made 
in order to achieve recommended nutrient intakes.
• Biologically the nutrients that will need to be released from the foods 
during digestion and become available for absorption (i.e., the nutri-
ents need to be bioavailable and the consumer in good health).
• Demand, that is, consumers need to obtain (purchase or receive for 
free), like, and consume the food(s) and at the recommended fre-
quency and in the recommended amount.
• Supply, that is, how can it be ensured that the foods that are produced 
or manufactured become available for the intended consumers, are 
purchased or distributed to the beneficiaries, and so forth.
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Such a situation analysis, in combination with an approach for multisectoral deci-
sion making, has been developed in the form of the Fill the Nutrient Gap (FNG) tool 
by the World Food Programme (WFP), with input from the University of California–
Davis, Harvard University, Epicentre, the International Food Policy Research 
Institute (IFPRI), Mahidol University, and UNICEF [41]. The FNG was piloted in 
three countries in 2016, and will be consolidated and expanded in 2017 to approxi-
mately 12 countries, and more in 2018.
The premise of the FNG approach is that recommended nutrient intakes have 
been defined and that many people, especially where stunting and micronutrient defi-
ciencies are highly prevalent, do not meet their nutrient needs. Foods are the main 
source of nutrients, and actual food consumption is determined by context- specific 
factors such as food production, manufacturing, import and export, transport and 
distribution, prices relative to income, culture, knowledge, and so on. In order to 
improve food consumption in such a way that nutrient needs can be met, including 
among target groups with higher needs, the specific context needs to be better under-
stood, and different sectors need to work together to improve the situation.
The FNG consists of an analytical and decision-making component. The analyti-
cal component has two parts: (1) a situation analysis using available secondary data 
that focuses on the type and scale of nutrient intake deficits and enablers and con-
straining factors; and (2) a linear programming component, using the Cost of Diet 
tool developed by Save the Children UK, which assesses the costs to a household of 
meeting the nutrient intake recommendations of its members at the lowest possible 
cost, using locally available foods, and comparing that to their level of food expen-
diture [26,27].
The analytical components provide rich context-specific insights into the likeli-
hood that nutrient needs are met, and the main bottlenecks and main opportunities 
to improve the situation, considering both nutrition-specific and sensitive interven-
tion opportunities as well as potential delivery channels for reaching specific target 
groups.
The process through which the analyses are undertaken is the other essential 
component of the approach. The process starts when national-level stakeholders 
decide that they would like to have the FNG analyses conducted. This is typically 
when policy revisions (e.g., of nutrition or social protection) are due. In an inception 
meeting, the stakeholders jointly decide on the desired focus of the analysis (e.g., 
adolescent girls, pregnant and lactating women, and children under 2) and the spe-
cific, distinct geographical areas for which secondary data are likely to be available 
(e.g., urban versus rural and different regions). The inception meeting is attended by 
stakeholders from different sectors, including health, agriculture, social protection, 
education, trade and industry, and different constituencies including national gov-
ernment, UN agencies, academia, private sector, and civil society. The meeting aims 
to achieve a joint understanding of the approach, and a commitment to contribute to 
the analysis by sharing relevant sources of secondary data and reviewing the findings 
that are being put together by a technical team. Based on the results, stakeholders 
then jointly formulate recommendations for policies, as well as the programs that 
different sectors can undertake.
231Chronic Malnutrition
So far, the experiences have been very positive. Focusing discussions, which are 
informed by existing secondary data, on improving nutrient intake in the country’s 
context creates a common understanding and allows for the formulation of concrete 
recommendations for next steps among stakeholders. This multisectoral approach 
also aligns very well with that of the SUN movement.
CAN STUNTING BE AN INDICATOR OF BOTH THE NEED 
FOR NUTRITION INTERVENTIONS AND THEIR IMPACT?
Stunting is an indicator of chronic malnutrition used to monitor the undernutrition 
situation within a country over time, and across countries. It is the preferred indicator 
because it reflects the cumulative impact of nutrition insults (i.e., inadequate nutrient 
intake and disease across the first 1,000 days), and because it also reflects the impact 
of underlying and basic causes of malnutrition. Furthermore, it reflects other short- 
and longer-term consequences of undernutrition as well, including an increased risk 
of morbidity and mortality, suboptimal cognitive development and, hence, poorer 
schooling performance and income-earning later in life, and an increased risk of 
noncommunicable diseases. Stunting is a good indicator for monitoring improve-
ments to a population’s nutritional status over a longer period of time, at least a 
few years, as related to the cumulative exposure to nutrition-specific and sensitive 
policies and strategies, including proper safety nets and changes to the economic 
situation.
However, for two reasons, stunting may not be the best primary outcome indicator 
of the impact of a specific intervention. First, stunting accumulates over a substantial 
period of time, covering prepregnancy, which affects nutritional status at conception, 
pregnancy, early lactation, and the complementary feeding period, and is affected, 
both positively and negatively, by many different factors. Therefore, while a specific 
intervention may make a contribution to improving nutrition, it may not cover a 
long enough period of the first 1,000 days or be insufficient on its own to lead to a 
substantial change of stunting without concurrent improvement of other conditions 
as well. Second, as stunting is defined as inadequate linear growth (being too short 
for one’s age), it is only when specific nutrients that enable the adequate growth of 
bones and muscles are also consumed in required amounts that stunting will reduce 
[42]. These nutrients are provided by a diverse diet that includes plant-source foods, 
animal source foods, and fortified foods. Further, specific nutrition interventions 
may be a better source of certain nutrients (e.g., micronutrients) than of specifically 
those nutrients that are required to achieve linear growth. In that case, the interven-
tion may have a limited impact on stunting but still have a positive impact on other 
forms and consequences of chronic malnutrition, such as micronutrient deficiencies, 
cognitive development, and morbidity.
Therefore, it is very important that interventions to reduce undernutrition in a pop-
ulation are judged not only by their impact on stunting, but also by their impact on 
other forms and on the consequences of undernutrition, including micronutrient status 
and morbidity, and that targets are set and changes monitored for dietary intake, dis-
ease and infection, and maternal nutrition, as well as their underlying factors.
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CONCLUSION
Chronic malnutrition refers to a process of suboptimal nutrition, due to nutrient 
needs not being met and suffering from disease and infection, which continues over 
a prolonged period of time and to a state of undernutrition that has several short- 
and longer-term consequences. The consequences are due to the effects of the accu-
mulated nutritional deficits on growth, health, and development, including higher 
morbidity and mortality, poorer school performance, and lower income-earning 
potential due to suboptimal cognitive and physical development early in life, and an 
increased risk of noncommunicable diseases.
Stunting, or shortness for age, is the main population-level indicator of prolonged 
or “chronic” malnutrition. However, in order for it to be interpreted, it is important to 
understand and use it correctly. Ongoing exposure to undernutrition has both imme-
diate and longer-term consequences, which are revealed in diverse ways, not only as 
a height deficit that also takes time to accumulate. Stunting among the under-fives 
indicates the risk of individuals currently in the 1,000 days window, among whom 
undernutrition should be prevented because of immediate and irreversible conse-
quences, and the vulnerability of those 5 years and under to adverse conditions, such 
as an increased risk of malaria and diarrhea during the rainy season. Indicators of 
success of preventing undernutrition are not limited to a reduction of stunting, but 
also include other effects of improved nutritional status, such as reductions of mor-
bidity, micronutrient deficiencies, and low birth weights.
Meeting nutrient requirements is a prerequisite for the prevention of undernu-
trition and requires the consumption of a diverse diet, which should also include 
animal source foods and fortified foods. The limited availability and affordability 
of a diverse diet are major constraints to meeting nutrient requirements. In order 
to substantially improve nutrient intake among the targeted population, rather than 
select a commodity based on evidence of its impact from other contexts, the choice 
should be guided by knowledge of the local context. Context-specific information is 
required with regard to the likely magnitude and characteristics of the nutrient intake 
gap, food preferences and practices, manufacturing possibilities and costs of specific 
nutritious foods, and possible distribution mechanisms, including whether certain 
consumers can be reached through market channels or public sector distribution. 
Such context-specific solutions should be designed and implemented in a coordi-
nated manner by governments, the UN, donors, the private sector, and civil society 
stakeholders across health, food, and social safety-net systems.
Interventions for reducing undernutrition in a population should be judged not only 
by their impact on stunting, but also by their impact on other forms and consequences 
of undernutrition, including micronutrient status and morbidity. A country’s progress 
in reducing chronic malnutrition needs to be monitored over time, and should use a 
range of indicators of chronic malnutrition and health as well as of dietary intake (e.g., 
diversity and special nutritious foods), factors affecting the consumption of different 
foods (e.g., price, affordability, availability, knowledge), factors related to maternal 
nutrition (e.g., age at first pregnancy, or the school enrollment of adolescents), cover-
age of preventive health services, and hygiene and sanitation practices.
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16 Nutritional Regulation 
of the Growth Plate
Julian C. Lui
INTRODUCTION
During embryonic development, bone formation begins with the condensation of 
mesenchymal stem cells. In a number of places in the body, such as the flat bones of 
the skull, bone formation is driven by a process called intramembranous ossification, 
where mesenchymal stem cells differentiate directly into bone-forming osteoblasts. In 
most other places, however, bones are formed by a different process known as endo-
chondral ossification (Figure 16.1; for review, see Kronenberg [1]). In this process, 
mesenchymal stem cells first differentiate into chondrocytes. These chondrocytes 
secrete cartilage matrix composed mainly of type II collagen. Proliferation of chon-
drocytes leads to an overall expansion of this cartilage tissue and, in the center of the 
cartilage, cells stop dividing and start enlarging to become type X collagen-producing 
hypertrophic chondrocytes. These hypertrophic chondrocytes drive cartilage matrix 
mineralization, and eventually undergo apoptosis, leaving a cartilage matrix scaffold 
for the invasion of blood vessels and osteoblasts to lay down bone matrix in the center 
of the cartilage, known as the primary ossification center. As chondrocytes continue 
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to proliferate, undergo hypertrophy, and are then invaded by osteoblasts, the long 
bones continue to lengthen and ossify in the center, resulting in longitudinal bone 
growth and an overall increase in body size and height. Gradually, as bones continue 
to grow in length, endochondral ossification becomes increasingly restricted to the 
cartilaginous structure found near the two opposite ends of long bones known as the 
growth plate. Within each growth plate, chondrocytes are arranged into three histo-
logically distinct zones called resting, proliferative, and hypertrophic zones. Closest 
to the epiphysis, round and slowly dividing resting chondrocytes serve as precursor 
cells capable of self-renewing and giving rise to new clones of proliferative chondro-
cytes. In the proliferative zones, cells are arranged in columns parallel to the long axis 
of the bone and, within each column, chondrocytes undergo rapid proliferation, push-
ing themselves gradually toward the center of the bone, where they undergo the same 
process of hypertrophy and apoptosis. In late adolescence, as adult height is gradually 
attained, the growth plate continues to narrow, until growth potential is depleted, the 
epiphyseal fuses, and growth in height stops.
ENDOCRINE REGULATION OF BONE GROWTH
The integrated processes of chondrocyte proliferation and hypertrophy are regulated 
and coordinated by a complex network of endocrine signaling molecules, including 
growth hormone (GH), insulin-like growth factor I (IGF-I), glucocorticoid, thyroid 
hormone, estrogen, and androgen (Figure 16.2).
Growth hormone InsulIn-lIke Growth Factor-I axIs
Both GH and IGF-I are potent stimulators of longitudinal bone growth (for review, 


















FIGURE 16.1 Endochondral ossification and histology of the growth plate. (a) Endochondral 
bone formation starts with a mesenchymal condensation. (b) Mesenchymal stem cells dif-
ferentiate into chondrocytes, and chondrocytes at the center of the cartilage mold start to 
hypertrophy. (c) Hypertrophic chondrocytes undergo apoptosis and draw the invasion of 
blood vessels and osteoblasts, building calcified bone in the primary ossification center (poc). 
(d) Later in bone development, the epiphysis also undergoes calcification, forming the sec-
ondary ossification center (soc), and the growth plate cartilage remains near the ends of long 
bone continues to drive bone elongation.
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circulation. When GH travels to the liver, it stimulates hepatic production of IGF-I, 
which in turn acts as an endocrine factor to stimulate chondrocyte proliferation and 
hypertrophy at the growth plate. GH can also stimulate the local production of IGF-I 
at the growth plate to stimulate growth in a paracrine/autocrine fashion. In addition, 
GH may also directly stimulate growth at the growth plate, independent of its effect 
on circulating IGF-I, mainly through recruiting resting zone chondrocytes into the 
proliferative columns. GH excess due to pituitary adenomas in childhood therefore 
results in gigantism and, conversely, GH deficiency in children results in decreased 
IGF-I and poor linear growth. Similarly, mutations in the GH receptor cause GH 
insensitivity syndrome, which can cause low IGF-I levels and poor linear growth. 
Normally, IGF-I provides a negative feedback to the pituitary to limit GH secretion; 
children with GH insensitivity therefore have elevated GH levels. Surprisingly, GH 
appears to be dispensable for fetal growth, as suggested by the relatively normal 
prenatal growth in individuals with GH deficiency or insensitivity (with modestly 
reduced IGF-I). In contrast, IGF-I appears to be important for both pre- and post-
natal growth, as suggested by the much more significant intrauterine growth retar-
dation and postnatal growth failure found in individuals with mutation of the IGF1 
gene or its receptor. Insulin-like growth factor II (IGF-II), which bears structural 
similarities with IGF-I, and also acts through the IGF-I receptor, is a paracrine/auto-
crine factor long known as an important stimulator of prenatal growth [3]. However, 
some recent clinical findings suggest that IGF-II may also be important for postnatal 
growth, as individuals with nonsense mutations of IGF2 demonstrated severe intra-
uterine growth retardation as well as postnatal growth restriction [4].
Normal linear growth requires an adequate intake of calories, protein, vitamins, 






















(Due to lack of
feedback from IGF-I)
FIGURE 16.2 A schematic model for nutritional regulation of endocrine signals important 
for bone growth. The effects of malnutrition are annotated by red lines and red arrows. The 
negative sign represents inhibitory effects.
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major effects of malnutrition, or negative energy balance, on limiting body growth is 
due to its effect on the GH–IGF-I axis. Importantly, inadequate calorie intake slows 
linear growth by downregulating GH receptor expression in the liver [5], thereby 
inducing a state of GH insensitivity that is similar to that observed in individuals 
with GH receptor mutations. Undernourished children therefore show decreased 
IGF-I levels and increased GH levels due to the lack of negative feedback.
Recent evidence suggests that malnutrition-induced GH insensitivity may, 
in part, be mediated by fibroblast growth factor 21 (FGF21). Unlike many other 
FGFs, which only act locally as paracrine/autocrine factors, FGF21 lacks the FGF 
heparin-binding domain and therefore can still act as a paracrine factor but also 
diffuse from the tissue of synthesis like a hormone. FGF21 can activate FGFR1 and 
FGFR3 [6], both of which transmit a growth-inhibitory effect in chondrocytes. Thus, 
for example, the activation of a mutation of FGFR3 causes achondroplasia, which 
causes severe short stature in children. Consistently, transgenic mice overexpress-
ing Fgf21 exhibit reduced bone growth, partly by increasing FGF signaling at the 
growth plate and partly by inducing GH insensitivity at the liver [7]. Recent stud-
ies suggest that FGF21 plays an important role in fasting-induced GH insensitivity 
and growth inhibition. Prolonged fasting increases circulating FGF21 in both mice 
[8] and humans [9] and, when placed under food restriction, Fgf21 knockout mice 
showed significantly increased linear growth and growth plate thickness as com-
pared to wild-type mice, strongly suggesting that growth inhibition by fasting is 
driven by Fgf21 [10]. Most importantly, decreased GH receptor expression and GH 
insensitivity were also corrected by ablation of Fgf21 [10], therefore suggesting that, 
at least in mice, decreased GH action during fasting is driven by fasting-induced 
expression of Fgf21.
In additional to inadequate calorie intake leading to GH insensitivity, protein 
deficiency alone may also impair bone growth by suppressing the GH–IGF-I axis. 
Previous studies have shown that protein deficiency, even when compensated with 
normal calorie intake, still led to impaired childhood growth and poor bone quality 
[11], in part due to decreased levels of GH, and thereby IGF-I production [12].
GlucocortIcoId excess
Apart from the GH-IGF-I axis, other hormonal systems may also directly regulate 
growth at the growth plate. Glucocorticoids, which are a subclass of steroid hor-
mones, are quite commonly used as anti-inflammatory and immunosuppressive drugs 
in children. Treatment with glucocorticoids at a high dose for an extended period of 
time often leads to decreased linear growth in children, which is in part due to the 
suppression of chondrocyte proliferation and increased apoptosis by glucocorticoid 
[13]. Normally, the glucocorticoid produced in our body is called cortisol, which 
comes from the adrenal gland, and its production is stimulated by the adrenocortico-
trophic hormone (ACTH) from the anterior pituitary. Individuals with a rare genetic 
disorder called Cushing’s disease, usually caused by a pituitary adenoma producing 
an excessive amount of ACTH, therefore also exhibit poor linear growth. In addition 
to glucocorticoid’s direct growth-inhibitory effect on the growth plate, it could also 
inhibit growth indirectly through other endocrine signals. Prolonged glucocorticoid 
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excess negatively regulates GH production [14] and also increases the release of free 
fatty acid [15], which in turn negatively regulates GH actions.
Endogenous glucocorticoid production and sensitivity increases under stressful 
conditions, such as illness and prolonged food restriction [16], which directly sup-
presses growth at the growth plate, and also indirectly suppresses growth, by sup-
pressing the GH–IGF-I axis.
thyroId hormone
Thyroid hormones produced by the thyroid gland, namely, 3,5,3′-triiodothyronine 
(T3) and thyroxine (T4), are important regulators of metabolism. T4 serves as 
a prohormone, which can be converted to the bioactive T3 by the enzyme type II 
iodothyronine deiodinase (DIO2) expressed in the thyroid and most other tissues, 
including the growth plate. Thyroid hormones are an important stimulator of normal 
linear growth. Hypothyroidism delays longitudinal bone growth and endochondral 
ossification, while thyrotoxicosis, which results in excessive production of thyroid 
hormones, accelerates both processes. Nonetheless, both hypothyroidism and thyro-
toxicosis eventually lead to short stature. Thyroid hormones support bone growth by 
promoting the recruitment of resting chondrocyte into a proliferative zone, as well as 
stimulating chondrocyte hypertrophy [17]. Thyroid hormones are also essential for 
the normal deposition of the extracellular matrix by stimulating the production of 
type II and type X collagens and the synthesis of alkaline phosphatase [18]. Thyroid 
hormones also indirectly stimulate growth by modulating the production of GH and 
IGF-I. In humans with hypothyroidism and in thyroidectomized mice, both GH and 
IGF-I levels are decreased, and replacement of GH in hypothyroid rats or thyroid 
hormone receptor knockout mice partially rescues bone growth [19]. Among the 
four different isoforms of thyroid hormone receptors (TR-α1, -α2, -β1, -β2, encoded 
by two genes, THRA and THRB) found in humans, TR-α1 and -α2 are more highly 
expressed in the growth plate, and therefore appear to elicit much of the effect of 
thyroid hormone on longitudinal growth. Consistently, the homozygous deletion of 
THRB showed some delay in skeletal maturation, but exhibited normal growth [20], 
while homozygous deletion of THRA has not yet been described. So far, most cases 
of thyroid hormone resistance found in humans that showed postnatal growth retar-
dation is caused by a dominant negative mutation of either TR-α or TR-β recep-
tors [21]. Studies in humans showed that malnutrition decreases both T3 and T4 
levels, and thereby slows linear growth [22]. Similarly, iodine deficiency, which is 
very common in some developing countries, leads to thyroid hormone deficiency and 
decreased linear growth. In several animal models, however, it was shown that food 
restriction mostly reduces T3 levels rather than T4 [23], suggesting that malnutrition 
may affect the conversion of T4 to T3 rather than thyroid hormone production.
estroGen, androGen, and leptIn
Another important hormonal system that regulates linear growth is the sex steroids. 
During puberty, estrogens and androgens are produced by the gonads and are associ-
ated with the pubertal growth spurt. This growth acceleration is primarily induced 
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by estrogen rather than androgen, because a near-normal growth spurt is observed in 
individuals with androgen insensitivity [24], but little or no growth spurt occurs in 
individuals with deficiency of aromatase [25], an adrenal enzyme that is responsible 
for the conversion of androgens into estrogens. This growth-stimulatory effect of 
estrogen during puberty is mediated in part through increasing GH production, as 
well as its direct action on growth plate chondrocytes [26]. Although estrogen stimu-
lates longitudinal growth, it also accelerates skeletal maturation, in part through 
accelerating the depletion of resting chondrocytes in the growth plate [27]. In chil-
dren with precocious puberty, premature estrogen exposure therefore leads to pre-
mature epiphyseal fusion and decreased final height and, conversely, in individuals 
with hypogonadism, a lack of estrogen leads to delayed epiphyseal fusion and tall 
stature. Androgens (like testosterone) per se, without conversion to estrogen, may 
also help stimulate bone growth. In boys, dihydrotestosterone, a nonaromatizable 
androgen, can accelerate linear growth [28]. Apparently, unlike estrogen, this effect 
is not associated with an increase in circulating GH or IGF-I.
Malnutrition also strongly attenuates the reproductive axis, therefore decreas-
ing the levels of both estrogen and androgen. Some recent studies have shown that 
this is driven, in part, by decreased levels of a hormone from the adipose cells called 
leptin (for  review, see Sanchez-Garrido and Tena-Sempere [29]). Leptin was origi-
nally described as a circulating hormone involved in feeding behavior and energy 
homeostasis, but was later also found to be important for controlling the timing of 
puberty, and thus indirectly affecting bone growth. Along with kisspeptin, leptin is a 
major permissive signal for the onset of puberty. In malnourished children, decreased 
body fat mass leads to decreased leptin, and insufficient leptin in the body thereby 
delays the onset of puberty and the pubertal growth spurt. Whether leptin has an effect 
on bone growth, independent of its regulation of puberty, remains controversial. Mice 
with a loss-of-function mutation of the leptin gene (ob/ob mice) have shorter femur 
length but increased overall body length [30], and leptin administration in ob/ob mice 
increases bone length, suggesting a growth-promoting effect [31]. Nevertheless, leptin 
administration has many indirect effects, such as altering GH, IGF-I, and glucocorticoid 
levels; therefore it is unclear whether leptin has a direct effect on the growth plate. 
More importantly, clinical cases of leptin or leptin receptor mutations in humans are 
either associated with tall stature or have no effect on linear growth [32]. Therefore, it 
remains unclear whether leptin stimulates or suppresses bone growth in humans.
calcIum, phosphate, and VItamIn d
One particular micronutrient that is important for bone homeostasis and bone growth 
is vitamin D. Vitamin D can be obtained from some foods as well as dietary supple-
ments, but most people are reliant on endogenous synthesis through exposure to 
sunlight. Sunlight allows the photoconversion of 7-dehydrocholesterol to cholecal-
ciferol (vitamin D3) in the skin, which is then stored in adipose tissues. Vitamin D 
deficiency can therefore result from inadequate exposure to sunlight or prolonged 
food restriction (less common).
Cholecalciferol itself is not biologically active. It is metabolized in the liver by 
vitamin D 25-hydroxylase to produce calcifediol (also known as 25-hydroxyvitamin D). 
243Nutritional Regulation of the Growth Plate
Calcifediol is then converted in the kidney by 1-α-hydroxylase into calcitriol, or 
1,25-dihydroxyvitamin D (1,25-OHD), the biologically active hormonal form.
Vitamin D is important in calcium homeostasis as it stimulates the absorption of 
calcium in the intestine. Because decreased calcium levels in blood increase para-
thyroid hormone levels, and consequently increase bone resorption, vitamin D is 
important for proper bone mineralization, and vitamin D (or calcium) deficiency 
results in undermineralization of the bones. In adults, it could lead to osteoporosis; 
in childhood, it causes a skeletal disorder known as rickets, which is one of the most 
common noncommunicable childhood diseases in developing countries [33]. In chil-
dren with rickets, the hypertrophic zone is expanded due to decreased mineralization 
and defective apoptosis of the terminal hypertrophic chondrocytes. These cellular 
changes thus help explain the bone deformity and widening metaphysis often seen 
in rachitic bones.
Genetic studies in mice have provided important insights into the molecular 
mechanisms by which vitamin D deficiency impairs childhood bone formation and 
growth. Targeted ablation of vitamin D receptor (Vdr) in mice leads to hypocal-
cemia, hyperparathyroidism, hypophosphatemia (due to hyperparathyroidism), and 
rickets [34]. However, prevention of abnormal mineral ion homeostasis in Vdr-null 
mice using a high-calcium and high-phosphorus diet has prevented the develop-
ment of rickets, suggesting that impaired mineral ion homeostasis, rather than 
Vdr-mediated signaling itself, is the primary cause of impaired bone growth [35]. 
Importantly, mutations in PHEX in mice, which causes hypophosphatemia (but only 
slightly lower calcium), and mice fed with a low-phosphorus high-calcium diet, both 
developed rachitic bones [36]. Similarly, children with X-linked hypophosphatemia, 
which results from increased urinary phosphate excretion, have decreased phospho-
rus but normal levels of calcium and vitamin D in blood, but also developed rickets 
and short stature. Taken together, evidence from mouse models and human disease 
collectively suggest that impaired growth in rickets is primarily caused by phosphate 
deficiency, rather than the lack of vitamin D or calcium per se.
INTRACELLULAR REGULATION OF BONE GROWTH
Clearly, chondrogenesis and normal chondrocyte functions are regulated by mul-
tiple different intracellular signaling pathways, genes, and epigenetic mechanisms. 
The purpose of this section is not, therefore, to exhaustively describe all these 
intracellular regulatory mechanisms. Rather, it focuses on a few that have recently 
been found to be relevant to the nutritional regulation of bone growth.
mtor sIGnalInG pathway
The mammalian target of rapamycin (mTOR) signaling pathway is perhaps the 
most relevant signaling pathway connecting nutritional status and cell growth (for 
review, see Laplante and Sabatini [37]). mTOR is a member of the phosphatidylino-
sitol 3-kinase (PI3K)-related kinase protein family and was initially discovered in 
yeast to be the mediator of toxic effects of a macrolide called rapamycin. Later, two 
mTOR-containing protein complexes were identified in mammalian cells, and were 
244 The Biology of the First 1,000 Days
named mTORC1 and mTORC2. Both mTORC1 and mTORC2 are highly sensitive to 
rapamycin but, in addition, mTORC1 also responds to other intracellular and extra-
cellular signals, such as growth factors, stress, amino acids, and energy levels, and 
is known to mediate multiple downstream signaling pathways to regulate protein 
and lipid synthesis, cell cycle progression, and autophagy. In contrast, mTORC2 is 
mainly involved in the regulation of cytoskeletal organization in response to growth 
factors. The mTORC1-mediated signaling pathway therefore appears to be an impor-
tant intracellular mechanism, allowing mammalian cells to assess nutritional status 
and make cellular decisions on cell survival, growth, and proliferation.
One of the key immediate upstream regulators of mTORC1 is a heterodimer 
of tuberous sclerosis 1 and 2 (TSC1 and TSC2) (Figure 16.3). TSC1/2 acts as a 
 GTP-ase- activating protein (GAP) for a Ras family protein called Rheb (or Ras 
homolog enriched in the brain). When bound to GTP, Rheb interacts with mTORC1 
to stimulate its kinase activity. Like most GAPs, TSC1/2 negatively regulates the 
activity of Rheb (or any Ras proteins) by catalyzing the conversion of the active 
GTP-Rheb back to the inactive GDP-Rheb. Consequently, TSC1/2 serves as a nega-
tive regulator of mTORC1 activity. One of the many growth factors that stimulate 
the mTOR pathway through TSC1/2 is IGF-I. IGF-I stimulates both Ras and PI3K 
signaling pathways, which subsequently lead to increased phosphorylation of Erk (or 
extracellular signal-regulated kinases) and Akt, respectively. Because both phospho-
Erk and phosphor-Akt inhibit TSC1/2, IGF-I signaling stimulates mTORC1 activ-
















FIGURE 16.3 A schematic model for nutritional regulation of mTORC1 signaling. Green 
arrows denote activation, black arrows denote effects, and red blunted arrows denote 
inhibition.
245Nutritional Regulation of the Growth Plate
The  decreased chondrocyte proliferation and hypertrophy during food restriction 
may therefore be in part mediated intracellularly through decreased IGF-I and inhi-
bition of mTOR signaling in chondrocytes.
Another important upstream regulator of mTORC1 is adenosine monophosphate-
activated protein kinase (AMPK). In a low energy state, the ratio of AMP to ATP 
increases in the cell, which in turn leads to an increase in AMPK activity. AMPK 
directly phosphorylates and activates TSC2, which leads to the inhibition of Rheb. In 
addition, AMPK also phosphorylates and allosterically inhibits one of the key com-
ponents in mTORC1, which is called regulatory-associated protein of mammalian 
target of rapamycin (raptor). The end results of both events ensure the suppression 
of the mTOR pathway in response to a decreased energy level in cells. Similar to 
decreased IGF-I levels, this alternative mechanism mediated by AMPK likely con-
tributes in part to the inhibition of mTOR signaling during malnutrition.
The role of mTOR signaling specifically in chondrocytes and in longitudinal 
bone growth has been elucidated by the infusion of the mTOR inhibitor, rapamycin, 
directly at the tibia. Rapamycin treatment inhibits bone growth by strongly suppress-
ing hypertrophy differentiation and type X collagen production [38]. These findings 
were consistent with the cellular effects of mTOR signaling described earlier and 
support its potential role in terms of growth inhibition during malnutrition.
epIGenetIcs and sIrtuIns
Epigenetics broadly refers to changes in gene functions without involving changes in 
the genomic DNA sequence. More specifically, it is often used to describe changes 
in DNA modifications and histone modifications, such as acetylation, methylation, 
and ubiquitination. The involvement of epigenetics in childhood growth is not a new 
concept, in general, but has gathered much attention due to some recent clinical 
findings of mutations in histone- and DNA-modifying genes causing overgrowth 
syndromes [39].
Several independent studies collectively suggested the involvement of histone 
deacetylases (HDAC), which are enzymes that remove acetylation from histones, in 
the regulation of bone growth of individuals in a malnourished state. First, HDAC 
in general suppresses growth in chondrocytes, because knockout mice of HDAC3 
showed decreased bone growth [40], while the treatment of HDAC inhibitors in chon-
drocytes stimulated expression of type II collagen as well as Sox9, which is an impor-
tant transcription factor for chondrogenesis [41]. In contrast, HDAC overexpression 
downregulates the expression of aggrecan and type II collagen in chondrocytes [42]. 
Importantly, some members of a specific class of HDAC called sirtuins, which are 
NAD-dependent acetylases, were shown to be stimulated by food restriction. It was 
found that the expression of SIRT1 and 6 was upregulated by food restriction, both 
in vitro and in vivo. The enzymatic activity of SIRT1 was also positively regulated 
by NAD+ (or nicotinamide adenine dinucleotide), which reflects energy status and 
increases during fasting (for review, see Guarente [43]). There are many downstream 
effectors of SIRT1 [43], but that which linked sirtuins back to the mTOR signaling is 
AMP kinase [44]. SIRT1 deacetylates and activates STK11 (also known as LBK1), 
which is a kinase that activates AMPK [45]. SIRT1 upregulation during fasting may 
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thus suppress growth in part by inhibiting mTOR signaling though AMPK, as dis-
cussed earlier (Figure 16.4).
Interestingly, some evidence has suggested that sirtuins may also be involved in 
the intracellular mechanisms that downregulate the GH–IGF-I axis during fasting. 
Resveratrol, which is a SIRT1 activator, significantly decreases GH secretion in the 
pituitary [46]. Similarly, neural-specific SIRT6 knockout mice have reduced GH and 
IGF-I levels, which have contributed to postnatal growth retardation in these mice 
[47]. However, it is important to point out that these findings were not consistent with 
what is seen in malnourished children, where GH insensitivity (and thus increased 
GH levels), rather than decreased GH levels, is usually observed.
mIcrornas
MicroRNAs (miRNAs) are small (18–24 nucleotides long) noncoding RNAs involved 
in the regulation of gene expression. Longitudinal bone growth requires the expres-
sion of certain miRNA at the growth plate, as a cartilage-specific knockout of Dicer, 
which encodes for the endoribonuclease needed to process miRNAs, has led to severe 
growth retardation. Genetic studies in mice showed that the two major miRNAs 
involved in bone growth are miR-140 and the let-7 family (for review, see Lui [48]). 
Importantly, the expressions of several miRNAs at the growth plate, including miR-
140, were downregulated in response to general food restriction in mice [49]. It is yet 
unclear which and how many downstream target genes are important for mediating 
the effect of miR-140 on the growth plate; however, one predicted target of miR-








(at the pituitary) Protein synthesis,
cell growth, etc.
Longitudinal bone growth
at the growth plate
AMPK
FIGURE 16.4 A proposed model for nutritional regulation of intracellular mechanisms 
important for bone growth. Green arrows denote activation and red blunted arrows denote 
inhibition. The effect of sirtuins on the GH–IGF-I axis remains unclear, as it has been sup-
ported by experimental evidence but has been contradicted by clinical findings.
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suppressed by miR-140 in vitro, which provided an interesting possible intracellular 
mechanism for growth suppression during fasting. Food restriction suppresses the 
expression of miR-140, which in turn leads to derepression of SIRT1 (along with 
other molecular targets). Consequently, the upregulation of SIRT1 leads to acetyla-
tion and inhibition of TSC2, thus suppressing the mTOR signaling pathway impor-
tant for cell growth (Figure 16.4).
GROWTH PLATE SENESCENCE AND CATCH-UP GROWTH
Growth deceleratIon and Growth plate senescence
In humans, longitudinal bone growth is rapid in early life, but decelerates with age 
and gradually ceases during adolescence. Although linear growth is regulated by 
various endocrine factors, as mentioned earlier, this age-associated decline in growth 
rate does not appear to be caused by changes in hormonal levels; rather, it depends on 
a mechanism intrinsic to the growth plate itself, called growth plate senescence [50]. 
Clinically, the degree of growth plate senescence is perhaps defined as a child’s bone 
age, which is assessed by taking a single x-ray of the child’s left hand and wrist, and 
the degree of skeletal ossification is evaluated by pediatric endocrinologists. Growth 
plate senescence is characterized by both structural and functional changes, includ-
ing the gradual depletion of resting zone chondrocytes, a decreasing proliferation 
rate in the proliferative zone, and the diminishing size of the terminal hypertrophic 
cells with age. These changes occur with increasing age but do not appear to be 
driven by time or age per se, and instead depend on growth itself [51]. This observa-
tion implies a negative feedback mechanism by which linear growth is regulated: 
growth leads to the depletion of growth potential and advances growth plate senes-
cence, therefore driving growth to gradually slow and cease, setting a fundamental 
limit on linear bone growth.
Growth plate senescence model For catch-up Growth
Growth plate senescence may also help explain the clinical phenomenon of catch-
up growth, which is defined as a greater-than-normal linear growth rate for chron-
ological age following a period of growth inhibition [52]. Clinically, catch-up 
growth has been observed after prior growth inhibiting conditions such as malnu-
trition, hypothyroidism, glucocorticoid treatment, and celiac disease, is resolved. 
Previously, catch-up growth had been ascribed to a homeostatic mechanism driven 
by the central nervous system. Subsequent studies have shown, instead, that catch-
up growth results from delayed growth plate senescence [51]. Because of the nega-
tive feedback described earlier, normal growth gradually uses up growth potential 
and drives growth plate senescence. Therefore, growth-inhibiting conditions may 
instead preserve growth potential and delay growth plate senescence. When the 
condition resolves, the growth plate grows more rapidly than is normal for chrono-
logical age, resulting in catch-up growth (Figure 16.5). In malnourished children, 
growth plate senescence could be delayed by two independent mechanisms. First, 
the general inhibition of linear growth by malnutrition could help preserve growth 
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potential in the growth plate. Second, because estrogen accelerates growth plate 
senescence and epiphyseal fusion by depleting the number of resting chondrocytes 
[27], malnutrition also delays senescence by shutting down the reproductive axis, 
and thereby estrogen production, through leptin deficiency [29]. Based on the con-
cept of growth plate senescence, catch-up growth should completely correct the 
growth deficiency over time, once the underlying problem is resolved. However, 
children with prior growth deficiency often end up shorter than is expected of 
their genetic potential, even after catch-up growth. Future research into growth 
plate senescence may help better understand and overcome this permanent loss in 
growth potential.
CONCLUSION
Longitudinal bone growth is driven by chondrogenesis, and the proliferation 
and hypertrophic differentiation of chondrocytes at the growth plate cartilage. The 
growth plate is regulated by complex interactions between different endocrine sys-
tems, epigenetic mechanisms, and intracellular signaling pathways. Nutrition plays 
an important role in modulating these multiple regulatory mechanisms of the growth 
plate, thereby only permitting rapid linear growth when the organism is able to 
take in plentiful nutrients. As children grow and continue to increase in height, the 
growth plate gradually ages (becomes senescent), leading to functional and struc-
tural declines of the growth plate and a decrease in growth velocity, until growth 
stops and adult height is attained. The temporary inhibition of bone growth during 
childhood may also slow down aging of the growth plate, which may help explain 
the spike in growth rate when growth inhibition is resolved, a clinical phenomenon 













leading to “catch-up growth”
Normal senescence
gp appears less senescent
for its chronological age
FIGURE 16.5 The growth plate senescence model for catch-up growth. gp, growth plate.
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17 Gestational Weight Gain 
and Body Composition 
in Pregnant and 
Postpartum Women
Elisabet Forsum
GESTATIONAL WEIGHT GAIN AND ITS COMPONENTS
There has been considerable controversy over the years as to what is desirable 
weight gain during pregnancy, and guidelines have varied considerably over time. 
For example, the authors of an American textbook in obstetrics in 1966 stated that 
“excessive weight gain in pregnancy is highly undesirable for several reasons; it is 
essential to curtail the increment in gain to 28 lb (12.5 kg) at most and preferably 15 lb 
(6.8 kg)” [1]. Later, however, this policy of severe weight restriction of 6.8 kg was 
challenged when it was recognized that it was associated with low infant birth weight 
and with health problems in the offspring [1].
Based on a review of evidence available at the time, Hytten and Leitch in 1971 [2] 
defined optimal weight gain during pregnancy. These authors described the physi-
ological norms for gestational weight gain (GWG), and the weight gain associated 
with optimal reproductive performance with respect to infant birth weight, infant 
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survival, and incidence of preeclampsia. This weight gain was found to be 650 g at 
10 weeks, 4,000 g at 20 weeks, 8,500 g at 30 weeks, and 12,500 g at term [2]. Hytten 
and Leitch [2] also described the components of this gain in terms of organs and tis-
sues, as well as in terms of molecules (i.e., water, fat, and protein). Figure 17.1 shows 
how the product of conception (i.e., fetus, placenta, and amniotic fluid) and maternal 
tissues (i.e., uterus, breasts, blood, tissue fluid, and maternal stores) contribute to 
GWG. According to Prentice et al. [3], the weight gained at term consists of a little 
more than 8 kg water, about 990 g protein, and slightly more than 3 kg body fat. As 
indicated in Figure 17.1, pregnancy is associated with the retention of water or tissue 
fluid. It is important to point out that Hytten and Leitch [2] emphasize that a success-
ful outcome of pregnancy, for women as well as for infants, may well occur despite 
large variations in GWG.
In its 1990 report, the Institute of Medicine (IOM) [4] recommended that lean and 
underweight women should gain more weight during pregnancy than normal-weight 
women, who, in turn, were recommended to gain more weight than overweight 
women. The impetus for this is that a low GWG is associated with adverse effects for 
the infant, such as low birth weight and, possibly, preterm birth, while a high GWG 
is associated with adverse outcomes for the mother, such as preeclampsia, gesta-
tional diabetes, and caesarean section, as well as large infants. Another important 
reason was that optimal GWG is a function of the women’s prepregnant nutritional 
status, which was described by a woman’s category of body mass index (BMI). By 
acknowledging this important effect of the prepregnancy BMI, this report [4] intro-
duced a novel way to recommend GWG. The IOM guidelines were revised in 2009 
[5] and Table 17.1 shows GWG recommendations for American women in accor-
dance with the two reports [4,5]. In 1990, no recommendation was given to obese 
women, reflecting a lack of sufficient scientific data [4]. An important reason behind 
the revision of the recommendations in 2009 was that the number of overweight 
and obese women had increased. Furthermore, more women were becoming preg-











FIGURE 17.1 The components of weight gained during a normal pregnancy. (Reproduced 
from Hytten FE, Leitch I, The physiology of human pregnancy, London: Blackwell Scientific 
Publications, 1971. With permission.)
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hypertension or diabetes, which increased their risk of adverse pregnancy outcomes. 
Recommendations for the GWG of obese women are therefore an important addition 
to the 2009 IOM report [5]. In spite of the extensive scientific evidence underpin-
ning the IOM guidelines, they are not universally accepted. Many countries have 
no GWG recommendations, and those who have country-specific recommendations 
may not use the IOM 2009 guidelines [5,7]. Recommended GWG for maternal BMI 
subgroups also varies across countries [7]. This may, to some extent, be explained by 
the fact that women from different populations, and of different ethnic backgrounds, 
may need to gain different amounts of weight. However, the paper by Alavi et al. [7] 
gives the impression that these discrepancies in GWG guidelines stem in part from 
a lack of appropriate evidence and the failure to recognize the importance of such 
guidelines.
Individual women may gain very different amounts of weight during pregnancy, 
and the size of the fat component of GWG, estimated by Prentice et al. [3] to be 
slightly more than 3 kg for healthy women, is also highly variable. In a study of 
pregnant women from New York, Lederman et al. [8] identified a significant positive 
relationship between weight gain and fat retention (r = 0.81, p < 0.0001). Based on 
data from 63 American women, Butte et al. [9] also reported such a relationship (r = 
0.76, p = 0.001). Expressing GWG (x) and fat mass gain during pregnancy (y) in kilo-
grams, this relationship was described by the following equation: y = 0.675x – 3.89.
TABLE 17.1
Recommendations by the Institute of Medicine for Gestational Weight Gain 
of Women in Accordance with Their Body Mass Index (BMI) before Conception








Low (BMI <19.8 kg/m2) 12.5–18 Underweight 
(BMI <18.5 kg/m2)
12.5–18
Normal (BMI = 19.8–26.0 
kg/m2)
11.5–16 Normal weight 
(BMI = 18.5–24.9 kg/m2)
11.5–16
High (BMI >26–29.0 kg/m2) 7–11.5 Overweight 





Source: Institute of Medicine, Nutrition during pregnancy, Washington, DC: The National Academy 
Press, 1990; and Institute of Medicine and National Research Council, Weight gain during preg-
nancy: Reexamining the guidelines, Rasmussen KR, Yaktine AL, editors, Washington, DC: The 
National Academies Press; 2009.
a Refers to weight (kilograms) gained during the complete pregnancy.
b Represents BMI cutoff as defined by the World Health Organization, Obesity: Preventing and managing 
the global epidemic, Geneva: Report of a WHO Consultation, 2000, p. 9.
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ASSESSMENT OF BODY COMPOSITION OF WOMEN 
DURING REPRODUCTION
Information regarding composition of the human body is required to understand its 
biology and function, relevant in relation to human health, and fundamental when 
assessing nutritional requirements. Pregnancy affects the female body in several 
ways, which has important consequences when methodology commonly used in 
human body composition research is applied to women during reproduction. Many 
methods will assess the composition of the mother and fetus as a complete unit, 
which may or may not be relevant for a particular research question. Furthermore, 
many commonly applied methods may be associated with health hazards (e.g., radia-
tion), which limits their use during pregnancy. Based on knowledge of the compo-
sition of the human body, Wang et al. [10] published a five-level model, providing 
fundamental information on body composition and organizational rules for research 
in this area. The model is intended to improve terminology and to describe how com-
monly used body composition concepts are associated with each other. As described 
next, pregnancy affects conditions at all of these five levels.
LeveL I (AtomIc)
The human body is composed of about 50 elements, but oxygen, carbon, hydrogen, 
nitrogen, calcium, and phosphorus account for >98% of body weight [10]. The whole 
body content of most major elements can be measured in vivo (e.g., potassium by 
whole body counting or nitrogen by prompt-γ neutron activation) [10]. Such tech-
niques have been used to study women during reproduction. For example, using 
whole body estimates of potassium and nitrogen, Butte et al. [9] assessed protein 
gain and loss during pregnancy and postpartum for women with different BMI 
before pregnancy.
LeveL II (moLecuLAr)
The major components of the molecular level are water, fat or lipid, protein, min-
eral, and glycogen. Mineral may be divided into osseous and extraosseous or non-
osseous. Glycogen represents a minor component and is often ignored. Only water 
and osseous mineral can be directly estimated, while measurement of components 
included in one of the other four levels is required to assess the remaining molecu-
lar components [10]. Sowers et al. [11] studied bone minerals in women before and 
after pregnancy to investigate how the fetal demand for calcium (approximately 
30 g during a complete pregnancy) affects the femoral bone density of the mother. 
Body water is commonly assessed by means of dilution methods [12], often using 
stable isotopes of water (2H or 18O) as tracers. The body water content of pregnant 
women has also been successfully measured by means of bioelectrical impedance 
[13]. However, recent reports indicate that this methodology is associated with 
problems such as lack of appropriate validation studies and poor precision during 
gestation [14,15]. Based on a two-component model (a model where the body is 
considered to consist of two components, i.e., fat and fat-free mass) [12], estimates 
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of total body water can be used to calculate total body fat by assuming that the 
water content of the fat-free mass is constant (usually 73% in healthy nonpregnant 
adults). Thus, total body fat is equal to body weight minus total body water divided 
by 0.73. However, during pregnancy, the water content of the fat-free mass in the 
body increases. In 1988, van Raaij et al. [16] published figures describing how this 
content increases throughout gestation. The IOM recommends using these figures 
when assessing body composition of pregnant women based on total body water and 
a two-component model [5].
LeveL III (ceLLuLAr)
The human body is composed of the following three main components at the cel-
lular level: cells, extracellular fluid, and extracellular solids [10]. Although conceptu-
ally important, little research has been directed at this level, possibly because some 
of these components are difficult to measure [10]. All components at this level are 
altered in pregnancy when the number of cells in the body increases. The amount of 
extracellular fluid and, consequently, extracellular solids also increases. Considerable 
attention has been devoted to measuring extracellular water during gestation due to 
its relationship with edema, which often is present in pregnant women and is asso-
ciated with hypertensive complications. The amount of extracellular water can be 
assessed by means of the tracer sodium bromide [12], and intracellular water can be 
calculated as total body water minus extracellular water.
LeveL Iv (tIssue system)
Cells are organized in tissues, such as muscle, adipose, and connective tissue. Many 
tissues can be further divided into subclasses. For example, adipose tissue can be 
divided into subcutaneous and nonsubcutaneous or visceral. During pregnancy, sev-
eral maternal tissues increase in size, and new tissues are formed as the fetus and its 
adnexa develop. Details of how pregnancy affects the size and function of various 
tissues, organs, and physiological systems have been published [17]. Magnetic reso-
nance imaging has been used to assess the volume of adipose tissue in different parts 
of the maternal body throughout a reproductive cycle [18].
LeveL v (WhoLe Body)
Important variables at the whole-body level are body weight and height, which may 
be combined to calculate BMI, an index intended to describe the level of body fat-
ness. For obvious reasons, BMI is less useful in pregnant than in nonpregnant indi-
viduals. The assessment of skinfold thickness is another commonly used method to 
study body fat during pregnancy, which has the advantages of being simple and can 
describe the distribution of subcutaneous fat or adipose tissue (Figure 17.2). Marshall 
et al. [15] provided evidence suggesting that this methodology may be acceptable 
in larger studies. Equations to convert skinfolds to total body fat are available for 
pregnant women [14]. However, during pregnancy, several problems are associated 
with such methodology [14].
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The assessment of body volume and body density, that is, body weight per body 
volume, is very important in body composition methodology. Estimates of body den-
sity are often used to assess body fat based on a two-component model [19], if the 
densities of body fat and fat-free mass are known. For fat, this figure is considered 
to be 0.9007, with little variation, while the figure for fat-free mass decreases during 
pregnancy as a consequence of the body water retention associated with this condi-
tion. Previously, body volume and density were estimated using underwater weigh-
ing, but air displacement plethysmography is presently more commonly applied [19]. 
A specific device, the Bod Pod™, can be used for this purpose and is commercially 
available. Air displacement plethysmography is applicable in pregnant women if per-
formed in an appropriate way [20]. For example, this technique requires information 
about the thoracic gas volume of the subject at the time of testing. The procedure to 
estimate this volume is, however, quite demanding, and many subjects are unable to 
produce an acceptable value. Henriksson et al. [21] demonstrated that equations to pre-
dict thoracic gas volume from age and height and developed for nonpregnant women 
resulted in only a minor error in the estimate of body fat when applied in women in 
gestational week 32. Marshall et al. [15] have also presented data demonstrating the 
usefulness of air displacement plethysmography when assessing body composition 
during pregnancy.
An important factor to consider when body fat is assessed using the two-component 
model based on body density is that the density of fat-free mass is variable and esti-














FIGURE 17.2 Skinfold thickness of various body regions at various stages of reproduction. 
Thickness (mm) of six skinfolds at different stages of reproduction. A, before pregnancy; B, ges-
tational week 16–18; C, gestational week 36 30; D, gestational week; E, 5–10 days postpartum; 
F, 2 months postpartum; G, 6 months postpartum. Values are averages with SDs and obtained 
from 24 healthy Swedish women. (Data from Forsum E, Sadurskis A, Wager J, Estimation of body 
fat in healthy Swedish women during pregnancy and lactation, Am J Clin Nutr 1989, 50:465–73.)
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fat. During pregnancy, the biological variation in fat-free mass density appears to 
increase initially and then be followed by a decrease [22]. Similar observations were 
made for variations in the fat-free mass water content during pregnancy [23]. This 
is not surprising, since water is the main component of fat-free mass [19] and has 
a major influence on its density. These observations indicate that two-component 
models, based on the assessment of body water or body density, are as valid in late 
pregnancy as they are in nonpregnant individuals, if appropriate figures for fat-free 
mass hydration or density are used. However, more studies are needed to confirm 
and extend this statement.
A common goal in body composition studies during reproduction is to assess total 
body fat. Such estimates have limitations, as indicated earlier, and tend to require 
assumptions that may be affected by pregnancy. To avoid some frequently made 
assumptions, it is often recommended that estimates of women’s body fat during 
reproduction should be obtained using methods based on three- or four-component 
models. A commonly used three-component model has been published by Going 
[19], and has also been used during reproduction [22–25]. Three- or four-component 
models used in women during reproduction have been published by Fuller et al. [26], 
Pipe et al. [27], Kopp-Hoolihan et al. [25], and Lederman et al. [8]. Unfortunately, 
studies based on three- or four-component models tend to be costly and demanding 
for subjects and investigators. This limits their application in population studies.
As obvious from the preceding text, the influence of pregnancy on body com-
position has been extensively studied at the various levels described by Wang et al. 
[10]. When conducting body composition studies in postpartum women, it is often 
assumed that the basic conditions are the same as for other nonpregnant women. 
This is reasonable, since there is limited information indicating that such differences 
exist at all, and further, there is no specific reason to suspect that important differ-
ences exist in the nonpregnant versus postpartum state. However, studies of fat-free 
mass hydration of women 2 weeks after delivery [23,24] showed that this value was 
still slightly higher than the value generally considered to be appropriate for non-
pregnant women. These observations probably reflect that the transition back to the 
nonpregnant state requires a certain amount of time.
FUNCTIONAL ASPECTS ON BODY FAT DURING REPRODUCTION
Body FAt And energy metABoLIsm durIng PregnAncy 
In reLAtIon to BIrth WeIght
After conception, several metabolic and physiological changes occur in the pregnant 
body. These are mediated by hormones secreted by the corpus luteum, the embryo, 
and later the placenta. The increase in resting energy metabolism, as well as altera-
tions in glucose and lipid metabolism, represent important metabolic changes. The 
circulatory system adapts in response to the increased demand for transportation, 
which, together with the retention of water and fat in the body, represent important 
physiological changes. These changes create a demand for energy, and pregnancy 
is associated with an increased requirement for dietary energy [28]. The main part 
of the increased energy needs is due to the rise in resting energy metabolism and 
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the retention of body fat, while the energy content of the fetus is relatively small. 
According to recent estimates the energy requirements for an entire pregnancy are 
321 MJ, the “energy cost of pregnancy” [28]. About 50% is required for the increase 
in energy metabolism and approximately 45% for body fat retention [28]. However, 
studies on pregnant women from different countries have shown that these figures 
vary in response to the nutritional situation in which women live. Table 17.2 shows 
the energy costs of fat retention and increases in the resting energy metabolism for 
pregnant women from different countries, ranging from well-nourished Swedish 
women to undernourished Gambian women. The data presented in this table suggest 
a relationship between the increase in resting energy metabolism and the energy 
equivalent of the amount of body fat retained during pregnancy. Of special interest 
is that undernourished Gambian women showed a decreased resting energy metabo-
lism, loss of body fat during pregnancy, and delivery of babies with low birth weight. 
However, when supplemented with extra dietary energy during gestation, these 
Gambian women maintained their prepregnant resting energy metabolism and even 
retained some body fat. The birth weight of their babies was also slightly higher than 
the corresponding values for unsupplemented Gambian women. The data in Table 17.2 
have been interpreted to represent a functional plasticity in maternal metabolism of 
benefit for fetal survival under harsh dietary conditions [29].
Table 17.2 also indicates that women from affluent countries tend to retain more 
fat during pregnancy than their counterparts from poor countries. In addition, there 
is some evidence to suggest that, when average data from different populations are 
used, the body fat content before conception is positively related to the total energy 
TABLE 17.2
Increase in Maintenance Energy and Energy Equivalent of Retained Body Fat 








Birth Weight of Infants 
(Mean ± SD; kg)
Sweden 22 213 239 3.56 ± 0.44
England 12 158 155 3.77 ± 0.58
The Netherlands 57 144 89 3.46 ± 0.53
Scotland 88 126 103 3.37 ± 0.40
Thailand 44 98 57 2.98 ± 0.35
Philippines 40 89 57 2.89 ± 0.40
The Gambia, 
unsupplemented
10 –43 –20 2.94 ± 0.14
The Gambia, 
supplementeda
12 6 92 3.13 ± 0.10
Source: Data from Prentice AM, Goldberg GR, Energy adaptations in human pregnancy: Limits and 
long-term consequences, Am J Clin Nutr 2000, 71(5 Suppl):1226S–32S; and from references 
therein.
a During pregnancy women were supplemented with approximately 670 kJ per day for 6 days a week.
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cost of pregnancy [29]. The data in Table 17.2 indicate that there may be a relation-
ship between fat retention during pregnancy and the birth weight of infants when 
population averages are used. However, this relationship is much less evident for 
women within a population. For example, Butte et al. [9] found no such relationship 
when 63 healthy American women were studied using appropriate body composition 
methodology. Similar observations were made by Kopp-Hoolihan et al. [25].
Available evidence suggests that pregnancy is associated with a strong tendency 
to retain body fat. It may therefore appear surprising that, as indicated earlier, the 
correlation between the amount of fat retained and infant birth weight is weak or 
nonexistent. However, it may be relevant to note that, although the amount of fat 
retained by a healthy pregnant woman (i.e., slightly more than 3 kg) may appear 
considerable, it is only a fraction of the total amount of fat in her body. Therefore, 
when the impact of maternal body fat on fetal growth is studied, the total body fat 
content, rather than the amount of fat retained during pregnancy, may be the relevant 
variable to consider. This suggestion is supported by observations showing that the 
risk of having a large for gestational age infant increased with increasing maternal 
BMI [30]. However, BMI is not a perfect estimate of body fatness, and corresponding 
studies using appropriate body composition methodology are needed. A study based 
on air displacement plethysmography of women in gestational week 32, as well as 
of their newborn infants, identified a relationship between maternal and infant body 
fatness for girls but not for boys [20]. It may be argued that estimates of body fatness 
in gestational week 32 include the fat content of the fetus. In this study, however, this 
amount represented only about 0.4% of the total body fat of these women [20]. Also, 
a study of women with gestational diabetes mellitus (GDM) indicated that maternal 
fatness may influence fatness of male and female infants differently [31].
mAternAL Body FAt versus InsuLIn resIstAnce And LePtIn
It is generally considered that the resting metabolic rate correlates significantly with 
fat-free mass in humans, while the contribution of fat mass to the variation in resting 
energy expenditure is much smaller [32]. However, there is some evidence to indi-
cate that the latter relationship is enhanced by pregnancy. For example, in 22 healthy 
women, Löf et al. [33] found a significant correlation between total body fat and 
resting energy expenditure in both gestational weeks 14 and 32, but not before preg-
nancy. Furthermore, Bronstein et al. [34] found that fat mass, but not fat-free mass, 
was a highly significant predictor of the resting energy expenditure in pregnant 
women, whereas the opposite was found in nonpregnant women. These observations 
indicate that the metabolic activity of adipose tissue increases during pregnancy. It 
is therefore of interest to consider the metabolic variables associated with the body 
fat content of women during reproduction.
In healthy pregnancy, there is a slight decrease in fasting blood glucose levels and 
an increased insulin response to a glucose load, which is due to an increased insulin 
resistance [35]. The latter increase helps to direct glucose in the maternal blood to 
the placenta and, ultimately, to the fetus. In women with GDM, blood glucose levels 
and insulin resistance are increased, and such women tend to deliver large infants 
[35]. Overweight and obesity are well-known risk factors for GDM, and it is therefore 
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not surprising that, for healthy women in gestational week 32, variables describing 
body fatness were significantly associated with glucose homeostasis variables in the 
circulation, such as glucose, insulin, homeostasis model assessment–insulin resis-
tance (HOMA-IR), hemoglobin A1c, and insulin-like growth factor binding protein-1 
[36]. These observations can be reconciled with the fact that an effect of obesity, a 
condition characterized by a high body fat content, is to increase insulin resistance. 
In a study on 17 healthy women, the relationship between body fatness and insulin 
resistance (measured as HOMA-IR) was steeper in gestational week 32 than it was 
before pregnancy, which suggests that pregnancy enhances the relationship between 
body fatness and insulin resistance [37].
The so-called adipokines represent bioactive compounds produced by human adi-
pose tissue and acting locally and distantly through autocrine, paracrine, and endo-
crine mechanisms [38]. They impact on multiple functions such as immunity, insulin 
sensitivity, blood pressure, and lipid metabolism, as well as on appetite regulation 
and energy balance [38]. It is therefore not surprising that their relationship with 
body fat has been studied during reproduction. Of special interest is the adipokine 
leptin, which is considered to have effects on food intake and energy expenditure 
[38]. Serum leptin concentrations have been found to correlate with body fatness 
before and during pregnancy, and changes in body fat during reproduction also cor-
related with corresponding changes in serum leptin [37]. The significance of these 
observations is, however, unclear and the area deserves further study.
Body FAt throughout A reProductIve cycLe
After delivery, women tend to lose weight, and the mobilization of body fat is often 
a part of this weight loss. In fact, it is often considered that the fat gained during 
pregnancy represents a physiological energy store to be used during lactation, when 
demands for dietary energy are higher than during pregnancy. However, available 
data do not support the statement that fat loss is a biologically programmed part 
of human lactation [3]. Prentice et al. [3] suggest that about 500 g body fat may be 
mobilized per month to contribute to the energy cost of lactation, and also that this 
cost may well be covered in other ways, such as an increased energy intake or a 
decrease in physical activity. Available studies indicate that, on average, lactating 
women mobilize less than 500 g body fat per month [39,40].
It has long been recognized that adipose tissue in different body locations dif-
fers in metabolic activity [41]. Such differences have also been demonstrated during 
reproduction [41,42]. It is therefore of interest to investigate where the fat retained 
during pregnancy is located and from which depots it is mobilized postpartum. 
In a group of healthy Swedish women, adipose tissue volume was investigated by 
means of magnetic resonance imaging before conception, as well as at 5 to 10 days 
and 2, 6, and 12 months after delivery [18]. In this way it was possible to demon-
strate, as shown in Figure 17.3, that these women placed most of the fat retained 
during pregnancy in adipose tissue on the trunk and a smaller amount on the thighs. 
Furthermore, for the thigh compartment, changes in size postpartum were corre-
lated with a score based on a combination of lactation length and intensity [18]. For 
the other compartments shown in Figure 17.3, no such correlations were found [18]. 
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These observations support the statement that the thighs have a specific biological 
function to store fat during pregnancy for use during lactation, a statement that can 
be reconciled with observations regarding changes during reproduction in enzymatic 
activities of adipocytes from the thigh region [41]. Furthermore, the observation that 
women placed a significant amount of fat on the trunk can be reconciled with recent 
results showing that, during pregnancy, normal-weight women accumulated fat in 
adipocytes from subcutaneous abdominal adipose tissue [42].
That fat retained during pregnancy is found in specific depots was already dem-
onstrated by Taggart et al. in 1967 [44]. These authors found that thigh and trunk 
skinfolds increase during pregnancy, while triceps skinfold tend to decrease around 
parturition, and then increase. Later, Forsum et al. [45] made similar observations in 
Swedish women and confirmed that the triceps skinfold, which decreased at the end of 
pregnancy, showed an increase during the postpartum period (Figure 17.2). Collectively 
these observations suggest that the amount of fat in different body depots varies during 
the reproductive cycle, a statement that can be reconciled with observations suggest-
ing an increased metabolic activity of adipose tissue during pregnancy and lactation.
REPRODUCTION IN OVERWEIGHT AND OBESE WOMEN
The currently used definitions of overweight and obesity are based on BMI and 
are given in Table 17.1. Recent data [46] show that the prevalence of these condi-
tions has been increasing worldwide over the last decades in all population groups. 
Consequently, the number of women of reproductive age who are overweight or 
obese has also increased. According to the World Health Organization (WHO), this 



























FIGURE 17.3 Adipose tissue volume in different body compartments of healthy Swedish 
women 5–10 days and 2 months postpartum (n = 15) as well as 6 (n = 13) and 12 months 
(n = 10) postpartum [18]. Figures are averages and represent differences versus the corre-
sponding prepregnant figures. (Reproduced from Sohlström A, Body fat during reproduc-
tion in a nutritional perspective: Studies in women and rats, thesis, Karolinska Institute, 
Stockholm, 1993. With permission.)
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of pregnancy complications, and heavier birth weight and obesity in children” [47]. 
In 2009, the IOM stated, “Evidence from the scientific literature is remarkably clear 
that pre-pregnancy BMI is an independent predictor of many adverse outcomes of 
pregnancy” [5]. Maternal overweight and obesity are associated with complications 
in the mother during pregnancy, as well as at and after delivery. Excessive GWG adds 
to these problems. For the mother, there are increased risks of preeclampsia, GDM, 
and complications during delivery. For the infant, there is a risk of being large-for-
gestational-age at birth, possibly associated with an increased risk of overweight and 
obesity later in life [5]. Therefore, overweight and obesity in women of reproductive 
age is clearly becoming more of a public health issue. An additional concern is that 
there is a negative association between maternal obesity and the initiation as well as 
the continuation of lactation [48]. A large study among Danish women demonstrated 
that the risk of early termination of full or any breastfeeding rose with the increasing 
prepregnant BMI of the women [49]. In conclusion, overweight and obesity represent 
serious threats to the health of women and their children. However, the mechanisms 
involved are not completely known. Body composition studies of women during the 
reproductive cycle may help to identify and describe such mechanisms.
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18 Body Composition 
Changes from Infancy 
to Young Childhood
Daniel J. Hoffman and Pamela L. Barrios
INTRODUCTION
Human growth is a dynamic process that involves the complex regulation of tissue 
development from the moment of conception through adulthood. Fundamental to 
this process is the need for sufficient substrates required for cellular growth and 
energy to facilitate growth and development. Thus, when nutrients are sufficiently 
available and readily absorbed, growth and development occur in a healthy manner. 
However, when there are interruptions to either nutrient availability, and/or absorp-
tion or existing pathologies that influence the endocrine system, growth is disrupted, 
delayed, or ceases. Central to growth, from conception through early childhood, is 
the development of tissues that form organs and support normal homeostatic pro-
cesses, promoting health and decreasing the risk of various diseases. For the major-
ity of children, body tissues are most often grouped with the two major depots of 
body composition: fat mass (FM) and lean body mass (LBM). Yet these compart-
ments are not constant in terms of their proportion as a child grows, and changes in 
the relative proportion of one or the other can create a condition in which “healthy” 
growth is altered and the risk of disease increases.
The study of human body composition is thought to date back to work by Adolphe 
Quetelet, the French mathematician who, in 1835, used body weight (kilograms) 
divided by the squared term for height (meters) as a means of normalizing differ-
ences in body size between people [1]. This simple calculation came to be known as 
the body mass index (BMI) and was the first attempt to compare the body weight 
of adults; children were compared using a similar index, with the exception that 
height was calculated as the cubic term of length (meters), or the ponderal index. 
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It is worth noting that neither BMI nor the ponderal index are meant to describe body 
fatness, but they are both very highly correlated with FM in large samples of adults. 
However, as science advanced and the various body compartments became more 
clearly identified in terms of their physiological role, the need to characterize body 
weight, rather than simply comparing it between persons or over time, became more 
important. Thus, the use of various anthropometric measures, including waist cir-
cumference and skinfold measures at specific landmarks of the body, complemented 
BMI as a means of describing the body weights of children and adults. Recently, 
advanced methods to assess body compartments, namely, FM, LBM, and total body 
water (TBW), have allowed for more precise methods to fully characterize body 
composition in children and adults.
Body composition may also play a role in the programming in early life of a 
variety of health outcomes, such as type 2 diabetes, obesity, and cardiovascular dis-
ease [2]. While it is unclear as to the mechanism by which poor growth in utero 
or during early childhood influences the risk of these diseases, there is some sug-
gestion that the development of body composition may play a role. In short, it is 
hypothesized that alterations in specific tissue development during key windows, 
such as the first trimester of gestation or the first 1,000 days may “program” tissue 
function, such as altered pancreatic function or dysfunctional response to stress by 
the hypothalamic-pituitary axis, increasing the risk of chronic diseases later in life. 
Therefore, understanding how different nutritional environments in early life affect 
both body composition and weight gain is of great importance. The following sec-
tions describe the changes in body composition in infancy and early childhood, 
growth patterns and body composition, and the relationship between poor growth 
and body composition as a risk factor for adult diseases.
ELEMENTS OF HUMAN BODY COMPOSITION
Early knowledge of human body composition was based on whole body carcass anal-
yses of human fetuses, infants, and adults from the 1900s [3–6]. However, no similar 
data exists between infancy and adulthood, except for one 4.5-year-old male child 
who died of tuberculosis meningitis [7]. Fortunately, several methods have been 
developed to measure body composition indirectly, increasing our current knowledge 
of this missing age period [8,9]. Still, when it comes to infants, these methods have 
limited application as they are fairly invasive, may need active participant coopera-
tion, and may involve radiation exposure. Nonetheless, the development of precise 
methods that are not invasive has expanded greatly since the early 1990s, including 
the use of stable isotopes and air displacement, allowing for newborn infants and 
young children to be measured over the course of months or years. These methods 
have advanced the field of neonatal body composition greatly, as discussed below.
Whole body composition is often assessed using a variety of models. The earli-
est, simplest, and most widely used model to assess body composition is the two-
compartment model (2C) model, where body weight is divided into FM and the 
remaining tissues categorized as LBM [10]. Due to the challenges of directly mea-
suring FM and LBM, the 2C model calculates LBM by extrapolating one or more of 
its subcompartments, TBW or total body potassium (TBK), with the assumption that 
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their relative concentrations are constant at a given age. After determining LBM, 
FM is then calculated as the difference between body weight and LBM. Aiming 
to reduce some of the limitations from the 2C model, the three-compartment (3C) 
was developed, in which body weight is divided into FM, TBW, and the remain-
ing solids, such as skeletal mass. The four-compartment (4C) model further divides 
remaining solids into proteins and minerals [11,12]. Finally, the five-compartment 
(5C) model is the most comprehensive means of describing body composition, using 
the following five levels: atomic, molecular, cellular, tissue system, and whole body 
[12]. Each additional level adds a layer of complexity to the measurement of body 
composition, often requiring a new technique (e.g., dual-energy x-ray absorptiom-
etry [DXA], isotope dilution), yet the 5C model is a robust means of accounting for 
the interindividual variability of FFM. Nonetheless, the 4C model is the most robust 
practical method for measuring body composition [11], and has been used in children 
as young as 5 years of age [13]. Among many advantages of using the 4C model, the 
most important for children is that hydration, bone mineral content (BMC), and body 
density are measured directly and not assumed.
BODY COMPOSITION DURING INFANCY
Body composition from birth through early childhood often undergoes rapid changes 
associated with normal growth processes [14]. Understanding these changes and the 
relative contributions of LBM and FM to weight during infancy can enhance our 
knowledge of the nutritional needs of both healthy and sick infants, and provide 
important physiological insight into anthropometric measures. Over the past few 
decades, there has been a great interest in the relationship between early nutrition, 
growth, and future health outcomes, due to the large volume of evidence associating 
a number of diseases in adulthood with experiences in early life [2,15,16].
Whereas body composition references exist for adults, there is very limited ref-
erence data for the neonatal and early childhood periods [17]. One of the earliest 
analyses documented a rapid decrease of LBM hydration during the first few weeks 
of postnatal life [6], and cadaver studies showed that newborn infants have a higher 
total body water mass (TBW) relative to weight [18], consistent with data indicating 
that hydration decreases as one ages [19]. In 1982, Fomon and colleagues published 
age- and gender-specific body composition data from birth to 10 years of age in a 
model with FM, LBM, and TBW, with the assumption that boys weighed 0.15 kg 
more than girls at birth [20].
In particular, for the male reference infant, there was a distinct increase in FM 
as a percentage of body weight from birth to one year, from approximately 14% to 
23%. At the same time, the percentage of body weight as protein remained constant 
at 13%, while the hydration of LBM decreased from almost 70% at birth to 61% at 
one year. When reported as a percentage of FFM, there was an increase in protein 
from 15% to almost 17%, and a negligible decrease in TBW from 81% to 79%, from 
birth to one year. Similar changes in the same components of body composition were 
reported for girls. Although this study provided extremely important body composi-
tion data, it was a preliminary and crude representation of body composition during 
infancy and later years, as it extrapolated information for all ages based on three 
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time periods (birth, 6 months, and 9 and 10 years for boys and girls, respectively). 
However, the foundations were laid for future studies to test the findings reported 
by Fomon to better understand changes in body composition during the first 1,000 
days. With the advent of advanced imaging techniques and the wider use of stable 
isotopes, more data are now available to build on the work of Fomon and colleagues.
In 2000, Butte et al. published body composition reference data for infants in a 
longitudinal study of 76 children, studied for the first 2 years of life [21]. Body com-
position was assessed using a multicompartment model, with TBW measured using 
deuterium dilution, bone mineral content (BMC) using dual energy x-ray absorp-
tiometry, and total body potassium using whole body counting [21]. Age-related 
changes in LBM and FM were characterized and the rapid “chemical maturation” 
during the developmental period was modeled as previously described by Fomon 
[20]. Briefly, similar changes in the percentage of FM and the percentage of body 
weight as protein and TBW for both boy and girl reference infants, as well as the per-
centage of LBM as TBW, were consistent with those reported by Fomon [20]. More 
important are the data from the longitudinal aspect of this study, as the incremental 
changes in body composition were also reported. In terms of body weight, both boy 
and girl infants gained weight at a lower rate from birth through the first 2 years of 
postnatal life, from approximately 32 g/d to 6 g/d. When considering the specific 
components of body composition, the accretion of FM and LBM occurred at a slower 
rate from birth through 2 years, 20 g/d to 2 g/d and 13 g/d to 3 g/d, respectively. The 
very rapid growth rate in utero and during the first few months of postnatal life is 
consistent with the decreased rate of protein accretion as reported from 2.6 g/d to 
1.1 g/day from birth to 24 months. In human infants, there is a rapid increase of adi-
pose tissue during the third trimester of pregnancy, which reaches its peak around 
6 months postpartum [8,17]; at this time there is a decline in %FM as fat deposition 
begins to slow compared to LBM (Figure 18.1) [8,21,22,23,24].
Changes in body composition for healthy infants are mostly attributed to loss 
of TBW, given that most infants lose between 5% and 10% of their birth weight in 
the first postnatal days [19]. In fact, some weight loss even occurs during the first 
24 hours after birth, mostly due to water loss from skin and/or changes in renal func-
tion. In one study, the mean weights at days 1 and 2 were significantly less than the 
mean weight at day 0 [25]. Verma reported that a strong determinant of maximum 
weight loss in babies is maturation, and that gestational age is inversely related to 
transepidermal water loss in the first month of life [26]. Adaptation to life outside 
the uterus for infants includes the keratinization of their skin after a week [27], while 
the release of natriuretic hormones called atrial natriuretic peptides prompts the con-
traction of the extracellular compartment [28]. As the child grows, the amount and 
distribution of TBW changes with a decrease in extracellular volume and an increase 
in intracellular volume [19]. Reference values for FM and LBM of boys and girls 
from published data are summarized in Tables 18.1 and 18.2 [6,20–25,23,29,24–34], 
respectively, and clearly show the consistency of values reported from a number of 
different studies.
With regard to body fat distribution in infants, little has been reported in the lit-
erature given the challenges of accurately measuring body fat distribution. However, 
one study was conducted in which body composition and adipose tissue distribution 
273Body Composition Changes from Infancy to Young Childhood
was measured using MRI in newborns, and during the first 4 months of life [23]. 
The advantage of using MRI over other approaches is the fact that FM is generally 
derived from calculations that use a number of assumptions regarding LBM. Using 
MRI, such assumptions are no longer needed, and a more direct assessment of FM 
is possible. Using MRI, Harrington et al. showed that babies born appropriate-for-
gestational-age have very little internal-abdominal adipose tissue (20 ± 11 g), with 
the majority of the fat being subcutaneous (693 ± 205 g) [28]. These findings were 
confirmed by Modi et al. [30] in a study with full-term Asian Indian and white 
European infants, where the predominant adipose tissue at birth was superficial sub-
cutaneous nonabdominal FM (445 g and 504 g, respectively), and the intraabdominal 
adipose tissue was very low (40 g and 24 g, respectively). The same study high-
lighted ethnic differences in adipose tissue distribution that may help to detect a pro-
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FIGURE 18.1 Fat mass and fat-free mass at different body weights according to four differ-
ent cohort studies. (Continued)
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changes in body composition during growth make every attempt to include a sample 
of boys and girls from diverse ethnic groups. In fact, one of the major criticisms of 
reference models to date is that most infant cohorts are too homogenous in terms 
of race and ethnicity, but the logistics and expense of measuring a large number of 
diverse infants often limits the heterogeneity and size of such studies.
Finally, more recent studies using a number of different techniques than those 
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FIGURE 18.1 (CONTINUED) Fat mass and fat-free mass at different body weights accord-
ing to four different cohort studies. (Data from Fomon SJ, Haschke F, Ziegler EE et al., Am J 
Clin Nutr 1982, 35(5 Suppl):1169–75; Butte NF, Hopkinson JM, Wong WW et al., Pediatr Res 
2000, 47(5):578–85; Fields DA, Gilchrist JM, Catalano PM et al., Obesity 2011, 19(9):1887–
91; Olhager E, Flinke E, Hannerstad U et al., Pediatr Res 2003, 54(6):906–12; Carberry AE, 
Colditz PB, Lingwood BE, Pediatr Res 2010, 68(1):84–88.)
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at birth, most likely due to the ethnic differences in the populations from which the 
study samples were selected (Tables 18.1 and 18.2 [6,20–25,23,29,24–34]). As shown 
in Figure 18.1, there is an overall agreement between the various approaches used 
to measure body composition in infants. While there are clear divergences in body 
composition data based on the technique used and when analyzed by age and body 
weight, such differences are most likely due to inherent differences in populations 
used in the study, and suggest that gender is a major determinant of whole body 
composition during the first year of life.
POOR GROWTH AND BODY COMPOSITION
Aside from changes in body composition during “healthy” growth, the importance 
of the first 1,000 days is most relevant when one considers not only the acute impact 
of poor nutrition and infectious diseases on the health of a child, but also the rela-
tionship with health and disease in adulthood. For almost two decades, research has 
revealed clear associations between poor growth in utero or during early childhood 
and an increased risk of chronic diseases in adulthood [35–38]. At the same time, new 
research is providing convincing evidence that supports a number of mechanisms to 
explain earlier associations, giving support to the notion that the first 1,000 days 
are important for a lifetime of health.
In terms of body composition, poor growth during gestation and in the first 2 years 
of life is not only associated with metabolic adaptions that favor fat deposition, but 
also with unhealthy fat accumulation and central adiposity [39,40]. However, the pre-
cise mechanisms, be they intrauterine nutrition or a postnatal, environmental factor 
(e.g., postnatal diet, breastfeeding, or physical activity) remain unclear. Nonetheless, 
a large number of studies have reported that small size at birth is associated with a 
high BMI or FM, compared to adults or peers of normal birth weight [41,42]. A study 
of birth weight and body composition reported that birth weight was negatively cor-
related with central adiposity in children from the United States [43]. It was also found 
that birth weight is associated with higher lean tissue mass, but not higher adipose 
tissue mass [44]. These results may be interpreted to suggest that poor growth in utero 
is related to the poor development of lean body mass, a factor that may explain greater 
fat deposition during growth following in utero nutrient restriction.
Considering the components of body composition, children who were born small 
for gestational age are reported to have greater central FM, independent of total FM, 
when assessed using a precise imaging technique for body composition (dual energy 
x-ray absorptiometry, DEXA) [45]. A similar study found that low birth weight was 
associated with higher central adiposity [46], even after controlling for physical 
activity and socioeconomic status, postnatal variables that are known to influence 
body composition. A limitation to both studies was that DEXA does not discrimi-
nate visceral fat, which is reported to have a high turnover of fatty acids, promoting 
chronic risk of disease, and subcutaneous fat. Regardless, it is clear that poor growth 
in utero is a risk factor for unhealthy body fat distribution even among children who 
are not obese.
While the association between birth weight and FM is of great importance, one 
needs to determine whether birth weight is associated with LBM. For example, a 
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cohort study of infants who were followed through adolescence reported that each 
standard deviation increase in birth weight was associated with a 1.2 kg increase 
in LBM, but not FM [47]. Based on this study, relative to long-term health, poor 
growth in utero may be implicated in the poor accumulation of metabolically active 
tissue, and may result in abnormal substrate metabolism (e.g. insulin resistance) or 
reduced energy expenditure for the same body weight. Such findings are consis-
tent with research on children who were stunted, defined as a height-for-age z-score 
more than 2 standard deviations (SD) below the mean of a reference population [48]. 
Studies of stunted children in Brazil and South Korea have consistently reported that 
children who have experienced growth deficits have lower rates of fat metabolism 
compared to normal height children [49,50]. In the Brazilian cohort, stunted children 
who had their body composition measured over a 4-year period deposited more fat in 
their central region compared to normal height children, independent of total body 
FM [51]. Thus, it is clear that nutritional insults, either a lack of proper nutrients 
or infectious diseases that interrupt nutrient absorption, early in life have profound 
metabolic and body composition implications later in life.
POOR GROWTH AND ADULT CHRONIC DISEASE
Of great importance is the determination of when and how poor nutrition during 
“critical periods” of development, such as the first 1,000 days, influence disease 
risk and adult health. Perhaps the most well-known of such studies is that of the 
Dutch famine, in which a cohort of men born before, during, and after the famine 
in Holland of 1944–1945 were studied for body weight in relation to exposure to 
famine during gestation [52]. Men who were exposed to the famine during late ges-
tation and early infancy were less likely to be obese as adults than men who were 
exposed to the famine during the first two trimesters of gestation. These results 
clearly suggest that early, prenatal exposure to undernutrition is related to weight 
gain later in adulthood.
While deficits in weight can be recovered, linear growth deficits are less likely to 
be recovered, even with adequate nutriture, especially if the deficit occurs between 
birth and 2 years of age [53]. A study of 228 Brazilian children who attended a nutri-
tion rehabilitation center reported that age at the beginning of treatment affected the 
likelihood of recovery [54]. Briefly, children aged 12 to 23 months and 24 months 
and older were 30% and 51% less likely to recover from undernutrition, respectively, 
than children who were treated up to 12 months. In this study, children 24 months 
and older showed a slower rate of recovery and had to be treated longer to fully 
recover from undernutrition [55]. Based on these studies, it is clear that proper nutri-
tion during the first 1,000 days is essential not only for maintaining normal changes 
in body composition during rapid growth, but also for preventing permanent growth 
retardation (i.e., stunting). Nonetheless, stunting is a challenge for health profes-
sionals, as the ability to improve height in countries with extreme social and eco-
nomic hardships is complicated, and often met with little success, despite efforts to 
improve overall nutrition. Thus, as previously discussed, the timing of nutrition on 
health is critical in terms of later disease risk, as well as the ability to recover from 
nutritional insults.
283Body Composition Changes from Infancy to Young Childhood
With regard to body fat distribution later in childhood, a number of studies have 
investigated body composition in children who were growth retarded in early life. 
For example, in Senegal, adolescent girls who were stunted before the age of 2 were 
more likely to accumulate subcutaneous fat on the trunk and arms than nonstunted 
girls, despite having the same BMI [56]. A longitudinal study in Guatemala was 
among one of the first to report that stunting was associated with central fat distribu-
tion [57], such that men and women who had been severely stunted as children had 
significantly greater abdominal fatness as adults, independent of total FM and other 
confounding factors. These studies support the hypothesis that stunting increases 
not only the risk of obesity, but also of anthropomorphic phenotypes associated with 
chronic diseases.
In terms of how poor nutrition in the first 1,000 days has lifelong effects on body 
composition and health, it is well documented that nutritional deficits during the 
first two years of childhood that are severe enough to result in moderate to severe 
growth retardation are often associated with an increased risk of chronic diseases, 
including obesity in later life [58,59]. Moreover, broad economic changes in transi-
tional countries have seen changes in food systems that favor excess energy intake; 
thus, many countries are hosting a “double burden” of both under- and overnutrition. 
Furthermore, the recurrence of infectious diseases is also related to stunting and, in 
some world regions, there has been little progress in preventing such diseases. It is 
worth noting that considerable effort is now being made to understand how infec-
tions, as well as the microbiome, may mediate changes in growth relative to diet. 
Regardless, much more needs to be done to improve our understanding of how body 
composition changes during early childhood, and the role of such changes on health 
outcomes and later risk for chronic diseases.
CONCLUSION
From the moment of conception through the first two years of postnatal life, the dynamic 
process of growth and development occurs at a rapid pace, and the body composi-
tion of a newborn child undergoes a series of changes as the process of “healthy” 
growth proceeds. In general, early models of body composition changes from birth 
to age 2 years relied on a number of assumptions to allow for the precise assessment 
of LBM and FM in neonates and infants. As new methods were developed, such 
assumptions were no longer needed, and more accurate estimates of body composi-
tion were available. Although such differences in methods could have resulted in 
marked divergences between early and later cohorts of children, no such observa-
tions were reported. Instead, there is a clear consistency in the data among a large 
number of cohorts from across the world, although some differences in body fat 
distribution have been reported for different ethnic/racial groups or children who 
are growth retarded. Briefly, it can be seen that infants increase their %FM during 
the first year, coinciding with a decreased rate of accretion of FM and LBM. Such 
changes are accompanied by a decrease in the hydration of LBM, reflecting tissue 
changes during the first year of postnatal life.
Perhaps more important than these broad changes in body composition in the 
first 1,000 days is the body of work that supports the concept that disruptions to 
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“healthy” growth may interrupt the growth process in such a way that body composi-
tion and metabolic changes increase the risk of chronic diseases later in life. What is 
still unclear is how interactions between diet and the gut influence growth, and the 
degree to which micronutrient deficiencies alter bone growth as a moderating factor 
in lower LBM accretion during periods of undernutrition. These questions have great 
potential to advance the understanding of how normal or abnormal growth influence 
body composition throughout life.
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19 Early Life Gut 
Microbiome
Christopher J. Stewart and Stephen P. Cummings
INTRODUCTION
The human body has trillions of microbes inhabiting every surface exposed to the 
environment, both inside and out, termed the microbiome (micro = small, biom = 
 community in a distinct environment). The largest community of microbes is found 
within the gastrointestinal tract where the gut microbiome in healthy adults is esti-
mated to harbor 1014 bacterial cells, which roughly equates to 100 to 300 times the 
number of genes in the human genome. This collection of microbes assembles largely 
through chance, but the assembly is not without design. Microbes have existed on earth 
for 3.5 billion years, based on the oldest discovered fossilized evidence; humanity has 
therefore coevolved with its microbial flora, and they play a pivotal role in the neonate, 
facilitating maturation of the immune system, protection from potential pathogens, 
and digestion of gut contents for the synthesis of essential vitamins and nutrients.
Improvements in high-throughput methodologies, coupled to reducing costs, have 
profoundly improved our ability to survey the microbiome. To date, the vast majority of 
human microbiome studies have focused on the bacterial community in the gut. Typically, 
a variable region of the universal 16S rRNA gene is amplified, giving 250bp fragments 
that allow identification of bacterial genera. Large-scale studies of human populations, 
such as the Human Microbiome Project (HMP), have revealed that the human microbi-
ome is unique to an individual and remains highly stable through adulthood in healthy 
individuals. Research is now focused on how perturbations in normal microbiome devel-
opment occur and the subsequent risk factors associated with a range of diseases.
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The initial development of the microbiome has important consequences for immedi-
ate and long-term health. The infant gut microbiome is thought to reach adultlike profiles 
at around 3 years of age. Thus, the first 1,000 days of life are critical, and this chapter 
addresses the factors influencing gut microbiome development through this time.
FACTORS AFFECTING THE NEONATAL GUT 
MICROBIOME: DAY 0 TO 30
Under normal circumstances neonates are generally thought to be sterile in the intrauter-
ine environment, with the first exposure to microbes occurring during birth. However, 
intriguing emerging evidence also suggests that bacterial DNA might be present in the 
placenta. Although the question remains elusive of when exactly the first exposure of 
the neonate to microbes takes place, the diversity of the human microbiome immedi-
ately after birth is low and increases from this point on. The first microbes to interact 
with the neonate have significant roles in educating the immune system, programming 
healthy immune development and metabolic programming. Primary colonizers of the 
gut microbiome include mixture of cutaneous and enteric facultative anaerobes, domi-
nated by lactic acid bacteria including Lactobacillus, Enterococcus, Streptococcus, and 
coagulase-negative staphylococci. In a matter of days, these primary colonizing bacte-
ria deplete the oxygen supplies within the gut, resulting in the growth of strictly anaero-
bic bacteria including Bifidobacterium, Clostridium, and Bacteroides [1].
During the first month of life the development of the microbiome is highly chaotic 
and largely stochastic. The main factors contributing to initial microbial exposure 
are related to the maternal microbiome, with mode of delivery and gestation also 
playing crucial roles. This section explores the prenatal and postnatal phases, dis-
cussing the importance of these influences on the developing neonatal microbiome.
Maternal MicrobioMe
There are many factors that influence the maternal microbiome at various body sites, 
which in turn influence the neonatal microbiome (Figure 19.1). The main factors 
shaping the maternal microbiome include diet, environment (e.g., socioeconomic 
status), and antibiotic exposure [2]. For instance, diet is known to have significant 
effects on the gut microbiome, due to altering favorable growth conditions from 
undigested dietary components, and likely has some influence on the oral com-
munity. Given the placental microbiome seems linked to the oral community, such 
effects may have direct implications to the developing fetus [3]. It should be noted 
that evidence of a placental microbiome is an active area of study with particular 
focus on whether these organisms are viable (or only detected due to presence of 
DNA) and to what extent the findings are biased by contaminants.
The maternal gut, vaginal, and skin microbiomes all contribute to the initial expo-
sure of viable organisms to the neonate, which is discussed in detail in the next sec-
tion. Again, the environment of the mother will influence the bacterial communities in 
each of these body sites, with variation between different geographies, socioeconomic 
classes, and cultural traditions having the most pronounced effects. Independent of 
birth mode, maternal skin microbiome is transferred to the neonate through the initial 
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stages of life from holding, cuddling, kissing, and breastfeeding. Importantly, the 
skin microbiome varies drastically based on the specific site, with sebaceous sites 
dominated by Propionibacterium and moist areas dominated by Staphylococcus and 
Corynebacterium [4]. The role of feeding in modulating the developing offspring micro-
biome is discussed later in the chapter, but noteworthy for this section is that the maternal 
milk microbiome is influenced by several factors, including maternal weight, diet, and 
antibiotics. Thus, even after birth, the maternal diet continues to be a significant driver 
of the early infant microbiome, with reduced diversity in obese and high-fat-consuming 
mothers [5]. It is also well understood that the milk microbiome is not stable and changes 
over the course of lactation [6], with evidence suggesting a correlation between the early 
milk microbiome with the oral microbiome [5]. In light of such evidence and associations 
of the placental microbiome with oral bacterial communities, it is important to determine 
the true extent of oral communities in seeding other sites, and how therapeutic manipula-
tion can be tailored to maximize oral health in the prenatal and postnatal stages.
Despite the numerous ways in which the maternal microbiome is altered, it is well 
established that full-term, vaginally delivered, breastfed neonates represent the “gold 























FIGURE 19.1 The maternal influence of the neonatal microbiome. Schematic shows the 
major influences to the mother’s microbiome in the prenatal phase, which are then changed in 
the perinatal phase, and ultimately affect the neonate in the postnatal phase.
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Delivery MoDe
In the first 24 hours of life, neonatal skin and gut microbiomes resemble the bacte-
rial community from the mode of birth [7]. Vaginally delivered neonates are initially 
colonized by bacterial communities that resemble the vaginal microbiome, result-
ing in dominant bacteria genera including Lactobacillus, Prevotella, and Atopobium 
[7]. Specifically, the vaginal microbiome is usually dominated by one of the fol-
lowing species of Lactobacillus: L. crispatus, L. iners, L. jensenii, or L. gasseri 
[8]. Intriguing evidence suggests that a lack of dominance by Lactobacillus spp., 
accompanied by increased Gardnerella and Ureaplasma abundance, is associated 
with an increased risk of preterm birth [8]. In contrast, cesarean delivery results in 
the offspring microbiome being more comparable to the skin microbiome [7]. Rates 
of caesarean delivery are increasing worldwide and are more common in preterm 
infants. This has been shown to result in delayed colonization, with a gut initially 
dominated by environmental bacteria, specifically a high prevalence of Clostridium, 
Escherichia, Streptococcus, and Staphylococcus [9]. Following neonates longi-
tudinally has revealed higher levels of Bifidobacteria and Bacteroides, with less 
Clostridium (importantly Clostridium difficile), in vaginally delivered infants com-
pared to cesarean section [10].
It is noteworthy that the infant gut microbiota more resembles its own mother’s 
vaginal microbiota than that of nonrelated mothers, but there is a lack of distinct 
similarity with the respective maternal skin microbiota [7]. What this means in 
terms of the long-term health status of the infant remains unknown, but the con-
sensus is that initial acquisition of the maternal vaginal microbiome is beneficial to 
the infant and may protect against some diseases and conditions, including allergy, 
obesity, and asthma. This hypothesis was tested in a recent pilot study aimed to seed 
microbiome of neonates born by caesarian section with the maternal vaginal com-
munity [11]. This involved incubating a gauze in the mothers vagina for one hour 
prior to cesarean delivery; immediately following birth the gauze was rubbed in the 
neonate’s mouth, face, and body. Although the cohort was small (n = 4), in all cases 
where the cesarean delivery babies were exposed to vaginal fluids, the microbiome 
more closely represented the vaginal community and vaginally delivered infants, 
compared to other cesarean delivered infants [11]. Providing the mother has been 
screened for group B Streptococcus, such seeding techniques are unlikely to have 
negative consequences for neonates, but further work is needed to confirm the ben-
efit of such procedures. Indeed, recent evidence suggests the effect of birth mode is 
lost in the first 6 weeks of life [12], but it is possible that the immune development in 
the first weeks of have long-term consequences [13].
The profound effects of birth mode on the neonatal gut microbiome are generally 
lost over time, typically within the first 30 days of life, with other factors overriding 
this initial microbiome composition.
Gestational aGe
The gestational age refers to the number of weeks from the last menstrual cycle of 
the mother to the birth of the infant. A normal pregnancy, where an infant is delivered 
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full term, will last 38 to 42 weeks. Babies born at less than 37 weeks gestation are 
considered preterm. However, most research exploring preterm infants is focused on 
very low birth weight (VLBW; <1500 g) infants born at less than 32 weeks gesta-
tion. The management and care of preterm infants has resulted in a relatively high 
survival rate compared to that two decades ago. Preterm neonates generally have 
a unique and unnatural beginning to life, where they are immediately housed in 
incubators with limited environmental exposure. In comparison, term neonates do 
not generally have restricted environmental contact and will be exposed to a much 
greater number of microbes in the days immediately following birth. Given the 
importance of the developing neonatal microbiome, a number of studies have been 
performed to characterize the preterm gut microbiome and determine how this dif-
fers from that of full-term infants.
The overall acquisition of a stable and diverse gut microbiome is delayed in pre-
term infants [14], with preterm infants expected to have lower diversity in the first 
month of life compared to term infants. In general, a low diversity is perceived as a 
negative to an individual’s overall health status. Perhaps more alarming for preterm 
infants are the specific bacterial genera that are delayed or missing from the gut 
microbiome. One or a combination of Staphylococcus, Klebsiella, Enterococcus, 
and Escherichia typically dominate the preterm gut microbiome [15]. This is in con-
trast to term infants, who have a much more even community and abundant genera, 
such as Bifidobacterium, Clostridium, Lactobacillus, and Bacteroides. Importantly, 
“beneficial” bacteria, which are thought to confer positive influences on the host’s 
well-being, are more abundant in term infants. Specifically, preterm infants show a 
delayed and reduced development of bifidobacteria and lactobacilli [16].
Interestingly, a recent study by La Rosa et al. [17] showed that the preterm gut 
microbiome underwent a patterned development per increasing postconceptional 
age, once the cohort was stratified by gestational age, with the slowest microbial 
assembly in the most preterm infants. The study suggested that antibiotics, feed-
ing, and single- versus open-room housing did not significantly affect overall gut 
microbiome profiles. Although this study has yet to be replicated or validated, these 
findings suggest that assembly of the preterm gut microbiome is nonrandom, and the 
pace of assembly is dependent on the degree of prematurity (gestational age).
Coupled to the increased prevalence of antibiotics in the preterm population, it is 
important to consider that limited environmental exposure is likely to be the primary 
reason for much of the contrast between preterm and term neonates. For preterm neo-
nates, discharge from the neonatal intensive care unit (NICU) represents a significant 
change in microbial exposure, comparable in some respects to that of term infants fol-
lowing birth. It was recently shown that following discharge from the NICU, preterm 
infants are able to establish a gut microbiome comparable to healthy term infants in 
both overall diversity and the individual bacterial genera that reside in the gut [18]. 
However, the point at which the preterm gut microbiome converges with that of term 
infants remains elusive (Figure 19.2). The same study also showed that despite increas-
ing bacterial variability between infants over time, the functional metabolic profiles of 
each infant converged. Such findings suggest that, in the absence of a specific patho-
gen, the exact identities of the bacteria are of less importance than the capacity of the 
gut microbiome to have the necessary overall function.
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FACTORS AFFECTING THE INFANT GUT 
MICROBIOME: DAY 31 TO 364
The initial seeding of the microbiome in the prenatal stages and through birth rep-
resents an important period in the colonization of the newborn infant. However, at 
this stage the deliberate manipulation of the gut microbiome is generally not feasible, 
with little scope for clinical intervention. In other words, while a range of variables 
will affect the initial exposure to microorganisms, such variables are often difficult 
to control (e.g., birth mode and gestation). While the long-term influence of such 
variables is important to understand, clinical trials are typically focused on variables 
that can be controlled. From a clinical perspective, it is of paramount importance to 
comprehensively understand how a single or combination of interventions will influ-
ence the developing gut microbiome in the neonate and infant stages of life.
Following birth and over the first months of life, the gut microbiome is chaotic 
and highly dynamic, with large shifts in the overall bacterial community potentially 
occurring from day to day [15,19]. This early stage of life represents a key window 
for the manipulation and long-term establishment of a stable and diverse community, 
which is typically regarded as stable from childhood and throughout adulthood. The 
gold standard for establishing a healthy gut microbiome is thought to result from 
















FIGURE 19.2 The development of the gut microbiome in preterm compared to term infants. 
Factors on the left describe what is reduced or increased in preterm populations. The ques-
tion mark represents the unknown time at which the preterm microbiome converges to that 
of term infants.
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stage, FTVDBF infants tend to have relatively high abundances of Bifidobacterium, 
Bacteroides, Clostridium, and Atopobium. The percentage of facultative to strict 
anaerobes in the FTVDBF infant gut microbiome at day 90 is 60% to 40%, respec-
tively [20].
This section portrays this key phase of life, focusing on variables that can gener-
ally be controlled, such as antibiotics and supplementation. This represents an excit-
ing area of research, and clinical trials aimed to more comprehensively understand 
the mechanisms of these interventions offer important avenues for understanding the 
role of the gut microbiome in programming long-term host health.
FeeDinG
Given the importance of seeding the microbiome with beneficial bacteria, it is not 
surprising that breast milk contains a range of beneficial microorganisms, including 
lactobacilli and bifidibacteria [21]. Historically assumed to be sterile, more than 700 
different bacterial species have been detected in human milk, commonly includ-
ing species from the genera Weissella, Leuconostoc, Staphylococcus, Streptococcus, 
and Lactococcus [5]. The importance of a feeding regime for the early development 
of the gut microbiome became apparent when researchers realized that the bacteria 
in stool did not resemble the mode of delivery after the initial week of life. As dis-
cussed, lactobacillus represents a major genus of the vaginal microbiome, but this 
genus is relatively low in abundance in the gut microbiome. By analyzing bacterial 
taxa at the strain level, it has been shown that specific bacterial strains transferred 
from maternal breast milk successfully colonize the neonatal gut [22].
Although relatively conserved compared to other sample types (e.g., stool), the 
microbial community in breast milk is different between different mothers and 
can change over time within the same individual [23]. Hunt et al. [23] found the 
most abundant genera of bacteria in human milk from American mothers were 
Streptococcus, Staphylococcus, Serratia, and Corynebacteria, and reported notably 
lower levels of lactobacilli and bifidiobacteria compared to European cohorts. Even 
within the same geographical location, differences in the number and diversity of 
bacteria in the breast milk microbiome arising from dietary influences have been 
reported in both human and animals. In macaques, a high-fat diet in the maternal 
pre- and postnatal stages influenced the developing offspring gut microbiome, most 
notably in the abundance of Campylobacter [24]. Importantly, this was not related to 
obesity per se, rather it was a direct effect of the high-fat diet. However, in a human 
population Cabrera-Rubio et al. [5] found that the weight of the mother negatively 
correlated with the diversity of bacteria in her offspring. The long-term influences on 
the gut microbiome from the epigenetic signatures of previous generations’ dietary 
habits will be important to understand, but such data is currently elusive.
As well as the direct passage of viable microbes, human milk also confers pro-
tection against pathogens through the transmission of maternal immunoglobulin A 
(IgA) [25]. IgA is the first source of antibody-mediated immune protection in the 
neonatal gut and has been shown to prevent the translocation of bacteria as well as 
promote long-term gut homeostasis by regulating the gut microbiome [26]. Human 
milk oligosaccharides (HMOs), which have no direct nutritional value for the infant, 
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constitute a major proportion of breast milk. The role of HMOs is to serve as a 
prebiotic for the successful colonization and growth of beneficial bacteria typically 
derived directly from the breast milk. Furthermore, breast milk contains lactofer-
rin, which is an iron-binding protein that reduces the availability of iron in the gut, 
preventing the overgrowth of potentially pathogenic iron sequestering bacteria [27]. 
Thus, breast milk serves as a symbiotic by providing both prebiotic and probiotic 
properties to the infant enteric ecosystem.
Infant formula is a mix of lactose, fat, HMOs, and protein, and is manufactured 
to complement or replace human milk when exclusive breastfeeding is not possible 
or opted against. The effects of maternal breast milk, compared to infant formula, 
on the neonatal microbiome are summarized in Table 19.1. The influence of breast 
milk or formula on the diversity remains inconsistent, with both reported to increase 
bacterial diversity in the gut microbiome of the neonate [28,29].
Interestingly, after the introduction of complementary foods, the gut microbiota 
of breastfed infants changes to reflect that of formula-fed infants. This occurs as 
the result of a significant increase in the abundance of the genera Enterococcus and 
Enterobacter, and the appearance of facultative and obligate, particularly anaerobes 
Bacteroides, Clostridium, and other anaerobic Streptococci [30]. Furthermore, tran-
sition to family (table) foods has been shown to be a key event that drives infant 
gut microbiome composition, eclipsing previously important influences such as birth 
mode, gestational age, antibiotic use, and maternal weight [31].
Receipt of formula has been associated with infectious diseases, inflammatory 
mediated conditions, and long-term allergy risk. For example, feeding with an 
exclusive human milk-based diet significantly reduced the incidence of necrotiz-
ing enterocolitis (NEC) and late onset sepsis (LOS), resulting in significantly lower 
mortality compared to infants fed a bovine-based diet and formula [32]. This might 
reflect the lower numbers of Bifidobacterium common to formula-fed infants [33]. 
Thus, an active area of research is currently focused on determining the best alterna-
tive to breast milk, with promise shown by donor milk, allowing an exclusive human 
breast milk diet.
TABLE 19.1
Comparison of Breast Milk and Formula on the Neonatal Microbiome
Breast Milk Infant Formula












Risk of neonatal disease Reduced Increased
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Disease anD antibiotics
The number of infant deaths in the United States is around 6 infants for every 1,000 
births. A major cause of infant death is prematurity, and the increasing number of 
infants surviving preterm birth has presented new problems. Despite increased and 
novel research efforts [34], little improvement has been made in the rate of mor-
tality due to preterm disease such as NEC and sepsis, which account for >20% of 
all preterm mortality [35]. Significant morbidity associated with prematurity, such 
as delayed growth and cognitive and neurological functioning, are also common to 
infants delivered preterm. To reduce the risk of infections, vulnerable neonates may 
undergo a short course of antibiotics. Concerns regarding antibiotic treatment related 
to the gut microbiota include the spread of antibiotic resistance among pathogens, 
and that alteration of the microbiota will interfere with human–microbe interactions 
that are fundamental to human development.
Antibiotics have been demonstrated to play a significant and long-term role in 
altering the bacterial composition within the gut microbiota. Antibiotics are com-
monly prescribed to neonates, particularly preterm infants, where standard practice 
is to administer antibiotics for 48 hours following birth, and longer if infection is sus-
pected. This is likely to result in the delayed development of a diverse gut microbiota 
in preterm infants. Understanding the direct impact of antibiotic administration on 
the developing gut microbiome is extremely challenging. The type of antibiotics, the 
combination used, their dosage, and length of time of administration vary hugely 
between individual infants, reflecting the patient’s needs and the preferences and 
experiences of the clinicians treating the individual. These variables and issues with 
robust sample collection mean that monitoring the exact effects on the gut micro-
biota in vivo is extremely difficult. Nonetheless, when the role of ceftriaxone was 
studied in term breastfed infants, a decreased count of total bacteria was observed, 
particularly Enterobacteriaceae, enterococci, and lactobacilli [36]. Ceftriaxone was 
also shown to cause a disappearance of Bifidobacterium spp. with a preservation of 
potentially pathogenic Streptococcus spp. and Staphylococcus spp. The total bacte-
rial load was also significantly reduced following antibiotic administration for NEC 
in preterm infants; however, by 2 weeks postdiagnosis the load was comparable to 
that of controls [37].
suppleMentation
As appreciation for the significance of the gut microbiome in health and disease has 
risen in recent years, so too has the interest in manipulating its development with 
probiotics and prebiotics. Probiotics are live microorganisms, which can colonize the 
host and provide benefits to health, both directly (e.g., producing a substrate for the 
host) and indirectly (e.g., preventing overgrowth of potential pathogens). Prebiotics 
are substrates that promote the growth of beneficial bacteria. Symbiotics are a com-
bination of prebiotics and probiotics.
The neonatal and infant stages represent the most important windows for estab-
lishing beneficial microbes in the gastrointestinal tract. This is currently a highly 
active area of research, with substantial pharmaceutical investment. Although further 
298 The Biology of the First 1,000 Days
work is needed, it is not unreasonable to suggest that in the next decade the use of 
probiotics in early life will be routine practice in the most vulnerable populations. 
The use of probiotics and prebiotics in preterm infants seems particularly important 
for establishing long-term health, although recent large trials have produced opposing 
results. An Australian study of 1,099 preterm infants showed a significant reduction in 
NEC (but not sepsis) resulting from a probiotic containing Bifidobacterium infantis, 
Bifidobacterium lactis, and Streptococcus thermophiles [38]. Conversely, a UK study 
of 1,310 preterm infants using a probiotic containing a single strain of Bifidobacterium 
infantis found no significant effects on the incidence of neonatal disease [39]. While 
these two studies represent large observational findings, more focused mechanistic-
based studies are ongoing to systematically determine the optimal combination of 
microbes, as well as the dosage and prebiotic substrates. For instance, recent work 
has shown that administration of L. reuteri competitively excludes enteropathogenic 
E. coli, a major cause of diarrheal infant death, from mucus and epithelium intestinal 
models; however, the efficacy of L. reuteri was strain specific [40].
While results are still emerging, it has been shown that probiotics can profoundly 
shift the gut microbiome in neonates, unsurprisingly due to much larger relative 
abundances of the probiotic species in the probiotic recipients [16,41–43]. The even-
ness of the community also tends to increase, indicating increased ecological stabil-
ity. A recent novel finding explored preterm infants who received probiotics matched 
to controls through the NICU and postdischarge, showing that the Bifidobacterium 
strain used in the probiotic colonized long-term at three times the expected level, 
but the Lactobacillus strain used was only detected while probiotics were being 
administered (suggesting unsuccessful colonization) [16]. Such studies highlight 
important issues around the selection of the most appropriate probiotic to use for 
successful long-term colonization. It should also be noted that probiotics have been 
trialed for the prevention of allergic disease in mothers and infants, with an appar-
ent reduced incidence of eczema, but not asthma, allergy, or other allergic condi-
tions [44]. Overall, probiotics are rarely shown to have negative consequences and, 
at worst, tend to have no overall effect.
Although less researched than probiotics, the potential for prebiotics to modulate a 
health gut microbiome is huge. As discussed, much of the beneficial nature of breast 
milk is thought to result from its prebiotic properties. However, supplementation of 
HMOs to the feed of 12 preterm infants did not result in the expected increase in bifi-
dobacteria [45]. For early infancy, one of the most prominent probiotics is lactofer-
rin, which is known to help protect against infection and promote nutritional status 
[27]. Lactoferrin has been shown to specifically inhibit pathogenic bacteria in the gut 
microbiome by scavenging free iron to such an extent that remaining concentrations 
are too low to enable the growth pathogenic E. coli [46]. The effects of prebiotics on 
the overall gut microbiome structure will emerge in the coming years.
TRANSITION FROM INFANT TO CHILD: 
DAY 365 TO 1,000 AND BEYOND
Neonatal and, to a lesser degree, infant gut microbiome development is chaotic, 
dynamic, and highly individual. As discussed in the preceding sections, the temporal 
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development of the bacterial community during this time can be influenced signifi-
cantly by environmental, host-related, and clinical variables. By 1 to 3 years of age 
there is generally less clinical intervention, and the gut microbiome reaches a “cli-
max community” of microbes that will generally remain stable through adulthood 
[47] (Figure 19.3). Although there is no specific gut microbiome in adults, com-
pared to neonates and infants there is a notable increase in the Bacteroidetes at the 
expense of Proteobacteria, while Firmicutes remains relatively dominant from birth. 
The more adultlike gut microbiome is predominantly characterized by increased 
abundances of the genera Clostridium, Faecalibacterium, Blautia, Ruminococcus, 
Lactobacillus (Firmicutes), Bacteroides, and Prevotella (Bacteroidetes), as well as 
Bifidobacterium [1].
The exact age at which the adultlike community establishes is not yet known 
and likely varies between individuals, especially driven by nutritional status and 
geography, with Western populations reaching maturation by 1 year of life [48]. 
In a study comparing the gut microbiome of children aged 0 to 3 years between 
three extreme groups (American Indians from the Amazon, Rural Malawains, and 
urban Americans) the bacterial profiles were distinct between the groups, but the 
Western American children were the greatest outliers [47]. Notably, bifidobacteria 
still dominated the communities from all locations. Although the gut microbiome is 
still developing, there are many factors contributing to the microbes that colonize 
it. Aside from the geographical and dietary extremes discussed earlier, more subtle 
influences within a given population may have profound long-term effects. Having 
siblings results in a higher proportion of Bifidobacterium compared to single infants 
[10].
Perhaps unsurprisingly, the gut microbiomes of twins are more comparable to 
each other than those of other nonrelated infants, but it is unclear if this is driven by 
comparable environmental exposure or genetic influence [49]. Exposure to animals, 
such as household pets, will also shape the developing gut microbiome [50]. A recent 
study showed that the gut microbiome profiles of preterm infants at 1 to 3 years of 
age was comparable to that of term infants in terms of both diversity and the abun-
dant bacterial genera [18]. The same study also found no profound lasting effects on 
the gut microbiome from a previous diagnosis of disease, number of days of antibi-
otics, gestational age, birth mode, and mode of delivery. These findings are further 
supported by a recent study, which found that the same variables do not influence the 








FIGURE 19.3 The schematic shows that diversity increases from day 0 to day 1,000 of life. 
Birth mode, initial feeds, and weaning are major events in which the diversity increases more 
rapidly.
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gut microbiome long term, with the additional finding that maternal weight also has 
no lasting effect [31].
There is currently a progressive increase in metabolic and immune-mediated 
diseases in infants and children for which the developing gut microbiome might 
have important consequences. Studies exploring the gut microbiome in allergic 
disease and obesity have risen in recent years, but the direct effect of the gut 
microbiome on these conditions is not well determined [51]. Still, it is reasonable 
to postulate that the gut microbiome will have important influences. For exam-
ple, a reduced abundance of Bacteroides, which is common to the Western diet 
associated with low dietary fiber intake, was shown to predict atopic eczema [52]. 
Likewise for obesity, a reduced abundance of Bifidobacterium and an increased 
prevalence of Staphylococcus was found at 1 year of age in infants who went on to 
become obese at 7 years of age [53].
The neonatal and infants phases seem the most applicable for modulation of 
the gut microbiome. However, in certain circumstances, such as following anti-
biotic administration, there may be a clear rationale for seeding a beneficial gut 
microbiome though the use of probiotics and prebiotics. Although microbiome 
research has offered unprecedented information on the role of microbes in health 
and disease, the field as a whole is still emerging. Further work is needed to ascer-
tain the extent to which microbiome findings are causative and the subsequent 
mechanisms, proving causality over existing correlations. The next decade offers 
huge promise for microbiome research, no more so than for the developing infant, 
where the first 1,000 days offers a key window to establish a beneficial population 
contributable to long-term health.
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INTRODUCTION
The gastrointestinal tract is one of the primary lines of defense for the body against 
pathogens. In a state of health, the gut is able to respond to a pathogen or allergen 
through various mechanisms. The gut microbiota enhance these defense mecha-
nisms, improve intestinal immunity, aid in nutrient and drug metabolism, and syn-
thesize some nutrients [1]. A disturbance in any of the finely tuned mechanical and 
immunological components of the intestinal tract, or the microbiota, is likely to dis-
rupt these functions [2]. Prominent causes of gut disruption include inflammation, 
infection, chemotherapy, radiation, parental nutrition, pharmaceuticals (e.g., anti-
biotic administration), various diseases, and environmental exposures. Variations 
can result from diet, gastric acidity, intestinal motility, overall immune status, and 
general hygiene [3]. Infants and young children are particularly vulnerable to these 
disruptions because of their developing immune system, and rapid growth and devel-
opment phase [4]. This chapter will discuss some of the important factors that affect 
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our knowledge. Environmental enteropathy (EE), as one of the most prominent con-
ditions affecting the gut flora and function, will be addressed in some detail. This 
chapter will describe the epidemiology and pathophysiology of EE, its health impli-
cations, diagnostic methods, and trials for treatment. Promising avenues for new 
diagnostic tools and interventions will be highlighted.
EPIDEMIOLOGY
Tropical enteropathy is a subclinical disorder seen in the gastrointestinal tract that 
affects millions of individuals, particularly those living in low-income countries [5]. 
Tropical enteropathy was first described in adults, both “natives” and “Westerners,” 
living in the tropics in Africa, Asia, and South America, from which the disor-
der obtained its name [6–9]. It was absent in residents of temperate countries, and 
resolved for those who moved or relocated to Western countries [10,11]. Residents 
of semitropical regions, in affluent communities with good sanitation, had a similar 
intestinal morphology to those of temperate regions. Ethnicity was not an impor-
tant determinant of the differences seen in gut function, with a greater resemblance 
found between those residing in the same region, as opposed to those from a similar 
country of origin. People with a higher socioeconomic status were found to have 
a better intestinal absorptive capacity [12]. This suggested that the quality of the 
environment played a more important role than the climate in the pathogenesis, and 
so the name was expanded from tropical enteropathy to environmental enteropathy, 
with environmental to more widely mean “acquired” [13]. A more recent term, envi-
ronmental enteropathic dysfunction (EED), is being used to encompass the func-
tional effects of enteropathy.
Environmental enteric dysfunction occurs after birth [14], and many of the histo-
pathological findings accompany cases of malnutrition [15]. Unlike tropical sprue, 
which is characterized by diarrhea, steatorrhea, and fatigue, EED is largely asymp-
tomatic. Disruption of the intestinal functions seen in EED could be the result of 
bacterial overgrowth, repeated infection from various pathogens (bacterial, viral, or 
protozoal), water contamination, environmental toxins, food allergens, and/or mal-
nutrition, yet the exact etiology remains unknown [13]. It is likely that a combination 
of these rather than a single factor are responsible EED. For example, while bacterial 
infection is endemic in many of these environments, it has only been associated with 
enteropathy in a few cases [16]. Food and water contamination, and poor sanitation 
have been proposed as important underlying factors [17].
DEFINITION
Environmental enteropathy is defined as a subclinical disorder resulting in struc-
tural and functional changes to the small intestine. The morphologic changes are 
proposed to occur through a T-cell mediated process characterized by a disrup-
tion in the balance between the proinflammatory (e.g., tumor necrosis factor alpha 
and interferon gamma) and regulatory cytokine-producing cells (e.g., transforming 
growth factor beta) [18]. The alterations include villous shortening and atrophy, crypt 
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hyperplasia, and inflammatory cell infiltrate (e.g., lymphocytes and plasma cells) in 
the epithelium and lamina propria [16] (Figure 20.1). Gut function is consequently 
impaired. The damage to epithelial cells results in a loss of essential enzymes, and 
the decrease in the functional surface area of the intestinal epithelium causes mal-
digestion and malabsorption. An increase in gut permeability occurs due to the 
epithelial disruption leading to microbial translocation. This translocation into the 
systemic circulation consequently causes a state of chronic inflammation [16,19]. and 
altered intestinal resistance. The resulting in lowered immunity, increased suscepti-
bility to infection, and loss of appetite, propagates the inflammation and malnutrition 
cycle (Figure 20.2) [20,21]. Continuous exposure to the enteric pathogens results in 
a state of perpetual hyperstimulation of the mucosal immune system. This is likely 
(a) (b)
crypt villus crypt villus
FIGURE 20.1 Histological changes in (a) mucosa of children with EED show villous atro-
phy, crypt hyperplasia (crypt to villous ratio < 1), and increased inflammatory cells in lamina 
propria compared to (b) normal intestinal mucosa. (Reproduced from McKay S, Gaudier E, 
















FIGURE 20.2 The relationship between undernutrition, the gut microbiota, the immune 
system, and environmental enteropathy. (Reproduced from Kau AL, Ahern PP, Griffin NW 
et al., Nature 2011, 474:327–36. With permission.)
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why oral vaccines, such as polio and rotavirus vaccines, are less effective in children 
with EED [22].
The well-established role of zinc in the immune response has prompted interest 
in examining its role in EED [23]. It is likely that the relationship between zinc defi-
ciency and EED is bidirectional. As a result of the decreased functional surface area 
of the intestine in EED, zinc homeostasis is impaired. There is a decrease in dietary 
zinc absorption and a failure to conserve endogenous zinc [24]. Additionally, zinc 
deficiency contributes to EED by disrupting the intestinal barrier function, induc-
ing intestinal inflammation, increasing intestinal permeability, and therefore sus-
ceptibility to infections, including EED [24,25]. Zinc deficiency in children with 
EED also increases the burden of illness by decreasing absorption of other nutrients, 
impairing adaptive immune function, and aggravating the state of chronic systemic 
inflammation [2].
The emerging science of nutritional metabolomics carries the promise of better 
defining the pathways involved in enteropathy. In a recent targeted metabolomics 
study, researchers found alterations in serum metabolites among enteropathic chil-
dren, including lower serum phosphatidylcholines, sphingomyelins, tryptophan, and 
higher serum glutamate, histidine, serine, taurine, serotonin, and acetylcarnitine, 
compared to healthy children [26]. These metabolites are involved in key roles in 
differentiation, growth and development, gut health, and energy metabolism. Future 
trials are necessary to better elucidate the role these metabolites have in the patho-
logical pathway of EED.
HEALTH IMPLICATIONS
If EED is asymptomatic, why does it matter? Although initially, EED is asymp-
tomatic, the bacterial proliferation, inflammatory infiltration, and changes in 
absorptive functions indicate that there is an underlying state of ill health [27]. 
Combined with recurrent diarrhea and other infections, and poor living condi-
tions that threaten adequate nutrient intake and sanitary conditions, the negative 
impacts on child growth and development seem inevitable. Superadded diarrhea 
may result from bacterial overgrowth or lactose intolerance due to the loss of lac-
tase from intestinal brush border damage, with subsequent dehydration and acido-
sis if not promptly treated [28].
Many of the risk factors associated with EED, such as poverty, water contamina-
tion, and unsanitary conditions have also been proposed to impact early childhood 
development [17]. The state of chronic inflammation, and altered microbiota and 
immune response makes infants particularly prone to repeated infections [20].
Stunting, a simple proxy for healthy child growth, is an outcome variable of EED 
[13]. The exact mechanisms through which EED contributes to the pathogenesis of 
growth faltering are not fully understood. Most evidence stems from observational 
studies, but the postulated mechanisms include intestinal dysfunction and distur-
bance of the gut environment, a concurrent state of malnutrition, and intestinal and 
systemic inflammatory response [18,29]. Bacterial translocation, which occurs with 
EED, was also found to be positively associated with growth failure [18]. Future 
studies are needed to understand the exact relationship between EED and growth 
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failure. Studies should be initiated early in life (at birth or during the postnatal 
period) to determine whether EED is a cause of, a result of, or is aggravated by, 
malnutrition [30].
DIAGNOSIS
A definitive diagnosis of EED-altered intestinal architecture requires an intesti-
nal biopsy, which was first developed by Crosby–Kugler [31]. However, in infants 
and young children who suffer no clear clinical symptoms, this would obviously 
be a measure that is neither feasible nor acceptable, especially in resource poor set-
tings [30]. Diagnosing EED using an intestinal biopsy would also bring about other 
challenges, such as practicality, safety, cost, uncertainties regarding the number of 
samples required, and risk of sampling error [32]. Several other measures have been 
proposed to serve as a proxy [33,34], yet no single validated and reproducible diag-
nostic biomarker exists [30].
The dual absorption test is the most commonly used measure in the field. It allows 
the examination of both the absorptive capacity and epithelial integrity/gut barrier 
function [32], with lactulose to mannitol (or rhaminose) ratio most commonly used. 
Lactulose is a disaccharide which, in the case of a normal intestinal lumen, is nonab-
sorbable, and mannitol is a monosaccharide that is readily absorbed through a normal 
mucosa via a passive transcellular route not requiring a transporter, but not metabo-
lized in the body. Both sugars are filtered through glomeruli and not reabsorbed, and 
hence are measurable in urine. Measuring the concentration of the monosaccharide 
alone is used to assess the absorptive capacity of the intestine; disaccharide alone is 
used to assess intercellular tight junctions. Therefore, in enteropathy there will be a 
decrease in mannitol and an increase in lactulose absorption, as a result of mucosal 
cell injury and the disruption of tight epithelial junctions, respectively [35]. There is 
no consensus on the diagnostic cutoff for lactulose:mannitol (L:M) ratios, which may 
be the result of the variations in many test parameters, as discussed later, but 0.12 is 
most frequently utilized in the literature [32]. In addition to varying test parameters, 
it may be unclear how to identify “normal” in conditions where adaptive and patho-
logical conditions may be very close. A 5-hour urine collection period is commonly 
the standard but is often not practical in field situations [32]. The doses of the sugars 
used in the test should be adjusted according to body weight; otherwise, side effects 
such as diarrhea and vomiting can occur. As gastric emptying could affect absorp-
tion kinetics, standard fasting should be followed. A reverse solvent drag may occur 
as a result of this hyperosmolar solution, which could be remedied by administering 
the sugars with a liquid meal [36].
A great deal of heterogeneity exists with the use of this biomarker, which is the 
result of many factors. Controllable factors include differences in inclusion/ exclusion 
criteria, pretest requirements, sugar dosage, posttesting collection methods and 
times, detection techniques/methods for assessing analyst concentrations, and dis-
playing and interpreting results [30,37] (Box 20.1). These factors may be improved 
and standardized to allow for better reproducibility of the L:M ratio diagnostic test. 
Bacteriuria may also alter test results by lowering sugar concentrations in urine [38]. 
The sugar loads can also disrupt intestinal permeability, giving false results  [29]. 
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What defines normal test values have been developed from “healthy” children in 
Western countries; these values should be validated against ones obtained from 
healthy children living in the same regions as those suffering from EED. Other non-
controllable influences may be the result of different etiological factors, geographic 
settings, and variations in individual response [39]. Although little can be done to 
change the latter, defining the parameters for possible causes of heterogeneity accu-
rately over time may provide some useful patterns. Noteworthy, a reduced lactulose 
and mannitol excretion can occur concurrently giving an unchanged ratio; hence, 
there is value in reporting the sugar absorption test results in addition to the ratio 
[40]. There is certainly some merit in using the L:M test as a measure of gut dysfunc-
tion, including its safety, and longstanding use in the literature [32].
Citrulline, a nonprotein amino acid produced by enterocytes, has been pro-
posed as a potential biomarker for EED but has not been formally examined [13]. 
Glutamine and derivative amino acids are the main precursors of citrulline, which 
is almost exclusively produced from bowel epithelial cells in the upper and middle 
portions of the intestinal villi [41]. Loss of the small bowel epithelial cell mass has 
shown decreased circulating levels of citrulline in celiac and Crohn’s disease, and 
intestinal dysfunction [42,43]. Dietary citrulline is only significantly found in water-
melon and is thus not affected by exogenous sources, since plasma citrulline levels 
are reflective of de novo gut epithelial cell synthesis [44]. Low citrulline concentra-
tions are also correlated with hypoalbuminemia and anemia [45]. More research is 
needed to explore the potential of plasma citrulline as a biomarker for the functional 
absorptive capacity of the small intestine in children.
Fecal biomarkers reg1B, alpha-1-antitrypsin, myeloperoxidase, calprotectin, and 
neopterin are biomarkers of enteric inflammation and have been more commonly 
used in combination to assess EED. Their low cost and feasibility, especially in chil-
dren, has been appealing, although they are nonspecific and have not been systemati-
cally evaluated. However, they do hold promise in terms of their use in combination 
with other biomarkers. It has been suggested that a composite score should be set 
BOX 20.1 SOURCES OF HETEROGENEITY IN 
LACTULOSE:MANNITOL (L:M) RATIO TEST
• Inclusion/exclusion criteria of participants (e.g., breastfeeding, HIV 
positive, severe malnutrition, suffering other illnesses)
• Pretest requirements (e.g., fasting versus nonfasting, fasting duration)
• Sugar load (i.e., not all studies dose sugar load to body size)
• Posttesting collection methods and times
• Detection techniques/methods for assessing analyst concentrations 
(e.g., high-performance liquid chromatography–mass spectrometry)
• Displaying results (e.g., arithmetic versus geometric mean)
• Interpreting results (i.e., lack of cutoff standardization)
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up, providing a set of diagnostic criteria consisting of a number of parameters for 
the assessment of inflammation, immune activation, mucosal permeability, and gut 
absorptive function. This “enteropathic index” should be developed in consideration 
of the different purposes it may need to serve such as population screening, indi-
vidual diagnosis, and clinical management. It should be noted that these parameters 
should also be evaluated for their potential to serve as predictors of subsequent stunt-
ing, risk of diarrhea, and vaccine responsiveness [13,43,46].
TREATMENT
Informed trials for the treatment of EED have been increasing over the past decade, 
using a number of interventions, either separate or in combination, to strengthen 
immune defenses, combat the different proposed etiologies, and/or remedy/reverse 
the negative health outcomes (Table 20.1). Yet, to date, none of these have proven 
successful in the treatment of EED. The structural and functional changes of EED—
disrupted mucosal integrity, impaired immune function, and compromised digestion 
and absorption—are also thought to impact the success of malnutrition interventions 
and vaccine programs [22,47].
Many of the intervention trials have used surrogate outcome measures such as 
stunting and child development, and have generally failed to improve these out-
comes. Although this is the ultimate goal of EED control, other factors contribute 
to these outcomes, making the failure or success of treatment not EED-specific, 
and again emphasizes the lack of knowledge with respect to the exact pathophysiol-
ogy of enteropathy. This could explain why a handwashing trial in Pakistan was 
able to reduce diarrhea, while there was no effect on stunting [48]. Pilot interven-
tions being evaluated to reduce enteropathy include the administration of antibiotics, 
single or multiple micronutrient supplementation, and the improvement of water and 
sanitation. However, if children globally received interventions of vitamin A and 
zinc supplementation, balanced energy protein supplementation, complementary 
TABLE 20.1
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feeding, breastfeeding promotion, and prenatal micronutrient supplementation for 
their mothers, with 90% coverage, stunting would only decrease by less than a quar-
ter [49]. More experimental evidence is clearly needed to delineate the different 
causal pathways to stunting, and outline the relative contribution of enteropathy to 
its pathogenesis.
Water, sanitation, and hygiene (WASH) efforts have not been able to completely 
protect children in the critical first 3 years of life. This may, arguably, be due to the 
lack of specificity of these interventions for this particular age group, or the fact that 
many of these interventions were focused on improved sanitation, water treatment, and 
maternal/caregiver handwashing [50]. Ngure et al. argue that WASH needs to encom-
pass important vectors of soil, animal feces, and infant foods to be more effective [50].
Nutrition has been a significant player in many of the interventions geared toward 
the prevention, treatment, and control of EED. Effective nutrition interventions can 
(1) promote healing of the mucosal barrier and strengthen immunity; (2) replenish 
the body and reallocate key nutrients lost through malabsorption and inflammation; 
(3) allow for catch-up growth; (4) enhance appetite; and (5) restore the microecology 
of the gut [51]. Although malnourished children who took part in a 4-week nutrition 
feeding program showed an improvement in growth indicators and some histologic 
morphology, their intestinal function failed to recover. Furthermore, the mucosal 
architecture and growth faltering returned 1 year after follow-up, indicating that 
the persistence of environmental insults make short-term solutions ineffective [52]. 
Multiple micronutrient supplements given to children aged 1 to 3 years in Malawi 
showed a transient modest improvement, yet there was no change in linear growth 
[53]. A focus on diet-based interventions is under way using, for example, common 
beans and cowpeas to ameliorate the inflammatory response associated with EED, 
as well as to provide a more nutritious replacement for low-quality complementary 
foods, and one that is a good source of protein and micronutrients [54]. Improved 
nutrition could reduce the impact of infections on growth and development by multiple 
mechanisms that include (1) strengthening the immune system; (2)  compensating for 
malabsorption and replenishing key nutrients in the body; (3) allowing for catch-up 
growth; (4) improving appetite; and (5) restoring healthy gut flora [51].
The benefits of short-chain fatty acids (SCFA) in the control of the inflammatory 
response and aiding mucosal healing provides another promising avenue for treat-
ment. Probiotics are another avenue for treatment to correct underlying dysbiosis and 
to restore the ecological balance of the microbiota from the use of antibiotics [55]. 
Probiotics have showed some promise in restoring normal gut flora and inhibiting 
pathogenic overgrowth [56]. However, human trials failed to show any evidence of 
benefit from the administration of omega-3 fatty acids and probiotic supplements in 
the treatment of EED [33,55].
Human trials have shown that zinc supplementation decreased intestinal perme-
ability and partially alleviated EED, albeit transiently [57,58]. Amino acids also play 
an important role in maintaining gut health, and supporting gut barrier integrity and 
function [59,60]. In addition, 9% to 12% of body protein is synthesized in the gut 
[61]. Mainly based on animal models, suggestions for supplementation with specific 
amino acids (e.g., arginine, glutamine, glutamate, sulfur containing amino acids and 
their metabolites, glycine, lycine, threonine, methionine, serine, proline, and the 
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amino acid-derived compounds, polyamines) have been made to aid in the process of 
mucosal healing, and resume normal gut physiology and metabolism [62]. Evidence 
also supports the important role that polyamines have in restoring enterocyte func-
tion, and mucosal healing [63]. Glutamine has also been associated with improved 
mucosal barrier function in some animal and human studies; however, findings have 
not been consistent, and it has not been successful in improving growth indicators in 
children with EED [64–66]. It should be noted that in many low-income countries 
the human immunodeficiency virus (HIV) remains a huge burden, and 30% of preg-
nant women with HIV in low-income countries do not have access to antiretroviral 
therapy [67]. Mother-to-child transmission rates increase from 2%–5% to 15%– 45% 
in the absence of any intervention. Although the number of cases of children with 
HIV is declining, 134,000 new cases were registered in 2013 [68]. It is possible that 
EED with HIV may be a distinct pathophysiological entity, and one that requires a 
different approach to treatment, as seen in adults [69].
Certain pathogens have been associated with EED, such as Citrobacter rodentium 
or hookworm [70], which require the use of antihelminths and antibiotics as other 
routes for treatment. The administration of a broad-spectrum antibiotic to children 
in Malawi failed to improve gut barrier function and, in some instances, disrupted 
the gut microbiome balance. It could be that bacterial overgrowth is not an essential 
etiological factor in the pathogenesis of EED or that repeated exposures prevent a 
single antibiotic course from eliminating EED [52,71]. In India, the administration 
of azithromycin to infants showed an improvement in calprotectin and myeloper-
oxidase, yet the immunogenicity of the oral polio vaccine showed no improvement, 
suggesting that EED may not always be an important player in the immunogenicity 
of oral vaccines. Conversely, a single dose of albendazole offset the progression of 
EED in a randomized control trial among rural Malawian children [57].
In impoverished societies, EED is entrenched in the downward spiral of malnutri-
tion and inflammation/infections. Although many well-informed efforts have been 
made to remedy EED, they are still speculative to a great extent, as seen by their 
modest, inconsistent, or short-term results. This is likely the consequence of the 
intertwined relationship between child health, growth, development, and nutrition, 
with EED impacting all of these domains. Some outstanding research gaps are high-
lighted in Box 20.2. A better understanding of the biological mechanisms underlying 
EED are needed to be able to develop and evaluate intervention packages that target 
these links.
BOX 20.2 HIGHLIGHTS OF THE MAIN KNOWLEDGE 
GAPS IN THE UNDERSTANDING OF GUT 
MICROBIOME, EED, AND OTHER EXPOSURES
• Identify range of sequelae of EED for childhood and adulthood
• Ideal macronutrient (e.g., essential amino acids and fatty acids) and 
micronutrient (e.g., zinc and vitamin A) profiles for EED treatment
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OTHER EXPOSURES
A newborn slowly develops a complex and diverse microbial ecosystem that closely 
resembles the adult microbiota by approximately 2 years of age [72]. Recent evi-
dence suggests that microbial colonization of the previously presumed sterile infant 
gut occurs in utero. Mothers, therefore, share much of their microbiome with the 
fetus in utero, during delivery and lactation, and possibly later, by being exposed to 
similar environments. The infant’s microbiome is influenced by the mother’s diet, 
health status, mode of delivery, gestational weight gain, type of feeding, genetics, 
and the use of antibiotics [73,74]. In vaginal delivery, the newborn likely acquires the 
bacteria through the mother’s fecal material, which passes during birth and comes 
in contact via the perineal and anal area. Infants born by cesarean section have dif-
ferent flora than infants born vaginally, and their microbiota is somewhat similar to 
that of the mother’s skin, likely because of contact through the abdominal incision 
[75]. The different bacterial colonization acquired through these delivery methods at 
many times persists beyond the neonatal period, and may contribute to the differen-
tial susceptibility to allergies and other diseases in later childhood [76].
Gestational age is another factor that impacts gut flora. Premature infants show 
a delay in the establishment of normal microbiota, which is further impacted by the 
• Carrying out clinical studies to test/demonstrate the efficacy of the 
nutrient combinations for EED treatment
• Relative contribution of the proposed etiological factors to the patho-
genesis of EED
• Delineate the relationship between EED and malnutrition (cause, 
consequence, or symbiotic)
• Establishing testing protocols and standardization of L:M testing to 
improve reproducibility and allow for comparability across studies 
(e.g., urine collection period, saccharide dosage)
• Establishing consensus on diagnostic criteria that include carefully 
chosen parameters of function and injury
• Discovering field-friendly, cheap, and validated biomarkers of func-
tion for screening, surveillance, and interventions
• Exploring possible early exposures of the microbiome affecting food 
intolerance and allergies later in childhood
• Better understanding of how the metabolic changes seen in EED 
impact nutrient requirements and homeostasis, including altered 
intake, bioavailability, utilization, and losses
• Monitoring effect of antibiotic exposure on the developing intestinal 
immune system
• Measuring duration of the microbial disruptions after the various 
exposures
• Mapping colonization pattern of infant microflora exposed to a mix-
ture of breast milk and formula milk
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use of perinatal antibiotics [77]. Given that many premature infants are in neonatal 
intensive care units postdelivery, hospitalization is likely a confounder in the rela-
tionship between microbiota and prematurity through the acquisition of nosocomial 
bacteria. Interestingly, it is not only premature babies that have a different micro-
biota pattern; newborns delivered at 37 weeks have also shown a different microbiota 
picture than those born later [78]. More research is needed to map the gut microbi-
ome of preterm infants through early childhood to examine the potential impacts on 
growth, development, and overall health.
Exposure to antibiotics is another important factor that can disrupt the intestinal 
microbiota balance. This is especially true in early life, since the body’s immune 
system is just beginning to develop and establish immunological tolerance [4]. 
Broad-spectrum antibiotics can affect 30% of the gut bacterial load, resulting in 
a substantial decline in taxonomic richness, diversity, and composition [79]. This 
may result in the overgrowth of nonsensitive organisms, the colonization of new 
organisms, or the development of resistance across existing strains. The magni-
tude, duration, nature of the disruption, and the time taken to restore gut flora will 
likely depend on many factors, such as the antimicrobial spectrum, and the route 
and duration of the administration. Infants’ gastrointestinal dysbiosis can also be 
caused by antibiotic administration to mothers during the perinatal and postnatal 
periods. During pregnancy, mothers take antibiotics against infection or the pre-
mature rupture of membranes, resulting in the different microbiota composition of 
infants. Interestingly, the microbiota of breastfed infants showed a faster recovery, 
as compared to those who were formula fed [80]. The gastrointestinal tract dysbiosis 
also appears to alter the antiviral immune response to systemic viral infections, even 
under strict standards of hygiene [81].
Another source of antibiotic exposure is through the consumption of farm crops 
and animals that have been treated with antibiotics. This overexposure to antibiotics 
can disrupt many physiologic equilibria and the intestinal milieu’s overall inflamma-
tory tone [82], which has body-wide and long-term repercussions, such as obesity, 
metabolic syndrome, insulin resistance, altered immunity, increased susceptibility to 
infection, and inflammatory bowel disease [83–85].
A flora with a diet-dependent pattern can be seen as early as 4 days of age, as 
seen by the infant microbiota’s similarities to the mother’s colostrum within the first 
few days of life [86]. A distinct bacterial intestinal colonization pattern is seen in 
breastfed neonates, as compared to formula-fed neonates [87]. Generally, “benefi-
cial” microbiota were seen in term infants born vaginally, at home, and who were 
exclusively breastfed [87].
The mother’s health and dietary practices also impact the infant’s gut flora. Poor 
diet, obesity, and diabetes interfere with the development of a stable, healthy intesti-
nal microbiome in infants, affecting cell programming, and the metabolic and bio-
chemical pathways that impact a child’s weight. This dysbiosis has also been shown 
to have other long-term health consequences [74]. Maternal probiotic supplementa-
tion also reported differences in the colonization of the newborn gut that persisted 
up to 2 years of age [88].
Diet is an important influencer of the gut microflora, and its interactions with 
gut flora have been increasingly studied in recent years [89]. As the child transitions 
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to table foods, there is an upsurge in the abundance of Bacteroidetes, which are 
positively correlated with SCFA levels (acetate, propionate, and butyrate) and other 
changes consistent with a more stable adult microbiome profile. SCFA levels and 
bacterial load are generally higher after the introduction of solid foods [81].
Infant feeding practices continue to influence immunity for up to 3 to 5 years, and 
sometimes well into adulthood, mediated by the gut microflora [90]. Some studies 
have also shown differences in gut environment composition in those exposed to veg-
etarian foods and fermented vegetables showing more diverse lactobacillus strains 
[91]. Animal models have also shown that protein energy malnutrition changes the 
intestinal flora by causing bacterial overgrowth in various parts of the gut. Similarly, 
substituting a low-fat, plant polysaccharide-rich diet with a Western high-fat, high-
sugar diet altered the structure of the microbiota in mice [92]. Iron fortification has had 
adverse effects on Kenyan infants’ gut microbiome, increasing pathogenic bacteria 
and inducing inflammation [93]. The alterations in nutrient availability result in an 
adaptation mechanism of nutrient absorption, and many of these alterations have been 
proposed in the pathogenesis of obesity, such as changes involving increased extraction 
of additional calories from ingested foods [84]. Similarly, gut microbiota play a key 
role in the metabolism of dietary choline and phosphatidylcholine through the enzyme 
trimethylamine oxidase, producing trimethylamine N-oxide, which has been linked to 
atherosclerosis and cardiovascular disease events [90] (Table 20.2).
CONCLUSION
The gut flora plays an important role in many body functions. Environmental enter-
opathy remains one of the most important, and challenging, conditions to impact the 
gut flora in low-income countries, proving to be a particular challenge in infants and 
children with developing immunity and increased susceptibility to infection. This is 
an added burden in countries struggling with malnutrition, repeated infection, HIV, 
and poor environmental conditions. Although we have described various factors that 
TABLE 20.2
Important Factors That Affect the Gut Flora Prenatally, at Birth, and 
Postnatally






















Macro- and micronutrient 
deficiencies
Probiotics
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impact gut flora composition, and possibly function, the exact pathophysiology of 
these pathways remain largely unknown. Without an understanding of the metabolic 
and pathologic pathways, and the presence of some consensus on ideal biomarker 
or a combination of biomarkers to assess the different aspects of gut function (e.g., 
inflammation, absorption, permeability) and developmental outcomes, designing 
successful interventions seems like an unachievable task.
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INTRODUCTION
Food allergies are classified into two categories: those that are mediated by immuno-
globulin E (IgE) antibodies and those mediated by immune cells (non-IgE mediated) 
[1]. Although it is possible to develop an IgE-mediated allergy to any food, most 
individuals with allergies react to one, or a combination, of nine common foods: 
cow’s milk, soy, egg, wheat, peanut, tree nuts, sesame, fish, and shellfish [2]. The 
most common symptoms associated with food allergy in children include urticaria 
(hives), angioedema, eczema, enterocolitis, enteropathy, irritability, vomiting, diar-
rhea, and anaphylaxis [1].
Allergic disease, and in particular food allergies, significantly impact general 
health perception, parental emotional distress, and family activities [3]. Young chil-
dren are particularly at risk of developing food allergy, and it is estimated that up 
to 10% of toddlers have food allergy, compared with 1% to 2% of adults [1,4]. Why 
young children are becoming increasingly sensitized to food allergens is the focus of 
ongoing research. The development of tolerance to multiple foods during early life 
is essential to survival, and the immune mechanisms that enable the development 
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of tolerance are highly developed and regulated. Food allergy in an infant or child 
represents a failure to develop tolerance to a food protein and is associated with 
aberrant T helper cell 2 (Th2) balance [5]. Environmental factors such as maternal 
dietary patterns and micronutrient supplements, as well as postnatal factors such as 
the mode of birth, feeding type, early infections, timing, and type of solid foods, 
and exposure to allergens all influence the developing immune system [6]. However, 
it has become clear that these environmental factors may exert differing effects, 
depending on genetic predisposition, and are modulated by epigenetic effects on 
gene expression.
Fewer allergies are observed in low-income countries; however, rates appear to be 
increasing as these countries adopt more Westernized lifestyle patterns [7,8]. There 
also appear to be important migration effects; the HealthNut cohort in Melbourne 
had a high rate of food allergy and eczema among children born to Asian immi-
grants [9]. This difference in allergy rate was significantly higher than that in chil-
dren born in Asia who migrated to Australia with their parents [9]. The reasons for 
this increased incidence is unclear, and is likely to be due to multiple mechanisms. 
In this chapter, following an overview of the hypotheses of allergy development, we 
examine the evidence relating to dietary influences on development of food allergy, 
and discuss the most recent infant feeding guidelines for allergy prevention.
HYPOTHESES OF ALLERGY DEVELOPMENT
The reasons why some individuals develop allergies are complex and multifactorial. 
The main hypotheses about the etiology of allergy include the hygiene and dual 
allergen exposure hypotheses.
Hygiene HypotHesis
The hygiene hypothesis is based on the observation that people living in European 
farming communities have lower rates of food allergy and asthma compared to those 
in the city [10]. It is hypothesized that the farming environment and lifestyle leads 
to greater exposure during infancy to bacterial markers called endotoxins that influ-
ence the microbiome, which in turn promotes tolerogenic immune pathways.
In a Swedish study, washing dishes by hand was associated with a lower incidence 
of allergic disease as compared with using automated dishwashers [11]. The protec-
tive effect of dishwashing by hand was stronger in children eating fermented foods 
and foods purchased from the farm door [11]. This effect may be related to exposure 
to beneficial microbial exposures not destroyed by high-temperature machine dish-
washing. In Westernized countries, there has been an increased consumption of vir-
tually sterile processed foods. The influence of the consumption of highly processed 
foods on the gut microbiome may be one of the mechanisms by which Western-style 
diets are associated with increases in atopy [12]. The hygiene hypothesis has been 
further supported by observations that birth by cesarean section is associated with 
an increased risk of food allergy or atopy [13], with the mechanism postulated to be 
related to the lack of inoculation with maternal gut flora that occurs during a normal 
vaginal delivery.
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Dual allergen exposure HypotHesis
The dual exposure to allergen hypothesis proposes that tolerance to antigens occurs 
in the neonate through high-dose oral exposure, and that allergic sensitization occurs 
through low-dose cutaneous exposure [14]. It is hypothesized that there is a bal-
ance between these processes and is an issue particularly for babies with eczema 
who have filament aggregating protein (filaggrin) mutations, resulting in altered 
skin barrier function and abnormal immune reactivity [14]. It is proposed that food 
proteins (from the household environment) pass through the disrupted skin barrier, 
leading to Th2 responses, IgE production, and sensitization to the allergen [15]. This 
may be particularly problematic for infants at risk of developing allergy (including 
babies with eczema), where allergenic foods are consumed by household members 
but avoided in the infant’s diet as the baby is exposed to the allergen via their skin, 
but not the potentially protective oral route.
DIETARY INFLUENCES ON DEVELOPMENT OF ALLERGY
Our diet has the potential to alter the tendency toward allergy by immunomodulatory 
effects of dietary components and exposures to allergens. Infants may be exposed 
to nutritional influences via the maternal diet while they are in utero, during breast-
feeding, or as they start consuming solid foods [16].
Maternal dietary patterns associated with decreased sensitization in their chil-
dren include Mediterranean diets, and the consumption of fruits, vegetables, and 
fish [12]. These nutrient-rich foods and dietary patterns contain immunomodulatory 
factors, including polyunsaturated fatty acids, antioxidants, vitamin D, prebiotics, 
and probiotics. These factors may foster a healthy immune system by modifying the 
immune response or the functioning of the immune system. It is also possible that 
women who consume these types of diets have other associated lifestyle factors that 
are associated with a reduced risk of allergy development, such as the avoidance of 
tobacco smoke, and less exposure to environmental pollutants [17].
long-CHain polyunsaturateD Fatty aCiDs
Omega-3 long-chain polyunsaturated fatty acids (LCPUFA), found predominantly 
in marine oils, modulate the immune system by the inhibition of inflammatory path-
ways and may be the reason diets containing fish are associated a lower risk of atopic 
disorders [12]. Diets rich in omega-3 LCPUFA may alter the immune system by 
affecting Th cell balance, specifically inhibiting Th2 cell differentiation, and thereby 
reducing IgE-mediated allergy. The effect of omega-3 LCPUFA in the maternal diet 
during pregnancy and lactation on development of childhood allergy has been tested 
in many randomized controlled trials (RCTs), with inconsistent results. The most 
recent Cochrane Review of maternal supplementation with omega-3 LCPUFA con-
cluded that, although there was little effect of omega-3 supplementation during preg-
nancy and/or breastfeeding in the reduction of allergic disease in children, there were 
some reductions in atopic disease outcomes, including food allergy and eczema in 
the first year in children born to women at high risk of allergy [18]. Since this review, 
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the results of the Copenhagen Prospective Studies on Asthma in Childhood2010 
(COPSAC2010) have been published [19]. In the COPSAC2010, pregnant women were 
randomized to large doses (2.4 g) of omega-3 LCPUFA or a placebo (olive oil) per 
day during the last trimester of pregnancy, and their offspring were  followed to 
5 years of age. The study reported that, for children born to the intervention group, 
the absolute risk of a persistent wheeze or asthma was reduced by one-third, with 
further analysis suggesting that this effect was strongest in the children of women 
whose blood eicosapentaenoic acid and docosahexaenoic acid levels were in the low-
est third of the trial population. Supplementation with omega-3 LCPUFA may be not 
recommended for all women, but might be useful for subgroups, such as those with a 
family history of food allergy or with poor omega-3 LCPUFA status. LCPUFA have 
many effects, and supplementation may be not without risk, as it has been associated 
with longer gestational length [20].
The effect of direct supplementation of infants’ diets with omega-3 LCPUFA has 
also been investigated. The Childhood Asthma Prevention Study (CAPs) was an 
RCT conducted in children with a family history of asthma, which supplemented 
diets with omega-3 LCPUFA and restricted the dietary intake of dietary omega-6 
fatty acids from 6 months of age to 5 years of age [21]. The study found no effect on 
asthma, eczema, or atopy at 5 years of age. Schindler et al. [22] reviewed nine more 
studies, including a total of 2,704 infants, that assessed the effect of higher versus 
lower intake of LCPUFA on allergic outcomes in infants for the Cochrane database. 
The Cochrane Review concluded that there is no evidence that PUFA supplemen-
tation in infancy has an effect on infant or childhood allergy, asthma, dermatitis/
eczema, or food allergy; however, the authors noted that the studies were of variable 
quality and heterogeneous in nature.
antioxiDants
There is an association between maternal fruit and vegetable intake and less atopy 
in their babies [12], which may be due to the antioxidant content of diets rich in 
fruits and vegetables. The antioxidant vitamins (C, A, and E) and minerals (zinc 
and selenium) present in fruit and vegetables may protect against atopic disease of 
the airway by protection against oxidant damage and inflammation of the airways 
[23]. However, there have been no antioxidant supplementation trials to test the link 
between antioxidants in the maternal diet and atopy development.
Vitamin D
Vitamin D is a fat-soluble vitamin and hormone with many roles, including immu-
nomodulation, a process in which the immune response is altered. Vitamin D is 
obtained through the action of sunlight on skin and, in smaller amounts, through 
diet. Interest in poor vitamin D status and increased allergy risk began with the 
observation that people living at lower latitudes with greater sun exposure have fewer 
allergies; this has been shown in the United States and Australia [24]. However, this 
association has not been demonstrated in cohort studies or RCTs with vitamin D 
supplementation. The Barwon infant study [25] found no association between low 
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vitamin D levels at 6 months of age and egg allergy at 1 year of age. Higher cord 
blood vitamin D was associated with less eczema, but not with food sensitization or 
food allergy at 1 year of age in a subset of infants enrolled in an RCT comparing the 
effect of fish oil supplementation during infancy on allergic outcomes [26].
ALLERGEN EXPOSURE: TIMING AND TYPE OF ALLERGENS
maternal allergen aVoiDanCe During pregnanCy
Avoidance of common allergens in the maternal diet during pregnancy is not recom-
mended as a strategy for allergy prevention in Australia and other countries, includ-
ing the United States and Europe. Avoiding the consumption of common allergens 
during pregnancy does not reduce the incidence of sensitization to allergens in chil-
dren [12], and the restricted diet is associated with lower pregnancy weight gain [27].
Does BreastFeeDing preVent allergy?
Breast milk is the gold standard for infant feeding, and has many benefits for both 
the mother and child. In addition to its nutritional benefits, breast milk contains 
many nonnutritional components, including antibodies, cytokines, and other immu-
nomodulatory components [28]. The evidence that breastfeeding is protective against 
allergy, specifically food allergy, is weak; however, this may be due to methodologi-
cal issues. A recent systematic review and meta-analysis including the results of 89 
studies reported that breastfeeding is associated with less asthma at 5 years of age, 
with a greater effect in low- to middle-income countries [29]. This review reported 
that there is weak evidence for breastfeeding and the prevention of other atopic dis-
eases, including eczema and rhinitis, with no effect of breastfeeding on development 
of food allergy [29]. The lack of protective results for breastfeeding and food allergy 
may be due to reverse causality, as highly atopic families are more likely to breast-
feed and feed for longer, and the authors note that this should be adjusted for when 
reporting the results of trials investigating breastfeeding and allergy development. 
There are other innate issues with studies investigating the effects of breastfeeding, 
including the inability to randomize exposures. Additionally, the lack of evidence 
for breastfeeding and protection against food allergy may also be because many 
of the cohort studies included in the systematic review were conducted prior to the 
food allergy epidemic [29]. Some of the limitations of the cohort studies have been 
addressed by the only randomized trial of breastfeeding exposure in Belarus [30]. 
In the PROBIT study, women were cluster randomized via attendance at maternal 
health centers that followed the World Health Organization Baby Friendly Hospital 
Initiative (WHO BHFI) advice or other health centers [30]. Allergic sensitization 
was assessed using skin prick testing, and allergy symptoms were scored using stan-
dardized protocols. A total of 17,046 mother–infant pairs were randomized into the 
trial, and 13,889 were reviewed at 6.5 years of age. Although infants whose mothers 
attended the WHO BHFI health centers breastfed for longer, the results of this RCT 
did not support the protective effect of prolonged breastfeeding against allergic sen-
sitization, and the development of asthma, hay fever, or eczema [30].
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Food allergens consumed by the mother appear in her breast milk [31], and avoid-
ance of allergens in the maternal diet during lactation does not reduce the incidence 
of sensitization in the infant. However, there are emerging data, specific to egg, that 
the inclusion of egg in the maternal diet during early lactation is associated with 
increased levels of egg-specific IgG4 in their babies, which may be important for 
tolerance development [32].
WHat aBout inFant Formula?
Not all infants are breastfed, and many breastfed infants have infant formula top-up 
feeds. Infant formula is usually based on modified cow’s milk protein, and this is often 
an infant’s first exposure to an allergen. For the prevention of allergy, there is insuf-
ficient evidence to recommend the use of soy-based formulas, goat-milk-based for-
mulas, formulas containing LCPUFA, or formulas containing pre- or probiotics [17].
Partially hydrolyzed infant formula has been promoted as a means of prevent-
ing development of allergy and, until recently, infant feeding guidelines in Europe, 
America, and Australasia [33–35] supported the use of hydrolyzed formulas for non-
breastfed infants in place of standard cow’s milk formula if the infant has a family 
history of allergy. A recent systematic review and meta-analysis by Boyle et al. [36] 
investigated whether hydrolyzed cow’s milk formulas can prevent allergic or auto-
immune disease. This review, commissioned by the UK Food Standards Authority, 
included 37 eligible intervention trials of hydrolyzed formula, with over 19,000 par-
ticipants. There was evidence of a conflict of interest and a high or unclear risk of 
bias in most studies of allergic outcomes, and evidence of publication bias for studies 
of eczema and wheeze. Overall, the authors reported that there was no consistent evi-
dence that partially or extensively hydrolyzed formulas reduced the risk of allergic 
or autoimmune outcomes, and this is reflected in newer infant feeding guidelines for 
allergy prevention guidelines [37].
Complementary FooDs: WHen anD WHiCH FooDs?
When considering the introduction to solid foods, issues specific to the prevention 
of allergy relate to the timing of introduction to solid foods and the type of foods 
introduced [29,38–40]. In the last 10 years, there has been a reversal of recommen-
dations regarding the introduction to solid foods for prevention of allergy. While 
guidelines are used to promote delayed introduction to solid foods, and staged and 
delayed exposure to common allergens, this was not associated with a reduction in 
the prevalence of food allergy and, in fact, may have contributed to the increasing 
prevalence. The change in guidelines has occurred as available evidence to inform 
these recommendations has shifted from population-based cohort studies to RCTs 
and systematic reviews of RCTs.
Several randomized controlled trials have investigated the timing of including 
common allergens in an infant’s diet. Whereas most of the trials have considered 
single allergens, peanut [41] and egg [42–45], one trial [46] investigated the effect of 
adding multiple allergens into an infant’s diet before one year of age. The outcomes 
of the single allergen trials are summarized in Table 21.1.
329Effects of Early Diet on Childhood Allergy
TABLE 21.1
Summary of Results from Single Allergen Allergy Prevention Studies
Trial Allergen Intervention Result
LEAP [41] Peanut RCT
Peanut vs. no peanut from 4–11 
months
Group 1: peanut SPT <1 mm: 
n = 530
Group 2: peanut SPT 1–4 mm: 
n = 98
Peanut allergy at five years:
Group 1
Peanut group: 1.9%
Control group: 13.7% (p < 0.001)
Group 2
Peanut group: 10.6%
Control group: 35.3% (p = 0.004)
STAR [43] Egg DBPC RCT
Egg (n = 49) vs. no egg (n = 37)
From 4–8 months
Infants with eczema
Egg allergy at one year:
Egg group: 33%
Control group: 51%
RR 0.65; 95% CI: 0.38, 1.11; p = 0.11
STEP [42] Egg DBPC RCT
Egg (n = 407) vs. no egg 
(n = 410)
From 4–10 months
Infants with family history of 
atopy but without eczema
Egg allergy at one year:
Egg group: 7.0%
Control group: 10.3%;
ARR 0.75; 95% CI: 0.48, 1.17; p = 0.20)
Egg-specific IgG4 levels:
Egg group median: 1.22 mg A/L
Control group: 0.07 mg A/L; 
p < 0.0001
HEAP [44] Egg RCT
Egg (n = 184) vs. no egg 
(n = 199)
From 4–12 months
Sensitization to hen’s egg at one year:
Egg group: 5.6%
Control group: 2.6%
RR 2.20; 95% CI: 0.68, 7.14; p = 0.24
Hen’s egg allergy at one year:
Egg group: 2.1%
Control group: 0.6%
RR 3.30; 95% CI: 0.35, 31.32; 
p = 0.35
BEAT [45] Egg RCT
Egg (n = 165) vs. no egg 
(n = 154)
From 4–8 months
Infants with family history of 
allergic disease and 
EW-SPT <2 mm




OR 0.46; 95% CI: 0.22, 0.95; p = 0.03
IgG4 to egg proteins and IgG4/IgE 
ratios higher in egg group (p < 0.0001) 
Note: A/L, antigen per liter; ARR, adjusted relative risk; DBPC, double-blind placebo-controlled; 
EW-SPT, egg white skin prick test; IgE, immunoglobulin E; IgG4, immunoglobulin G4; OR, odds 
ratio; RCT, randomized controlled trial; RR, relative risk; SPT, skin prick test.
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The Learning Early About Peanut (LEAP) allergy study [41] compared early 
(4–11 months) with delayed (5 years) introduction to peanut in children at high risk 
of peanut allergy defined as preexisting eczema and/or egg allergy. The study dem-
onstrated an 11%–25% absolute reduction in the risk of peanut allergy in high-risk 
infants (and a relative risk reduction of up to 80%) if peanut was introduced between 
4 and 11 months of age [41].
Four trials investigating the timing of introduction to egg have been published 
[42–45]. Although none of the trials reported statistically significant differences in 
rates of egg allergy at 1 year of age in infants fed egg early compared with later 
introduction to egg, there was a trend toward lower rates of egg allergy in the groups 
of children introduced earlier to egg. Meta-analysis of the egg trials (including 1,915 
participants) showed evidence that egg introduction at 4 to 6 months was associated 
with a lower risk of egg allergy compared with later egg introduction (RR 0.56; 95% 
CI: 0.36, 0.87; p = 0.009) [39]. The authors concluded that there is moderate certainty 
that early introduction to egg, compared to delayed introduction to egg, will reduce 
the risk of IgE-mediated egg allergy by up to 30%. It was of concern, however, that 
many infants screened for these trials already had clinical egg allergy prior to the 
introduction of solid foods, indicating that, at least for egg allergy, sensitization and 
allergy development takes place very early in life, and there may need to be some 
level of caution for some subgroups of the population, such as babies with severe 
eczema, when introducing egg into the diet.
The EAT study [46] was the first randomized controlled trial to test the effect of 
early introduction to solid foods (from 3 months) compared with the UK guidelines 
on allergy development of exclusive breastfeeding until introduction to solid foods at 
6 months. The study found no significant difference in food allergy rates in the primary 
analysis (intention to treat analysis) between the early and standard introduction groups. 
There was no difference in breastfeeding rates at 12 months for individuals in the early 
introduction group, compared with the exclusive breastfeeding group, showing that ear-
lier introduction of allergenic foods did not have an impact on breastfeeding [47].
Meta-analysis of the LEAP and EAT studies showed evidence that peanut introduc-
tion at 4 to 11 months of age was associated with a lower risk of peanut allergy when 
compared to delayed introduction to peanut (RR 0.29; 95% CI: 0.11, 0.74; p = 0.009) [39].
UPDATED INFANT FEEDING GUIDELINES 
FOR PREVENTION OF FOOD ALLERGY
Ten international allergy and immunology bodies released a joint consensus com-
munication in 2015, highlighting new evidence from the LEAP study regarding the 
potential benefits of early, rather than delayed, peanut introduction during the period 
of complementary food introduction to prevent peanut allergy in high-risk infants [35]. 
This has led to the development of Australian Infant Feeding Consensus Guidelines 
[48] and an addendum to the USA National Institute of Health Feeding Guidelines for 
Reduction of Peanut Allergy [49] (Box 21.1). Whereas the Australian guidelines pro-
vide general information related to inclusion of allergens in the infant diet, the U.S. 
guidelines provide advice related to the inclusion of peanut into an infant’s diet strati-
fied by degree of risk, defined as the presence of eczema and/or egg allergy.
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CONCLUSION
The risk factors for developing childhood food allergy are complex and multifac-
torial, depending on a combination of genetic, nutritional, and environmental fac-
tors. Early life nutrition exposures and feeding practices play an important role, as 
does the maternal diet during pregnancy. The most recent public health guidelines 
for infant feeding to prevent food allergy promote exposure to common allergens, 
particularly peanut, in the first year of life. There are many other potential factors, 
BOX 21.1 INFANT FEEDING GUIDELINES 
FOR THE PREVENTION OF FOOD ALLERGY
Australian Infant Feeding Consensus Guidelines [37]:
• When your infant is ready, at around 6 months, but not before 4 months, 
start to introduce a variety of solid foods, starting with iron-rich 
foods, while continuing breastfeeding.
• All infants should be given allergenic solid foods including peanut 
butter, cooked egg, and dairy and wheat products in the first year of 
life. This includes infants at high risk of allergy.
• Hydrolyzed (partially and extensively) infant formula are not recom-
mended for prevention of allergic disease.
U.S. National Institute of Allergy and Infectious Diseases Guidelines, 2010 
[50]:
• Restriction of maternal diet during pregnancy or lactation is not 
recommended as a strategy for preventing the development of food 
allergy.
• It is recommended that all infants be exclusively breastfed until 4 to 
6 months of age (unless contraindicated for medical reasons).
• It is recommended that introduction of solid food should not be 
delayed beyond 4 to 6 months. Potentially allergenic foods may be 
introduced at this time as well.
U.S. National Institute of Allergy and Infectious Diseases Addendum 
Guidelines for Introduction to Peanut, 2017 [49]:
• Addendum guideline 1—For infants with severe eczema, egg allergy, 
or both:
• Strongly consider evaluation by specific peanut IgE measurement 
and/or skin prick testing and, if necessary, an oral food challenge. 
Based on test results, introduce peanut-containing foods.
• Earliest age of peanut introduction: 4 to 6 months.
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including the influence of a variety of foods and nutrients, and the role of processing 
on foods, that are yet to be explored.
There are concerns regarding the potential for increasing incidence of food 
allergy in low- to middle-income countries as they adopt more Westernized food 
and lifestyle patterns, and it is possible that early intervention may prevent this 
increase.
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INTRODUCTION
The field of epigenetics is currently garnering a great deal of interest, exploring 
how our very molecular makeup in the form of modifications to the genome can be 
altered by factors as diverse as aging, disease, nutrition, stress, alcohol, and exposure 
to pollutants. Epigenetic changes have previously been implicated in the etiology of 
a variety of diseases [1], notably in the development of certain cancers [2], and inher-
ited growth disorder syndromes [3], but the exploration of epigenetics’ role in fetal 
programming is still in its infancy. This chapter focuses on how nutritional expo-
sures during pregnancy may affect the infant epigenome, and the impact that such 
modifications may have on the long-term health of the child. We start by describing 
some keys concepts in epigenetics and discuss windows of epigenetic plasticity in 
the context of the developmental origins of health and disease (DOHaD) hypoth-
esis. We then review some of the key mechanisms by which nutrition can affect the 
epigenome, with a particular focus on the role of one-carbon metabolism. We finish 
by outlining some of the child health outcomes that have been linked to epigenetic 
CONTENTS
Introduction ............................................................................................................ 335
A Brief Primer on Epigenetics ............................................................................... 336
Time Points of Plasticity in the Epigenome ........................................................... 337
Which Parts of the Epigenome Are Most Susceptible to Environmental 
Influences?......................................................................................................... 338
Epigenetics and the Developmental Origins of Health and Disease ...................... 339
Maternal Nutrition Exposures and the Infant Epigenome .....................................340
One-Carbon Metabolism ...................................................................................340
Studies Investigating One-Carbon Metabolites and Epigenetics ...................... 343
Polyunsaturated Fatty Acids .............................................................................. 345
Body Mass Index ...............................................................................................346
Vitamin C and Demethylation ...........................................................................346




336 The Biology of the First 1,000 Days
dysregulation, and discuss possible next steps that need to be realized if insights 
into the basic science of epigenetics are to be translated into tangible public health 
benefits.
A BRIEF PRIMER ON EPIGENETICS
Epigenetic processes describe changes to the genome that can alter gene expression 
without changing the underlying DNA sequence [4]. These changes are mitotically 
heritable, and involve the interplay of DNA methylation, histone modifications, and 
RNA-based mechanisms (Figure 22.1). DNA methylation most commonly occurs 
at loci where a cytosine is found next to a guanine on a DNA strand along its linear 
sequence, hence termed cytosine-phosphate-guanine or CpG sites. It involves the 
covalent bonding of a methyl (CH3) group to the cytosine at the 5′ carbon position 
to form 5-methylcytosine. CpGs found in high densities are termed CpG islands. 
Roughly two-thirds of human genes contain CpG islands in their promoter regions, 
although repetitive elements in the genome can also contain many CpG sites [5]. 
CpGs are generally methylated in nonpromoter regions and unmethylated at pro-
moter regions. Methylation at CpG sites in promoters is usually associated with tran-
scriptional silencing, although not consistently [6]. Although methylation is the most 
studied chemical alteration to date, others modifications (e.g., hydroxymethylation) 
can occur at cytosine bases [7].
DNA methylation is catalyzed by DNA methyltransferases (DNMTs). Mammals 
have three types of DNMT. DNMT1 recognizes hemimethylated DNA; therefore, 















FIGURE 22.1 An overview of epigenetic mechanisms. (From Yan MS-C, Matouk CC, 
Marsden PA, J Appl Physiol 2010, 109:916–26.)
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maintain methylation patterns of the original template strand (maintenance methyla-
tion). DNMT3a and 3b appear to primarily methylate fully unmethylated CpG sites 
(de novo methylation) [7]. DNA methylation is important for a host of biological 
processes, including transcriptional silencing, X-chromosome inactivation, genomic 
imprinting, and the maintenance of cellular identity by enabling tissue-specific gene 
expression [8].
DNA is tightly woven around histone proteins, forming compact complexes of 
DNA and protein called nucleosomes. Nucleosomes, in turn, are packed together 
to form chromatin. Within the nucleosomes, the histone proteins are arranged in an 
eight-part formation, comprising two copies each of histones H2A, H2B, H3, and 
H4. Histone modifications involve various posttranslational chemical alterations to 
the amino acids of the histone tails, including acetylation of lysine, methylation of 
lysine and arginine, phosphorylation of serine and threonine, and the ubiquitination 
of lysine [9]. There are several mechanisms by which chemical modifications of 
CpG sites and histones are thought to influence gene expression. The methyl group 
from 5-methylcytosine may block transcription factors either directly or through the 
recruitment of a methyl-binding protein. Alternatively, the DNMT enzymes acting 
on CpG sites may be physically linked to other enzymes, which bring about histone 
methylation and deacetylation [10]. Although chromatin remodeling is intricately 
controlled, a simplified summary is that the hyperacetylation of histones and hypo-
methylation of histones and CpGs is associated with a euchromatin (open) configu-
ration, generally associated with facilitation of transcriptional activity. Conversely, 
hypoacetylation of histones and hypermethylation of histones and CpGs is associ-
ated with a heterochromatin (closed) structure and transcriptional repression [11].
Although noncoding RNAs do not code for proteins, many are functional and 
may affect gene expression [12]. Of those that influence gene expression, microRNAs 
(miRNAs) have been the most studied to date. These are short pieces (~22 nucleo-
tides) of RNA that affect the epigenome through binding to target mRNAs control-
ling the expression of key regulators such as DMNTs and histone deacetylases [13]. 
In turn, CpG methylation and histone modifications can influence the transcription 
of certain miRNA classes [14]. MicroRNAs may also affect gene expression directly 
by binding to messenger RNAs, repressing their translation [14].
TIME POINTS OF PLASTICITY IN THE EPIGENOME
Times of increased cell turnover, such as during fetal development and infancy, may 
be particularly susceptible both to epigenetic errors and to environmental influences 
[15]. In this chapter, we focus on DNA methylation and the in utero period, to include 
periconception, since this falls within the first 1,000 days window, and is also a 
period of exceptionally rapid cell differentiation and complex epigenetic remodeling 
(Figure 22.2). In the first 48 hours after fertilization, there is rapid (active) demeth-
ylation of the paternal genome and a slower (passive) demethylation of the mater-
nal genome [16]. Erasing the epigenetic marks in the zygote prior to the blastocyst 
stage is important to enable pluripotency of the developing cells [8]. Imprinted genes 
and some retrotransposons (defined later) are known to resist demethylation at this 
stage [17]. Remethylation then occurs in tissue-specific patterns after implantation, 
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during the process of gastrulation and differentiation of the somatic cells through-
out pregnancy. A second wave of demethylation occurs during the epigenetic repro-
gramming of primordial germ cells (PGCs) in the developing embryo at the point of 
their migration to the genital ridge [18]. Parental imprints are erased at this stage in 
preparation for the laying down of sex-specific imprints in the PGCs. Remethylation 
of sperm cells occurs before the birth of the child, and in oocytes over the duration 
of their maturation [18]. The periconceptional period is therefore one of huge dyna-
mism in the methylome, representing a window in which epigenetic errors could 
have significant consequences for the health of the child.
Which Parts of the ePigenome are most suscePtible 
to environmental influences?
There are some regions of the genome that demonstrate increased interindividual 
epigenetic variation, and may be particularly vulnerable to the impact of environ-
mental influences [19]. These include imprinted genes, metastable epialleles, and 
transposable elements. Imprinted genes show monoallelic expression, whereby only 
the maternally or paternally inherited allele is expressed [20]. If a gene is “paternally 
expressed” it means the expressed allele comes from the father and the maternal 
allele is imprinted (silenced). In regard to growth, paternally expressed genes tend 
to promote in utero growth, whereas maternally expressed genes restrict growth, 
and this forms the basis of the “parental conflict theory” [21]. Metastable epial-
leles (MEs) are genomic loci whose methylation state varies between individuals, 
but where variation is correlated across tissues originating from all germ layers in a 
single individual [22]. This indicates that the marks have been laid down in the first 
few days after conception before cell types start to specialize. MEs therefore provide 
a useful device to study the influence of the periconceptional environment, including 
maternal nutrition, on the offspring epigenome [23,24]. Transposable elements (TEs) 



































FIGURE 22.2 Epigenetic remodeling in embryogenesis. (From Perera F, Herbstman J, 
Reprod Toxicol 2011, 31:363–73.)
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mobile and can insert into new chromosomal locations throughout the genome. They 
are thought to make up more than half of the human genome [25]. TEs arise either 
through the use of RNA as an intermediate for transposition (DNA is transcribed to 
RNA, reverse transcribed to DNA, and then inserted by reverse transcriptase to form 
a retrotransposon), or through the complete DNA sequence being cut and pasted 
directly (forming DNA transposons, which are less common in the human genome). 
TEs are potentially functionally disruptive, for example, if transposed into a func-
tional gene or when increasing copy number, and this may be one reason why most 
are silenced epigenetically [26]. Some TEs are thought to be vulnerable to the influ-
ence of nutrition at key time points [27], and their variable methylation patterns have 
been shown to affect neighboring gene expression, most notably in the Agouti mouse 
experiments detailed later in this chapter.
EPIGENETICS AND THE DEVELOPMENTAL 
ORIGINS OF HEALTH AND DISEASE
The DOHaD hypothesis describes the idea that environmental insults experienced 
early in life can increase the risk of adverse health outcomes throughout the life 
course. DOHaD grew out of David Barker’s seminal work following a cohort born in 
Hertfordshire between 1911 and 1930. His early studies found an inverse relationship 
between birth weight and blood pressure at age 10, with a stronger association at age 
36 [28]. His findings soon expanded to identifying associations between low birth 
weight and adult-onset chronic disease [29], patterns that were also seen in different 
cohorts such as the Nurses’ Health Study I & II [30] and in Helsinki [31].
Although low birth weight provides a useful proxy for an adverse intrauterine 
environment, subsequent studies have attempted to pinpoint time points of vulner-
ability more precisely. Data from famine studies have been particularly useful in this 
respect. The Dutch Hunger Winter occurred toward the end of World War II, when 
the Western Netherlands was under German control from November 1944 to May 
1945. Nazi blockades cut off food and fuel, and the siege was coupled with a harsh and 
early winter. Calorie intake varied from 500 to 1,000 kcal per day, depending on the 
area and time period. An estimated 4.5 million people were affected, 20,000 of whom 
died [32]. Exposure to famine during pregnancy has been associated with a wide 
range of offspring phenotypes, from lower birth weight [33] to increased adult blood 
pressure [34], obesity [35], and risk of schizophrenia [36]. Furthermore the specific 
timing of famine exposure in utero appears to have different programming effects. 
For example, exposure in midgestation is associated with a doubling of the prevalence 
of obesity for men aged 18 to 19, yet exposure in the third trimester is associated with 
lower obesity [35]. Many of these associations are also found from records spanning 
the Chinese Great Leap Forward, where famine was particularly severe from 1959 
to 1961. For example, famine exposure in utero is associated with a doubled risk of 
schizophrenia in later life [37], as well as increased hyperglycemia at age 41 to 42, a 
trend that is exacerbated if an affluent diet was consumed later in life [38].
Although these two famine studies provide rich epidemiological evidence that 
nutritional exposures in early life are associated with later disease risk, they are 
unable to determine precise causal factors, for example, if the effects are driven by 
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depleted maternal energy, deficient levels of certain micronutrients, or a combination 
of both. The Pune Maternal Nutrition Study (PMNS) in the Maharashtra State of 
West-Central India sheds some light on more specific nutritional exposures that may 
be relevant for DOHaD mechanisms. PMNS is a prospective cohort of 797 women, 
followed pre- and throughout pregnancy, and their offspring. Higher maternal intake 
of green leafy vegetables, milk, and fruit, and higher erythrocyte folate concentra-
tions, were associated with larger size babies [39]. Higher maternal folate status at 
28 weeks gestation predicted higher offspring adiposity and insulin resistance at the 
age of 6, low maternal vitamin B12 status was associated with offspring insulin resis-
tance, and a combination of high maternal folate and low B12 produced the strongest 
associations [40].
Attention is now shifting to an investigation of the mechanisms that may mediate the 
observations above. In this respect, epigenetic modifications to the genome are emerg-
ing as a leading candidate that may, at least partially, explain some of the observations 
described in the DOHaD literature. For example, Heijmans et al. selected 60 individu-
als conceived during the Dutch Hunger Winter, and compared them with nonexposed 
siblings. Five CpG sites within IGF2 (a maternally imprinted gene controlling fetal 
growth) were less methylated in individuals exposed to famine at periconception, but 
there was no difference in methylation for individuals exposed to famine in late gesta-
tion [41]. Indeed, the most recent study from the same group confirms that exposure to 
famine in the first 10 weeks of gestation shows a greater signature in the adult blood 
methylome (58–59 years) compared to exposure later in gestation [42]. Whilst the exact 
mechanisms are so far unknown, one concept being debated is the “thrifty epigenome” 
hypothesis. This proposes that early life insults mold an epigenetic signature to pro-
gram a phenotype that is “adapted” to the intrauterine environment, which may be prob-
lematic if the environment into which the child is born then changes [43]. Under this 
hypothesis, malnutrition in pregnancy could program “thrifty” epigenotypes, designed 
to reduce metabolic rate and store energy in an attempt to adapt to a nutritionally poor 
environment, but may subsequently trigger symptoms of metabolic disease if the envi-
ronment changes to one of relative nutritional abundance.
MATERNAL NUTRITION EXPOSURES AND THE INFANT EPIGENOME
There are a variety of factors, both nutrition-related and otherwise, which may impact 
the infant epigenome in utero through maternal exposure (Figure 22.3). Of these 
exposures, particular attention has been paid to the role of one-carbon metabolites in 
the periconceptional period and during embryonic development [44]. In the follow-
ing section, we give an overview of one-carbon metabolism, and discuss evidence 
for the influence of one-carbon metabolites on the infant epigenome. We also briefly 
review other maternal nutrition exposures that have generated research in a human 
intergenerational setting: maternal BMI, polyunsaturated fatty acids, and vitamin C.
one-carbon metabolism
The one-carbon pool is composed of one-carbon units and the two main carriers that 
activate, transport, and transfer these units: tetrahydrofolate (THF) and S-adenosyl 
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methionine (SAM). One-carbon units are used as substrates for a whole range of 
intricate biochemical processes, including cellular biosynthesis, redox status regula-
tion, and genome maintenance through the regulation of nucleotide pools. However, 
it is their role in transmethylation reactions that is central to the notion of diet-
epigenome interplay, and this requires an understanding of how folate, methionine, 
homocysteine, transsulfuration, and transmethylation metabolic pathways interact 
(Figure 22.4).
S-adenosyl methionine (SAM) methylates a wide variety of acceptors in reactions 
catalyzed by methyl transferases. Over 200 methylation reactions are required for 
transcription, translation, protein localization, and signaling purposes [45], but it is 
the methylation of cytosine bases and amino acids on histone tails that play a role in 
epigenetics. The donation of SAM’s methyl group forms S-adenosyl homocysteine 
(SAH), which is further hydrolyzed to homocysteine (Hcy), where it is maintained in 
an equilibrium state that thermodynamically favors SAH over Hcy [46]. A buildup 
of Hcy results in an increase in SAH, which in turn impedes methylation reactions 
since SAH competes with SAM for the active site on methyl transferase enzymes 
[47]. The SAM:SAH ratio is therefore often used as a proxy indicator of methyla-
tion potential [48]. In order to maintain favorable methylation conditions, Hcy has 
to be removed from the system. One way in which this can happen is by accepting a 
methyl group to form methionine, which can then in turn be condensed with ATP to 
form SAM and continue the cycle. Hcy can also be removed through its irreversible 
degradation to cystathionine and cysteine in the transsulfuration pathway requiring 
vitamin B6.
The methylation of Hcy to methionine uses two distinct pathways. The major 
pathway is the vitamin B12-dependent reaction involving folate metabolic pathways. 




















FIGURE 22.3 Potential maternal factors impacting the fetal epigenome.
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The one-carbon units attach to the N5 or N10 position, or bridge the two. THF can be 
converted into N5,10-methylene-THF using a methyl group primarily from serine with 
vitamin B6 as a cofactor. N5,10-methylene-THF is either used in the thymidylate syn-
thase pathway for DNA synthesis and repair, interconverted to N5,10-methenyl-THF, 
N10-formyl-THF (used in purine synthesis) and formate (an important one-carbon 
donor) forms, or irreversibly reduced to N5-methyl tetrahydrofolate (methyl-THF) 
through the action of 5,10-methylene THF reductase (MTHFR) and vitamin B2 as a 
cofactor. It is methyl-THF that then provides the methyl group for the methylation of 
Hcy, and in the process regenerates THF. The alternative pathway for the methyla-
tion of Hcy, predominantly used in the liver and kidneys, uses the methyl group from 
betaine, a product formed through the oxidation of choline. This description and 
Figure 22.4 give a very simplified overview of the complex and interlinking meta-
bolic pathways involved, some of which occur with different enzymes in different 
cellular compartments [49]. However, this brief overview helps explain why deficien-
cies in the key methyl donors of choline, betaine, or folate, alongside deficiencies 
in vitamins B2, B6, and B12, which play essential coenzyme roles, may disrupt the 
metabolic pathways that are responsible for DNA methylation. Genetic variants in 
proteins coding for enzymes used in key one-carbon metabolic processes can also 
affect activity at critical nodes and alter the flow of metabolites [50].
studies investigating one-carbon metabolites and ePigenetics
Perhaps the most famous animal experiments demonstrating how epigenetic changes 
driven by maternal diet in pregnancy can dramatically alter phenotype in the off-
spring come from the agouti mouse. In one experiment, pregnant dams were fed a 
diet that varied in methyl donor content (folic acid, choline, betaine, and vitamin 
B12). Their isogenic pups showed variable methylation at an intracisternal A particle 
(IAP), a retrotransposon upstream of the agouti gene that is a metastable epiallele. 
The degree of methylation at this locus altered expression of the agouti gene, result-
ing in permanent phenotypic differences. The most obvious change was in fur color, 
but differences were also found in appetite, adiposity, and glucose tolerance, factors 
highly relevant to life-long chronic disease risk [19,27]. A similar experiment in a 
different strain of kinky-tailed mice showed that methyl donor content of the mater-
nal diet also altered methylation at an IAP on the Axin gene, producing pups with 
varying levels of tail kink [51].
Human studies exploring associations between individual one-carbon metabolites 
and epigenetic effects are few and far between, especially those involving an inter-
generational study design. Homocysteine and vitamin B6 are two examples that are 
described in human cross-sectional studies assessing immediate effects on health at 
one time point within a single generation. Hyperhomocysteinemia has been associated 
with hypomethylation in several studies [52] supporting the hypothesis that epigenetic 
mechanisms may play a partial role in observed associations between hyperhomocys-
teinemia and decreased cardiovascular health via inflammation, free radical forma-
tion, and atherogenesis [53]. Low vitamin B6 levels may decrease N5,10-methenyl-THF 
through reduced serine hydroxymethyltransferase (SHMT) activity (Figure 22.4), 
stressing the thymidylate synthase pathway for DNA repair and incorporating more 
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uracil into DNA. This reduces genome stability through increased chromosome breaks, 
which, in turn, have been associated with increased levels of global DNA hypomethyl-
ation alongside a putative increased risk of tumor development [54].
Of the human studies using an intergenerational design, folate, vitamin B12, and 
choline have been most frequently investigated. Due to its role in preventing neural 
tube defects and involvement in some cancer therapies, folic acid has been extensively 
reviewed [55]. Increased periconceptional folic acid consumption has been associated 
with increased methylation in infants at a differentially methylated region (DMR) of 
the IGF2 gene, although these associations have not been established consistently [56]. 
Additional studies have found that maternal folate levels in late pregnancy influence 
offspring methylation patterns in the imprinting control region of IGF2 [57] and also 
in the imprinting regulator ZFP57 [58]. Despite the timing of maternal folate mea-
surements, these findings support the importance of nutritional status around concep-
tion, since many DMRs appear to have their methylation pattern established prior to 
gastrulation [59]. There are fewer studies assessing the effect of maternal vitamin B12 
status on the infant epigenome. However, preliminary evidence suggests that mater-
nal vitamin B12 levels at first antenatal visit are inversely correlated with infant cord 
blood global methylation levels [60]. For choline, one intervention study investigated 
the effect of supplementing mothers in the third trimester with daily choline of 480 mg 
versus 930 mg [61]. Higher maternal choline intake was associated with increased 
methylation of CRH and NR3C1 promoter regions within fetal placental tissue.
The complex interlinking metabolic pathways involved in one-carbon metabo-
lism may be more appropriately investigated by exploring the joint effects of relevant 
methyl donors and coenzymes. Researchers in The Gambia have been exploring 
human diet–epigenome interactions by exploiting a natural experimental design, in 
which fluctuations in energy balance and maternal nutritional exposures display a 
distinct bimodal seasonal pattern. The Gambia experiences a rainy (“hungry”) sea-
son from July to September (Figure 22.5a), a planting season with increased energy 
expenditure, depleted food stores, and peaks of malarial and diarrheal diseases. 
The dry (“harvest”) season occurs from February to April (Figure 22.5b), when 
(a) (b)
FIGURE 22.5 The Gambian (a) rainy/“hungry” and (b) dry/harvest seasons in Keneba, 
West Kiang. (Photo by Andrew M. Prentice.)
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harvesting takes place, leading to improved food security. Despite overall house-
hold food stores being more replete in the dry season, the rainy season offers the 
increased availability of certain micronutrients made available from rain-fed green 
leafy vegetables. It has been known for several decades that Gambian children born 
during the rainy season are up to 10 times more likely to die prematurely in young 
adulthood than those born during the dry season [62]. However, the processes under-
lying these findings have yet to be fully delineated, and nutrition-related epigenetic 
regulation in early embryonic development is emerging as one plausible contributory 
mechanism. A recent study compared women conceiving in the peak of the dry and 
the peak of the rainy season [24]. Maternal periconceptional plasma concentrations 
of folate, vitamin B2, methionine, betaine, and the SAM:SAH and betaine:dimethyl 
glycine ratios were higher in the rainy season, and concentrations of vitamin B12, 
homocysteine, and SAH were lower. This suggested that the maternal metabolome 
during the rainy season contained higher concentrations of methyl donors and exhib-
ited a higher methylation potential than the dry season metabolome. Indeed, off-
spring of these rainy season conceptions had higher levels of CpG methylation at six 
MEs in peripheral blood monocytes compared to the offspring of those conceived in 
the dry season, with similar patterns in hair follicle DNA [24]. A subsequent study 
details the genome-wide search for MEs susceptible to the periconceptional environ-
ment using two independent approaches [63]. Both found VTRNA2-1 as their top hit, 
an imprinted gene that was also found to exhibit increased hypomethylation among 
Gambian offspring conceived in the dry season compared to the rainy season. Taken 
together, the results support the hypothesis that maternal nutrition during the peri-
conceptional period can impact the infant epigenome in humans and has triggered 
further research into the possible phenotypic consequences.
Polyunsaturated fatty acids
Several studies indicate that increased consumption of ω-3 PUFAs is associated with 
reduced homocysteine levels [64]. In the context of early life nutrition, maternal fatty 
acid intake influences infant fatty acid composition via placental transfer and breast 
milk, with maternal PUFA intake potentially affecting infant appetite control, neuroen-
docrine function, and metabolic programming [65]. Investigating whether one-carbon 
pathways and epigenetic mechanisms are involved is of increasing interest. In rodent 
models, providing a maternal diet with excess folic acid and restricted vitamin B12 
(designed to reflect the nutritional situation in much of rural India) is associated with 
increased maternal oxidative stress, lower level of offspring placental and brain doco-
sahexaenoic acid, and decreased placental global methylation [66]. However, maternal 
supplementation with PUFAs seems to partially ameliorate the disrupted one-carbon 
metabolism associated with this diet [67]. One potential mechanism is through PUFAs 
upregulating enzymes responsible for the methylation of homocysteine to methionine 
[68], which in theory could increase the SAM:SAH ratio and help overcome the impact 
of reduced MTHFR activity brought about by the restricted vitamin B12. An additional 
recent hypothesis describes how a decreased maternal PUFA intake may increase the 
availability of methyl groups for DNA methylation since there would be reduced PUFAs 
for phosphatidylcholine synthesis and therefore less demand for methyl groups for this 
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pathway. The disruption to the one-carbon pathways brought about by low PUFA lev-
els is thought to alter epigenetic programming of placental genes, increasing the risk of 
aberrant methylation in offspring and adverse pregnancy outcome [69]. Human evidence 
at the intergenerational level, however, is currently limited to a study by Lee et al. [70]. 
Here, mothers were given either 400 mg of ω-3 PUFA (n = 131) or placebo (n = 130) 
daily from approximately 18 weeks gestation to birth. Among mothers supplemented 
with PUFAs, there was increased global methylation (measured at LINE-1 repetitive ele-
ments) in offspring of mothers who smoked (n = 26 case, 26 control) [71], and increased 
offspring IGF2 promoter 3 methylation in preterm infants (n = 16 case, 20 control) [70].
body mass index
Maternal body mass index (BMI) shows some association with infant epigenetic pat-
terns [72]. However, it can be difficult to define exactly what BMI represents as an 
exposure, since it does not always correlate well with body composition [73] and is a 
proxy for a wide range of potential metabolic disorders [74]. In an intergenerational 
setting, both maternal underweight and overweight is associated with epigenetic pat-
terns in infant cord blood [72]. The mechanism by which BMI influences epigenetics 
is so far unknown. Although SAM has been shown to be independently, positively 
associated with fat mass in older adults, alongside a higher rate of converting methio-
nine into SAM in obese individuals, the absence of a rise in the SAM:SAH ratio 
means conclusions are hard to draw [75]. Paternal BMI may also be a relevant expo-
sure to consider, since neonates born to obese fathers in a U.S. study showed hypo-
methylation at some loci within imprinted genes (MEST, PEG3, NNAT), independent 
of maternal obesity [76].
vitamin c and demethylation
As outlined earlier, the periconceptional period is a time of widespread remodel-
ing of the offspring epigenome, including rapid erasure (demethylation) of paren-
tal epigenetic marks and subsequent remethylation (Figure 22.2). In demethylation, 
5-methylcytosine (5mC) can be sequentially oxidized to different states by ten-
eleven translocation (TET) dioxygenases that use vitamin C (ascorbate) as a cofac-
tor [77]. In vitro studies, for example, indicate that adding vitamin C to mouse or 
human embryonic stem cells increases activity of TET enzymes, with active demeth-
ylation seen in the germline and associated gene expression changes [78]. Vitamin C is 
therefore  an  important factor to consider in epigenetic processes during early 
embryogenesis, although in vivo studies will be required to explore whether vitamin C 
deficiency could play a role in aberrant demethylation.
In this section we have identified some of the key ways that maternal nutrition 
might influence the offspring epigenome. Other exposures, both nutrition-related 
and otherwise, may also be involved. These include maternal stress [79], toxin expo-
sure [80], maternal hyperglycemia [81], the microbiome [82], dietary polyphenols 
[83], vitamin D [84], vitamin A [85], and infection [86]. As evidence builds, it will 
be necessary to explore how these multiple exposures work together to influence the 
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infant epigenome and to more clearly define the potential consequences for human 
health. It is to the latter point that we now turn.
PHENOTYPES ASSOCIATED WITH THE IMPACT OF MATERNAL 
EXPOSURES ON THE INFANT EPIGENOME
Most population-based epigenetic studies to date have been limited to exploring 
either associations between maternal exposures and infant epigenetic patterns, or 
between infant epigenetic patterns and later phenotypes. Evidence linking maternal 
exposure to infant phenotypes with epigenetics as a mediating mechanism is scarce.
The first category of associations, linking maternal exposures to infant epigen-
etic patterns, was reviewed earlier. A number of studies linking infant epigenetic 
patterns with later phenotypes have focused on imprinted genes as candidate loci, 
due to their role in fetal growth [17] and a range of diseases [3,20]. It has been sug-
gested that imprinted genes may be more vulnerable to the effects of epigenetic 
dysregulation, since epigenetic mechanisms underpin their monoallelic expression. 
On chromosome region 11p15.5 there are two imprinting control regions (ICRs) of 
interest: the H19/IGF2 domain (ICR1) and the KCNQ1/CDKN1C domain (ICR2). 
Hypomethylation of ICR1 and hypermethylation of ICR2 are associated with 
Russell-Silver syndrome (RSS; an undergrowth disorder), whereas hypermethylation 
of ICR1 and hypomethylation of ICR2 are associated with Beckwith-Wiedemann 
syndrome (BWS; an overgrowth disorder) [3]. In addition to the aberrant methylation 
found at ICR1 and ICR2, some studies suggest patients with RSS and BWS show 
methylation defects at multiple gene loci [87]. Evidence for associations between 
growth-related phenotypes (other than RSS and BWS) and methylation patterns at 
several imprinted gene loci is slowly accumulating. Other phenotypes investigated to 
date include intrauterine growth restriction [88], small for gestational age [89], birth 
weight [90] and later adiposity [91].
Several studies describe associations between maternal one-carbon metabolites 
and infant growth-related outcomes, for example, vitamin B12 [92], folate [93], and 
homocysteine [94]. What then is the evidence that these associations are mediated 
through epigenetic mechanisms? Preliminary evidence from the Dutch Hunger 
Winter, as described earlier, suggests that exposure to famine in pregnancy, particu-
larly around conception, is associated with differential methylation in genes linked to 
growth, and development [41], and that famine exposure is also related to a wide range 
of offspring cognitive health and cardiometabolic risk factors six decades later [95]. 
It is, however, difficult to establish the direction of causality, since disease states can 
also influence the epigenome [96]. This issue of reverse causality is particularly per-
tinent to studies using a retrospective cohort design. Stronger evidence comes from 
prospective cohorts, such as the Newborn Epigenetics Study (NEST) in the United 
States. Hoyo et al. describe a positive association between maternal folate levels in 
the first trimester and birth weight [90]. Increased maternal folate was also associated 
with increased methylation at MEG3, PLAGL1, and PEG3 in infant cord blood, and 
decreased methylation at IGF2. Five differentially methylated sites were associated 
with birth weight, and it was speculated that the association seen between maternal 
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folate and birth weight could be mediated by differential methylation at MEG3, H19, 
and PLAGL1. In a more recent study from the same cohort, McCullough et al. found 
maternal plasma concentrations of homocysteine in the first trimester were inversely 
associated with birth weight, particularly in males [97]. Children born to mothers 
with the highest quartile of plasma B12 showed lower weight gain between birth and 
3 years. However, only maternal vitamin B6 was positively associated with cord meth-
ylation at a DMR from MEG3. A further example comes from Godfrey et al., who 
found that higher methylation of RXRA and eNOS in umbilical cord tissue was asso-
ciated with offspring adiposity at age 9, and that higher RXRA methylation was also 
associated with lower maternal carbohydrate intake in early pregnancy [91].
Given the scarcity of existing data and the many potential confounders in cohort 
studies, there is not yet any clear consensus on the extent to which epigenetics is 
involved in the etiology of suboptimal growth, particularly in the more widely inves-
tigated phenotypes of IUGR and SGA [98]. Similarly, although prepregnancy folic 
acid supplementation is known to prevent neural tube defects, the extent to which 
this protection is epigenetically mediated is not yet clear [56]. In the next few years, a 
number of prospective cohort studies should shed further light on the links between 
early life exposures and phenotypes, mediated by epigenetic mechanisms. In the 
meantime, we can use the literature from the range of studies described earlier to 
speculate that periconceptional nutritional insults may influence epigenetic mecha-
nisms in the infant, causing disruption at multiple loci and potentially leading to a 
broad spectrum of phenotypic consequences in later life.
NEXT STEPS
The field of epigenetic epidemiology is in its infancy. Future challenges include the 
need to consider a much larger number of candidate genetic regions (a challenge that 
will be met as rapid improvements in technology facilitate epigenome-wide associa-
tion studies with ever increasing genomic resolution); the need to focus on tissue 
types most appropriate to the phenotype of interest; and the need to integrate data 
on genetic variation, gene expression, and other epigenetic mechanisms such as his-
tone modifications and miRNAs. Investigations will also need to assess the extent 
to which postnatal exposures may interact with periconceptional effects. Finally, 
although we focus on the maternal periconceptional environment in this chapter, 
there is growing interest in the potential for paternal exposures to affect the infant 
epigenome transgenerationally via sperm methylation profiles [99]. Despite limited 
human evidence to date, this is an area of great potential public heath relevance.
Once disrupted epigenetic patterns can be better mapped onto phenotypes, the signifi-
cance for public health impact becomes more tangible. Can we design and test nutritional 
interventions to “correct” a suboptimal maternal metabolome, hence reducing patterns 
of aberrant methylation in the infant epigenome and reducing the burden of ill health? 
Despite the current complexities of disentangling the web of multiple exposures influenc-
ing the infant epigenome, as technology advances, collaborations grow, and knowledge 
is gained, the field of nutritional epigenetics has the potential to impact the health of 
children not only within the first 1,000 days but also across multiple generations.
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INTRODUCTION
The first 1,000 days of life is a critical window of development, determining suscepti-
bility to adult obesity and cardiometabolic health [1,2]. Environmental insults during 
this rapid development phase may result in irreversible adverse outcomes. Animal 
and human studies provide evidence for the fetal origins of adult noncommunicable 
disease hypothesis [3–5]. This hypothesis suggests that intrauterine exposures affect 
the fetus’s development during sensitive periods, and increases the risk of noncom-
municable diseases in adult life [3–5]. Systematic reviews confirm evidence of inverse 
epidemiological associations between birth weight and later development of hyper-
tension [2] and coronary heart disease [6]. The fetal origins of disease hypothesis has 
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been challenged as a possible statistical artifact [7], but has been confirmed by later 
studies with high follow-up rates and adjustment for confounders [8,9].
Early animal studies of severe undernutrition [10] and later human studies both 
showed a relation between fetal stressors and subsequent development of chronic dis-
eases [3,4]. Natural experiments such as the Dutch famine cohort showed that pre-
natal undernutrition was associated with low birth weight, followed by adult obesity 
and glucose intolerance when adults were raised outside of a famine environment 
[11]. Birth weights and cardiovascular death rates studied in men born during 1911 to 
1930 in the United Kingdom showed that low birth weight was associated with hyper-
tension and ischemic heart disease mortality [3]. In adults born in Finland between 
1924 and 1933, and who were followed up in 1971, the incidence of type 2 diabetes 
increased with decreasing birth size and placental weight [12]. Based on these early 
studies, small birth size was regarded as a marker of poor fetal nutrition and intrauter-
ine growth restriction, independent of gestational age. Fetal programming and low 
fetal growth rates increased susceptibility to adult diseases [4], and promoters of pre- 
and postnatal growth were regarded as protective against ischemic heart disease [3].
THE CRITICAL PERIOD DETERMINING SUSCEPTIBILITY 
TO ADULT CHRONIC DISEASE: FETAL OR POSTNATAL LIFE?
Fetal nutrition is a more important programming stimulus affecting fetal growth 
than birth weight [13]. Birth weight may be an intermediate, rather than a primary 
indicator of the relationship between fetal growth and adult disease. Low birth 
weight infants who became overweight later in life were at an increased risk of sev-
eral adverse events: insulin resistance at the age of 8 years [14], higher blood pres-
sure at the age of 50 [15], and a higher incidence of coronary heart disease during 
late adulthood [6,16]. Thus, childhood or adult adiposity may modify the association 
between birth weight and later cardiovascular outcomes, indicating that catch-up 
growth can modify early intrauterine stressors [14,15,17].
Many early studies reported birth weight together with weight later in life. It is 
difficult to distinguish if later cardiovascular outcomes are triggered by either birth 
weight or later overweight, or an interaction between fetal and postnatal exposures [7]. 
Although later studies of multiple postnatal growth measures suggest that both periods 
are important, it is not clear whether decreased postnatal growth or catch-up growth 
is harmful [1]. In a Finnish cohort, both low birth weight and accelerated growth from 
0 to 7 years were associated with adult hypertension [18], whereas combined low birth 
weight followed by suboptimal infant growth gave rise to the highest risk of adult 
ischemic heart disease [19]. These results indicate a need for more serial growth data 
to determine the contribution of growth periods to future health outcomes [1]. Three 
possible explanations for the association between early growth and later cardiovascular 
outcomes emerge from recent studies, namely, (1) fast postnatal growth itself increases 
risk of later obesity and cardiovascular disease [20,21]; (2) factors related to fetal growth 
restriction increase risk of cardiovascular disease [15]; and (3) an interaction between 
the two increases risk [22]. Studies of the fetal origins of adult disease should include 
the fetal period and repeated growth measures through the life course. A simplified 
diagrammatic presentation of developmental programming is shown in Figure 23.1.
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A clear definition of catch-up growth is needed to differentiate between the effects 
of growth periods on adult disease. Catch-up growth is defined as a growth trajec-
tory above the normal limits for age after transient growth inhibition, and refers to 
a beneficial realignment to genetic potential after growth faltering and not excessive 
infant weight gain [1]. This interpretation is important, since associations of birth 
weight with later outcomes span the entire birth weight spectrum, not just the low-
birth-weight end [1].
CRITICISMS OF THE FETAL ORIGINS OF DISEASE HYPOTHESIS
Epidemiologists from a variety of fields have challenged the fetal origins of disease 
hypothesis. In the field of the fetal origins of adult disease, perinatal epidemiologists 
regard increasing birth weight as beneficial, while developmental origins epidemi-
ologists regard low birth weight as less important and higher birth weight as not 
necessarily beneficial [1,2].
Lucas et al. [7] criticized the statistical adjustment for current body size widely 
applied in longitudinal studies of the fetal origins of disease, and stated that the sta-
tistical interpretation of some growth results was incorrect. They stated that failure 
to distinguish between the prenatal and postnatal factors affecting adult disease is 
problematic. Further, they argued that postnatal catch-up growth, rather than fetal 
programming, may primarily affect later health [7].
Other critics maintain that epidemiological studies disregard the role of genet-
ics, because a gene mutation may be associated with low birth weight and offspring 
insulin resistance, resulting in type 2 diabetes and hypertension, both phenotypes of 
the same insulin-resistant genotype [23]. Monogenic diseases may impair the sens-
ing of maternal hyperglycemia, decreasing insulin secretion or increasing insulin 
resistance, and impairing fetal growth. Polygenic influences resulting in fetal insulin 
resistance may result in lower birth weight. Genetic insulin resistance may cause 
abnormal perinatal vascular development, and explain increased adulthood risk of 
hypertension and vascular disease. However, it is likely that both genetic and envi-
ronmental factors may predispose the infant to type 2 diabetes and hypertension [23].
EPIDEMIOLOGICAL CHALLENGES IN STUDYING 
THE FETAL ORIGINS OF ADULT CHRONIC DISEASE
Adjustment for Adiposity At the endpoint
Low birth weight is not associated with adult chronic disease risk in all studies. In 
some, this inverse relationship was only present after adjustment for endpoint adi-
posity, since adult adiposity is positively associated with adult chronic disease [15]. 
In studies of the relationship between birth weight and type 2 diabetes, unadjusted 
for endpoint body mass index (BMI), the relationship is J-shaped, with increased 
risk at both ends of the birth weight spectrum [9]. The underlying mechanism at 
the high birth weight end may be that maternal gestational diabetes is causing obe-
sity and diabetes risk in offspring. Adjustment for endpoint BMI reveals an inverse 
and linear association across the birth weight spectrum, reflecting reduced risk at 
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higher birth weights, a pattern attributed to a “thrifty phenotype” [4]. This hypoth-
esis proposes early undernutrition, programming permanent dysregulation of glu-
cose homeostasis, and development of type 2 diabetes. Reduced insulin secretion 
and insulin resistance, combined with obesity, aging, and physical inactivity, are 
the most important determinants of type 2 diabetes, confirmed by epidemiological 
evidence [14]. The relationship between poor fetal growth and insulin secretion and 
possible gene and environment interactions is less clear [1]. More research is neces-
sary to better understand the contributions of maternal hyperglycemia and postnatal 
growth on offspring type 2 diabetes risk later in life.
sociAl And economic fActors As confounders or explAnAtory VAriAbles
Cardiovascular diseases are related to both low birth weight and poor adulthood 
socioeconomic circumstances. Controlling for offspring socioeconomic factors in 
adulthood is necessary to determine prenatal influences, particularly when social 
class changes across generations [2]. Poor maternal diet and strenuous physical work 
due to low socioeconomic circumstances may directly affect maternal energy and 
nutrient reserves, and have adverse effects on fetal growth and birth weight [24].
fetAl Growth And size At birth Are two different indicAtors
As birth weight is only one aspect of fetal growth, stronger associations may exist 
between birth length, or lean and fat masses and later outcomes, possibly due to a 
trimester-specific restriction of fetal growth [3]. Measures of fetal size at birth are 
prone to measurement error [25]; ultrasound measures of fetal growth are therefore 
more useful. The contribution of gestational age on adult outcomes is unclear, and 
determinants of preterm birth and fetal growth may differ [13,25]. Birth weight is 
the result of many determinants, some possibly unrelated to susceptibility to adult 
disease. Conversely, some prenatal determinants of adult outcomes may be unrelated 
to fetal growth [25].
BIOLOGICAL MECHANISMS OF THE FETAL ORIGINS OF ADULT 
OBESITY, CARDIOVASCULAR DISEASE, AND TYPE 2 DIABETES
mAternAl nutrition durinG preGnAncy
In animal models, maternal undernutrition during pregnancy had lasting effects on 
offspring metabolism, growth, and disease [10]. Pregnant rats on low-protein diets 
delivered offspring of lower birth weight that went on to exhibit elevated blood pres-
sure and glucose intolerance in adult life [5]. In humans, the nutritional needs of a 
young, physically immature, undernourished mother compete with those of the fetus, 
while the placenta also competes with both for energy and protein sources [26].
Except at extremes of intake, maternal energy and macronutrient intake have rela-
tively little impact on birth weight [25], but may be important in circumstances of 
prolonged negative energy balance [24]. In an animal study, insufficient glucose sup-
ply to the fetus was associated with reduced insulin and insulin-like growth factor-1 
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(IGF-1) concentrations, restricting fetal growth [27]. Infants of mothers with type 2 
diabetes and gestational diabetes tend to have high birth weights, due to increased 
glucose availability [28]. Figure 23.2 presents the intergenerational insulin resistance 
cycle in an environment of undernutrition and overnutrition, or a transition from 
undernutrition to overnutrition and the resultant fetal programming of insulin resis-
tance [22].
Subsistence farming populations from developing countries experience  seasonal 
energy shortages, due to variations in food availability and energy expenditure 
related to food production. The impact of seasonal maternal diet and physical 
activity on neonatal size was examined in a prospective study in rural India [24]. 
Maternal energy and protein intakes were around 70% of recommended dietary 
allowances, and showed significant seasonal variation, with peak values during har-
vest time. Mean birth weight and length, adjusted for prepregnancy weight, parity, 
gestation, and offspring sex, was highest after longer exposure to harvest time during 
pregnancy and lowest after longer exposure to the lean season. Regression analy-
sis showed that maternal energy intake at 18 weeks of gestation had a significant 
positive association with birth weight and length, whereas maternal physical activity 
at 28 weeks was negatively associated with birth weight. Higher maternal energy 
intakes, coupled with lower physical activity in late gestation, were associated with 
higher birth weight. These observations indicate that complete exposure to harvest 
time in late gestation could increase birth weight by 90 g, increasing further by low-
ering excessive maternal physical activity during harvest time [24,29].
Apart from the known roles of n-3 fatty acids in reducing the incidence of pre-
term birth [30], and folate deficiency in causing neural tube defects, little is known 










































FIGURE 23.2 Fetal programming. The intergenerational insulin resistance cycle in an 
environment of undernutrition and overnutrition, or a transition from undernutrition to over-
nutrition. (Adapted from Tomar AS, Tallapragada DS, Nongmaithem SS et al., Curr Obes 
Rep 2015, 4(4):418–28.)
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relationship between maternal body size and circulating fuels, respectively, and neo-
natal size, was studied in the Pune Maternal Nutrition Study (1993–1996) [29]. The 
mothers were Indian, young, short and thin, and mostly vegetarian. At between 18 
and 28 weeks gestation, fasting glucose concentrations remained stable, whereas 
total cholesterol and triglyceride concentrations increased and HDL-cholesterol con-
centrations decreased. The mean birth weight of the offspring was relatively low, 
at 2,666 g. Total cholesterol and triglycerides at both 18 and 28 weeks, and plasma 
glucose only at 28 weeks, were positively associated with birth size. The results did 
not change when preterm deliveries were also considered, suggesting an influence of 
maternal lipids on neonatal size in addition to the well-established effect of glucose 
during late pregnancy.
Folate is a methyl donor in the placenta for amino acid conversion and the genera-
tion of intermediates essential for cell division. Disordered one-carbon metabolism 
during early fetal development may increase later metabolic risk [31]. The reproduc-
ibility of the associations between maternal homocysteine concentrations and fetal 
growth found in the Pune birth cohort were explored in an observational study in 
Mysore, India. In this latter study, plasma vitamin B12, folate, and homocysteine 
concentrations were measured at around 30 weeks gestation in the mothers, and the 
children’s glucose and insulin concentrations, as well as neonatal anthropometry 
were measured at three ages: 5, 9.5, and 13.5 years [31]. Maternal homocysteine 
concentrations were inversely associated with all neonatal anthropometric measure-
ments, and positively associated with glucose concentrations in the children at 5 and 
9.5 years of age. Maternal serum folate concentrations, but not maternal vitamin B12, 
were positively associated with insulin resistance in the children at 9.5 and 13.5 years 
of age [31].
In rural Gambia, cycles of rainy and dry seasons and a dependence on subsis-
tence farming lead to annual variations in dietary intakes, compounded by the sea-
sonal cycles of energy expenditure [32]. These cycles of nutrient availability and 
energy expenditure in mothers may affect fetal growth and development, offering 
a natural experiment to explore mechanisms by which early nutrient availability 
affects long-term pregnancy outcomes. In a prospective study of mothers’ peri-
conceptional dietary intakes and the plasma concentrations of key methyl-donor 
pathway substrates, 2,040 women were followed until pregnancy. Conception at 
the peak rainy (“hungry”) season or the peak dry (“harvest”) season, and pre-
dicted biomarker concentrations at conception were modeled. The offspring of 
rainy season conceptions, when mothers depended more on fresh green plant 
foods from the field, which are high in folate, had significantly higher levels of 
DNA methylation at the six remaining metastable epialleles (MEs) in periph-
eral blood lymphocytes (PBL). During the harvest season, when pregnant women 
had unlimited access to dry cereal foods and lower physical activity, there were 
increased periconceptional serum cysteine and homocysteine concentrations, pre-
dicting decreased systemic infant DNA methylation. Maternal serum riboflavin 
concentrations predicted increased ME methylation, while increased maternal 
BMI predicted decreased systemic infant DNA methylation. The consequences of 
these variations in methylation are unknown, but the possible implications of epi-
genetic variation at MEs induced by differences in maternal micronutrient status 
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and BMI at conception may have important implications for noncommunicable 
disease risk later in life [32].
The effects of periconceptional multiple micronutrient supplementation on pla-
cental function in later pregnancy were assessed in a double-blind randomized 
placebo-controlled trial [33]. Primary outcomes were midgestational uteroplacental 
vascular endothelial function and placental active transport capacity. Uteroplacental 
vascular endothelial function was not significantly different between the two groups, 
but placental active transport capacity improved marginally, indicating a possible 
benefit of periconceptional micronutrient supplementation [33].
plAcentA size And function
Placenta size increases until late in gestation, supporting ongoing fetal growth. 
Placental vascularization during early pregnancy determines later placental nutri-
ent transfer capacity and, ultimately, fetal growth [13]. Maternal undernutrition 
restricts placenta development, compromising nutrient and oxygen delivery to 
the fetus in both term and preterm infants. Larger placentas were associated with 
higher prepregnancy BMI, excessive gestational weight gain (GWG), and gesta-
tional diabetes mellitus (GDM) among the mothers. Low placental weight was 
associated with lower birth weight-for-gestational-age z-score in both term and 
preterm infants [28]. The placenta has endocrine as well as metabolic and trans-
fer functions, and is important to understanding associations of fetal growth with 
adult health [13].
Women with gestational diabetes transfer excess glucose across the placenta, 
which contributes to fetal overgrowth. Placental size may be an important media-
tor between pre-pregnancy BMI, GWG, gestational diabetes, and increased fetal 
growth. A study showed that excessive GWG and GDM may represent a state of 
intrauterine overnutrition, with abundant placental nutrient supply, causing macro-
somia [28]. Prepregnancy obesity and excessive GWG were positively associated 
with birth weight-for-gestational-age z-score at birth only among term births [28]. 
Other adverse risk factors may contribute to preterm birth and also impact fetal 
growth. Intrauterine inflammation may induce preterm birth, as well as poor fetal 
growth, which may in turn influence placental growth [13]. Placental weight, thick-
ness, width, length, and cord placement position may predict neonatal outcomes. 
Placental size may also increase due to remodeling from a prior injury. Therefore 
placenta weight alone may not reflect placental function as a determinant of fetal 
growth [28].
Evidence suggests that the placenta plays a key role in fetal programming of car-
diometabolic diseases [13,34]. The oxygen and nutrients that support fetal growth 
rely on the entire nutrient supply line, from maternal diet and body size to uterine 
perfusion, placental function, and fetal metabolism. Interruptions of this line at any 
point could result in programming the fetus for future risk of cardiovascular disease 
[34]. Progesterone and placental lactogen promote maternal glucose delivery, IGF-1 
promotes fetal growth, and 11 β-hydroxy-steroid dehydrogenase type 2 inactivates 
glucocorticoids. These endocrine functions may play a role in fetal programming of 
future metabolic diseases [34].
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A possible mechanism to explain the development of hypertension in later life is that 
pressure in the fetal circulation might be raised as a method of maintaining placental 
perfusion when the mother is undernourished [35]. The raised blood pressure may 
persist after birth. Alternatively, intrauterine growth retardation may trigger acceler-
ated postnatal growth, accompanied by an accelerated increase in blood pressure [35].
Certain periods of fetal life may be critical for organ development. One proposed 
underlying causal pathway for the fetal origins of adult chronic disease is based on 
the hypothesis that a congenital nephron deficit underlies predisposition to hyperten-
sion in adult life [36].
mAternAl metAbolism durinG preGnAncy
Maternal metabolism may influence fetal metabolic profiles directly through the pla-
centa, or indirectly via influences of maternal hormones and/or placental metabolism. 
In utero exposures may include maternal behaviors, such as smoking and diet, or 
maternal metabolism, which may be associated with obesity or diabetes. The rela-
tionship of maternal midpregnancy corticotropin-releasing hormone (CRH) levels 
and offspring levels of adiponectin and leptin at the age of 3 years was studied in 
a prospective prebirth cohort study in the United States [37]. Maternal CRH blood 
levels were positively associated with levels of adiponectin, but not with leptin levels 
at age 3 years. There was no association between maternal CRH and birth weight for 
gestational age. The mechanism underlying the positive association between maternal 
levels of CRH and offspring adiponectin is unclear, but higher adiponectin may not be 
associated with a healthy metabolic profile in young children. The authors speculated 
that the increase in adiponectin was a compensatory response to increased insulin 
resistance in those children whose mothers had high midpregnancy CRH [37].
There is evidence from animal studies that the gut microbiome influences the 
diet-related metabolic profile [38]. Further research is necessary to explore metabo-
lite profiles associated with gut microbiota in human populations during pregnancy. 
The gut microbiome is explored in detail in Chapter 19 of this book.
smokinG And pollution durinG preGnAncy
The deleterious effects of pollution and maternal smoking during pregnancy are well-
known examples of prenatal exposures affecting fetal growth, but with unknown 
long-term health effects. A systematic review of 14 observational studies (n = 84,563 
children) examining the association between maternal prenatal cigarette smoking 
and overweight offspring showed that offspring of smokers were at increased risk for 
being overweight at ages 3 to 33 years, compared with children of nonsmokers [38]. 
Differences between smokers and nonsmokers could not be explained by sociodemo-
graphic or behavioral confounders [39].
Genetic And epiGenetic fActors
Inherited fetal gene expression potentially underlies susceptibility to disease, but 
the maternal genome also affects the fetal environment and may affect fetal gene 
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expression. The association between maternal hypertension, low birth weight, and 
hypertension in the offspring could be partly of genetic origin [13]. However, the 
subsequent pattern of development appears to be responsive to environmental influ-
ences. Developmental plasticity evolved to match an organism to its environment, but 
a mismatch between the resultant phenotype and the current environment increases 
cardiovascular risk [40]. Epigenetic processes appear to be key mechanisms in the 
developmental origins of chronic noncommunicable disease [40].
A study of undernutrition over 50 generations in a rat model showed low birth-
weight, high visceral adiposity, and insulin resistance (using hyperinsulinemic-
euglycemic clamps) in undernourished rats, compared to age-/sex-matched control 
rats [41]. Undernourished rats also had higher serum insulin, homocysteine, endo-
toxin, and leptin levels, but lower adiponectin, vitamin B12, and folate levels. The 
undernourished rats had an eightfold increased susceptibility to Streptozotocin-
induced diabetes compared to controls. These metabolic abnormalities could not 
be reversed after two generations of nutrient rehabilitation. Altered epigenetic sig-
natures in the insulin-2 gene promoter region of undernourished rats were also not 
reversed by nutrition, and may contribute to the persistent adverse metabolic profiles 
in similar multigenerational undernourished human populations [41].
In the Pune Maternal Nutrition Study and the Parthenon Cohort Study in Mysore, 
India (discussed earlier), evidence of causality within a Mendelian randomization 
framework of the association between maternal total homocysteine and offspring 
birth weight was studied [42]. This was assessed using a methylenetetrahydrofolate 
reductase (MTHFR) gene variant rs1801133 by instrumental variable and triangula-
tion analysis, separately, and meta-analysis. Offspring birth weight was inversely 
related to maternal homocysteine concentration adjusted for gestational age and 
offspring sex in these studies and in the meta-analysis. Maternal risk genotype at 
rs1801133 predicted higher homocysteine concentration and lower birth weight, 
adjusted for gestational age, offspring sex, and rs1801133 genotype. Instrumental 
variable and triangulation analysis supported the causal association between mater-
nal homocysteine concentration and offspring birth weight. These findings suggest 
a causal role for maternal homocysteine metabolism in fetal growth and support 
interventions to reduce maternal homocysteine concentrations [31,42].
A quasi-experimental study was performed to evaluate the impact of the Dutch fam-
ine of 1944–1945 during specific periods of pregnancy, or any time in gestation, on 
genome-wide DNA methylation levels of offspring at 59 years [43]. They compared 
individuals with prenatal famine exposure and time or sibling controls without prena-
tal famine exposure. They also studied the impact of shorter pre- and postconception 
exposure periods. Famine exposure during gestation weeks 1 to 10, but not during later 
gestation, was associated with increased DNA methylation of four specific dinucleo-
tides. Exposure during any time in gestation resulted in increased methylation of two 
specific dinucleotides, while exposure around conception was associated with methyla-
tion of only one dinucleotide. This dinucleotide, cg23989336, is involved in the deter-
mination of body size in knockout mice studies [44]. All dinucleotides identified in this 
study were linked to genes involved in growth, development, and lipid metabolism. The 
authors identified early gestation, but not mid or late gestation, as a critical time period 
for DNA methylation changes affecting body size after prenatal famine exposure [43].
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FUTURE STUDIES
Animal studies of fetal growth will continue to contribute new knowledge and are 
useful to study nutrient and oxygen delivery, as well as processes altering these 
pathways. Serial ultrasound measures to measure human fetal growth parameters 
throughout pregnancy will also contribute useful information due to potential issues 
with statistical growth trajectory models. Placental morphological pathology, as well 
as using specimens of placenta, maternal prenatal blood, and umbilical cord blood 
may be applied to measure markers of altered blood flow, endocrine and transport 
characteristics, or activity of specific enzymes related to later noncommunicable dis-
ease risk [34].
The fetal origins of disease theory arose from historical cohort studies, namely, 
the Dutch famine cohort [11]. A collaboration of five birth cohorts from low and 
middle-income countries (Brazil, Guatemala, India, Philippines, and South Africa) 
has made it possible to analyze pooled longitudinal data from Consortium for Health 
Orientated Research in Transitioning Societies (COHORTS) [45]. More than 22,000 
mothers were enrolled before or during pregnancy and almost 20,000 children are 
being followed up; analyses will be adjusted for maternal variables and breastfeed-
ing duration [45]. New cohort studies of preconceptional and pregnant women have 
been and are continuing to be planned to overcome the limitations of the earlier 
studies and to explore mechanisms of pathways gleaned from these early studies 
[21,39]. These studies will take decades for adult disease outcomes to occur. The 
associations between maternal exposures and offspring health in adolescence are 
being studied in the Growing Up Today Study cohort and their mothers, from the 
Nurses’ Health Study II [39].
Metabolomics studies focus on systematic analysis of low-molecular intermedi-
ates in biological fluids. Such investigations may target specific intermediates asso-
ciated with obesity or insulin resistance, or could search for novel biomarkers [46]. 
Metabolomics studies have potential to provide valuable information on the physio-
logical response to nutrient intake and could be informative for fetal origins research 
when quantified during key developmental stages of pregnancy. Metabolite profiles 
associated with specific dietary patterns, or behaviors, such as smoking and physi-
cal activity can be identified [46]. Whereas birth weight and fetal growth are crude 
measures of the intrauterine environment, cord blood metabolomic profiling at deliv-
ery could improve assessment of adverse fetal growth outcomes, and guide future 
interventions to avoid such risks. The metabolomic profile could give an indication 
of impaired nutrient transfer to the fetus during development [46].
PUBLIC HEALTH INTERVENTIONS REGARDING 
FETAL PROGRAMMING
Epidemiological findings of associations between birth weight and later health out-
comes provide evidence of programming of noncommunicable disease in humans. 
Experimental animal evidence also shows that in utero environmental stressors 
produce lifelong alterations in metabolism and pathology. These implications are 
important for developing countries undergoing a transition from infectious disease 
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to noncommunicable disease burdens, as well as the nutrition transition from an 
active, low-calorie lifestyle to a sedentary, high-calorie lifestyle occurring globally 
[47]. Available data indicate that a lower birth weight combined with later higher 
attained BMI confers the highest risk for obesity and cardiovascular disease later 
in life [6,14,15,17]. Successive generations in developing countries are likely to have 
increasing proportions with a high cardiometabolic risk profile. Efforts to prevent 
the development of obesity in areas undergoing such epidemiological, economic, and 
nutrition transitions are paramount.
The implications for policy recommendations regarding fetal programming are 
not yet clear. Birth weight is only a marker for underlying etiological pathways, 
whereas the true etiological factors are largely unknown. More targeted interven-
tions to modify cardiometabolic risks due to fetal programming can be designed 
when these factors are more clearly identified. Interventions to increase birth weight 
per se may not be effective and could be harmful. The focus should rather be on 
improving the health of women of reproductive age to improve the well-being of 
their offspring. Examples include the strengthening of efforts to prevent childbear-
ing before the age of 19 years [45], and restriction of maternal weight gain to 20 kg 
or less for overweight and obese women to curb adolescent adiposity [39]. Strategies 
to reduce excessive adiposity gains during early postnatal life and in the preschool 
years may reduce midchildhood blood pressure, which may also affect adult blood 
pressure and cardiovascular disease risk [21]. These results indicate that interven-
tions to prevent excessive weight gain during pregnancy and early postnatal life may 
be beneficial.
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INTRODUCTION
The 2013 Lancet series on Maternal and Child Nutrition included a comprehensive 
review of interventions that affect the nutritional status of women and young chil-
dren in low- and middle-income countries (LMICs). The series’s authors estimated 
that if 10 known effective interventions were scaled up to 90% coverage, we could 
eliminate 15% of under-5 deaths and reduce stunting by 21% globally [1]. The objec-
tive of this chapter is to review and update this work with the latest research evidence 
on the effectiveness of these 10 and other nutrition-specific interventions to prevent 
poor growth and improve child survival during the crucial first 1,000 days of life. We 
will focus primarily on interventions delivered at scale through the health system. 
Outcomes of interest include birth outcomes (preterm, small for gestational age, low 
birth weight), risk of subsequent growth faltering (stunting, wasting), and mortality 
during the first 5 years of life. We will not consider effects on anemia, developmen-
tal outcomes, or overweight/obesity risk, nor will we address the broader range of 
 nutrition-sensitive interventions that affect more distal determinants of nutritional 
status (including food production systems, water and sanitation, and household 
socioeconomic status). Others have provided comprehensive reviews of these impor-
tant strategies [2].
Interventions are presented by the continuum of care from pregnancy through 
early childhood (Figure 24.1). We will describe each intervention, identify the gen-
eral biological mechanism through which it is understood to have an effect, and 
review the latest evidence on effectiveness.
MATERNAL INTERVENTIONS
Interventions to improve maternal nutritional status before and during pregnancy 
can have long-lasting effects on child growth and survival. Several interventions 
delivered to women before or during pregnancy affect neonatal outcomes (Table 
24.1), including the risk of preterm and small for gestational age (SGA) births, as 
well as neonatal mortality [3]. Babies who are born preterm or SGA are at higher 

















FIGURE 24.1 A conceptual map of interventions, risk factors, and outcomes.
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Asia are at a higher risk of being wasted from very soon after birth than children in 
other regions [6].
Since the 2013 Lancet series, a team at Oxford has released the INTERGROWTH–
21st standards to assess fetal growth and size at birth. The standards were created 
using the same concept and approach as the 2006 World Health Organization (WHO) 
Growth Standards for children aged 0 to 59 months, following cohorts sampled from 
eight geographically diverse urban populations of mothers who received appropriate 
nutrition and health care support throughout pregnancy and delivery. The studies 
showed that when mothers receive adequate care and nutrition, and environmental 
stresses on growth are low, fetal growth is the same across geographical contexts 
[7]. An analysis of 16 prospective cohorts of newborns from LMICs showed that the 
TABLE 24.1
Maternal Intervention Effects
Intervention Outcome of Interest Effect Size (95% CI)
Periconceptual folic acid 
supplementation
Neural tube defects RR: 0.31 (0.17, 0.58)
Iron supplementation in pregnancy Iron-deficiency anemia RR: 0.33 (0.16,0.69)
Low birth weight RR: 0.84 (0.69, 1.03)
Multiple micronutrient 
supplementationa
Low birth weight RR: 0.88 (0.85, 0.91)
SGA RR: 0.90 (0.83, 0.97)
Stillbirth RR: 0.91 (0.85, 0.98)
Calcium supplementation in 
pregnancy
Preterm births RR: 0.76 (0.60, 0.97)
Balanced energy-protein 
supplementation in pregnancy
SGA RR: 0.79 (0.69, 0.90)
Stillbirth RR: 0.60 (0.39, 0.94)
Birth weight MD: +40.96 g (4.66, 77.26)
Note: RR, relative risk; MD, mean difference.
a Effects are compared to iron or iron-folic acid supplementation.
TABLE 24.2
Impact of Birth Outcomes on Stunting and Mortality
Birth Outcome 
Group
Relative Risk of 
Stunting at 12–60 
Months (95% CI)
Relative Risk of 
Neonatal Mortality 
(95% CI)
Relative Risk of 
Postneonatal Mortality 
(95% CI)
Term, not SGA 1 (reference group) 1 (reference group) 1 (reference group)
Term, SGA 2.43 (2.22, 2.66) 3.06 (2.21, 4.23) 2.20 (1.57, 3.08)
Preterm, not SGA 1.93 (1.71, 2.18) 9.44 (5.08, 17.55) 2.85 (1.65, 4.99)
Preterm, SGA 4.51 (3.42, 5.93) 16.20 (10.00, 26.23) 5.77 (3.17, 10.49)
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prevalence of SGA was 23.7% (95% confidence interval [CI]: 16.5%, 31.0%) using 
the INTERGROWTH–21st standard, compared with 36.0% (27.0%, 45.0%) using 
the previous 1999–2000 U.S. birth weight reference [8].
Micronutrient interventions
Deficiencies in iodine, folic acid, iron, calcium, and other micronutrients are com-
mon in women of childbearing age in LMICs. Micronutrient interventions currently 
implemented at scale include the provision of supplements containing iron and folic 
acid during routine antenatal care visits, staple food fortification with folic acid, and 
sometimes other micronutrients.
Iron Folic Acid Supplementation
The WHO recommends daily iron and folic acid (IFA) supplementation for preg-
nant women to reduce maternal anemia [9]. Folate plays an important role in DNA 
methylation and cell replication, and is protective against neural tube defects (NTDs) 
when consumed preconception or during the first 12 weeks of pregnancy. A 2015 
Cochrane Review found a 69% reduction in risk for NTDs, similar to that published 
in the 2013 Lancet series [10]. There are no available studies designed to detect an 
impact on neonatal mortality [10].
Another 2015 Cochrane Review found that consumption of iron-containing tablets 
(iron or IFA) during pregnancy is associated with a 67% reduction in iron-deficiency 
anemia at term (based on six studies with 1,088 women) [11]. Iron supplementation 
is associated with a 16% reduced risk of low birth weight (11 studies with 17,613 
women) [11].
Multiple Micronutrient Supplementation
Multiple micronutrients (MMNs) are broadly defined as supplements that contain 
three or more micronutrients [12]. In 1999, the United Nations Children’s Fund 
(UNICEF), the United Nations University, and the WHO developed a MMN tablet 
known as UNIMMAP, which contains one recommended daily allowance of vita-
min A, vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, folic acid, vitamin C, 
vitamin D, vitamin E, copper, selenium, and iodine, as well as 30 mg of iron and 
15 mg of zinc. A new Cochrane Review published in 2015, looking at any MMN 
compared to iron or IFA, found similar effect sizes as reported in the 2013 Lancet 
series on low birth weight (12% reduction) and SGA (10% reduction), but no longer 
found a significant effect on preterm births. It also reported an effect of MMN on 
stillbirths (9% reduction) [12]. This review was based on 17 trials, including a total 
of 137,791 women, primarily in developing countries, and the quality of the evidence 
was rated as high.
Food Fortification
Salt iodization is the most common form of food fortification globally. Iodine defi-
ciency can cause hypothyroidism and, when it occurs among pregnant women, 
can harm fetal neurological development. The prevention of cretinism is the pri-
mary outcome of increased iodine supply, but there is also mixed evidence that 
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it reduces neonatal mortality. Similar to the 2013 Lancet series, a 2014 review on 
 population-wide salt iodization deemed the evidence insufficient to draw any con-
clusions about mortality effects [13], but a 2012 review of iodized oil supplementa-
tion for pregnant women that included two randomized controlled trials with over 
37,000 participants showed a significant but varied impact on infant mortality (25% 
to 60% reduction, depending on the severity of iodine deficiency and baseline infant 
mortality levels) [14].
Other staple food fortification interventions being promoted in LMICs include 
the fortification of cooking oil, flour, or condiments with iron, folic acid, vita-
min  A, vitamin D, iodine, zinc, and multiple micronutrients. Generally, studies 
find that consumption of fortified foods by women leads to improved micronutrient 
status and reduced anemia. Little evidence is available for the subsequent impact 
of maternal fortified food consumption on growth and mortality outcomes  in 
young children [15].
Calcium Supplementation
Calcium supplementation in pregnancy is recommended to address hypertensive dis-
orders of pregnancy (preeclampsia and eclampsia), which are a major cause of mater-
nal morbidity and mortality and can lead to negative birth outcomes. A 2014 review 
of calcium supplementation during pregnancy found similar effect sizes as reported 
in the 2013 Lancet series [16]. Among women with low calcium intake, daily cal-
cium supplementation of more than 1,000 mg per day significantly reduces risk of 
preterm births (24% reduction), as well as gestational hypertension and preeclampsia 
in mothers. Twice-daily consumption of 500 mg tablets delivered alongside IFA is a 
more feasible approach than the WHO-recommended 1,500 mg per day [17].
Balanced Protein-energy suPPleMentation
In addition to the micronutrient deficiencies, pregnant women in low-resource set-
tings may also have inadequate energy intake. Because maternal weight gain dur-
ing pregnancy is important for healthy birth outcomes, food supplementation in 
pregnancy can be an appropriate approach for women with low prepregnancy BMI. 
Balanced protein-energy supplementation (in which protein provides less than 25% 
of the total energy content) is recommended to improve outcomes. In practice, bal-
anced protein-energy supplementation is most commonly implemented among HIV-
infected women or populations at high risk of food insecurity.
The 2013 Lancet series cited studies showing the impact of balanced protein-
energy supplementation on SGA, stillbirths, and birth weight. A more recent 2015 
Cochrane Review (Ota et al. [18]) showed similar impacts (21% reduction in SGA, 
40% reduction in stillbirths, and an average 41 g increase in birth weight). An earlier 
systematic review found a larger increase in birth weight among underweight women 
compared to adequately nourished women [19], but Ota et al. did not find a differ-
ence between these subgroups. It is important to note that evidence supporting the 
Ota et al. results was only rated as being of moderate quality; many of the studies 
included in the review were published in the 1970s and 1980s, and are not exclusively 
from low-income countries. (The SGA result was based on seven trials with 4,408 
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women, while the stillbirth results were based on five studies with 3,408 women, 
and the birth weight results were based on 11 trials with 5,385 women.) The authors 
highlight the need for targeting balanced protein-energy supplementation specifi-
cally to undernourished women (BMI <18.5 kg/m2), as adequately nourished women 
are at risk of negative birth outcomes from excessive energy and/or protein intake—
an important consideration, given the growing proportion of obese and overweight 
women in LMICs [18].
INTRAPARTUM/NEONATAL INTERVENTIONS
A number of important nutritional interventions affecting child survival take place 
in the period immediately following childbirth and during the neonatal period, that 
is, the first month of life (Table 24.3).
early initiation of Breastfeeding
Initiation of breastfeeding is defined as “early” if it takes place within one hour of 
birth. Despite the health benefits of early initiation, rates are low in most countries 
due to a number of cultural practices including prelacteal feeding and the avoidance 
of colostrum. Early initiation rates are below 60% worldwide, although it is higher 
in LMICs than in higher-income countries [20]. The 2013 Lancet series concluded 
that “the exact scientific basis for the absolute early time window of feeding within 
the first hour after birth is weak,” but more recent evidence has shown that early 
initiation appears to have an additional protective effect beyond that of exclusive or 
TABLE 24.3
Neonatal Intervention Effects
Intervention Outcome of Interest Effect Size (95% CI)
Early initiation of 
breastfeeding
Neonatal mortality Initiation within 1 hour (reference 
group)
Initiation 2–23 hours—RR: 1.41 
(1.24, 1.62)




Early initiation of 
breastfeeding
OR: 1.25 (1.19, 1.32)




Asian populations—RR: 0.87 
(0.78, 0.96)




Intraventricular hemorrhage RR: 0.59 (0.41, 0.85)
Necrotizing enterocolitis RR: 0.62 (0.43, 0.90)
Note: OR, odds ratio; RR, relative risk.
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continued breastfeeding more generally. A prospective cohort study including over 
99,000 infants found that, compared to infants initiating breastfeeding within the 
first hour of life, those initiating within 2 and 23 hours of birth had a 41% higher risk 
of neonatal mortality, and those initiating within 24 and 96 hours of birth had a 79% 
higher risk of neonatal mortality [21]. These analyses provide the most persuasive 
evidence that early initiation has an effect on mortality that is independent of the 
effect of exclusive breastfeeding.
Recent evidence also indicates that breastfeeding promotion interventions can 
have a significant impact on improving early initiation behaviors. A meta-analy-
sis by Sinha et al. (2015) found a 25% increase in breastfeeding initiation within 
one hour, based on all promotion interventions (49 studies) [22]. The most effective 
interventions were those in the community and home environments (85% increase, 
three studies), while those in the health facility setting were much less effective (11% 
increase, 29 studies).
neonatal vitaMin a suPPleMentation
Although the effectiveness of periodic large-dose vitamin A supplementation among 
children aged 6 to 59 months has long been established (see later), neonatal vitamin 
A supplementation has been more recently examined, and remains controversial. 
The intervention consists of 50,000 IU of vitamin A administered within 72 hours of 
birth, which is thought to improve immune system function.
Early evidence cited in the 2013 Lancet series suggested a 14% reduction in 
the risk of mortality at 6 months of age [23] but, more recently, several large-scale 
randomized trials in Asia and Africa have found conflicting results. Taking the 
results of all studies together, it seems that Asian populations, which are more 
at risk of maternal vitamin A deficiency, show a benefit for neonatal supplemen-
tation (13% reduction in mortality at 6 months), whereas African populations, 
with much lower rates of vitamin A deficiency, do not benefit [24]. As a result, it 
seems that this intervention is only “justified in populations where documented 
levels of maternal vitamin A deficiency is moderate to high, specifically in South 
Asia” [25].
delay of uMBilical cord claMPing
In 2014, the WHO released recommendations to delay umbilical cord clamping by 
at least one minute in all neonates who do not require emergency interventions that 
necessitate removal from mother [26]. Delayed cord clamping leads to increased 
hemoglobin concentration and blood volume in the neonate. The Cochrane Review, 
cited in the 2013 Lancet series, was updated later in 2013, and continued to show 
these results [27]. In both term and preterm infants, delayed cord clamping is associ-
ated with reduced risk of iron deficiency anemia and improved iron stores up to 6 
months of age. Delayed cord clamping can reduce the risk of intraventricular hemor-
rhage and necrotizing enterocolitis by 41% and 38%, respectively, among preterm 
infants, although the effect on infant mortality overall was not significant, possibly 
due to inadequate data [28].
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CHILD INTERVENTIONS
Preventive and curative interventions to address undernutrition continue to play 
an important role throughout the early childhood period (Table 24.4). They have 




Intervention Outcome of Interest Effect Size (95% CI)
Exclusive breastfeeding 
(0–5 months)
All-cause child mortality Exclusive BF (reference group)
Predominant BF—RR: 1.48 (1.13, 1.92)
Partial BF—RR: 2.84 (1.63, 4.97)





Exclusive BF (reference group)
Predominant BF—RR: 1.70 (1.18, 2.45)
Partial BF—RR: 4.56 (2.93, 7.11)




All-cause child mortality Continued BF (reference group)
No BF (6–11 months)—RR: 1.76 
(1.28, 2.41)






OR: 1.44 (1.38, 1.51)
Continued breastfeeding 
(6–23 months)
OR: 1.61 (1.17, 2.20)
Complementary 
feeding education
Height-for-age z-score (HAZ) SMD: 0.23 (0.09, 0.36)
Weight-for-age z-score (WAZ) SMD: 0.16 (0.05, 0.27)
Stunting RR: 0.71 (0.56, 0.91)
Supplementary food 
provision
Weight MD: 0.12 kg (0.05, 0.18)
Height MD: 0.27 cm (0.07, 0.48)





RR: 0.70 (0.58, 0.86)




RR: 0.62 (0.18, 0.81)
Zinc supplementation Diarrhea incidence RR: 0.87 (0.81, 0.94)
Pneumonia incidence RR: 0.81 (0.73, 0.90)
Diarrhea mortality RR: 0.50 (0.27, 1.00)
Pneumonia mortality RR: 0.51 (0.20, 1.00)




RR: 0.72 (0.69, 0.85)
Note: BF, breastfeeding; RR, relative risk; OR, odds ratio; SMD, standard mean difference; MD, mean 
difference.
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Breastfeeding ProMotion
Only 37% of children under 6 months of age in LMICs are breastfed exclusively in 
accordance with WHO recommendations [29] that they receive no foods or liquids 
other than breast milk [20]. A 2015 review by Sankar et al. reaffirmed findings cited 
in the 2013 Lancet series that there is a dose–response relationship with mortality 
[30]. All-cause mortality was 14.4 times higher in nonbreastfed infants, 2.84 higher 
in partially breastfed, and 1.48 higher in predominantly breastfed compared to exclu-
sively breastfed infants aged 0 to 5 months. In addition, Sankar et al. provided new 
relative risks (RRs) for infectious causes: infection-related mortality was 8.66 times 
higher in nonbreastfed infants, 4.56 times higher in partially breastfed infants, and 
1.7 times higher in predominantly breastfed infants, compared to exclusively breast-
fed infants aged 0 to 5 months [30].
Per WHO recommendations, older children aged 6 to 23 months should continue 
to breastfeed while gradually introducing age-appropriate complementary foods. The 
updated review found smaller protective effects of breastfeeding on all-cause mortality 
in this older age group (RR 1.76 at 6–11 months, and RR 1.97 at 12–23 months) com-
pared to those cited in the 2013 Lancet series [30].
Strategies to promote exclusive breastfeeding include facility-based counseling, 
home or community-based outreach, mass media interventions, and workplace pol-
icies including maternity leave protection laws. The 2015 review by Sinha et al., 
which included 130 intervention studies in both high-income and LMIC settings, 
found an overall 44% increase in exclusive breastfeeding among those who received 
a promotion intervention compared to those who did not [22]. Sinha et al. went fur-
ther than the 2013 Lancet series and reported effect sizes by subcategory of inter-
vention. Facility-based interventions had the highest impact (OR 1.46 [1.37, 1.56]) of 
the single intervention strategy studies, while a combination of facility and commu-
nity interventions together increased the OR to 2.52 (1.39, 4.59) [22]. Impacts were 
higher in low-income countries than in high-income contexts. Fewer studies looked 
at interventions to promote continued breastfeeding from 6 to 23 months of age. The 
overall effect from 18 studies was a 61% increase in continued breastfeeding. Effects 
on continued breastfeeding were higher in urban settings than rural, higher-income 
than lower-income settings, and in children 12 to 23 months as compared to those 6 
to 11 months [22].
ProMotion of age-aPProPriate coMPleMentary feeding 
and Provision of suPPleMental food
Mothers are advised to begin introducing semisolid and solid foods to infants at 
6 months of age, and to gradually introduce a diverse variety of age-appropriate 
nutrient-dense complementary foods along with breast milk until the child reaches 
24 months of age. Dietary diversity is associated with better micronutrient intake 
and improved growth in this age group [31]. Interventions to improve complemen-
tary feeding have been evaluated, with stunting as the priority outcome [32]. There 
is growing interest in examining these interventions’ impact on wasting, but most 
studies have not systematically reported wasting outcomes [33,34].
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Preventive interventions for children aged 6 to 23 months fall into two general 
categories: education only, and provision of a supplement that contains energy and 
micronutrients (with or without education). Interventions within each category vary 
widely in terms of the content and frequency of messages, form and dose of supple-
ments, age groups targeted, duration, and baseline nutritional status of the popula-
tions, which can make it difficult to summarize the overall effect.
Education Only
The 2013 Lancet series presented estimates from a 2011 review of complementary 
feeding interventions in both food-secure populations and food-insecure popula-
tions (measured by the percentage of the population living above or below US$1.25 
per day, respectively) [32]. The pooled analysis for both groups found that educa-
tional interventions alone led to a significant improvement in height-for-age z-scores 
(HAZ; standard mean difference [SMD] 0.23, based on five studies), weight-for-age 
z-scores (WAZ; SMD 0.16, based on six studies), and stunting rates (RR 0.71, based 
on five studies). The HAZ and stunting rate effect sizes were of similar magnitude in 
both food-secure and food-insecure populations, whereas the WAZ effect was only 
significant among food-insecure populations.
Provision of Supplement with Energy and Micronutrients
Supplements range from providing child and/or household rations of staple foods 
(e.g., corn, oil, milk) to specially formulated products, including fortified flours (e.g., 
corn-soy blend) and lipid-based formulations (e.g., Plumpy’Doz). The 2013 Lancet 
series reported that “overall, the provision of complementary foods in food inse-
cure populations [with or without education] was associated with significant gains 
in HAZ (SMD 0.39; 95% CI 0.05–0.73, seven studies) and WAZ (SMD 0.26, 95% 
CI 0.04–0.48, three studies), whereas the effect on stunting did not reach statistical 
significance (RR 0.33, 95% CI 0.11–1.00, seven studies)” [1]. A more recent review 
by Kristjansson et al. analyzed the evidence from nine randomized controlled trials 
(RCTs) that provided food supplements to children aged 6 to 59 months in LMICs, 
regardless of food security status [35]. The majority of studies were in children 
aged 6 to 23 months, and in populations with low mean growth z-scores at baseline. 
 Six-month interventions were associated with statistically significant increases in 




It is estimated that one-third of children worldwide are vitamin A deficient due 
to lack of dietary diversity, leading to decreased immune system capacity and 
increased mortality from a number of infectious diseases [36]. Periodic high-dose 
vitamin A supplementation of children aged 6 months and older is one of the few 
nutritional interventions that is implemented at public health scales across LMICs. 
More than 80 countries have programs for vitamin A supplementation [25], often 
delivered alongside other interventions using a campaign strategy. A large body of 
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evidence (43 randomized trials with over 215,000 children), cited in the 2013 Lancet 
series, supports the impact of vitamin A supplementation, which reduces all-cause 
mortality by 24% in children 6 to 59 months, as well as diarrhea and measles inci-
dence [37]. It is important to note that many of these studies were conducted several 
decades ago and, in the intervening period, causes of child mortality globally have 
shifted. As a result, it is more appropriate at this point to use cause-specific effect 
sizes (in this case, a 30% reduction in diarrhea-specific mortality due to vitamin A 
supplementation [38]), and apply this only to the proportion of the population that is 
thought to be vitamin A deficient.
Because vitamin A deficiency is a risk factor for severe measles, supplementation 
has also been recommended as a treatment for measles. In 2010, a meta- analysis 
(based on six studies, high-quality evidence) found that two or more doses (of 
200,000 IU for children ≥1 year of age or 100,000 IU for infants) of vitamin A as a 
treatment reduced measles mortality by 62% [39].
Preventive Zinc Supplementation
Zinc supplementation consists of a daily dose of 10 mg; although many trials have 
tested its effect, this intervention is not currently implemented on a public health 
scale in any country. The 2013 Lancet series concluded that “preventive zinc supple-
mentation in populations at risk of zinc deficiency reduces the risk of morbidity 
from childhood diarrhea and acute lower respiratory infections and might increase 
linear growth and weight gain in infants and young children” [1]. This evidence 
came from a 2011 review that showed a 13% reduction in diarrhea incidence and a 
19% reduction in pneumonia incidence (based on 18 studies from LMICs), as well as 
an 18% reduction in all-cause mortality among children 12 to 59 months (this effect 
was not significant when children 6–12 months were included) [40]. Another meta-
analysis showed a significant improvement in linear growth for zinc-supplemented 
children compared to placebo (based on 36 studies) [41]. A more recent Cochrane 
Review  shows nonsignificant effects for all-cause mortality, diarrhea mortality, 
pneumonia mortality, and pneumonia incidence, with the only significant effect 
found in a 13% reduction in diarrhea incidence, but the results of this analysis cannot 
be used because it failed to appropriately exclude trials where iron was given with 
zinc [42]. Thus, results of previous analyses that included only trials that compared 
zinc supplements to placebo should be used and are unchanged from what was in the 
2013 Lancet series.
As mentioned earlier regarding vitamin A, given the shift in causes of child mor-
tality over time, it is now more appropriate to apply cause-specific mortality rates 
to the percentage of the population that is thought to be zinc deficient. In the case 
of zinc supplementation, reanalysis carried out for the Lancet 2013 series showed 
cause-specific effect sizes among zinc-deficient individuals of 50% reduction in 
diarrhea mortality and 49% reduction in pneumonia mortality [1].
Zinc is also recommended for treating diarrhea. Since 2004, the WHO guideline 
for treating diarrhea has included 20 mg zinc per day (10 mg per day for infants 
under 6 months) for 10 to 14 days, along with oral rehydration solution and continued 
age-appropriate feeding [43]. The addition of zinc to the diarrhea treatment regimen 
has been shown to decrease the duration and severity of diarrhea episodes, with a 
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protective effect lasting up to 3 months. Based on diarrhea hospitalization data, zinc 
is estimated to decrease child mortality due to diarrhea by 23% [44].
Multiple Micronutrient Supplementation
Micronutrient powder (MNP) sachets for the home-based fortification of comple-
mentary foods are recommended by the WHO [45] and have been evaluated in sev-
eral programmatic contexts. A 2013 review of 17 trials found that, although they 
have an impact on iron status and anemia in children 6 to 59 months, there is no 
effect on growth [46]. The lack of effect on growth may be explained by the rela-
tively lower dose of zinc in MNP compared to zinc supplements [47,48], a reduction 
in zinc bioavailability due to high phytic acid content of foods mixed with the MNP, 
and/or the adverse effects of iron supplements on diarrhea and growth [49,50].
More recently, a category of supplements known as small quantity lipid-based 
nutrient supplements (SQ-LNS) has been introduced, which contain a complete daily 
requirement of micronutrients for their target age group in a lipid-based matrix that 
provides less than 120 kcal energy along with essential fatty acids. Trials in children 
6 to 23 months are ongoing, but findings to date are mixed, with some populations 
demonstrating improvements in length and weight outcomes but others not [51,52]. 
A systematic review of these SQ-LNS studies is needed.
ManageMent of severe acute Malnutrition
Severe acute malnutrition (SAM) (defined as WHZ <–3 SD, or mid-upper arm cir-
cumference [MUAC] <115 mm, or presence of bilateral pitting edema in feet) is an 
acute condition, with generally low prevalence outside of emergency contexts, but 
a very high risk of mortality. In the past, all children with SAM were treated on an 
inpatient basis, but now WHO guidelines support community-based rehabilitation of 
SAM children age 6 to 59 months without complications, using specially formulated 
ready-to-use therapeutic foods (RUTFs) [53].
About 15% of all children with SAM will have complications (e.g., concur-
rent infections) that require the child to be stabilized in a facility with fluid man-
agement and dietary support, and treated for infections before being discharged 
to community-based care. A review prepared for the 2013 Lancet series used a 
Delphi process to systematically weigh expert opinion in the face of limited trial 
evidence, and reported that the overall recovery rate for these children who start 
as inpatient cases (most of whom transfer from facility to outpatient protocols 
described later) is 71% (interquartile range [IQR] 25%–95%) [54]. With improved 
treatment, case fatality rates have declined to 3% to 35% and are highest among 
HIV-infected children [1].
There have been relatively few randomized trials that test the efficacy of outpa-
tient treatment of SAM without complications, but substantial programmatic expe-
rience has established it as the standard of care. The 2013 Delphi process review 
estimated the recovery rate for outpatient SAM treatment at 80% (IQR 50%–93%) 
[54]. A 2013 Cochrane Review, including four RCTs, all conducted by the same team 
in Malawi, found that outpatient treatment protocols are only marginally better than 
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inpatient treatment in terms of overall wasting recovery rates, but are associated with 
faster recovery time and lower mortality [55]. Under ideal conditions, recovery rates 
of up to 90% are considered feasible, but are unlikely in contexts with relative high 
rates of pediatric HIV infection [56].
ManageMent of Moderate acute Malnutrition
Taking a “treatment” approach to rapidly rehabilitate children aged 6-59 months 
with moderate acute malnutrition (MAM) (defined as –3 < WHZ < –2 SD, or 115 ≤ 
MUAC < 125 mm, without bilateral pitting edema) remains controversial. Unlike 
SAM, there is currently no globally endorsed guidance for MAM treatment outside 
of emergency contexts. MAM treatment programs generally use food ration pack-
ages that include fortified corn-soy blend (CSB) and oil and, in some food insecure 
settings, a lipid-based ready-to-use supplementary food (RUSF) product with a simi-
lar macronutrient composition, but a different dose and micronutrient profile than 
the RUTF used in SAM treatment. The 2013 Delphi process review reports recovery 
rates for MAM treatment at 84% (IQR 50%–100%) [54]. In comparing supplemen-
tary feeding programs that used CSB to those using RUSF, children in the RUSF 
group were more likely to reach exit criteria, with WHZ that was 0.11 (0.04–0.17) 
greater at discharge, but there was no difference in mortality outcomes between 
groups [54].
CONCLUSION
The nutrition community has identified many effective interventions to address nutri-
tional deficiencies and improve birth outcomes, growth, and survival. As described 
in the 2013 Lancet series, implementing these interventions at scale through the 
health system, and integrating them with nutrition-sensitive efforts in other sectors 
is an ongoing challenge [1,2]. Nutrition must be recognized as a core component of 
the maternal, neonatal, and child health agenda [25].
A second, related challenge is to improve the monitoring and evaluation of nutri-
tion program delivery and impact. Currently, our measurement of nutrition interven-
tion coverage at scale across LMICs is, for the most part, limited to what is captured 
in household surveys, such as the Demographic and Health Survey (DHS) and 
Multiple Indicator Cluster Survey (MICS). Little is known about the actual coverage 
of infant and young child feeding promotion and food supplementation interven-
tions, acute malnutrition screening, and treatment programs, or the entire category 
of nutrition-sensitive interventions.
We must develop and implement new measurement approaches that enable coun-
tries to assess the impact of nutrition policies and programs and scale. Since the pub-
lication of the first Lancet nutrition series in 2008 and the launch of the Scaling Up 
Nutrition (SUN) movement in 2010, we have seen governments and donors respond 
to calls for increased investments in nutrition. However, if we cannot measure and 
demonstrate the actual progress that has been made, we will not be able to sustain 
these efforts.
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Interventions for the 
First 1,000 Days
Jessica Fanzo and Haley Swartz
INTRODUCTION
Nearly three decades of research support a strong relationship between the complex 
biological processes that can occur during the first 1,000 days of life and the resulting 
multiple burdens of malnutrition, including undernutrition (measured as stunting and 
wasting), overweight and obesity, and micronutrient deficiencies. Although gaps in 
knowledge remain, the field of nutrition has made commendable progress in identify-
ing which policies, programs, and initiatives “work” to improve nutrition for the most 
vulnerable groups, particularly among women and children. To date, most evidence 
on programmatic successes reflect “nutrition-specific” interventions, well described 
in Chapter 24. Such interventions, highlighted in the 2008 and 2013 Lancet series on 
undernutrition, reflect 10 interventions in three areas, primarily in the health sector: 
improving micronutrient uptake through fortification or supplementation, treatment 
of acute malnutrition, and counseling for breastfeeding and complementary feeding.
Scaling-up coverage of these 10 nutrition-specific recommendations to 90% of the 
population in 34 countries, where 90% of the world’s stunted children reside, would 
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result in an estimated 20% decline in stunting and a 60% reduction in wasting [1]. Such a 
decline in undernutrition could be much larger if the international nutrition community 
were to go beyond the core 10 nutrition-specific areas to include “nutrition-sensitive” 
approaches. Nutrition-sensitive interventions inherently involve systems engagement, 
incorporating multiple sectors and disciplines in the fight against undernutrition.
Nutrition-specific interventions primarily target the immediate causes of under-
nutrition: inadequate dietary intake and diseases, as shown in Figure 25.1 [2]. The 
primary objective of nutrition-sensitive interventions is not necessarily direct reduc-
tions in undernutrition, but rather indirect improvements in nutrition among program 
beneficiaries. Many nutrition-sensitive approaches focus on the indirect and long-
term consequences of both the underlying and basic causes of childhood nutrition 
(in Figure 25.1, light and dark blue, respectively). The two types of interventions 
could be complementary and mutually reinforcing: nutrition-sensitive programs and 
policies may serve as the delivery mechanism for nutrition-specific interventions to 
mothers and children, given appropriate funding, capacity, and technical support.
This chapter will delve into the evidence on the types of nutrition-sensitive 
approaches and the sectors responsible for program implementation; the relationship 
between nutrition-sensitive interventions and the first 1,000 days of life; approaches 
that are effective can be scaled now; and the layered complexity of scaling-up through 
multiple sectors and institutional arrangements. Box 25.1 highlights the main mes-
sages of nutrition-sensitive approaches, which are applicable to both the specific 
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FIGURE 25.1 UNICEF framework of the determinants of maternal and child under-
nutrition. (From United Nations Children’s Fund (UNICEF), Improving child nutrition: The 
achievable imperative for global progress, New York: UNICEF, 2013. With permission.)
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NUTRITION OUTCOMES REQUIRE MULTIPLE 
SECTORS AND MULTIPLE SOLUTIONS
The first 1,000 days of life is the window of opportunity to influence child growth, 
nutritional status, and cognitive development [3]. A single intervention to alleviate 
early childhood stunting can have significant small to moderate effects [1]. In con-
trast, predictive models suggest that by combining micronutrient supplementation, 
food fortification, and disease control interventions, stunting prevalence could be 
reduced by one-third [1]. Further reductions in chronic undernutrition likely require 
a more comprehensive approach, combining nutrition-specific interventions with 
larger, multisector efforts [4].
In theory, multisectoral nutrition interventions can be a starting point. In 
practice, however, the realities of effectively working through multiple institu-
tions make such work incredibly difficult [5]. Some argue that nutrition should 
incorporate agriculture, health, water and sanitation, education, social protec-
tion, gender, and environment; however, historically, multisectoral collaboration 
has not worked well [6]. Recent scientific discovery and operations research, 
have provided more evidence and tools for researchers and policy makers to 
assimilate sectors and use systems approaches to nutrition. Such progress is 
reflective of the Sustainable Development Goals (SDGs). In particular, nutrition 
is inextricably linked to international development in SDG2, which aims to end 
BOX 25.1 HIGHLIGHTS OF NUTRITION-SENSITIVE 
APPROACHES IN THE FIRST 1,000 DAYS
• Nutrition-sensitive interventions are multisectoral, incorporating 
nutrition outcomes into health care, agricultural production, educa-
tion systems, social protection transfers, and early childhood devel-
opment (ECD) curricula.
• Healthy mothers produce healthy children. Improving childhood 
nutrition outcomes within the first 1,000 days of life requires pro-
gramming that is empowering to women, and sensitive to both gender 
and local contexts.
• Interventions that directly impact health and nutrition status in the 
first 1,000 days of life include water, sanitation, and hygiene (WASH); 
women-centered agricultural projects; and access to quality antenatal 
care.
• The empirical evidence evaluating the effect of nutrition-sensitive 
interventions on reductions in stunting, or low height-for-age, is sig-
nificant, but small in scale and scope.
• Nutrition-sensitive program evaluations must include rigorous design 
and measurable nutrition outcomes to further demonstrate evi-
dence of how to reduce childhood undernutrition and to achieve the 
Sustainable Development Goals (SDGs).
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hunger, achieve food security and improved nutrition, and promote sustainable 
agriculture [7].
Working through multiple sectors simultaneously can leverage synergies and 
catalyze gains extending beyond achievements through sector-specific programs 
that work in isolation [8]. Recent research documents potential synergies between 
health and economic interventions, suggesting multisector approaches may generate 
a wider range of benefits than single-sector approaches [9,10].
As shown in Figure 25.1, many factors influence the quality of diets and disease 
outcomes that ultimately impact nutrition outcomes [2]. The underlying causes of 
malnutrition affect households and communities, including household food inse-
curity; inadequate care and feeding practices for children; unhealthy household 
environments; and inaccessible, often inadequate health and education services. 
Interventions to address the underlying causes thus include access to an affordable, 
diverse, and nutrient-rich diet; optimal maternal and child feeding and care practices; 
access to adequate health services; and improved sanitation and hygiene practices to 
ensure a healthy environment. These factors directly impact the immediate causes 
of malnutrition: nutrient intake and utilization and the manifestation of disease. 
Food, health, and care are each necessary, but not sufficient conditions for adequate 
childhood nutrition. Social, economic, and political factors continually impact food, 
health, and care, highlighting how each underlying factor differs in relative impor-
tance from country to country. Understanding the immediate and underlying causes 
of undernutrition in a given context is critical to delivering appropriate, effective, 
and sustainable solutions to meet the nutritional needs of a country’s most vulner-
able groups. Last, the basic causes of undernutrition focus on historical structures 
and country-specific processes of societies. The determinants of such causes are 
complex, with major factors including poverty, socioeconomic, gender and social 
inequities, insufficient human rights, and lack of access to essential resources. At its 
core, the basic causes of undernutrition encompass larger political, economic, and 
legal factors. Such factors affect institutional leadership and policymaking at both 
community and national levels, highlighting how the theoretically “best” programs 
to promote adequate nutrition could be defeated, unsuccessful, or deprioritized in a 
country’s policy agenda. The factors that impact nutrition status are buried within 
these basic causes, deeply rooted in overarching societal norms [2].
In both programs and practice, policymakers have prioritized interventions that target 
immediate and underlying causes, which mainly consist of nutrition-specific approaches. 
Basic causes, or nutrition-sensitive interventions, are often underfunded, and overlooked 
as too politically sensitive or challenging to implement [11]. Such neglect has encouraged 
the practice of “targeting vulnerable groups” and “delivering packages” of commodities 
and services. Solutions to reduce the burdens of undernutrition require including basic 
causes and ensuring policies are sustainable to promote long-term change.
THE EVIDENCE FOR NUTRITION-SENSITIVE APPROACHES 
IN ADDRESSING THE FIRST 1,000 DAYS
Currently, there is no “systematic process for [the] collation of the implementation-
related evidence base about how to scale up the vast array of [both] nutrition-specific 
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and nutrition-sensitive interventions with quality and equity,” indicating further 
research is necessary on both nutrition-sensitive and nutrition-specific interventions 
[12]. Further, partial empirical evidence supports a direct relationship between 
nutrition-sensitive interventions and health improvements during the first 1,000 
days of life. In the 2013 Lancet series, Black et al. [13] adapted the United Nations 
Children’s Fund (UNICEF) framework, as shown in Figure 25.1, to explicitly 
include nutrition-sensitive approaches to address underlying causes of undernutri-
tion, along with factors of enabling environments that impact the basic causes of 
undernutrition. This new framework (Figure 25.2) outlines the necessary sectors 
with which the international nutrition community should engage to produce a com-
prehensive strategy for improving child nutrition [13]. As part of the Lancet series, 
Ruel et al. [14] further defined current evidence on nutrition-sensitive approaches 
and best practices. In this section, we will describe both types of intervention and 
the sectors responsible for implementing nutrition-sensitive approaches.
Agriculture And Food Security
Studies have shown that agricultural research, programs, and policy have put less 
emphasis on maximizing nutrition outputs from farming systems. Agriculture has 
instead had substantive impact on economic growth by enhancing farm productivity 
and food availability. A recent longitudinal analysis found that agricultural per cap-
ita income was more strongly associated with reductions in undernutrition than non-
agricultural income [15]. After controlling for income, the analysis indicated that as 
economic transformation proceeded, stunting declined at a faster pace in countries 
that supported growth in the agricultural sector than in those that did not. However, 
absolute reductions in stunting were quite modest; a doubling of per capita agricul-
tural income is associated with an approximately 15% decline in stunting [15].
Research has also demonstrated a strong association between dietary diversity, 
diet quality, and the nutritional status of children [16]. It is also clear that house-
hold dietary diversity is a sound predictor of the micronutrient density of the diet, 
particularly for young children [17]. Dietary diversity is a vital element of diet 
quality. The consumption of a variety of foods across and within food groups, 
and across different varieties of specific foods, guarantees the adequate intake 
of essential nutrients and important nonnutrient factors. In some communities, 
particularly among smallholder farmers, agriculture can make contributions to 
dietary diversity by increasing and/or improving diversity of landscapes and the 
availability of foods produced from those landscapes.
Broader nutrition-sensitive interventions focusing on the individual include the 
promotion of home gardens, biofortification, small-animal rearing, and women -
centered agricultural practices.
Two recent reviews have examined the impact of agricultural interventions on 
nutrition outcomes, showing that agriculture strategies improved dietary patterns 
and specific micronutrient intakes (vitamin A in particular); however, there was less 
of an effect on growth such as stunting and wasting [18–20]. Explanations for such 
minimal effects include a hypothesis that agricultural interventions may best reduce 
short-term undernutrition rather than chronic undernutrition, or study assessments 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































395Nutrition-Sensitive Interventions for the First 1,000 Days
occurred shortly after intervention, failing to capture long-term nutrition effects 
[20]. In a series of studies analyzed in different country contexts, overall household 
agricultural production had direct linkages with dietary quality and nutritional sta-
tus, although impacts can widely vary [21].
Women’s social status, empowerment, control over resources, time allocation, 
and health and nutritional status are key mediators in the pathways between agri-
culture inputs, intrahousehold resource allocation, and child nutrition [14]. However, 
there is a need for more studies to measure the effect of agriculture interventions on 
women’s time, knowledge, practices, health, and nutritional status.
SociAl Protection
Social protection programs target the immediate and underlying causes of maternal 
and child undernutrition. Conditional or unconditional cash transfers and/or an in-
kind food distribution that help stabilize household income and consumption over 
time are examples of social protection programs [14]. They generally operate with 
the goal of reducing vulnerability, investing in human capital, and breaking the inter-
generational cycle of poverty. Social protection has the potential to improve nutrition 
outcomes given the behavioral requirements of the program: targeted, nutritionally 
vulnerable populations, such as poor pregnant women or those who face economic, 
climactic, or social stresses, are required to enroll in an additional economic, social, 
or educational development program. For instance, school feeding programs encour-
age parents to enroll their children in school, and cash transfer stipends promote 
attendance at regular health checkups. Such components can serve as critical lever-
age points for nutrition-specific interventions [14].
Although programs vary in scope and scale, recent evidence indicates social pro-
tection interventions and poverty alleviation programs have direct effects on indi-
vidual nutrition outcomes [14,22]. In particular, one review noted that conditional 
cash transfers CCT significantly improved child anthropometry but had little impact 
on micronutrient status [23].
WAter, SAnitAtion, And Hygiene
One of the most effective and well-known development strategies to reduce child-
hood stunting in low- and middle-income countries (LMICs) incorporates water, 
sanitation, and hygiene (WASH) interventions. Since the 1990s, even minor improve-
ments in hygiene education, home handwashing practices, and the quality of both 
community drainage systems and home toilets have been associated with declin-
ing incidence of diarrhea morbidity, pneumonia, communicable diseases (CDs), and 
other infectious diseases.
WASH plays a fundamental role in improving nutritional outcomes. Fifty percent 
of malnutrition is associated with repeated diarrhea or intestinal worm infections 
as a result of unsafe water, inadequate sanitation, or insufficient hygiene [24]. In 
addition, a review found that poor WASH conditions have a significant detrimen-
tal effect on child growth and development resulting from sustained exposure to 
enteric pathogens [25]. A recent meta-analysis found that three individual WASH 
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interventions—solar disinfection of water, provision of soap, and improvement of 
water quality—had a small, albeit significant impact on stunting reductions in chil-
dren under 5 years old [26].
Diarrhea highlights the vicious cycle of undernutrition and the necessity to 
enhance WASH practices for children in the first 1,000 days of life. Meta-analyses, 
first conducted in 1990 and then updated in 2012, found that the highest incidence 
rate of frequent diarrhea episodes continue to be infants ages 6 to 11 months old, at 
5.3 episodes per year [27]. Frequent episodes of diarrhea in children under 2 years 
old can significantly increase the risk of stunting and impair cognitive development 
[28,29].
In LMICs, young children are often afflicted by environmental enteropathy, 
a syndrome causing changes in the small intestine of individuals who lack basic 
sanitary facilities and are chronically exposed to fecal contamination [30]. This 
condition decreases the ability of the intestinal tract to absorb nutrients critical for 
optimum growth and development, leading to serious consequences in nutritional 
status. Rates of environmental enteropathy are high in early life, particularly among 
young, breastfed infants who begin to consume complementary foods. Although 
these children eat greater amounts of solid foods, they are exposed to the outside 
environment and thus face an increased risk of consuming contaminated foods. Two 
interventions working together—an improved food system to ensure food safety, and 
hygienic toilets and community-based sanitation—have been shown to reduce enter-
opathy rates [31,32].
eArly cHildHood develoPment
Encompassing the first 1,000 days from birth through to primary school, early 
childhood development (ECD) programs aim to improve physical, cognitive, and 
psychosocial growth among young children. The World Bank categorizes 25 ECD 
interventions into “packages,” representing the five stages of life before age 5 [33]. 
In each stage, families are provided subsidized access to food and nutrition supple-
ments, as well as “psychosocial stimulation interventions,” which include household 
learning activities, formal preschool education, health services, and resources for 
improved health care [34]. Most of the interventions essential for a child’s growth 
and development are reflected in the six sectors discussed in this chapter, including 
but not limited to family planning, WASH, immunizations, deworming, and quality 
education [33]. Figure 25.3 provides an overview of the five standard support pack-
ages designed by the World Bank [33].
A meta-analysis comparing more than 20 small-scale ECD programs in LMICs 
found that integrated psychosocial stimulation interventions had a medium effect 
(d = 0.42) on the Bayley scale of childhood cognitive language and development, 
whereas standalone nutrition programming provided only a small effect (d = 0.09) 
[35]. In high-income countries, ECD programs—such as Head Start in the United 
States or the social pedagogical programs in Nordic countries—have been successful 
at reducing the intergenerational burdens of both undernutrition and poverty since 
the early 1990s [36,37]. LMICs, however, continue to face significant challenges 
in implementing multisectoral ECD programs. The implementation process will 






























































































































































































































































































































































































































































































































































































































































































398 The Biology of the First 1,000 Days
vary in each country, but effective ECD programs are costly. The responsibilities 
for program integration, targeting, and delivery frequently overlap between govern-
ment ministries. Evaluations of combined nutrition and psychosocial interventions 
should include a country-specific analysis of the implementation process, providing 
sufficient data on any program features that may have benefited child growth and 
development [34].
Women’S emPoWerment
The social status of women around the world plays a significant role in determin-
ing nutritional status of the most nutritionally vulnerable: adolescent girls, young 
women, and children under the age of 5. Insufficient gains in women’s social status 
can have detrimental consequences to improvements in children’s nutrition out-
comes. For example, in South Asia, women hold a lower social status than men [38]. 
With regard to food distribution, this, in turn, means that men and male offspring 
are given the highest quality and quantity of food, with women and female off-
spring allowed to eat the remaining food—resulting in higher frequencies of female 
undernutrition [38]. Lower social status also results in lower control of economic 
resources, which can have a negative impact on nutrition and health outcomes [39], 
as well as quality of life, psychological health, livelihood improvements, and over-
all earnings.
In LMICs, gender-sensitive and culturally salient programming is integral to 
improving maternal and child nutrition outcomes. Women’s empowerment is divided 
into three primary domains: control of resources and autonomy, workload and time, 
and social support environment. All three areas influence women’s decisions to have 
children and their associated nutrition status at birth, but the strength and direction 
of each effect varies by country, region, and household income [40].
FAmily PlAnning
The ability to delay both the age of marriage and the age of first pregnancy are 
two significant indicators of women’s health status and, in turn, child health rearing 
[41,42]. The child marriage rate, in particular, indicates the cultural complexities of 
introducing programs to enhance girl’s empowerment and, thereby, improve their 
own and their child’s nutritional status. Child marriage, defined as marriage before 
the age of 18, is common in six of the eight South Asian countries, with rates at 65% 
in Bangladesh, 47% in India, and 41% in Nepal [43]. One study of 125,000 Indian 
mothers and their children found that the risk of malnutrition, as measured by both 
underweight and stunting, was higher in young children born to mothers married 
as minors (<15 years), as compared to those born to women married later in life 
(>24 years) [44]. A meta-analysis evaluating maternal age at childbirth with child 
nutritional outcomes, including stunting at 2 years old, found that children born to 
mothers under the age of 19 are disadvantaged in both nutrition and health as com-
pared to children born to older mothers [45].
Generally, poor pregnancy outcomes are the second leading cause of mortality 
in adolescent girls [46]. In mothers under 20 years of age, risk of perinatal death 
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is 50% higher amongst newborns as compared to older mothers [47]. It is often 
found that children born to adolescent mothers have increased risk of low birth 
weight outcomes, with potentially, negative consequences into adulthood [48,49]. 
Improving the nutrition of adolescent girls and delaying their first pregnancy may 
be two key interventions, given the importance of intergenerational influences 
in the life cycle. Thus, improving the nutrition of adolescent girls before they 
become pregnant, during pregnancy and lactation, and increasing birth spacing 
may also help to break the vicious cycle of malnutrition and poverty.
Increasing the accessibility and quality of primary health services for women of 
reproductive age (WRA) has significantly improved nutrition among mothers and 
young infants. Programs that provide access to low-cost contraception and fam-
ily planning services have consistently improved birth outcomes for both mothers 
and children throughout LMICs. In particular, the demand for contraception in the 
world’s poorest countries remains high, with an estimated 222 million women in 
LMICs reporting unmet needs for modern methods [46]. Accessible, voluntary fam-
ily planning is not only crucial to directly improve reproductive health, but is also 
positively associated with advancements in health, schooling, and economic indica-
tors [50], all of which are important for adequate nutrition. Given the importance of 
family planning, efforts are ongoing to connect basic health services with a wider 
range of social support for women in LMICs.
educAtion
Education reflects both access to both primary and secondary schooling and nutri-
tion education. In LMICs, maternal education tends to delay pregnancy until later 
in life, promote healthy hygienic practices, increase women’s social status, and pro-
vide women opportunities for economic participation [51–53]. One of the strongest 
predictors of childhood nutrition status is maternal education [54]. Moreover, the 
effect of women’s empowerment through education on child health is consistent in 
the literature. Compared with educated mothers, children of less-educated women 
face a higher risk of undernutrition in utero and a lower chance of survival during 
both infancy and early childhood [55].
The formal education attainment of women, particularly literacy levels, influ-
ences nutrition and health outcomes. Women who are educated and have better 
access to adequate and appropriate nutrition information are able to elicit appro-
priate health-benefitting behaviors, and have more opportunities for employment 
and earning power [56]. In Eastern Ethiopia, researchers found through question-
naires and health assessments that pregnant women with low and medium power of 
household decision-making faced a twofold higher risk of malnutrition than those 
with higher rates of autonomy [57]. In Bangladesh, increased maternal and pater-
nal formal education led to decreases in child stunting [58]. In Indonesia, increased 
maternal and paternal education was associated with improved caregiving practices, 
including vitamin A capsule and immunization services, the use of iodized salt, and 
WASH behaviors [56].
In a cross-country analysis of 100 LMICs, Headey et al. [22] found that pub-
lic investment in education was a primary source for improving women’s nutrition 
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outcomes. Specifically, women’s secondary education, reductions in fertility which 
is, in turn, closely associated with changes in women’s education, asset accumu-
lation which is surprisingly weakly explained by economic growth, and increased 
access to health services were associated with stunting reductions [22]. In Nepal 
and Bangladesh, economic gains at the household level and rapid gains in education 
for both mothers and fathers both contributed to the 1.1 percentage point reduction 
in child underweight and stunting each year since 1997 [59]. In Nepal, asset accu-
mulation was also a primary determinant in reductions of stunting prevalence, but 
only maternal education significantly predicted improvements in severe stunting and 
height-for-age z-scores [59].
Moreover, women’s employment status, which is often dictated by education 
level, influences household income, which in turn impacts nutrition status. In South 
Africa, the chances of being undernourished during pregnancy increased two-fold 
for women whose household income was less than US$16 a day [56]. Similarly, in 
Bangladesh, poverty (directly linked to household income and employment status) 
was the most significant factor in predicting undernutrition among WRA [60].
HeAltH
The public health sector plays a critical role in the delivery of most of the high-
impact nutrition-specific interventions, which rely heavily on functioning health 
facilities, services, and personnel. In countries where government health services 
provide wide coverage and are easily accessible, health services are a logical and 
sustainable delivery channel for nutrition interventions [61].
Providing universal coverage of essential interventions throughout the life 
cycle in an integrated primary health care system has the potential to improve 
nutrition during the first 1,000 days of life. The continuum of care from mater-
nal to child health provides an opportunity to integrate nutrition services into 
essential primary health care packages. One aspect of primary health care that is 
crucial for improving the nutritional status of women and their children is ante-
natal and postpartum care. These critical points in time provide an opportunity 
for health care workers to meaningfully engage with women not only about their 
own health and nutrition, but also about the care of newborns and any future preg-
nancies. Preventative nutrition, dietary counseling, and routine physical screen-
ings can help women in areas related to their own health needs, as well as their 
families. These interventions can have important implications for women’s health 
outcomes, such as the prevention, screening, and management of infectious dis-
eases such as malaria and diarrhea (5). Multipronged interventions often rely on 
behavioral change communication (BCC), a variety of approaches and tools used 
to design nutrition and public health programs [62]. Interpersonal communica-
tion strategies on breastfeeding and complementary feeding have been shown to 
increase knowledge on health behaviors that contribute to improved nutrition for 
infants and young children [62]. Implementing health programming with nutri-
tion-specific interventions is likely to initiate greater reductions in child under-
nutrition than standalone health programming. Such projects would include the 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































403Nutrition-Sensitive Interventions for the First 1,000 Days
distribution of pneumonia, diarrhea, and deworming prevention materials along 
with nutrient supplement regimens such as iron folic acid supplements during 
pregnancy [63].
Working in tandem with nutrition-specific approaches, multisectoral programs 
can improve nutritional status within an infant’s first 1,000 days of life. Such pro-
grams include increased access to antenatal and postnatal care, child immuniza-
tions, malaria prevention and treatment, and promotion of optimal infant and young 
child feeding practices (including breastfeeding promotion and timely introduction 
of nutritionally adequate and safe complementary foods). All improve nutritional 
status within an infant’s first 1,000 days of life. Identifying ways to make sector 
investments sensitive to nutrition outcomes, the Global Nutrition Report [64] out-
lined target groups, types of nutrition-sensitive interventions, and delivery plat-
forms, all of which are discussed in this chapter. A summary of this report is found 
in Table 25.1.
FOR NUTRITION-SENSITIVE APPROACHES, 
LOCAL CONTEXT MATTERS
In a 2015 study modeling the makers and markers of development on stunting 
rates since 1970, researchers found that the female-to-male life expectancy ratio 
had a significantly stronger effect on reducing the childhood stunting in South 
Asia than in other regions, whereas national food availability has a far stronger 
impact in Latin American and Caribbean countries [65]. This difference is further 
clarified in Figure 25.4, which displays a stark difference in the share of various 
nutrition-sensitive interventions between South Asian and Sub-Saharan African 
countries.

































FIGURE 25.4 Comparing the contributions of underlying determinants to total reductions 
in childhood stunting in Sub-Saharan Africa and South Asia, 1970–2010 [65]. (From Smith L, 
Haddad L, World Dev 2015; 68:180–204. With permission.)
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Improvements in water safety and the provision of secondary school for girls 
account for nearly two-thirds of stunting reductions in Sub-Saharan Africa from 
1970 to 2010. While water safety was also a primary intervention in South Asia, 
an increase in the gender life expectancy ratio explained the greatest reduction in 
childhood stunting. Such differences between the two regions reflect the fact that 
South Asian countries prioritized policies to improve the underlying determinants 
of childhood undernutrition, namely, household access to safe water and women’s 
care practices, while Sub-Saharan countries have realized slow progress on the basic 
causes of malnutrition, such as adequate sanitation, nationwide food availabilities, 
and dietary diversity of the food supply [65]. In LMICs, priority setting must reflect 
baseline measurements of childhood nutrition levels, and investments in the health, 
education, and agricultural sectors must correspond to local contexts.
Effective delivery platforms, coverage, and participation are major gaps for all 
health and nutrition services. Several delivery platforms to reach vulnerable pop-
ulations exist, but there is dearth of information on what works where, and how 
to effectively sustain change. Some potential platforms include: the health system, 
especially antenatal care; community-based nutrition programs; child health days; 
social protection, especially conditional cash transfers the food environment; and 
agriculture food-based investments. Making these platforms more effective requires 
operations research in conjunction with capacity building and personnel training, 
the creation of technical guidelines, monitoring and evaluation of programs, and 
advocacy. Delivery mechanisms are highly dependent on the local context, which 
takes into account community ownership, cultural sensitivity, and the local political 
economy.
CONCLUSION
As countries have begun to set policy and priority agendas in pursuit of the SDGs, 
the international nutrition and development communities should promote and invest 
in targeted nutrition-sensitive, multisectoral interventions. Inextricably linked to 
the elimination of the multiple burdens of malnutrition is the critical window of 
opportunity to promote growth and development within the first 1,000 days of 
life. Because healthy children are born to healthy mothers, nutrition-sensitive pro-
gramming must be gender-sensitive, empowering girls and women both socially 
and economically. It is now crucial to invest in pilot tests and interventions that 
integrate diverse sectors, including health, WASH, agriculture, and education in 
order to maximize poverty reduction and to reverse the effects of intergenerational 
undernutrition.
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The Scaling Up Nutrition (SUN) Movement is a movement like no other. As of 2017, 
the movement is led by 59 “SUN countries” and the Indian States of Maharashtra, 
Uttar Pradesh, and Jharkhand (Figure 26.1). Multiple stakeholders from civil society, 
United Nations (UN) agencies, donors, business, and academia are all united by their 
conviction and determination to end malnutrition in all its forms.
One in three people are affected by malnutrition in nearly every country world-
wide. This is a global crisis, but the evidence needed to respond is known and well 
documented. Together, those in the movement are driven by the commitment and 
leadership of SUN countries. Progress is being made with strong political leader-
ship, increased investments, improved alignment, and multistakeholder, multisec-
toral collaboration.
Many SUN countries are reporting significant progress in reducing stunting, 
including Benin, Cambodia, Ethiopia, Ghana, Guinea-Bissau, Kenya, Kyrgyzstan, 
Malawi, Tanzania, Zambia, and Zimbabwe. Several other countries in the SUN 
Movement are also making significant strides with preliminary data showing 
promising trends. United with multiple sectors and stakeholders in a truly coherent 
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WHY IS NUTRITION IMPORTANT?
Every man, woman, and child has the right to adequate food and nutrition. This right 
is enshrined in several international human rights and other treaties. Most notably, 
the International Covenant on Economic, Social and Cultural Rights states clearly 
that the “right to an adequate standard of living includes food, housing, clothing” and 
recognizes the “fundamental right of everyone to be free from hunger.” Additionally, 
the Convention on the Rights of the Child obligates states parties “to combat disease 
and malnutrition, including within the framework of primary health care, through, 
inter alia, the application of readily available technology and through the provision 
of adequate nutritious food and clean drinking water, taking into consideration the 
dangers and risks of environmental pollution” [1,2].
The period of the first 1,000 days—from conception to 2 years of age—is a piv-
otal moment that determines a child’s destiny. Strong evidence shows that eliminat-
ing malnutrition in young children has multiple benefits (Figure 26.2). For example, 
it can
• Boost gross national product by 11% in Africa and Asia
• Prevent child deaths by more than one-third per year
• Improve school attainment by at least one year
• Increase wages by 5% to 50%




























FIGURE 26.2 The virtuous circle of improved nutrition.
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• Reduce poverty as well-nourished children are 33% more likely to escape 
poverty as adults
• Empower women to be 10% more likely to run their own business
• Break the intergenerational cycle of poverty [3]
The annual gross domestic product (GDP) losses from low weight, poor child 
growth, and micronutrient deficiencies average 11% in Asia and Africa—greater 
than the loss experienced during the 2008–2010 financial crisis [4]. Investing in 
nutrition has the potential to help break the poverty cycle and stimulate economic 
development. Every dollar invested can yield a return of US$16 [5].
Malnutrition (which includes the spectrum from undernutrition to obesity; also 
see Box 26.1) is linked to an estimated 45% of all under-5 mortalities [6]. It also 
impairs an individual’s productivity, which inhibits national growth with far-reaching 
consequences for so many indicators of socioeconomic progress. In this sense, mal-
nutrition represents an often invisible impediment to the successful achievement of 
the Sustainable Development Goals (SDGs) [7]. In other words, good nutrition is a 
maker and marker of development.
Malnutrition results not just from a lack of sufficient, adequately nutritious and 
safe food, but from a variety of contributing factors including health, care, education, 
sanitation and hygiene, access to food and resources, and women’s empowerment.
Over the past decade, global and country recognition of the threat that malnutrition 
poses to the health and future development of children, and therefore societies, has 
grown exponentially. Once viewed primarily as an issue that can be tackled through the 
health sector, the importance of a concerted approach is now widely accepted, involving:
• Multiple stakeholders, supported by the UN, civil society, business, aca-
demia, and donors
• Multiple sectors, including health, agriculture, women’s empowerment, 
planning, and education
• Multiple levels, from the highest levels of government to local community 
leaders
BOX 26.1 THE SCALE OF THE NUTRITION PROBLEM
• 2 billion people experience micronutrient malnutrition
• 1.9 billion adults are overweight or obese
• 156 million children under 5 years are too short for their age (stunted); 
50 million do not weigh enough for their height (wasted), and 41 mil-
lion are overweight; none of these children are growing healthily
• 794 million people are estimated to be calorie deficient
• 1 in 12 adults worldwide have type 2 diabetes
• In 14 countries, fewer than half of all children under 5 years old 
escape both stunting and wasting [8]
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In this context, the SUN Movement is a catalyst for change. The experiences of 
its members are contributing to strengthened evidence on effective actions required 
for achieving impact, and in shaping an enabling environment for good nutrition, fit 
to ensure that no one is left behind and that people everywhere benefit from good 
nutrition.
THE SCALING UP NUTRITION (SUN) MOVEMENT: 
HOW IT ALL STARTED
In 2008, a global food prices crisis struck, and the World Bank estimated that at 
least 100 million people were likely to be pushed back into poverty [9]. This was fol-
lowed by the global economic downturn in 2009, which pushed the poorest and most 
vulnerable to their knees, while the far-reaching implications of climate change on 
people’s livelihoods took hold. This triple threat of unstable food prices, economic 
uncertainty, and volatile climate-related events led to protests and demands for 
action by citizens across the globe. Hunger and malnutrition were finally recognized 
as political issues, and given a space on the global and national agendas.
At the same time, the evidence for tackling malnutrition was made clear beyond 
doubt. In 2008, Lancet published a series of papers on maternal and child under-
nutrition [10], which cataloged the impact of undernutrition on development and 
health, highlighted proven interventions to reduce undernutrition, and called for 
national and international action to improve nutrition for mothers and children. 
This helped prompt action by drawing the world’s attention to the high human cost 
of malnutrition, and to the inadequate response by development partners and coun-
tries alike.
It was against this backdrop that the SUN Movement was launched in 2010. Since 
then, the movement has catalyzed collective action to end malnutrition, bringing 
together governments, national and global civil society organizations, businesses, 
the UN system, and researchers and scientists across different sectors critical for 
the improvement of nutrition. It provides a space to convene, mobilize, share, learn, 
advocate, align, and coordinate actions.
HOW THE SUN MOVEMENT WORKS
SUN countries are fostering an enabling environment for scaling up nutrition 
by strengthening high-level commitments, building supportive policy and legal 
frameworks, implementing aligned actions behind a common set of results, and 
not only raising but more effectively spending resources for nutrition. They are 
doing this by investing in a set of capabilities that will empower actors at a coun-
try level to continuously improve country planning to end malnutrition; to mobi-
lize, advocate, and communicate for impact; build core capacities at all levels for 
multisectoral action; and ensure equity for all, with women and girls at the center 
(Figure 26.3).
SUN countries are building these capabilities through a peer-to-peer process that 
keeps governments in the driving seat, and national priorities and realities at the 
center. The SUN Movement’s support system adds value to this process by offering a 
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set of services that aim to unlock resources and intensify progress toward the move-
ment’s strategic objectives. This support system is comprised of the SUN Movement 
Secretariat and four networks—donor, UN, civil society, and business—as well as 
experts who offer technical support and leadership in nutrition (Figure 26.4). This 
support system responds and adapts to the breadth and width of SUN countries’ 
needs, expertise, and ambitions. It leverages its members’ experiences and their 










































































FIGURE 26.3 Strengthening core capabilities across SUN countries.
Lead Group
SUN Business Network (SBN)
United Nations Network (UNN)SUN Donor Network (SDN)
Civil Society Network (CSN)
SUN Movement Coordinator and Executive Committee and Multistakeholder Working Groups (MWG)








FIGURE 26.4 The SUN Movement Support System.
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During the period covered by its first strategy (2012–2015), the SUN Movement 
grew as a space for its members to convene and advocate for strengthened multisec-
toral and multistakeholder collaboration to scale up nutrition. Networks were set up 
(comprising donors, civil society, UN, and business), stakeholders in countries were 
mobilized, and members aligned around a set of engagement principles. Throughout 
its short history, the SUN Movement has evolved and, through effective advocacy, 
its members have been critical catalysts of change, their experiences contributing to 
evidence of effective interventions, and the shaping of the nutrition landscape.
During its first few years, the movement placed an emphasis on robust, multisec-
toral plans for nutrition and common results frameworks. Systems and processes for 
learning, harnessing and sharing experiences between countries and networks were 
established; a means for brokering technical assistance for countries lacking provid-
ers was developed, and a process of annual joint-assessment based on progress mark-
ers tied to the movement’s four strategic objectives has been established.
The SUN Movement Strategy and Roadmap 2016–2020 builds on the strengths 
and momentum from the movement’s work to date [11]. Forging new paths ahead, 
the consultative process through which the second strategy was developed has posi-
tioned the movement to respond to SUN countries’ demands, maximize the potential 
of SUN networks, and capitalize on the insight generated by the 2014 Independent 
Comprehensive Evaluation (ICE) of the SUN Movement [12].
The SUN Movement has been and will remain a continuous exercise in improve-
ment, through learning and adaptation. The 2016–2020 strategy is an expression of 
that. It takes stock of, and seeks to build on, the strengths and achievements of the 
movement’s first phase, while also charting new opportunities to achieve greater 
impact and further optimize its contributions to improving the nutritional status of 
communities.
THE GLOBAL NUTRITION CONTEXT
While the focus of the SUN Movement remains primarily on the reduction of stunt-
ing, many governments are adapting their national plans to address the multiple 
burdens of malnutrition, especially overweight and obesity. They recognize that mal-
nutrition, in all its forms, undermines peace and prosperity, while improved nutrition 
can lead to more just and sustainable futures for individuals, societies, and nations.
Momentum to improve nutrition is accelerating, and transformative change is 
achievable. The 2030 Agenda for Sustainable Development has committed all gov-
ernments to comprehensive, integrated, and universal transformations, which include 
ending hunger and malnutrition by 2030. They are galvanizing action around 17 
SDGs. While the ambition to “end hunger, achieve food security and improve nutri-
tion and promote sustainable agriculture” is captured in SDG 2, at least 12 of the 
17 global goals contain indicators that are highly relevant for nutrition [13]. Indeed, 
without adequate and sustained investments in nutrition, both directly and as part 
of an integrated set of interventions aimed at ending poverty and hunger, the full 
potential of the 2030 Agenda will not be realized.
The SDGs build on the six global nutrition targets agreed in the World Health 
Assembly (WHA) Resolution 65.6, which endorsed a Comprehensive Implementation 
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Plan on Maternal, Infant and Young Child Nutrition (MIYCN) in 2012 [14]. In 2013, 
the 66th session of the WHA agreed to halt the rise in diabetes and obesity as part of 
the adoption of the comprehensive global monitoring framework and targets for the 
prevention and control of noncommunicable diseases [15].
These WHA targets sit at the heart of the 2014 Rome Declaration and Framework 
for Action, which was the result of the Second International Conference on Nutrition 
(ICN2). The Rome Declaration calls for the UN system, including the Committee on 
World Food Security (CFS), to work more effectively together to support national 
and regional efforts, and enhance international cooperation and development assis-
tance to accelerate progress in addressing malnutrition [16]. Responding to this, the 
CFS established an Open Ended Working Group on Nutrition (OEWG) in October 
2015 to develop a clear vision for the role of the CFS on nutrition.
In April 2016, the United Nations General Assembly (UNGA) proclaimed the UN 
Decade of Action on Nutrition (2016–2025) to intensify action to end hunger and 
eradicate malnutrition worldwide, and ensure universal access to healthier and more 
sustainable diets—for everyone, everywhere. The Decade of Action on Nutrition 
coincides with the new Strategic Plan of the United Nations System Standing 
Committee on Nutrition (UNSCN), the dedicated platform for open, substantive, 
and constructive dialogue among UN agencies working on nutrition.
These commitments and agreed set of actions by the UN Member States are 
complemented by the “Nutrition for Growth (N4G) Compact,” which mobilized 
US$4 billion at the first N4G Summit in 2013. A major development resulting from 
the N4G Compact was the establishment of the Global Nutrition Report, which 
records advancements in meeting global nutrition targets, documents progress on 
commitments made, and makes recommendations for actions to accelerate prog-
ress [4].
The SUN Movement does not seek to replace the international nutrition architec-
ture, but it does aim to amplify the coherence of its members’ actions. Its members 
are guided by the strengthening governance of nutrition and are acting as catalysts 
for change. The (now) 59 governments that have committed to scaling up nutri-
tion, and the thousands of partners that are aligning their support behind them, are 
responsible and accountable for results. The lessons learned by these stakeholders 
are contributing to growing energy and momentum for improved nutrition, proving 
that more can be achieved together than is ever possible alone.
THE SUN APPROACH: SUPPORTING A MULTISECTORAL, 
MULTISTAKEHOLDER RESPONSE TO MALNUTRITION
Ambitious efforts to accelerate effective coverage of proven interventions are critical 
if SUN countries are to meet their national goals and commitments to achieve the 
WHA targets and the SDGs. There is now a wealth of evidence on key interventions 
that can significantly improve nutrition outcomes. This includes a set of 10 proven 
nutrition-specific interventions, including Infant Young Child Feeding, which, if suf-
ficiently scaled up, could eliminate approximately 900,000 deaths of children under 
5 years of age in the 34 high nutrition-burden countries, and reduce the number of 
children with stunted growth and development by 33 million [17].
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But we must go further. Nutrition-sensitive approaches have enormous poten-
tial to enhance the scale and effectiveness of nutrition-specific interventions. They 
address the underlying determinants of fetal and child undernutrition and develop-
ment, and incorporate specific nutrition goals and actions in agriculture, social safety 
nets, handwashing and other hygiene interventions, water and sanitation, health and 
family planning services, early child development, and education. In a recent budget 
analysis exercise conducted by 30 SUN countries, 25 were able to identify nutrition-
sensitive budget allocations across more than five of the key sectors: health; agricul-
ture; education; social protection; and water, sanitation, and hygiene (WASH) [18].
Strong policies, legislation, and frameworks are essential foundations for scaling 
up both nutrition-specific and nutrition-sensitive approaches. Examples include the 
International Code of Marketing of Breast Milk Substitutes [19], legal frameworks 
for maternity leave and breastfeeding protection, food fortification standards, salt 
iodization, and the Codex Alimentarius [20]. Although the SUN Movement does 
not set technical standards or develop normative guidance, it includes members that 
do. Working together, actors across the SUN Movement are working to support the 
development and dissemination of normative guidance, as well as to share best prac-
tices in operationalizing policies, monitoring impact, and encouraging adherence.
At a country level, national nutrition plans are the vehicles for translating policy 
into action and results. Countries in the SUN Movement are making progress in 
updating their national nutrition plans and engaging stakeholders to mobilize and 
align around a common set of results. They are directing negotiations among key 
sectors, a key process for accountability and a pathway for encouraging effective 
allocation of resources. Many SUN countries report significant progress in agreeing 
and implementing actions in line with common results frameworks and the policy 
management cycle. They are demonstrating that learning through implementation 
is key.
Current financial resources available for nutrition-specific and nutrition-sensitive 
interventions are woefully inadequate. In order to implement national nutrition plans 
at scale, SUN countries need not only to raise new money but also to better spend 
existing funds. A recent investment framework estimates that an additional US$7 
billion per year for the next 7 years is required to reach the WHA target of reducing 
the prevalence of stunting by 40%. The framework proposes that US$4 billion of this 
financing comes from governments of countries affected by undernutrition, US$2.6 
billion comes from donors, and the remaining US$400 million is raised through 
innovative financing facilities. The projected returns are huge: 3.7 million children’s 
lives saved, at least 65 million fewer stunted children, and 265 million fewer women 
suffering from anemia [21].
The global community has committed to optimizing all financing streams toward 
sustainable development and coordinating it for the greatest impact. Governments 
will need to better align their financing frameworks, and to be mindful of the need 
for coherence and alignment with climate change, health, and agriculture financ-
ing. Efforts to increase the effectiveness of development cooperation need to be 
enhanced, based on the basic principles of country ownership, a focus on results, 
cost effectiveness, inclusive partnerships, greater transparency, and improved 
accountability. While development assistance for improved nutrition outcomes will 
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be important, increased domestic resources are a clear means of sustainably financ-
ing nutrition. Financing streams for nutrition will need to be leveraged from domes-
tic public and private origins, international public and private sources, and blended 
finance. All public funds must positively impact the poorest and most vulnerable in 
all societies [22].
BOX 26.2 EMPOWERING WOMEN AND 
GIRLS TO IMPROVE NUTRITION
How girls are treated matters for nutrition. Not surprisingly, higher levels 
of gender discrimination are associated with higher levels of both acute and 
chronic undernutrition [23]. At the same time, improvements in women’s sta-
tus have been shown to account for around 12% of global reductions in the 
proportion of children who are underweight, and improvements in women’s 
enrollment in secondary education account for 43% of global reductions in the 
proportion of children who are underweight [24].
Nutrition matters for empowering girls. Improving the nutrition status of 
girls, adolescents, and women increases their ability to perform well at school 
and to become empowered in the workforce and the wider society. In short, 
those involved in the SUN Movement know that the virtuous circle of good 
nutrition and better futures starts with the girl child. Although every country 
is shaping its own set of solutions, some lessons are emerging from the SUN 
Movement.
First, women need to be at the decision-making table with adequate support 
and space for their voices to be heard. From state houses, parliaments, and 
ministries, to local authorities, communities, and households, women need 
equal access to opportunities, training, and information in order to contribute 
to the process of devising solutions to the nutrition-based challenges they face. 
For this reason, education and women’s knowledge of nutrition is critical. This 
requires investments to send and keep girls in school, but also in building 
knowledge related to infant and young child feeding, literacy, and vocational 
skills.
The stories of SUN countries make it abundantly clear that a community-
centered approach that ignites the power of sisterhood is essential. Women are 
very often best placed to decide how resources are used at home to improve 
nutrition. Supporting them to reach out to other women in their communi-
ties to share their experience, knowledge, and aspirations is vital. But it isn’t 
enough to only look to the women. Men must champion and actively engage in 
women’s empowerment. From presidents, to chiefs to husbands, fathers, and 
brothers, men must actively engage in ensuring that every member of their 
families can enjoy good nutrition [25].
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WHERE THE SUN MOVEMENT IS GOING
The SUN Movement is building on existing successes. SUN countries, supported 
by growing networks of partners, have set themselves the ambitious goal of trans-
forming the way in which they address undernutrition. SUN countries are beginning 
to put nutrition at the heart of their development policies. They have seen a dra-
matic increase both in high-level political commitment for nutrition and in bringing 
together diverse groups of people across sectors around common goals. They are 
setting clear targets, scaling up their programs, and putting in place the necessary 
legal and financial frameworks to support a nutrition revolution.
Together, stakeholders across the SUN Movement are acting to ensure that chil-
dren everywhere get the best possible start in life and reach their full potential. SUN 
countries have proven that a large-scale social movement is possible. It is time to 
support the SUN Movement to transform lives and societies.
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27 A Role for Preconception 
Nutrition
Taylor Marie Snyder, Homero Martinez, 
Sara Wuehler, and Luz Maria De-Regil
INTRODUCTION
Although the 1,000-day period between conception and a child’s second birthday is 
paramount in building a strong foundation for the child’s life, the significance of the 
preconception period must not be ignored. A woman’s weight, dietary habits, and 
nutrient stores practiced prior to and during early conception can influence preg-
nancy outcomes by altering both maternal and/or fetal metabolism during precon-
ception, conception, implantation, placentation, and embryo- or organogenesis [1].
Women’s preconception nutrition influences pregnancy outcomes by affecting 
the supply of nutrients early in pregnancy, which in turn influences fetal develop-
ment. However, some less intuitive risk factors that result from the inadequate, and 
possibly transgenerational, nutritional status of the women in childhood and during 
adolescence (e.g., maternal short stature) also increase maternal and infant perina-
tal mortality and morbidity. Therefore, it is critical to ensure adequate nutritional 
status for women starting in childhood, before the reproductive years [2]. Nutrition 
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interventions need to be integrated with other health and social interventions to maxi-
mize women’s human potential. The following sections elaborate on all these factors.
THE ROLE OF NUTRITION IN GROWTH AND DEVELOPMENT
PreconcePtion Weight and Pregnancy outcomes
Women of reproductive age are vulnerable to malnutrition in any of its forms: under-
nutrition, vitamin and mineral deficiencies, or overweight and obesity. Preconception 
underweight or overweight, short stature, and micronutrient deficiencies can all con-
tribute independently or simultaneously to increase maternal and fetal complications 
during pregnancy [3].
Prepregnancy overweight (body mass index [BMI] ≥25 kg/m2) approximately 
doubles the risk for the two highest causes of maternal mortality: gestational dia-
betes mellitus and hypertensive disorders of pregnancy, including preeclampsia [4]. 
Additionally, it is linked to a spectrum of adverse pregnancy outcomes, including 
obstetric anesthesia-related complications, maternal morbidity due to infection, 
poor lactation practices, prolonged gestation, preterm births, and decreased success 
with vaginal childbirth [3,5,6]. Maternal overweight is positively associated with 
large for gestational age (LGA) infants, macrosomia, childhood overweight, and 
childhood obesity [4,7,8]. It is also inversely associated with infants born low birth 
weight (LBW) and small for gestational age (SGA). Maternal obesity also confers an 
increased risk of fetal and neonatal death as well as childhood disease [4,7,8]. The 
risks associated with a high BMI can be reduced significantly during the postpartum 
and interpregnancy periods by practicing exclusive breastfeeding during an infant’s 
first 6 months and increasing physical activity [2].
At the other end of the spectrum, prepregnancy underweight, generally consid-
ered BMI <18.5 kg/m2, increases the risk of several negative outcomes: intrauterine 
growth restriction, stillbirth, preterm birth, SGA, and LBW [3,6]. Several obser-
vational studies from countries including China and Vietnam have evaluated the 
relationships between prepregnancy BMI and infant birth size, in addition to other 
health outcomes. These studies found that infants born to underweight women were 
at increased risk of being SGA [1]. It is also important to note that maternal under-
weight, which generally reflects preconceptional underweight, is one form of mater-
nal malnutrition, which in turn is independently associated with LBW [9]. 
micronutrient deficiencies
Micronutrient deficiencies (MNDs) can result from an inadequate dietary intake, 
low bioavailability of dietary nutrients, and increased nutrient requirements. The 
bioavailability of nutrients can be positively or negatively affected by dietary fac-
tors, such as vitamin C or phytate, or lifestyle habits such as smoking and consuming 
alcohol. 
In this line, physiological or pathological  conditions  like repid growth, menstrual 
bleeding, parasitic or other infactions (malaria, HIV) increase the daily requirements 
[2] (Table 27.1). Globally, an estimated 2 billion people (over 30% of the population) 
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TABLE 27.1
Common Micronutrient Deficiencies and Their Role, Potential Causes, 
and Risk Factors in Women of Reproductive Age [10–11]
Nutrient Role and Function Causes and Risk Factors of Deficiency
Iron Serves as a carrier of oxygen to the 
tissues from the lungs by red blood cell 
hemoglobin, as a transport medium for 
electrons within cells, and as an 
integrated part of important enzyme 
systems in various tissues.
Deficiency can:
• Cause microcytic hypochromic 
anemia
• Inhibit intellectual capacity
• Affect motor development, physical 
performance and productivity
• Increase the risk of LBW and 
maternal and infant mortality
Nutritional iron deficiency develops when 
the diet cannot supply enough iron to 
meet the body’s requirements.
Risk factors:
• Menstrual blood loss
• Pregnancy demands




• Hookworm or other parasites that lead 
to blood loss (more frequent in 
tropical countries)
Folate Coenzyme in the metabolism of nucleic 
and amino acids.
Deficiency can: 
• Interrupt physiological neural tube 
formation, neurological function, 
and brain development
• Cause NTDs and megaloblastic 
anemia 
• Increase risk of colorectal cancer 
and cardiovascular disease and 
stroke
Inadequate dietary intake of folate and 
folic acid, which is highly common 
globally.
Risk factors:
• Diets low in folate and/or folic acid
• High prevalence of the MTHFR 
C677T polymorphism
• Malabsorption conditions (e.g., 
coeliac disease and/or tropical sprue)
Iodine Responsible for the synthesis of thyroid 
hormones by the thyroid gland. Thyroid 
hormones impact bodily metabolic 
processes, growth, and development.
Deficiency occurring during fetal and 
neonatal growth and development can 
lead to:
• Irreversible damage of the brain and 
central nervous system. This damage 
may lead to irreversible mental 
retardation, most seriously to 
cretinism. It can also lead to 
retarded physical growth.
• Goiter, juvenile hypothyroidism, and 
iodine-induced hyperthyroidism
The iodine content of food depends on the 
iodine content of the environment in 
which it was grown or raised.
Risk factors:
• Diets low in iodine
• Lack of consumption of adequately 
iodized salt
(Continued )
426 The Biology of the First 1,000 Days
TABLE 27.1 (CONTINUED)
Common Micronutrient Deficiencies and Their Role, Potential Causes, 
and Risk Factors in Women of Reproductive Age [10–11]
Nutrient Role and Function Causes and Risk Factors of Deficiency
Calcium Plays an essential role in blood clotting, 
muscle contraction, nerve transmission, 
and the formation of bones and teeth.
Deficiency can lead to:
• Development of corticosteroid 
osteoporosis
Inadequate consumption of calcium, often 
associated with low consumption of dairy 
products.
Risk factors:
• Diets low in milk or milk-based 
products
• Vegan diet
• Adolescent growth spurt (when an 
increase in the rate of skeletal calcium 
accretion occurs)
Vitamin B12 Acts as a coenzyme in nucleic acid 
metabolism.
Deficiency can lead to:
• Megaloblastic anemia
Inadequate consumption and absorption of 
vitamin B12.
Risk factors:
• Diets low in B12
• Vegan diet (which offers no intake, as 
plants do not synthesize vitamin B12)
• Vegetarian diet (which offers a low 
intake, unless eggs, milk, and other 
dairy foods are consumed)
• Malabsorption disorders (rarely due 
to autoimmune disease)
• Hypochlorhydria associated with 
atrophic gastritis
Vitamin D Required to maintain normal blood levels 
of calcium and phosphate needed for 
the normal mineralization of bone, 
muscle contraction, nerve conduction, 
and general cellular function in all cells 
of the body.
Deficiency can lead to:
• Osteoporosis and blood loss
• Certain types of cancer
• Heart disease
• Dementia
Inadequacy is common in those with 
darkly pigmented skin or with limited 
sun exposure.
Risk factors:
• Diets low in vitamin D
• Being obese
• Lack of sun exposure
• Adolescent growth spurt
• Dress codes that do not permit the 
skin to receive direct sunlight
Source: Data from World Health Organization (WHO), Vitamin and mineral requirements in human 
nutrition, 2nd ed., Bangkok, Thailand: WHO, 2004; and Save the Children, Adolescent nutri-
tion: Policy and programming in SUN+ countries, London: Save the Children, 2015.
Note: NTDs, neural tube defects.
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are experiencing at least one micronutrient deficiency [2], with vitamin A, iodine, 
zinc, iron, and folate being the most widespread [12].
A mother’s micronutrient status is a strong determinant of her baby’s nutritional 
status, as micronutrients are transferred from mother to fetus across the placental 
barrier [2,4] (Table 27.2). The extent of transfer depends on the mechanism used 
by the micronutrient to cross the placental barrier, and is, therefore, micronutrient-
specific [2]. In the preconception period, micronutrients play an important role in 
fertility and reproductive function [4]. Through several biological pathways, micro-
nutrients are involved in the early stages of gestation during which organogenesis 
occurs [4]. Iron, iodine, zinc, and long-chain n-3 polyunsaturated fatty acids are 
essential to the development of the brain and nervous system, while insufficiencies 
of vitamins A, B6, B12, and folate during embryogenesis may lead to fetal malforma-
tions and pregnancy loss [1]. Although the role of vitamin D and calcium have been 
studied during pregnancy, the function of their status during the preconceptional 
period on later pregnancy outcomes remains to be studied.
Given its public health significance and effects on health, anemia (particularly 
due to iron deficiency) and folate insufficiency have attracted the attention of aca-
demia and policy makers. Anemia is defined as a low level of hemoglobin in the 
blood, which impairs oxygen delivery to the tissues by red blood cells [13]. Blood 
hemoglobin concentration is the most common indicator of anemia at the population 
level [12]. Worldwide, approximately 528 million women of reproductive age had 
anemia in 2011, of which 32.4 million were pregnant [14]. This means that the global 
prevalence of anemia was approximately 29% for all women of reproductive age and 
38% for pregnant women [14].
Causes of anemia vary across countries and populations. Although there are wide 
ranges in the proportion of anemia that is related to iron deficiency, on average about 
half of all anemia is attributed to iron deficiency [2,14]. Additional causes of anemia 
include deficiencies in other micronutrients (e.g., folate, and vitamins A and B12), 
acute and chronic infection and/or inflammation, and inherited or acquired blood 
disorders [14]. Iron deficiency anemia adversely affects cognitive and motor devel-
opment, and can affect physical performance and productivity [14]. Anemia during 
pregnancy is associated with LBW and an increased risk of both maternal and infant 
mortality [14].
There are currently no accurate global estimates of the prevalence of folate insuf-
ficiency among women of reproductive age [15]. However, there is strong evidence 
from a number of randomized controlled trials that taking folic acid around the time 
of conception and to about the first 28 days reduces the risk of neural tube defects 
(NTDs) by 69% [16]. Globally, it is estimated that approximately 303,000 newborns 
die within 4 weeks of birth every year due to congenital anomalies, including NTDs 
[17]. Between days 21 and 27 postconception, the neural plate closes to form what 
will be the spinal cord and cranium [10]. NTDs, such as spina bifida or anencephaly, 
result from the improper closure of the spinal cord and cranium, leading to death or 
varying degrees of paralysis.
Just as over and underweight during preconception can have consequences for 
pregnancy outcomes, micronutrient excesses can be just as detrimental as their 
deficiencies. Safe upper limits have been established for all life stages for many 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































430 The Biology of the First 1,000 Days
micronutrients [16]. In the periconceptional period, for example, an excess of vita-
min A can affect embryonic development and result in teratogenesis, and excess 
iodine can be harmful to the thyroid [10].
the role of ePigenetics
Nutritional factors can affect both male and female cells during embryonic and fetal 
development [21,22]. Although a woman’s oocytes (eggs) are formed exclusively dur-
ing her own fetal development, their quality can be affected by events or exposures 
experienced any time between her own conception and that of her offspring, includ-
ing nutritional deficiencies [2]. Epigenetic processes allow one genotype to display 
multiple phenotypes depending on environmental cues that can induce epigenetic 
and other responses that modify the growth and metabolic trajectory in the oocyte 
and embryo [2]. These cues can include maternal hyperglycemia or dietary imbal-
ances, such as under- or overconsumption of micronutrients, or an imbalance of 
nutrients involved in the methylation cycle [2].
PRECONCEPTION CARE AND NUTRITION
PreconcePtion care
Clinicians and researchers emphasize that many effective prenatal care interven-
tions would achieve better outcomes if started during the preconceptional period [2]. 
The preconceptional period has been divided into proximal and distal periods. The 
proximal period is the time immediately preceding pregnancy (up to 2 years prior 
to conception). The distal preconception period focuses on the mother’s early years, 
her adolescence, and the 2-plus years prior to a pregnancy (not necessarily the first 
pregnancy) [4]. Thus, effective preconception interventions are tailored to either the 
proximal or distal periods.
Preconception care is defined as any preventive, promotive, or curative health 
care intervention provided to women of reproductive age in the preconceptional 
period [4,5]. Care is aimed at improving health-related outcomes in all women, and 
her newborns and children holistically [4,5]. This encompasses initiatives that go 
beyond nutrition such as women’s education and empowerment. Preconception care 
includes targeted health interventions, such as receiving vaccinations and consuming 
vitamin and mineral supplements.
a sPecial emPhasis on the teenage girl
As mentioned earlier, maternal risk factors are rooted in childhood and adolescence. 
Adolescence represents the second major growth phase in an individual’s life. While 
no longer experiencing the changes associated with early childhood, adolescents 
undergo a period of rapid growth and maturation as the ability to reproduce is devel-
oped [23]. Cultural practices in which girls are fed last, after male family members, 
might, among other poor eating habits, increase the risk of developing malnutrition 
in this life stage [23]. Insufficient nutrition during childhood and adolescence can 
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also result in vitamin and mineral deficiencies which are associated with impaired 
physical and cognitive performance, and reduced immunological response [2,24]. 
The International Federation of Gynecology and Obstetrics recommends the promo-
tion of a varied and healthy diet as the first step toward meeting the nutrient needs 
of adolescents [2]. If a healthy diet cannot be achieved, adolescent girls can consume 
additional nutrients through supplementation or fortification of food staples and con-
diments, as described later.
An important aspect of adolescent health, one that complements nutrition inter-
ventions, is the prevention of teenage pregnancy and early attention to pregnancy 
care, if needed [4]. Prevention of adolescent pregnancy is crucial to avoiding com-
petition for nutrients between the growing adolescent and fetus, competition that 
may impair adolescent growth in benefit of the fetus [25,26]. As mentioned earlier, 
maternal short stature increases the risk of obstetrical intervention, maternal mortal-
ity, and childhood mortality [2].
External support of adolescents to ensure marriage and pregnancy do not occur 
too early may be necessary, because adolescent girls often lack the necessary educa-
tion, support, and access to health care to make decisions about their nutrition and 
reproductive health care [5]. High rates of child marriage are linked to poor family 
planning, higher fertility, unintended pregnancies, and an elevated risk for complica-
tions during childbirth [27]. Pregnant adolescents are at increased risk of complica-
tions at delivery, and of having preterm babies, or giving birth to babies of LBW or 
SGA [2,11,24]. Furthermore, very young mothers (under the age of 15) are often 
not physically mature enough to deliver a healthy, full-term baby and they have an 
increased risk of death or disability from maternal anemia, obstructed labor, fistula, 
preterm birth, and LBW [4,28].
Despite increased risks, married and unmarried adolescents are less likely than 
adults to use any form of contraception during sexual activity [5]. To prevent unin-
tended pregnancy, preconception care must include access to contraceptives, and 
education about their appropriate use, along with information about reproductive 
rights, including the right to abstinence [29,30].
male PreconcePtion health
The preconception health of the male partner is an incredibly important, yet 
often overlooked, element of preconception health. In addition to a woman’s eggs, 
male sperm can also be impacted by environmental factors experienced from the 
father’s conception through to the production of mature sperm [2,21,22]. Paternal 
preconception epigenetic exposures can influence the developmental path of the 
embryo, as spermatozoon (motile sperm cell) affect fetal growth in utero [18]. 
Paternal age, smoking habits, and exposure to environmental toxins are associated 
with the development of malformations, mental health disorders, and cancer in 
offspring [21,22].
Similarly, paternal micronutrient deficiencies, obesity, and poorly controlled dia-
betes may negatively impact sperm and egg quality, fertility, and the general health of 
offspring [2,21,22]. Both human and rodent studies have confirmed that paternal obe-
sity impairs basic spermatozoon function, sex hormones, and molecular composition 
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[21,22]. These results disrupt embryonic development and health, and thus increase 
the disease burden of their offspring, with the greatest impact on female offspring 
[21,22]. Furthermore, it has been hypothesized that paternal obesity at conception 
may increase the likelihood of offspring experiencing obesity and the corresponding 
negative consequences for multiple generations [21,22].
KEY INTERVENTIONS FOR IMPROVING MICRONUTRIENT STATUS
nutrition-sPecific interventions
A variety of interventions are used to address micronutrient deficiencies in women 
of reproductive age, which can broadly be categorized as dietary modification, sup-
plementation, biofortification, and fortification of staple foods and condiments at a 
central level or at the point of use. Factors such as the economy and health infra-
structure of a society can impact the feasibility and effectiveness of interventions, 
and therefore must be considered when tailoring solutions for the target population. 
Table 27.3 lists preconception health interventions that have the ability to improve 
the nutritional status of women of reproductive age, leading to indirect and direct 
pathways to optimize health and nutrition.
Many interventions geared toward improving nutritional status are closely tied to 
adapting human behaviors to embrace recommended preventative health measures. 
Thus, it is important to acknowledge the likelihood that following recommended pre-
ventive health measures is dependent on an array of factors influencing human behav-
ior. Elements impacting the efficacy of solutions include an individual’s perception of 
how susceptible they are to a given condition, and their perception of the seriousness of 
a given condition [31]. These perceptions are factored into their weighing of perceived 
benefits of preventive action against the perceived barriers, which ultimately deter-
mines their likelihood of taking the recommended preventative health actions [31].
dietary modification
Dietary changes often focus on an increase in dietary variety and encouraging 
behaviors that increase the intake, absorption, and utilization of micronutrients to 
satisfy requirements. For example, to prevent or alleviate iron deficiency, interven-
tions may include increasing intake of foods rich in bioavailable iron, increasing 
intake of foods in combination that enhance iron absorption, or decreasing foods that 
inhibit iron absorption [2,10].
Launching public health campaigns aimed to inform and influence behavioral 
change in all individuals is a strategy used to encourage dietary modifications, as 
well as to optimize other health and nutrition practices, thus also addressing pre-
conception. One benefit of public health campaigns is the broad reach of messages 
beyond individuals who are specifically seeking care. Large-scale strategies should 
address beneficial and detrimental local cultural beliefs, reach a broad age range of 
women, target those who may be considering pregnancy, develop preemptory aware-
ness and knowledge, and take into account various other demographics and personal 
characteristics [27,31].
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TABLE 27.3
Preconception Health Interventions That Can Improve Nutritional Status
Interventions Components of Interventions
General preconception care and 
routine health promotion
• Physical activity
• Adequate nutritional status, ranging from healthy weight to 
dietary diversity
• Appropriate weight control
• Specific nutrient intake
• Folic acid and other micronutrient consumption
Provide medically accurate and 
comprehensive information for 
reproductive health and family 
planning
• Pregnancy prevention
• Birth spacing (interpregnancy intervals)
• Considerations during advanced maternal age
Prevention of negative outside 
influences 
• Female genital mutilation
• Intimate partner violence
Prevention and treatment of 
sexually transmitted infections 
(STIs)
• Prevention components include medically accurate, age 
appropriate, sexual health education and access to effective 
methods of contraception
• Treatment components include access to medications, like 
antiretroviral for HIV/AIDS
Prevention and management of 
other infections (immunizations, 
vaccinations)
• Immunizations against vaccine-preventable diseases 
(e.g., tetanus, rubella, polio)
• Seasonal influenza vaccines
• Tuberculosis
• Deworming
Screen for, diagnose, and manage 






Screen for, diagnose, and manage 
mental health disorders
• A range of mental health disorders, including depression and 
anxiety
Lifestyle modifications (cessation 
of harmful behaviors)
• Secondhand smoke exposure
• Substance abuse, including alcoholism and smoking 
cigarettes
• Eating disorders
Environmental hazard prevention 
and exposure reduction
• Reducing exposure to lead, pesticides, and chemicals, 
including toxic medicines
• Provision of sanitation
• Access and use of clean water
• Elimination of disease vectors
• Prevention of overcrowding and indoor air pollution
Targeting needs of special 
populations
• Support for immigrants
• Emergency services for refugees
(Continued)
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In spite of being the ultimate goal, achieving an optimal diet is not feasible in 
many settings where access, availability, and affordability of foods are limited. 
Thus, other solutions are needed.
suPPlementation
Oral supplementation refers to the direct provision of micronutrients in the form of 
a pill, tablet, liquid, or other formulation. Supplements are given daily or intermit-
tently (e.g., weekly or every 6 months) depending on the formulation and intervention 
[32]. Supplementation is probably the most widespread public health intervention to 
address micronutrient deficiencies. It has proven to be effective, but challenges to 
implementation still remain.
Iron and folic acid are the nutrients most commonly supplemented among women 
of reproductive age prior to pregnancy or during the postpartum period. However, 
weekly supplementation is preferred over a daily dose as a preventive public health 
measure to prevent anemia due to iron deficiency [32]. In addition to iron, iodine 
supplementation may be necessary in settings where salt iodization coverage is lower 
than 90% [33]. Women of reproductive age in low- to middle-income countries often 
have multiple coexisting micronutrient deficiencies [24]. However, there is no recom-
mended supplementation scheme or composition of a supplement to address several 
deficiencies concomitantly in nonpregnant women.
food fortification
Food fortification is the addition of one or more essential nutrients to a food for the 
purpose of preventing or correcting a demonstrated deficiency in the general popula-
tion or in specific population groups [2]. Fortification is considered to be one of the 
most cost-effective nutrition interventions. In addition, it requires little to no active 
participation or behavior change by the end users [34].
Staple foods such wheat and maize flours, and rice are fortified in many countries 
[12,31]. The addition of iron and folic acid to wheat and maize flours has proven to 
TABLE 27.3 (CONTINUED)
Preconception Health Interventions That Can Improve Nutritional Status
Interventions Components of Interventions




Source: Data from Dean S, Imam A, Lassi Z et al., A systematic review of preconception risks and inter-
ventions, The Aga Khan University, 2011; World Health Organization (WHO), Global strategy 
for women’s, children’s and adolescent’s health 2016–2030, Italy, 2015; and Moos MK, Dunlop 
AL, Jack BW et al., Am J Obst Gynecol 2008; 199(Suppl. 2):S280–9.
Note: AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; STIs, sexu-
ally transmitted infections.
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be an effective and safe strategy to both increase iron stores and prevent NTDs [31]. 
For example, fortification of flour and ready-to-eat cereals in countries such as the 
United States, Canada, Chile, and Costa Rica has been linked to significant reduc-
tions in the incidence of NTDs in these countries [1]. Some sectors have expressed 
concern about the amount of folic acid that men are receiving through fortification. 
However, to date, there is no evidence that such an approach is not safe [35].
The most successful case of fortification is the addition of iodine to salt as a 
means of improving iodine status [33,36]. Over 120 countries have implemented this 
intervention, resulting in 71% of households worldwide having access to adequately 
iodized salt [37].
Point-of-use fortification, also known as “home fortification,” involves the addi-
tion of micronutrients in powder form to energy-containing foods [38,39]. These 
micronutrient powders can be added to foods during or after cooking. Point-of-use 
fortification is most commonly used for children under 2 years of age [38,39] and 
to our knowledge it has not been researched in the preconceptional period so as to 
inform a clinical or public health intervention.
Biofortification has emerged as another important intervention to correct selected 
micronutrient deficiencies. Biofortification can improve the nutrient density of staple 
food crops through conventional plant breeding, agronomic management, or genetic 
engineering [40]. Currently, the most common targeted micronutrients are iron, zinc, 
and vitamin A, due to the high prevalence of deficiencies of these micronutrients 
among children under the age of 5 and women of reproductive age in developing 
countries [41]. As staple foods predominate in the diets of the poor, and because 
it implicitly targets low-income households, biofortification can reach relatively 
remote areas and vulnerable populations [42]. Once established, a biofortified crop 
system can be sustained because nutritionally improved varieties continue to grow 
and be consumed without substantial additional inputs, even if donor attention and 
funding fades [42]. Furthermore, farmers often favor these mineral-packed seeds, 
because the trace minerals help their crops resist disease and other environmental 
stressors [42].
CONCLUSION AND RECOMMENDATIONS
A woman’s nutritional status influences important pregnancy outcomes that have 
long-term, intergenerational effects on women and their offspring. Critically, 
research indicates that maternal risk factors are rooted in childhood and adoles-
cence. Therefore, preconception care interventions must begin long before adoles-
cence and continue throughout women’s reproductive years, including during the 
intervals between pregnancies. The ultimate aim is to break the intergenerational 
cycle of undernutrition, where undernourished and stunted mothers give birth to 
premature or SGA infants, which in turn repeat the cycle.
Additional research is needed to strengthen and improve the evidence on the most 
effective interventions and delivery platforms to reach women. As preconception 
care is preventive rather than curative, interventions should address population-
wide improvements on micronutrient and nutritional status that are evidence-based 
and scalable. Also, efforts should be made to systematically explore the effects of 
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nutrition in the preconceptional period on the incidence of noncommunicable condi-
tions in the adult life of the offspring.
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28 Interpregnancy Intervals 
and Birth Spacing
Amanda Wendt and Usha Ramakrishnan
INTRODUCTION
The World Health Organization (WHO) has recognized the first 1,000 days of life 
as a critical window for the improvement of child growth and development. More 
recently, the preconception period has also been recognized as crucial, especially 
in populations where there are high levels of undernutrition. In addition to nutrition-
specific interventions, counseling that encourages both recommended birth intervals 
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and a delayed age of first conception, have been emphasized as important factors 
indirectly affecting maternal and fetal nutritional status. Since the early 1900s, 
researchers have reported associations of the time between two consecutive preg-
nancies and adverse birth outcomes [1]. Observational studies then and since have 
shown adverse outcomes to be associated with both short and long time intervals.
Short interpregnancy intervals (IPIs) are common in both high- and low-income 
countries around the globe (see Table 28.1). Two analyses, using Demographic and 
Health Survey (DHS) data from 72 and 61 countries, respectively, found that almost 
a quarter of all births followed short IPIs (<24 months) [2,3], with one reporting 
12% following long IPIs (>60 months) [3]. Even in the United States, only half of all 
pregnancies were conceived in the optimal IPI, defined as 18 to 59 months; a third 
of pregnancies began within 18 months of the previous birth and 15% after long IPIs 
(≥60 months) [4].
Recent systematic reviews have found that women with short IPIs are at increased 
risk for several adverse birth outcomes, namely, small for gestational age (SGA), 
preterm birth (PTB), low birth weight (LBW), stillbirth, early neonatal death [5,6], 
and uterine rupture in women attempting vaginal delivery after a cesarean section 
(VBAC) [7]. Long IPIs were also reported to be associated with PTB, LBW, SGA, 
labor dystocia, and preeclampsia [8,9].
However, for many outcomes, the relationship is less clear. Typically, studies 
assessing birth spacing have been observational; thus, unmeasured or residual con-
founding is an issue that must be considered [5]. Women with short IPIs are more 
likely to have a lower socioeconomic status (SES), use antenatal care services less, 
and are more likely to have an unplanned pregnancy; all of these factors are also asso-
ciated with adverse pregnancy outcomes. Longer IPIs are correlated with advancing 
maternal age and possible infecundity, both shown to be independently associated 
with poor birth outcomes. Finally, studies often differ in their exposure definition, 
in terms of both the interval measured and interval length. IPI is most commonly 
defined as the time from one birth outcome (e.g., live birth, stillbirth, abortion) until 
TABLE 28.1
Estimated Prevalence of Short and Long Interpregnancy Intervals by Region
<24 months (%) ≥60 months (%) Number of Intervalsa
Central Asia 33 12.8 3,699
Latin America and Caribbean 30.4 12.4 61,772
North Africa, West Asia, and 
Europe
30.1 15.7 32,400
Sub-Saharan Africa 19.9 9.6 198,747
South and Southeast Asia 24.7 14.8 75,150
Total 24.6 11.8 371,768
Source: Data from Rutstein SO, Trends in birth spacing, DHS Comparative Reports No. 28, Calverton, 
MD: ICF Macro, 2011.
a Weighted by number of intervals.
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the subsequent conception. Birth interval is also used, measuring the time from one 
live birth to the next. Interdelivery interval (IDI) similarly measures this interval, but 
includes other pregnancy outcomes. Birth interval or IDI measurement are therefore 
possible when the date of conception and gestational age are unknown. However, 
PTBs may artificially shorten the interval in these instances, overestimating the 
LBW associated with these intervals. None of these definitions take into account 
breastfeeding practices, which could further deplete maternal reserves in those who 
breastfeed and also quickly become pregnant. To account for this, some researchers 
measure the duration of the “recuperative interval” defined as the nonpregnant, non-
lactating interval between pregnancies [10].
Another issue is the variation of cutoff values used to define IPI duration as 
“short,” “long,” and even “optimal,” which makes comparisons challenging. The 
WHO currently recommends IPIs of longer than 24 months, with the strongest evi-
dence supporting avoidance of IPIs less than 18 months and longer than 59 months. 
Limited evidence of possible adverse effects associated with 18 to 27 month intervals 
led the consultation participants to compromise on a 24-month recommendation. 
This was also done to simplify the public health message (2 years), and to comple-
ment UNICEF’s recommendation of breastfeeding for the first 2 years of life. For 
pregnancies occurring after an abortion (spontaneous or induced), the recommended 
IPI was ≥6 months [11]. Many studies define short IPI using these categorizations 
or subsets, often with the shortest IPI defined as <6 months. However, other short 
or long IPI definitions include the WHO “optimal” interval recommendations or in 
some cases, the reference group also contains intervals the WHO has recommended 
to avoid [12,13].
Despite the inherent challenges of varying definitions of exposure and compari-
son groups between studies, evidence has demonstrated, with varying degrees of 
strength, the association of birth spacing with various maternal and infant outcomes. 
In this chapter, we first discuss hypothesized biological mechanisms to explain how 
short or long IPIs may result in adverse maternal and child outcomes, followed by a 
description of the evidence linking IPIs to these outcomes.
BIOLOGICAL MECHANISM HYPOTHESES
In 2012, Conde-Agudelo and colleagues reviewed existing hypothesized causal 
mechanisms relating short interpregnancy intervals to adverse maternal and child 
outcomes [14]. In the following, we outline mechanisms reviewed by Conde-Agudelo 
et al., as well as others relating to both short and long intervals (see Figure 28.1).
Maternal nutrient Depletion
Pregnancy and lactation are critical periods characterized by increased growth 
and development which, in turn, greatly increase requirements for energy, pro-
tein, calcium, essential fatty acids, and several micronutrients, such as iron, folic 
acid, and vitamin A. The maternal nutrition depletion hypothesis posits that during 
pregnancy and lactation, maternal energy and nutrient stores are depleted, and a 
recuperative interval (nonpregnant, nonlactating) of adequate length is needed to 
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recover these stores before the next pregnancy [15,16]. This hypothesis was first 
introduced over 50 years ago as “maternal depletion syndrome,” described as the 
cumulative effect of multiple pregnancies over a lifetime on nutritional status. In 
1992, the theory was redefined to focus on spacing from one pregnancy to the next 
and authors highlighted that both pregnancy and lactation were “depletion periods.” 
In addition, Winkvist described four types of women, defined by weight change 
over the reproductive cycle, and posited that only the “marginally malnourished” 
would have maternal depletion syndrome, defined as a state in which a “nutrient 
replete” status could be achieved with an adequate recuperative interval. Those 
who gained or did not change weight during the reproductive cycle were considered 
already replete; and severely malnourished women, though also depleted, would 
need improved nutrition to become replete as only extending the recuperative inter-
val would not be enough [16].
In these situations, where women are not consuming adequate nutrients during 
gestation, it was previously assumed that the fetus took priority and received nutri-
ents at the mother’s expense. However, this concept was challenged by animal stud-
ies, which found that upon food restriction during gestation, if there was maternal 
weight loss, even greater losses were observed in fetal birth weight [17]. This trend 
was further confirmed through a reanalysis of data collected during the Dutch fam-
ine (1944–1945), resulting in diet restriction lasting 7 months. Women affected dur-
ing their second to third or third trimesters who lost weight gave birth to infants with 
even greater birth weight losses. A pregnancy weight loss of 3% from preconception 
weight resulted in a 10% loss in infant birth weight [18]. This further supported the 
pattern seen in animal studies that, under maternal dietary restriction, infant growth 
is actually inhibited to a greater extent than maternal weight gain.
This differential partitioning of nutrients, which depends upon initial maternal 
nutritional status and consumption, was further explored by Winkvist et al. in 1994 
among women in Pakistan. Authors found malnourished women gained weight over 
the reproductive cycle, but infant weight decreased (from one pregnancy to the next). 
Marginally malnourished women lost weight over the reproductive cycle although 
infant weight increased. Well-nourished women did not show a difference on aver-
age of weight gain or infant birth weight changes over the reproductive cycle. Further 
analysis found that periods of overlap (when breastfeeding continued during the sub-
sequent pregnancy) led to weight gain in both malnourished groups. Authors hypoth-
esized that high reproductive stress may lead to partitioning of nutrients favoring 
maternal rather than fetal nutrition [19].
A recent systematic review examining this hypothesis found “unclear evidence,” 
as results of studies on this topic have been mixed [14]. Differences in the popu-
lations  studied, time of measurement (e.g., birth interval versus full reproductive 
cycle), initial nutritional status of the mother, and dietary intake during gestation 
all play an important role and different measures across studies make true compari-
sons challenging. Furthermore, to date, the majority of studies have only focused 
on anthropometric measures or hemoglobin. However, this could soon be exam-
ined further through several recent and ongoing randomized controlled trials, 
which are using periconceptional whole food or micronutrient supplementation to 
examine undernutrition effects on maternal and child outcomes [20]. These studies, 
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if previous IPI is documented, could provide further insight into the impact of IPI on 
micronutrient status, as well as how improved nutrition in the periconceptional phase 
influences this relationship.
There is some evidence suggesting that the effect of birth interval on poor 
pregnancy outcomes such as PTB and SGA may be explained by folate depletion. 
Findings from a large Dutch cohort study suggest that folic acid appeared to mediate 
the effect of birth spacing on birth weight and SGA [21]. “Early users” were defined 
as those reporting preconception folic acid consumption, “late users” reported con-
suming postconception, and “nonusers” did not report folic acid supplementation. 
For nonusers, a 1-month increase in IPI increased mean birth weight by 165 g (±40 g) 
and reduced the likelihood of SGA (OR: 0.38; 95% CI: 0.24–0.60) [22]. For both 
early and late folic acid users, these relationships were not statistically significant, 
suggesting that perinatal folic acid consumption may improve birth weight following 
a short IPI. Although the authors’ analysis was adjusted for several confounders, they 
noted that residual confounding was possible due to the different maternal character-
istics of women who consume versus do not consume folic acid supplements during 
pregnancy that were not captured in the analysis. Furthermore, it was possible that 
this effect was due to different micronutrients in the supplements consumed; how-
ever, 65% of the women reported consuming only folic acid [21].
BreastfeeDing–pregnancy overlap
As previously mentioned, several studies have shown that overlapping periods of 
breastfeeding and pregnancy are common across many countries, and are logically 
associated with shorter IPIs. This overlap has been hypothesized to adversely affect 
child growth in the womb, as well as to affect the lactation volume and milk quality 
of the previous and subsequent child. In 1990, Merchant et al. classified women who 
participated in the original Institute of Nutrition of Central America and Panama 
(INCAP) longitudinal study conducted in Guatemala from 1969 to 1977, according 
to birth interval and measures of overlap [23]. In this report, “long recuperative inter-
val” was defined as at least a 6-month nonlactating, nonpregnant period between 
pregnancies, while a “short recuperative interval” indicated less than 6 months. 
Those with an overlap of breastfeeding during pregnancy were classified as having 
a “short overlap” if the child was weaned in the first trimester, and a “long overlap” 
if weaning took place in the second or third trimester. This study showed a border-
line significant trend (p = 0.10) of increasing birth weight across the four groups as 
the duration of overlap decreased and recuperative interval increased [24]. Studies 
examining breastfeeding in association with overlap have also found evidence of 
reduced nutrient concentrations in breast milk [22].
physiological recovery froM previous pregnancy
Various adverse effects associated with short IPIs may also be due to detrimental 
effects associated with an incomplete physiological recover from the prior preg-
nancy. Brief descriptions of some proposed mechanisms are provided next.
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Infection Transmission
Women who acquire a “persistent” infection during their previous pregnancy fol-
lowed by a short birth interval may be at a higher risk of still being infected. Cheng 
et al. found that, compared to women with a birth interval of >36 months, those with 
a short birth interval (<12 months) were 60% more likely to test positive for group B 
streptococci infection in their subsequent pregnancy, which is associated with neo-
natal infection [23].
Maternal Inflammation
Another proposed mechanism posits that inflammatory processes present during a 
pregnancy may be carried over to the subsequent pregnancy, especially if they are in 
close succession. A U.S. study found recurrent PTB to be associated with placental 
inflammatory lesions, which were more common among women who experienced 
lesions in the previous pregnancy [25]. Elevated inflammation has also been posited 
as an explanation for the increased risk of preterm premature rupture of membranes 
(PPROM) associated with short IPI [26] leading to PTB [27].
Cervical Insufficiency
Cervical insufficiency, defined as early dilation or effacement of the uterine cervix 
before contractions or labor, could occur after short IPIs due to insufficient time for 
reproductive tissue muscle tone recovery and could lead to PTB [28]. One study 
found that normalization of the cervical tissue collagen content following spontane-
ous delivery occurred only after 12 months postpartum [29].
Abnormal Remodeling of Endometrial Blood Vessels
Short IPIs may not allow sufficient time for remodeling of endometrial blood vessels, 
which may lead to increased risks of placenta previa and abruption placenta [30]. 
Wax et al. also found an increased risk of placenta accreta, increta, and percreta in 
women with short cesarean to birth intervals [31], although no studies have exam-
ined this hypothesis further.
Uterine Scar Healing Following Cesarean Section
Short IPIs may increase the risk of uterine rupture among women attempting a 
vaginal birth after caesarean section (VBAC) [8]. Studies examining the thickness 
of the lower uterine segment (indicating scar strength from the previous cesar-
ean incision) found that IPIs under 6 months were associated with insufficient 
scar strength [32], and that complete uterine restoration did not occur until 6 to 
9 months [33].
effects of closely spaceD siBlings
Short birth intervals additionally mean that siblings of similar ages will be present in 
the household, and thereby could increase the risk of infectious disease transmission, 
especially in resource-poor settings. Shorter birth intervals have been associated 
with increased diarrhea [34] and Helicobacter pylori infection [35].
446 The Biology of the First 1,000 Days
physiological regression: long interpregnancy intervals
Longer IPIs have also been associated with adverse outcomes, such as PTB, LBW, 
SGA, preeclampsia, and labor dystocia [8,9]. Conde-Agudelo and Belizan found a 
lower risk of preeclampsia in subsequent pregnancies; however, this effect was not 
seen when IPI was 5 years or more, when the risk was equivalent to nulliparous 
women [30]. Overall, it is probable that the association between duration of IPI and 
adverse maternal and infant outcomes are due to multiple factors that likely vary 
depending on the woman’s nutritional status, breastfeeding practices, and previous 
birth outcome(s). All of the above factors typically vary at an individual and popula-
tion level in different settings, and may explain the conflicting evidence described in 
the following sections (see Table 28.2).
INTERPREGNANCY INTERVALS AND MATERNAL OUTCOMES
Maternal MorBiDity anD Mortality
Several studies have examined the association between IPI and maternal morbidi-
ties, such as hemorrhage, PPROM, maternal mortality, preeclampsia/eclampsia, and 
hypertensive disorders. However, there are often few studies to compare for a single 
outcome. In a 2012 systematic review, authors found only five moderate-quality 
studies examining short IPI and which measured in total 10 maternal morbidity out-
comes. No single outcome was reported adequately across three different studies, the 
criteria required to perform a meta-analysis [5].
Conde-Agudelo and Belizan analyzed data from over 450,000 pregnancies in 
Latin America and found a significant increased risk of third trimester bleeding and 
PPROM among women with IPIs of 0 to 5 months, compared to 18 to 23 months 
after adjustment for several potential confounders, including maternal age, parity, 
pregnancy outcome, and health care use [30]. Other studies have not found a signifi-
cant association between IPI and hemorrhage, bleeding, or PPROM outcomes [5]. 
For maternal death, Conde-Agudelo found an increased risk (OR: 2.5; 95%CI: 2.1, 
5.4) among women with IPIs of 0 to 5 months [30]. In Bangladesh, Rahman et al. did 
not find a significantly increased risk; however, the shortest IPI group examined was 
<12 months [36]. Overall, it appears that short IPI could be associated with adverse 
maternal outcomes; however, to allow comparison, further high-quality research and 
multiple studies assessing similar outcomes are needed.
For women attempting a VBAC, the evidence is more consistent. Two U.S. stud-
ies found an increased risk of uterine rupture following an interdelivery interval of 
<19 months [37] and IPI of <6 months [38]. In Canada, authors found a dose-response 
effect, as those with interdelivery intervals of <12 months had the greatest incidence 
of uterine rupture followed by 12 to 23 months with 24 to 35 months as the reference 
[39].
The evidence of adverse outcomes associated with longer IPIs also showed a 
clearer picture. A 2016 meta-analysis found increased odds of preeclampsia in IPIs 
of >4 years compared to 2 to 4 years (OR: 1.10; 95% CI: 1.102, 1.19) [9]. Conde-
Agudelo et al. (2007) also reported that longer IPIs were associated with an increased 
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TABLE 28.2
















* * 4 [9], 5 [5], 
22 [8]
Low




+ 4 [8] Low
Preeclampsia + 4 [9], 6 [8] Low
Labor dystocia + 1 [8] Low
Child Outcomes
Stillbirth 1.35 [5] (1.07, 1.71) 3 [5] Moderate
Early neonatal death 1.29 [5] (1.02, 1.64) 4 [6] Moderate
Preterm birthc,e 12 [5], 16 [6]
1.58 [5] (1.40, 1.78) Moderate
1.41 [5] (1.20, 1.65) Moderate
Low birth weightc 1.44 [5] (1.30, 1.61) 6 [5]
10 [6] Moderate
Small for gestational age 1.26 [6] (1.18, 1.33) 13 [6] Moderate
Birth defects + Low
Child Growth and Development
Stunting + 8 [10] Low
Malnutritiond * 35 [10] Low
Autism Spectrum 
Disorder
+ + 7 [40] Low
Schizophreniaf + 2 [41,42] Low
Note: +, trend of increased risk; *, unclear/mixed results.
a Studies included in reviews that assessed strength of the evidence of the respective association unless 
otherwise indicated. Numbers of studies where estimates are provided include only the number of stud-
ies used in meta-analyses.
b Maternal morbidities/mortality: Postpartum hemorrhage, premature rupture of membranes, third tri-
mester bleeding, preeclampsia (for short IPI), eclampsia, hypertensive disorders, maternal infection, 
uteroplacental bleeding disorders (placenta previa and placental abruption), gestational diabetes, pla-
centa accreta, puerperal endometritis, composite morbidity measure, maternal mortality, proteinuria, 
high blood pressure, maternal death.
c Preterm birth and low birth weight: Odds ratios reported considering IPIs <6 months as compared to 
study reference IPIs of <12 months or a subset.
d Child malnutrition: Stunting, underweight, wasting, weight change, MUAC.
e Number of studies on preterm birth (extreme and moderate combined).
f No review has assessed the relationship between IPI and schizophrenia.
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risk of preeclampsia and labor dystocia in a systematic review [8]. All six included 
studies examining preeclampsia in the 2007 systematic review showed an increased 
risk with longer IPIs. Two studies also reported a 10% to 12% increased risk for each 
additional interpregnancy or birth interval year [8]. Labor dystocia was evaluated in 
one high-quality study including 650,000 pregnancies. The authors found a dose-
response relationship, with intervals beyond two years showing increased odds of 
labor dystocia [43].
Maternal nutritional status
The association between IPI and maternal nutritional status has also been explored 
with mixed results. In a cross-sectional study in Latin America of over 450,000 preg-
nancies, Conde-Agudelo and Belizan found that women with an IPI of <6 months 
had a 30% increased risk of anemia as compared to 18- to 23-month intervals [30]. In 
Nigeria, a study found women with IPIs of <24 months had an increased anemia risk 
[44]. Two other studies found no significant association, though one only assessed 
clinical anemia [45,46].
INTERPREGNANCY INTERVALS AND CHILD OUTCOMES
stillBirth anD early neonatal Death
There are many studies examining the relationship of birth spacing to stillbirth 
and early neonatal death. However, only three studies on stillbirth and three 
for early neonatal death were included in a recent meta-analysis, as many poor- 
quality studies were excluded, such as those that did not consider any con-
founding variables or define IPI as <12 months or a subset of this group. The 
meta-analysis found an overall random-effects OR of 1.35 (95% CI: 1.07, 1.71) 
for stillbirth among pregnancies following an IPI of <7 months (or a subset) with 
“unexposed” groups’ IPI between 12 and 50 months (or a subset) [5]. Stillbirth 
was defined as fetal death ≥20 weeks of gestation in one included study [47] and 
as ≥28 weeks in the other two [48,49]. The meta-analysis on early neonatal death 
(death in the first week of life) resulted in an OR of 1.29 (95% CI: 1.02, 1.64), 
with similar IPI categorizations. Evidence for the association of both outcomes 
and short IPIs was assessed to be of “moderate” quality [5]. A 2006 review 
did not create pooled estimates on these outcomes; however, they created meta-
regression curves, which appeared to show higher risks for both outcomes in IPIs 
<6 months or >50 months [6].
preterM Birth
Preterm birth has been associated with short IPIs across many studies of higher 
quality. Conde-Agudelo et al. (2006) reported a J-shaped meta-regression curve 
and pooled estimates that showed highest risk of PTB among those with a low IPI 
(<6 months) (OR: 1.77; 95% CI: 1.54, 2.04) as well as an elevated risk for IPIs of 6 
to 11 months (OR: 1.23; 95% CI: 1.16, 1.31) and longer IPIs (>60 months) (OR: 1.27; 
95% CI: 1.17, 1.39) [6]. Similar results were obtained by Wendt et al. (2012), in which 
short IPIs (<6 months; 6–11 months) were significantly associated both with extreme 
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preterm birth (<33 weeks) and moderate preterm birth (<37 weeks). The authors con-
cluded that the evidence for short IPI and PTB was of moderate quality [5].
low Birth weight
Low birth weight, which can be due to PTB or restricted growth in utero, has also 
long been associated with shorter IPIs. A 2012 systematic review reported higher 
risks of LBW for IPIs less than 6 months, and a weaker but still significant elevated 
risk for 6 to 11 month IPIs compared to >12 months (<6 months OR: 1.44; 95% CI: 
1.30, 1.61; 6–12 months OR: 1.12; 95% CI: 1.08, 1.17) [5]. Conde-Agudelo et al. 
(2006) also reported similar pooled estimates for these IPI groups, and longer IPIs 
(≥60 months) were found to be associated with LBW (OR: 1.43; 95% CI: 1.27, 1.62) 
as compared with an 18- to 23-month interval [6].
sMall for gestational age
Conde-Agudelo and colleagues’s meta-analyses for SGA found an increased risk in 
shorter and longer IPIs, with the lowest risk group having an 18- to 23-month IPI 
[6]. For short IPIs (<6 months), the pooled odds ratio was 1.26 (95% CI: 1.18, 1.33). 
The odds ratio for long IPIs (≥60 months) was 1.29 (95% CI: 1.20, 1.39). In the meta-
regression curves constructed for PTB, LBW, and SGA, the risk of the outcome 
increased with IPIs of >6 months or <20 months [6].
Birth Defects
Fewer studies have examined the association between IPI and birth defects, and 
most reports come from high-income countries. Existing evidence suggests a pos-
sible increase in birth defects, especially among women with IPIs <6 months. 
Grisaru-Granovsky et al. reported an increased risk of congenital malformations 
(OR: 1.14; 95%CI: 1.04, 1.24) in IPIs of <6 months, compared to IPIs of 12 to 
23 months in a prospective study of over 400,000 pregnancies in Israel [50]. An 
increased risk of birth defects with both shorter IPIs (0–5 months OR: 1.15; 95% CI: 
1.03, 1.28) and longer IPIs (≥60 months OR: 1.15; 95% CI: 1.04, 1.26) when com-
pared to a reference IPI of 18 to 23 months was also found in a case control study in 
Washington state [51]. Another U.S. case control study identified gastroschisis cases 
through the National Birth Defects Study in 10 U.S. states. Women with IPIs of 
<12 months had an increased risk (OR: 1.7; 95% CI: 1.1, 2.5) compared to an 18- to 
23-month interval. Notably, a stronger association was found among women living 
in northern states (above 37°N latitude), especially with a winter/fall conception, 
suggesting a possible role for vitamin D depletion, which is also associated with 
inflammation [52].
chilD growth anD DevelopMent
Dewey et al. (2007) reviewed data from 52 studies, and found overall that longer 
birth intervals were associated with a reduced risk of malnutrition, but not in all pop-
ulations [10]. Outcomes reviewed included stunting, underweight, wasting, weight 
change, and mid-upper arm circumference (MUAC), and the evidence between short 
IPIs and child malnutrition was mixed [10]. However, a recent study, which used 
DHS data from 61 low- and middle-income countries, found that, compared to birth 
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intervals of 24 to 35 months, women with short intervals of <12 months or 12 to 
23 months had a small, increased risk of their child being stunted (<12 months: RR: 
1.09; 95% CI: 1.06, 1.12; 12–23 months: RR: 1.06; 95% CI: 1.05, 1.06) [2]. A major 
limitation, however, is the cross-sectional nature of the studies and absence of data 
on the overlap between pregnancy and breastfeeding.
The relationship between birth spacing and child development has often received 
less attention in contrast to maternal and pregnancy outcomes. However, this is an 
important area [11], especially for developmental disorders such as autism spectrum 
disorder (ASD), which is a major concern [40]. In a recent systematic review, Conde-
Agudelo et al. (2016) estimated that an IPI of less than 12 months was associated 
with a twofold increased risk of any ASD (pooled OR: 1.90; 95% CI: 1.16, 3.09) 
and a stronger association when only autistic disorder was considered (OR: 2.62; 
95% CI: 1.53, 4.50) [50]. Three of the included studies also found longer IPIs to 
be associated with increased risk of ASD. The authors also reported emerging evi-
dence that short IPIs were associated with developmental delay and cerebral palsy. 
The association between birth spacing and ASD was not attenuated by the typical 
confounding factors such as SES and parental characteristics or mediated by PTB 
and LBW [40]. The maternal folate depletion hypothesis may be a plausible explana-
tion. Periconceptional folic acid consumption has been associated with a reduced 
risk of autistic disorder, although not Asperger disorder or pervasive developmental 
disorder not otherwise specified [53], and folic acid supplementation may attenuate 
the relationship between IPI and ASD [54]. Additional hypotheses included the path-
ways of maternal stress, maternal inflammation, and residual confounding.
A few studies have also examined the association between birth spacing and schizo-
phrenia, which has been hypothesized to occur through maternal folate depletion [41]. 
Smits et al. (2004) reported an increased risk of schizophrenia, particularly among 
shorter birth intervals (15–20 months or, assuming term births, IPIs of 6–11 months) 
in a large cohort of 1.43 million people born from 1950 to 1983 in Denmark [55]. 
Women with a birth interval of ≤14 months (an estimated IPI of 0–5 months) did not 
show an increased risk compared to women with birth intervals of ≥45 months (IPI of 
approximately ≥36 months). The authors surmised that this was due to nonlactating 
women, who may recover both folate stores and fertility faster (although no informa-
tion on breastfeeding was collected) [41]. A 2011 study of a Swedish population (born 
from 1973 to 1980) also found that, compared to IPIs of 13 to 24 months, IPIs of 
<6 months and 7 to 12 months were also associated with increased risk of schizophre-
nia [42]. Overall, the evidence base for the association between IPI and schizophrenia 
is quite small, and further research is required to understand this connection.
INTERPREGNANCY INTERVALS FOLLOWING 
OTHER PREGNANCY OUTCOMES
Most of the birth-spacing research to date has focused on pregnancies following live 
births, although that is unfortunately not the only pregnancy outcome possibility. 
Studies that have examined pregnancy outcomes following miscarriages, stillbirths, 
or abortions have overall recommended shorter IPIs than the 18 to 23 month interval, 
which the data supports for IPIs following live births. The WHO recommendation 
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is to wait at least 6 months before the subsequent pregnancy to decrease the risk 
of adverse maternal and perinatal outcomes following a spontaneous or induced 
abortion [11], based largely on a large cross-sectional analysis conducted in Latin 
America [7]. A 2015 review for clinicians examined literature addressing birth 
spacing following other pregnancy outcomes and gave a moderate rating of B to 
the strength of the evidence regarding IPI recommendations following a live birth, 
spontaneous miscarriage, and cesarean delivery. Other pregnancy outcomes evalu-
ated received a low C rating due largely to the lack of available evidence and study 
heterogeneity (see Table 28.3) [56].
CONFOUNDING
When examining the relationship between IPI and maternal and child outcomes, it is 
important to note that this association can be confounded by many factors. Several 
characteristics, such as lower SES, less access to or utilization of health care ser-
vices, unintended pregnancy, postpartum stress, and unstable lifestyles, have been 
independently associated with shorter IPIs and adverse pregnancy outcomes. Longer 
IPIs may be associated with infecundity, a change of partner or other social/familial 
disruptions, advanced age, maternal illness, or unplanned pregnancies, which again 
are associated with adverse outcomes [5,8,10]. Many of these variables are quite 
challenging to measure accurately and, even when adjusted for, residual confounding 
TABLE 28.3
Interpregnancy Interval Recommendations Following Different Pregnancy 








Live birth 18–23 months 20 Moderate
Stillbirth 15–24 months 3 Low
Miscarriage
Spontaneous <6 months 3 Moderate
Ectopic/MTX 3–6 months 2 Low
Abortion
Medical >6 months 1 Low
Surgical 3–6 months 2 Low
Special Populations
Cesarean delivery 6–12 months 5 Moderate
Gestational trophoblastic 
disease (GTD)
12 months 1 Low
Source: Bigelow CA, Bryant AS, Obstet Gynecol Surv 2015, 70:458–64.
a Bigelow and Bryant assigned values of B and C were changed to moderate and low, respectively.
452 The Biology of the First 1,000 Days
remains a possibility. Studies that were included in the major systematic reviews on 
this topic did exclude research that did not adjust for any confounders. However, even 
including only those with adjusted analyses, studies of different populations and 
adjusting for different sets of confounders continue to add to the data heterogeneity 
of this topic.
POLICY IMPLICATIONS
Birth spacing is a modifiable risk factor and has the potential to greatly affect mater-
nal and perinatal outcomes at the population level. Due in part to the WHO’s recom-
mended birth-spacing intervals, some countries have integrated birth spacing into 
their maternal and reproductive health policy. For example, in India, the Ministry of 
Health and Family Welfare established a campaign called “Ek teen do” (one, three, 
two), including mass media messaging and health-worker incentives to encourage a 
spacing of 3 years between the first and second births [57]. In Vietnam, national 
guidelines dictate only two children, spaced 3 to 5 years apart, although this is not 
always followed at the population level [58]. However, overall, few countries have 
implemented birth-spacing programs or successfully addressed the unmet need for 
family planning services, which would include effective birth-spacing strategies [55]. 
Birth spacing has been recommended to be included as one of the key evidence-based 
interventions to address preconception care in order to decrease preventable maternal 
and infant deaths, and improve maternal and child nutrition [59]. Awareness of the 
importance of birth spacing by both health providers, women, and their families will 
be crucial to improving counseling and adoption of optimal birth-spacing practices.
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A Critical Opportunity 
for Intervention
Emily Mates and Anne Bush
INTRODUCTION
Adolescents are defined by the World Health Organization (WHO) as people aged 
between 10 and 19 years. The Lancet Commission on Adolescents 2016 analysis used 
a range of 10 to 24 years of age to cover the groups defined by the United Nations 
Department of Economic and Social Affairs (UNDESA) as adolescents (ages 
10–19 years), youths (ages 15–24 years), and young people (ages 10–24 years) [1].
As of 2012, there were 1.2 billion adolescents in the world, of which 90% live 
in low- and middle-income countries (LMICs). In industrialized countries, adoles-
cents make up 12% of the population, as compared to 19% in LMICs [2]. As more 
children are surviving beyond their fifth birthday, the population of adolescents is 
increasing [3].
There is growing awareness of the importance of adolescent health and nutrition, 
and increasing recognition that investing in adolescents’ health and well-being is 
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essential to achievement of the post-2015 development agenda. This is captured by 
the inclusion of adolescents within the United Nations Secretary General’s Global 
Strategy for Women’s and Children’s Health. The recent Lancet Commission on 
Adolescents [1] has also galvanized attention.
Understanding and evidence of the global situation on adolescent nutrition is lim-
ited. Most health and nutrition surveys start from age 15 years, resulting in a lack 
of information about those 10 to 14 years, for example, National Demographic and 
Health Surveys (DHS) typically focus on women of reproductive age (15–49 years). 
Anthropometric nutrition surveys almost exclusively focus on children under 5 years 
of age.
Nutrition intervention during adolescence is critical to influence current, future, 
and intergenerational nutrition and health, for the following reasons:
 1. Adolescents are a nutritionally vulnerable group, with high nutritional require-
ments due to rapid growth and sexual maturation.
 2. There is the potential to address nutritional deficits from the first decade of 
life and for catch-up growth.
 3. Adolescence provides an opportunity to break the intergenerational cycle of 
malnutrition.
 4. Improving nutrition/dietary practices at this age may have a positive impact 
on adult health.
 5. Adolescence is a period of openness to new ideas [1,4,5] and therefore pres-
ents an opportunity to target interventions behaviors and practices that will 
influence health outcomes in adulthood.
Each of these is discussed in more detail next.
ADOLESCENCE IS A TIME OF INCREASED 
NUTRITIONAL REQUIREMENTS
Increased nutritional requirements during adolescence reflects the fact that growth 
during adolescence is faster than at any other time in an individual’s life, with the 
exception of the first year. During this period adolescents gain up to 50% of their 
adult weight and skeletal mass and 15%–25% of their adult height [4], with changes 
in body shape and composition. Increased nutritional requirements (e.g., for iron and 
vitamin A) also result from adolescence being the period of sexual maturation [6,7].
Macronutrients: energy and Protein
The rapid rate of growth during and following puberty results in adolescents having 
some of the highest energy and protein requirements of any age group. Energy needs 
for growth have two components: (1) energy used to synthesize growing tissues, and 
(2) the energy deposited in those tissues, mainly as fat and protein [8].
These high requirements mean that adolescents are vulnerable to undernutrition. 
The term undernutrition is used to encompass low height-for-age (stunting), low 
weight-for-height (wasting), and low weight-for-age (underweight). It also includes 
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micronutrient deficiencies. If protein and energy intakes are inadequate, the biologi-
cal changes of adolescence may be affected. Undernutrition can result in a number 
of negative consequences for adolescents, including: delayed physical growth and 
sexual maturation, reduced work capacity, impaired cognitive ability, and height-
ened risk of chronic diseases in adulthood [9]. Adolescent girls who are stunted and 
become pregnant have an increased risk of complications such as obstructed labor 
and vesicovaginal fistula (a tract that develops between the vagina and the bladder 
as a result of prolonged, obstructed labor, causing uncontrollable leaking of urine 
through the vagina). Their infants are at an increased risk of low birth weight and 
preterm birth and, in turn, are more at risk of becoming stunted and giving birth to 
small infants themselves [1].
In some countries, up to half of all adolescent girls 15 to 19 years are stunted [2]. 
Based on information from 64 countries with available data, in 10 countries more 
than one-quarter of adolescent girls 15 to 19 years are underweight (BMI <18.5 kg/m2), 
while in India 47% are underweight [10].
Evidence points to the effectiveness of balanced protein-energy supplementation 
in addressing undernutrition in children and preventing adverse perinatal outcomes 
in undernourished pregnant women [11]. Other interventions to improve household 
food security, such as cash transfers, which provide a predictable direct transfer to 
increase household disposable income of vulnerable families, also show promise 
[11]. However, few interventions have specifically targeted adolescents or have been 
evaluated for their effectiveness during adolescence. As a result, little is known about 
the benefits or potential negative side effects (e.g., an increased risk of obesity) of 
interventions to address protein-energy malnutrition in this age group [1]. Although 
school-based feeding programs are increasingly being broadened to include adoles-
cents, there are few studies of its effectiveness in this age group. A systematic review 
in 2007 found only one study that included children up to 13 years, and results indi-
cated no effect on height or weight [12]. In only one subsequent study of its kind, 
school feeding has been shown to reduce anemia in girls aged 10 to 13 years, but did 
not have an impact on anthropometric indicators such as BMI [13].
At the other end of the scale, prevalence rates of obesity and overweight in ado-
lescents are increasing in LMICs, as well as in high-income countries (HICs). This 
likely, in part, reflects the greater consumption of foods that are high in added sugars 
and fats, combined with decreases in physical activity and possibly because they 
are stunted, lessening their energy requirements. Based on a reanalysis of DHS data 
from 2005 to 2010 from 58 countries with available data in 11 countries, the United 
Nations Children’s Fund (UNICEF) reported that more than one-fifth of adolescent 
girls 15 to 19 years were overweight (BMI >25 kg/m2) [10]. Obesity in adolescence 
is a strong predictor of adult obesity and associated morbidity [1]. Obesity is a risk 
factor for cardiovascular diseases and type 2 diabetes during adolescence and adult-
hood, and is associated with complications during pregnancy, such as gestational 
diabetes [2].
Thus, interventions targeted at adolescents to prevent overweight and obesity are 
critical, and should be focused on the adoption of healthy eating habits and physi-
cal exercise. A recent systematic review found evidence that interventions to pro-
mote good nutrition and prevent obesity can have a marginal effect on reducing BMI 
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in adolescence [7]. However, with a lack of data from LMICs, the findings in this 
review are limited to 10 studies from HICs only, so little is understood about what 
works in adolescence across other settings. The Lancet Commission on Adolescents 
concludes that multicomponent approaches, which include policy measures, educa-
tion strategies, and environmental changes to promote increased physical activity 
and healthy eating habits, are more likely to be effective than single-component 
approaches [1]. Some studies highlight specific barriers to increasing physical activ-
ity among adolescent girls, for example, suitable place and social support, and sug-
gest school-based approaches may also be effective [7]. Overall there is a lack of 
studies in this age group and more research to generate high-quality evidence of 
what works is required.
Micronutrients
As well as increasing requirements for energy and protein, the high velocity of 
growth during adolescence increases the requirements for many micronutrients, 
particularly those with a role in energy metabolism and tissue synthesis, including 
skeletal tissue, red blood cells, and muscle mass. Of particular importance are iron, 
folate, calcium, vitamin D, and zinc.
Iron
Iron requirements increase dramatically during adolescence in both girls and boys, 
and can exceed those for adult menstruating women [8]. This is a result of an expan-
sion in total blood volume, including a marked increase in hemoglobin mass and 
concentration, the increase in lean body mass, and the onset of menses in young 
females.
Low intakes combined with low bioavailability of iron during the period of 
increased requirements means that both adolescent males and females are vulner-
able to iron deficiency anemia (IDA), defined as low hemoglobin and low iron status. 
IDA reduces physical work capacity, affects cognitive function, and may depress 
physical growth [4], yet little is known about the effect of IDA on learning and edu-
cational attainment in adolescents [1]. Globally, IDA is the third highest cause of 
years lost to death and disability (DALYs) among adolescents [14]. The problem is 
particularly acute in Africa, where DALY rates due to IDA are the highest.
Interventions to address IDA during adolescence are therefore crucial to address 
these negative consequences. Adolescence also provides an opportunity to intervene 
to prevent future negative consequences of anemia in pregnancy. Even if an adoles-
cent girl has adequate iron status, low dietary iron intakes of foods with low iron 
bioavailability may result in the inability to maintain adequate stores of iron. Low 
iron stores in women of reproductive age may indicate an increased risk of IDA in 
future pregnancies, due to the additional requirements during pregnancy. IDA has 
also been associated with adverse maternal and fetal outcomes [15]. The risk of an 
infant being born with low birth weight (LBW) is significantly greater in the event 
of moderate maternal preconception anemia [11]. Poor iron and folic acid status has 
been linked with preterm births and fetal growth restriction [16].
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The significant negative consequences of IDA mentioned above provide a strong 
case for intervening in adolescence to prevent current problems and subsequent 
problems in pregnancy, although direct evidence of effective interventions in this 
age group remains limited. A recent systematic review [7] found that iron/iron folate 
supplementation alone or in combination with other micronutrients reduced the 
prevalence of anemia among adolescents, and that school-based delivery had the 
greatest effect on anemia reduction. However, 22 of the 31 studies included in 
the review were focused on females and 23 were conducted in LMICs, so findings 
were not generalizable across sexes or contexts. Beyond this, there is again a dearth 
of evidence for interventions specifically targeting adolescents, but population-wide 
interventions, including iron fortification of staple foods (such as wheat flour, maize), 
improving food security and nutrient density, regular deworming where intestinal 
helminths are common, and the prevention and control of malaria, will also benefit 
adolescents. The WHO recommends daily iron supplementation as a public health 
intervention for all menstruating adolescent girls and adult women living in settings 
where anemia is highly prevalent (>40% prevalence) [17]. During pregnancy, supple-
mentation with iron and folic acid [18] or multiple micronutrient supplements [19] are 
associated with improved outcomes, including a reduced risk of LBW and small for 
gestational age (SGA). However, it should be noted that the latest guidelines from the 
WHO only recommend iron/iron-folate and not multiple micronutrient supplementa-
tion during pregnancy [20].
Folate
Folate has an integral role in DNA, RNA, and protein synthesis, and can protect 
against neural tube defects as folate is required for neural tube closure during the first 
trimester of pregnancy. Recommended intakes of folate in adolescents (400 μg/day) 
are the same as for adults, and are based on the intake required during both precon-
ception and pregnancy to prevent neural tube defects. In view of the high require-
ments and low bioavailability, folic acid supplementation is recommended in at-risk 
groups. A 2015 Cochrane Review found a 69% reduction in the risk of neural tube 
defects with oral folic acid supplementation in doses ranging from 360 μg to 4,000 μg 
a day, with and without other micronutrients, before conception and up to the first 
12 weeks of pregnancy [21]. Thus, in contexts of early marriage and pregnancy, 
supplementation with folic acid during adolescence is an important nutrition inter-
vention. The WHO recommends daily folic acid supplementation with 400 μg/day 
(in combination with daily iron supplementation) commenced as early as possible, 
ideally before conception, to prevent neural tube defects [20].
Calcium and Vitamin D
Adolescence is a period with rapid accrual of bone mass. Approximately 40% to 
60% of adult bone mass is accumulated during adolescence, with over 25% devel-
oped during the 2-year period of peak skeletal growth [22]. Calcium and vitamin D 
are important nutritional factors influencing this process. As bone mineral density is 
a primary determinant of later-life osteoporosis and its complications, interventions 
to ensure adequate intakes of calcium and vitamin D during adolescence is a critical 
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opportunity to reduce the risk of osteoporosis later in life. Furthermore, randomized 
controlled trials have shown that exercise has the potential to improve bone health 
under conditions of adequate calcium intake [23]. Data from different countries sug-
gests that many adolescents are not achieving their recommended calcium intakes of 
1300 mg/day. For example, in the United States, Average Daily Intakes among ado-
lescent girls are 876 mg/day (less than 67% of the recommended dietary allowance 
[RDA]), and less than 15% of this group meets the RDA [22]. In developing countries, 
calcium intakes of children and adolescents are typically a third to a half of the RDA 
[24]. However, the benefits of supplementation have been found to be minimal, result-
ing in only small increases in bone mass that are short-lived once supplementation is 
discontinued. The reasons for such small effects of supplementation are unknown. 
A better approach is to support the achievement of adequate amounts of calcium 
from dietary sources (which have better bioavailability than supplements) as part of 
an overall approach to promote lifelong healthier eating habits in this age group [22].
The rapid growth of the skeleton during puberty increases requirements for the 
active form of vitamin D. Insufficient stores during the period of increased growth 
during adolescence may lead to vitamin D deficiency [8], and severe vitamin D defi-
ciency in adolescence is associated with reduced bone mass [22].
Vitamin D is synthesized in the skin through exposure to sunlight containing 
sufficient ultraviolet B (UVB) radiation, and this is the main source for most peo-
ple. However, the optimum sunlight exposure time to make adequate vitamin D is 
difficult to quantify due to the wide variety of factors affecting synthesis. These 
include latitude, season, time of day, amount of skin exposed, skin pigmentation, 
and use of sunscreen. In populations where children and adolescents are spending 
more time indoors and/or increasingly wearing sun protection when they do go out, 
this reduced exposure to UVB radiation means dietary sources of vitamin D become 
more important. Some countries (e.g., United Kingdom) have recently revised rec-
ommendations on vitamin D intakes to reflect this [25].
Calcium is also critical for pregnancy during adolescence, whereby maternal–
fetal competition for calcium means that adolescents are more at risk of gestational 
hypertension and preeclampsia than older mothers; calcium supplementation is there-
fore beneficial, especially in populations with low calcium intakes [26].
Zinc
Zinc is an essential component of a large number of enzymes and has a central role in 
cell division, protein synthesis, and growth. Adequate zinc intake is therefore crucial 
in adolescence, as pubertal growth spurts considerably increase requirements. In 
contexts where diets are nutrient-poor, lack diversity, and have poor bioavailability 
due to high phytate and fiber, zinc status may be compromised. Furthermore, during 
the third trimester of pregnancy, zinc requirements are approximately twice that of 
nonpregnant females [8].
There is little or no direct evidence for many micronutrients, on which to base 
requirements during adolescence, and therefore Reference Nutrient Intakes (RNIs) 
are extrapolated from adult values. RNIs are principally based upon popula-
tions of healthy individuals. Where relevant and possible, RNIs allow for varia-
tions in micronutrient bioavailability and utilization [8], but due to gaps in data and 
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understanding, they may not always be applicable to adolescents living in LMICs 
where diets often lack diversity and are nutrient-poor, and where there is typically a 
high burden of disease [9].
Micronutrient interventions during adolescence are critical to ensure that higher 
needs are being met to prevent negative consequences both during adolescence and 
later in life and to preempt additional demands of entering parenthood.
POTENTIAL FOR CATCH-UP GROWTH
There is increasing interest in adolescence as an additional opportunity for catch-
ing up on growth deficits from childhood [27,28]. This is mediated through a delay 
to maturation and/or an extended pubertal growth phase [27,29]. However, ques-
tions remain as to the extent to which catch-up growth is possible and its mecha-
nisms: whether it occurs before or during the pubertal growth spurt; how complete 
it is (i.e., whether it will affect the final adult height attained or just an accelerated 
growth spurt over a shorter time frame); and whether it is spontaneous or requires 
additional interventions [29]. Longitudinal data from the Young Lives Study shows 
that 36% of stunted children aged 8 years managed to catch up with their peers by 
age 15 [30]. Further empirical evidence on pubertal catch-up growth is provided 
by longitudinal data from rural Tanzania [31]. It may be that the effects of growth- 
promoting interventions initiated years before puberty are realized during adoles-
cence. Another question is whether catch-up growth interventions in adolescence are 
likely to improve other consequences of early growth retardation, such as cognitive 
impairment [29]. Again, results from the Young Lives Study show that children who 
caught up in height by age 15 had smaller deficits in cognitive function than children 
who remained stunted [30].
In summary, catch-up growth during adolescence offers potential in addition to 
the established window of opportunity for intervention during the first 1,000 days. 
However, Patton et al. [1] make the point that “any opportunity for catch-up will be 
restricted by early pregnancy and for that reason, delaying first pregnancy is essen-
tial in stunted adolescent girls.”
AN OPPORTUNITY TO INFLUENCE THE PRECONCEPTION 
PERIOD AND PREVENT THE INTERGENERATIONAL 
CYCLE OF MALNUTRITION
Adolescence is a critical preconception period when it is possible to influence the 
negative impacts of becoming pregnant early and/or in a less-than-optimal nutri-
tional state. It provides a timely opportunity to prepare for the additional demands of 
pregnancy and lactation, and to prevent early pregnancy with all its associated risks 
for the mother and the infant. It also provides an opportunity to enhance nutrition 
skills and behaviors that can have lasting benefits on household dietary practices.
Nutrition interventions in adolescent girls that will benefit adult pregnancy out-
comes include increasing prepregnancy weight and body nutrient stores; improving 
iron status to reduce the risk of IDA and associated complications; and improving 
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folate status to reduce the risk of neural tube defects in newborns and megaloblastic 
anemia in mothers [4].
However, of all the interventions, delaying teenage marriage and pregnancy will 
have the most significant impact on nutritional status and intergenerational cycle (see 
the section “Early Marriage and Adolescent Pregnancy”) [11].
NUTRITION BEHAVIORS AND PRACTICES DURING 
ADOLESCENCE HAVE CONSEQUENCES FOR PRESENT 
AND FUTURE ADULT HEALTH AND NUTRITION
Nutrient intakes during adolescence can affect health later in adulthood. For exam-
ple, calcium status and bone deposition during adolescence are important factors of 
bone mineral mass in adult. Optimizing calcium intake during adolescence reduces 
risk of osteoporosis later in life. Adequate iron and folic acid intake during adoles-
cence is important to prevent anemia, ensure adequate iron stores prepregnancy, 
and protect the health of future offspring (e.g., through the prevention of neural tube 
defects). Obesity in early adolescence not only compromises adolescent develop-
ment, but also predicts obesity later in life [32]. Furthermore, negative practices 
acquired during adolescence may continue through to adulthood.
ADOLESCENCE IS A PERIOD OF SIGNIFICANT 
DEVELOPMENTAL TRANSITION
Adolescence is a period of significant developmental transition, a time of openness to 
new ideas, and a time of making personal choices rather than following family pat-
terns. It therefore presents a key opportunity for health and nutrition education inter-
ventions, with the potential to impact lifetime eating habits and health. Moreover, 
adolescents are often the first to adopt new technologies, particularly through the 
Internet [5]. This creates opportunities for innovative delivery mechanisms; for exam-
ple, through social media rather than traditional health education services [1].
As described earlier, there are compelling reasons why adolescent nutrition is a 
critical time for intervention. However, there is limited evidence of the benefit of spe-
cifically targeting adolescents or of the effectiveness of interventions that have been 
proven effective in other populations or age groups [1]. The use of social media and 
information technologies, and interventions such as cash transfers, social protection, 
and microfinance initiatives are all potential approaches. However, there is a current 
lack of rigorous evaluations in all these areas and therefore a need for further high-
quality research [3].
In terms of delivery platforms, there are known difficulties in reaching adoles-
cents; for example, adolescent girls do not typically access standard maternal health 
services. Adolescents, particularly those in LMICs, are often disempowered and 
have low social status. School-based delivery strategies have been the most highly 
evaluated and show promise as platforms for nutrition interventions, as well as sex-
ual health and substance abuse prevention [3], but poor enrollment is a major limita-
tion in terms of overall coverage. What seems to be crucial is for specific nutrition 
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interventions to be integrated into a broader package of actions, which focus on 
delaying pregnancy as a priority, empowering young women through access to edu-
cation and health care, and increasing their control over household resources [1].
EARLY MARRIAGE AND ADOLESCENT PREGNANCY
Too often, adolescent girls are married before the onset of puberty and before they 
reach adulthood. Early marriage occurs in many LMICs, but is particularly common 
in parts of Asia and Sub-Saharan Africa. Evidence shows that approximately one in 
three girls in developing countries is married before the age of 18 and, importantly, 
one in nine is married before the age of 15 [33]. This translates into an estimated 
15 million adolescent marriages each year [34].
A complicating factor for interventions targeted at young women is that when 
adolescent girls are better nourished, it is common for menarche to start at younger 
ages. Earlier onsets of menarche may also lead to premature marriage and first 
childbirth, particularly in settings where age at menarche is positively associated 
with age at marriage and first childbirth [35]. While it is important, therefore, to 
improve the nutritional status of adolescent girls, interventions need to be mindful 
of potential risks, and it will be helpful to ensure that robust policies and com-
munity sensitization activities to delay marriage and first childbirth among adoles-
cent girls are implemented alongside any interventions. Legislation and laws can 
assist in protecting adolescents from the harms of child marriage; however, there is 
wide variation at national levels in their implementation, and customary or religious 
laws can take precedence. Guaranteeing 18 years as the minimum age for marriage 
requires the education and engagement of community leaders and professionals 
within the justice system, and governments have a duty to ensure the enforcement 
of legislation prohibiting child marriage, as it can be considered a priority health 
action for adolescents [1].
The sexual health risks that result in teenage pregnancy have considerable effects 
on the health and well-being of young women across the life course. Pregnancy (and 
early marriage) might signal the end of formal education, denying a young woman 
not only the opportunities that education provides for her own life (improved mental 
health, greater cognitive abilities, better opportunities for employment, etc.), but also 
the enhanced knowledge and confidence that schooling can give her to mother her 
own children. Recent data from South Africa (which has high rates of adolescent 
pregnancy and very high rates of coerced sex and violence against women and girls) 
showed that 75% of school-aged girls leave school because they are pregnant, and 
less than 50% return to complete their education [36]. This can also have an eco-
nomic cost, with a country losing the annual income a young woman would have 
earned over her lifetime if she had not had an early pregnancy.
Sex education is lacking in many countries, and some girls do not know how 
to avoid getting pregnant. They may feel too inhibited or ashamed to seek contra-
ception services, contraceptives may be too expensive, or they may not be widely 
or legally available. Even when contraceptives are widely available, sexually active 
adolescent girls are less likely to use them, compared to adults. Girls married young 
are more vulnerable to intimate partner violence and sexual abuse than those who 
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marry later, and they may be unable to refuse unwanted sex or resist coerced sex, 
which tends to be unprotected [14].
Early independence and self-sufficiency for a young married girl away from her 
family is likely to increase health risks, the consequences of which may negatively 
influence the health of the next generation: her own children [1]. Teenage pregnancy 
and early marriage also raise risks of poverty, and might limit undernourished girls’ 
growth. The United Nations Population Fund (UNFPA) estimated that pregnancy- 
and birth-related complications are the second leading cause of death of adolescent 
girls, and yet an overwhelming number of these deaths (74%) are preventable [37]. 
Adolescent girls are two to five times more likely to die from pregnancy-related causes 
than women aged 20 to 29 years [7].
Adolescents are particularly vulnerable in humanitarian and conflict situations to 
exploitation and gender-based violence, which may affect their access to food, nutri-
tion, and health services, including reproductive health. In addition, the incidence of 
early marriage and pregnancy can increase during these challenging situations [5].
The risks of adolescent births extend beyond those of the mother. Although there 
has been a marked, although uneven, decrease in the birth rates among adolescent 
girls since 1990, approximately 16 million adolescent girls still give birth each year, 
which equates to roughly 11% of all births worldwide; almost 95% of these births 
occur in LMICs [14]. It is estimated that there is a 50% increased risk of stillbirth and 
neonatal death, and an increased risk of preterm birth and LBW compared to older 
mothers [11]. Infants born SGA are three times more likely to die during the neonatal 
period [2], and infants with LBW are estimated to be twice as likely to die as those 
weighing 2.5 kg or more [38]. Those infants who do survive are at a greater risk of 
suffering continued nutritional deficits during childhood, and are more likely to grow 
up to be stunted mothers or fathers themselves. For women, this means perpetuating 
the “intergenerational cycle of undernutrition” [39], as short maternal stature has 
been estimated to be the most important risk factor for stunting in infancy and early 
childhood [40]. The risks for an infant born with LBW continue into adult life, with 
a higher chance of developing noncommunicable diseases, such as cardiovascular 
disease and type 2 diabetes [41]. Additionally, Patton et al. described the possibility 
of transgenerational epigenetic inheritance, whereby preconception influences alter 
patterns of gene expression that might pass to the next generation [1].
Where breast milk quantity and quality is concerned, although maternal under-
nutrition (unless it is severe) has a limited effect on the volume of breast milk, research 
indicates that maternal intakes/stores of essential fatty acids and key micronutrients 
do affect the concentrations of these nutrients in breast milk [42]. Recent research 
suggests significant effects of maternal deficiency on the concentration of B vitamins 
in breast milk, in particular for vitamin B12 [43]. The risk of infant depletion is there-
fore higher as a result. This is also relevant for vitamin A, where adequate content 
in breast milk is vital for infant status as infant stores are low at birth [38]. Although 
this research has not been conducted on adolescents, it can be hypothesized that 
these issues may be particularly relevant for adolescent mothers who already have 
higher requirements of key nutrients themselves and who are likely to become fur-
ther depleted during pregnancy. Adolescent girls are likely to have poorer access to 
and uptake of antenatal care, including micronutrient supplementation. Those girls 
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who do get pregnant are more likely to give birth without a skilled attendant, raising 
the health and nutritional risks both for themselves and for their infants [44].
In summary, undernourished girls are more likely to grow up to become stunted 
mothers and give birth to smaller, sicker babies, particularly if they become preg-
nant at a young age. Improving adolescent girls’ nutrition and delaying pregnancy 
is a critical opportunity to break this negative intergenerational cycle of malnutri-
tion. Ensuring the nutritional well-being of adolescent girls, enhancing women’s and 
girls’ equality and empowerment, and reducing rates of early marriage and ado-
lescent pregnancy, will therefore help countries reach the global nutrition targets 
proposed by the World Health Assembly for 2025 and the Sustainable Development 
Goals by 2030 [44].
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to Increase Our Knowledge 
of Biology during the 
First 1,000 Days
Richard D. Semba and Marta Gonzalez-Freire
INTRODUCTION
Proteomics (the study of the structure and function of proteins expressed by an 
organism) and metabolomics (the study of small, low molecular-weight metabolites 
and their cellular processes) are rapidly evolving disciplines that have great poten-
tial to provide fundamental insights into the biology of the first 1,000 days of child 
growth and development. The study of individual proteins and metabolites has a long 
tradition, but a collective approach to their study came recently. The terms proteome 
and metabolome were first mentioned in the published scientific literature in 1996 [1] 
and 1998 [2], respectively. German botanist Hans Winkler (1877–1945) originated 
the related term genome more than seven decades earlier [3].
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PROTEOMICS AND METABOLOMICS IN THE POSTGENOMIC ERA
In 2003, the Human Genome Project, which had the goal of mapping all the genes 
of the human genome, was declared complete [4]. In the postgenomic era, two major 
challenges in the life sciences include the elucidation of all the proteins and metabo-
lites in the human body. The proteome and metabolome have a level of complexity 
that far exceeds the genome. In humans, ~20,000 protein-coding genes give rise to 
~100,000 proteins and an estimated 1 million different protein-modified forms [5,6]. 
The many forms of proteins arise from mutations, RNA editing, RNA splicing, post-
translational modifications, and protein degradation; the proteome does not strictly 
reflect the genome. Proteins function as enzymes, hormones, receptors, immune 
mediators, structure, transporters, and modulators of cell communication and sig-
naling. The metabolome consists of amino acids, amines, peptides, sugars, oligonu-
cleotides, ketones, aldehydes, lipids, steroids, vitamins, and other molecules. These 
metabolites reflect intrinsic chemical processes in cells, as well as environmental 
exposures such as diet and gut microbial flora. The current Human Metabolome 
Database contains more than 40,000 entries [7]—a number that is expected to grow 
quickly in the future.
The goals of proteomics include the detection of the diversity of proteins, their 
quantity, their isoforms, and the localization and interactions of proteins. The goals 
of metabolomics include mapping the function of metabolic pathways, many of 
which remain partially or completely uncharacterized [8], as well as detecting and 
measuring the diversity and dynamic changes of metabolites. This fundamental 
work should help lead to the discovery of new biological mechanisms, biomarkers, 
drug targets, and pathways of disease. Proteomics and metabolomics are vital steps 
in the progress of science toward translational research, clinical trials, and personal-
ized medicine and nutrition. The research fields of cancer, neurology, endocrinol-
ogy, and cardiovascular disease have been in the vanguard in using proteomic and 
metabolomic approaches in scientific investigation. In contrast, the field of nutrition 
has been slow in applying these powerful techniques.
The technology to investigate the immense complexity of the proteome and 
metabolome has advanced rapidly over the last several years. Newer mass spectrom-
eters have greater sensitivity, higher reproducibility, better comprehensiveness, and 
more rapid throughput, allowing the identification and quantification of thousands of 
proteins and metabolites in tissues and samples. Mass spectrometers are the heart of 
the laboratory and the drivers of innovation. The Orbitrap mass analyzer was com-
mercially available in 2005 [9] and gave rise to subsequent generations of Orbitrap 
mass spectrometers. The comprehensive analysis of proteins and lipids has been 
increased dramatically by sequential windowed data independent acquisition of 
the total high-resolution mass spectra (SWATH-MS) on triple time-of-flight mass 
spectrometers [10,11]. Selected reaction monitoring (SRM; also known as multiple 
reaction monitoring), a targeted mass spectrometry technique, can use triple quad-
rupole, or QTrap, mass spectrometers to measure sets of proteins [12]. SRM allows 
the precise, antibody-free quantitation of proteins in a multiplexed fashion. Targeted 
metabolomic approaches can be conducted using QTraps. Some examples of these 
applications to the first 1,000 days are presented later. Nuclear magnetic resonance 
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spectroscopy can also be used to measure metabolites, with the advantage of mini-
mal sample preparation but the major disadvantage of low sensitivity.
TECHNOLOGICAL BREAKTHROUGHS ACCELERATE RESEARCH
Currently, it is possible to measure >10,000 proteins in a single biological sample, 
something that was not feasible several years ago. These advances are due not only 
to new innovations in mass spectrometry instrumentation, but also to improve-
ments in sample preparation and standardized guidelines for sample collection. 
The depletion of highly abundant proteins, such as albumin and immunoglobulins, 
facilitates the detection of low abundant proteins (the “deep proteome”). More 
effective electrophoresis and chromatography protocols and tools, such as stable 
isotope labeling with amino acids in cell culture (SILAC), isobaric tags for relative 
and absolute quantitation (iTRAQ), and tandem mass tags (TMTs), have facilitated 
the quantification of proteins [13–15]. Methods are also improving for the detection 
of posttranslation modifications (PTMs), such as phosphorylation, glycosylation, 
acetylation, ubiquitination, sumoylation, and citrullination. PTMs are important 
to study since they reflect the diversity of protein function. Many PTMs are dif-
ficult to study because they are labile to sample processing and mass spectrometry. 
For example, O-GlcNAcylation, an important PTM that rivals phosphorylation in 
abundance and distribution, has been especially challenging to detect and mea-
sure. Many proteins have functions that are unknown or not well understood. By 
studying the proteins with which a particular protein interacts, it is possible to 
deduce biological functions and pathways. Protocols have recently been developed 
for proteomic analysis of dried blood spots and formalin-fixed, paraffin-embedded 
tissues [16].
Many recent metabolomic studies have used so-called targeted approaches, in 
which a panel of well-characterized and validated metabolites is measured using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). Given the com-
plexity of various metabolites, there is no single analytical platform to measure the 
complete metabolome. At present, about 200 to 1,000 metabolites can be measured 
using LC-MS/MS in commercial labs or some academic labs, depending upon the 
type of sample.
Bioinformatics has played a vital role in the acceleration of proteomics and 
metabolomics. Raw MS data from proteomic analyses can be analyzed using open 
source search engines such as X!Tandem and OMSSA, or proprietary databases 
such as Mascot and Sequest. The software assigns sequence information for pep-
tides based upon the spectra, and then protein identifications based upon the specific 
peptides. Authoritative and comprehensive protein databases include neXtProt for 
human proteins [5]. Annotated databases such as Gene Ontology (GO) [17] and path-
way databases such as Kyoto Encyclopedia of Genes and Genomes (KEGG) [18] and 
Database for Annotation, Visualization and Integrated Discovery (DAVID) [19] are 
particularly useful for the identification of biological pathways in the resulting data 
from proteomic and metabolomics investigations. Online resources and databases of 
metabolites include Metabolomics Workbench, METLIN, and BiGG [20].
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WHAT CAN WE LEARN FROM PROTEOMICS 
ABOUT THE FIRST 1,000 DAYS OF LIFE?
In using a proteomic approach to understanding health, the investigator can pose 
a question about a certain disease phenotype. The first step can be a hypothesis-
free discovery phase study. As an example, let us say we would like to character-
ize the differences in circulating proteins among stunted and nonstunted children 
at 12 months of age. A cross-sectional study at 12 months of age would be sub-
ject to all the caveats and limitations about linear growth retardation, which begins 
in utero and is the sum of many biological factors prior to the phenotype of stunt-
ing at 12 months of age. However, we need an initial point of entry into a complex 
problem. An important reality is that mass spectrometry-based proteomics is expen-
sive and difficult to fund in the discovery phase. Sample processing can involve the 
depletion of high abundance proteins using expensive affinity purification columns. 
The sample depleted of high abundance proteins is often split into several differ-
ent fractions. Each sample fraction may require 2 to 4 hours of instrument time 
on a mass spectrometer; many university core facilities charge around US$100 per 
hour for instrument time. The proteomic analysis of a single blood sample obtained 
from a child in a rural field site could easily cost several hundred dollars, taking 
into consideration reagents, columns, and instrument time alone. One advantage of 
mass  spectrometry- based  proteomic approaches is that they generally require a 
small amount of plasma (~10 μL), in contrast to conventional antibody-based assays 
that require larger sample volumes.
There are three general approaches that are used in mass spectrometry-based 
proteomics: (1) data-dependent acquisition (DDA) usually done using Orbitrap mass 
analyzers; (2) targeted proteomics using SRM; and (3) data independent acquisition 
(DIA) using SWATH [21] (Figure 30.1). Samples are typically prepared using extrac-
tion and digestion with an enzyme such as trypsin. Large epidemiological studies 
can utilize a 96-well plate format and robotics for high throughput and lower vari-
ability in processing [22]. In DDA, a full spectrum of peptides is required of all the 
ion species that coelute at a certain point during the gradient and then fragmented 
at the MS1 level. This is followed by the collection of fragmentation spectra at the 
MS2 level that are used to identify the peptides. The instrument alternates between 
MS1 and MS2, but between cycles the ion species that are not fragmented in MS1 are 
lost and not detected. The Orbitraps are currently limited to a capacity of ~1 million 
ions with a restricted dynamic range. Targeted proteomics using SRM is based upon 
the fragmentation of peptides based upon their known mass-to-charge ratio (m/z) in 
the first quadrupole, followed by the collection of fragmentation spectra in the third 
quadrupole. Recently, as reported by Kusebauch and colleagues, it has theoretically 
been possible to detect and quantify any of the 20,277 proteins of the protein-coding 
genes in the human proteome using SRM [23]. The Human SRMAtlas currently 
consists of 166,174 proteotypic peptides representing the human proteome [23]. 
SRM assays can be multiplexed to simultaneously detect and quantify large sets of 
proteins in plasma [24]. Conventional antibody- or aptamer-based approaches that 
rely upon the recognition of epitopes often cannot differentiate highly homologous 
proteins or protein variants based upon a single amino acid substitution, and these 
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limitations can be overcome by use of SRM [25]. In DIA, all peptides are frag-
mented continuously across the entire mass range, giving rise to large multiplexed 
spectra. The dynamic range of DIA is about 4 to 5 orders of magnitude. There are 
now SWATH-MS libraries that can facilitate the identification of >10,000 plasma 
proteins [26]. One advantage of using SWATH is that once SWATH-MS data have 
been collected in an experiment, the data can be interrogated again in the future, as 
SWATH-MS libraries continue to evolve in their coverage.
Returning to the question we posed earlier, in the discovery phase, either DDA 
or DIA approaches could be used to identify differences in the expression of plasma 
proteins between children with or without a particular phenotype. In the past, pro-
teomic studies used small sample sizes and technology such as two-dimensional 
gel electrophoresis (2-DIGE), followed by mass spectrometry, to distinguish phe-
notypes in infants and children. These methods are relatively insensitive and have 































FIGURE 30.1 Examples of proteomic workflows. Proteins are extracted and digested with 
an enzyme (usually trypsin). Robotic sample handling in a 96-well format can greatly reduce 
variability. Peptides are separated and then ionized using electrospray. In data-dependent 
acquisition (DDA), a full spectrum of peptides is acquired in the quadrupole and fragmented. 
An Orbitrap mass analyzer is used to detect fragmentation spectra. In targeted selected reac-
tion monitoring, peptides with known mass-to-charge ratio (m/z) are selected in the first quad-
rupole and then fragmented, and then specific fragmentation spectra are used to characterize 
each peptide. In data-independent acquisition (DIA), which can utilize sequential window 
acquisition of all theoretical fragment-ion spectra (SWATH)-MS, ranges of m/z values, using 
fixed or variable ranges, are selected and peptides are fragmented. Fragmentation spectra are 
collected continuously in a time-of-flight mass spectrometer. (Adapted from Aebersold R, 
Mann M, Nature 2016, 537:347–55.)
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colleagues applied the more advanced proteomic approaches discussed earlier in 
order to identify circulating protein markers for micronutrient status, such as vita-
min E status [27].
An alternative to mass spectrometry-based proteomic approaches is the use of a 
platform based upon SOMAmers. SOMAmers are short, single-stranded deoxyoli-
gonucleotides that have been selected from large screening libraries for their ability 
to bind to specific epitopes in peptides or proteins [28]. A commercially available 
platform, SomaScan (SomaLogic, Inc., Boulder, Colorado) can measure >1,000 pro-
teins in a single, multiplexed assay. The advantage of the SOMAmer platform is rapid 
throughput and the lack of need for fractionation or other more laborious sample 
preparation. The potential disadvantages are the high cost, which is similar to that 
of mass spectrometry-based proteomic assays, the larger plasma volume required, 
the more limited ability of SOMAmers to distinguish between highly homologous 
proteins and sequence variants [29], and the semiquantitative nature of the results, 
which are expressed in relative fluorescent units [28]. With recent new advances, it 
should be possible to measure a few thousand different proteins using the SomaScan 
platform in the near future and achieve more accurate quantification with use of 
protein standards. The SomaScan platform has great potential for providing high-
throughput, rapid results for proteomic studies.
WHAT CAN WE LEARN FROM METABOLOMICS 
ABOUT THE FIRST 1,000 DAYS OF LIFE?
Metabolomics has been more widely applied to infant and child health than pro-
teomics. Plasma and urine metabolomics studies have been used to study prema-
turity, intrauterine growth retardation, inborn errors of metabolism, infectious 
diseases, and congenital malformations [30]. The first 1,000 days of life are associ-
ated with rapid bone and skeletal muscle growth, increases in organ size, and large 
developmental changes in the brain and nervous system. Alterations in specific met-
abolic pathways during this critical period may be revealed through metabolomics.
We recently used a targeted metabolomics approach to gain insight into the serum 
metabolome in over 300 stunted and nonstunted children aged 12 to 59 months in 
rural Malawi. This study revealed that stunted children had significantly lower 
serum concentrations of all nine essential amino acids and three conditionally essen-
tial amino acids (Figure 30.2) [31]. The mechanistic target of rapamycin complex 1 
(mTORC1) pathway is the master regulator of growth and is extremely sensitive to 
the availability of amino acids. If essential amino acids are lacking, mTORC1 will 
inhibit growth. These findings suggest that the relative scarcity of essential amino 
acids in the diet may be adversely affecting child growth through mTORC1 [32]. 
Foods with the highest quality protein, that is, those containing sufficient amounts of 
all nine essential amino acids, are animal source foods, which are relatively expen-
sive and rarely consumed by poor families in rural Africa.
Another finding from the metabolomics study of children in Malawi was the asso-
ciation of stunting with lower serum phosphatidylcholines and sphingomyelins [31]. 
These findings were suggestive that choline may be limited in the diet of stunted 
children. Serum choline was not specifically measured in the targeted metabolomics 
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platform that we used. In order to expand these investigations, we developed a new 
LC-MS/MS assay in our laboratory to measure serum choline. Stunting was also 
associated with lower serum choline concentrations (Figure 30.3) [33]. These find-
ings suggest that stunted children are not receiving adequate amounts of choline in 
their diet. The richest dietary sources of choline are animal source foods, especially 
eggs, which are rarely consumed by children in poor families from rural Africa.
Our targeted metabolomics studies also implicate another conditionally essential 
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FIGURE 30.2 Serum essential and conditional essential amino acids in stunted and nonstunted 
children in Malawi. Mean serum (a) essential amino acids, (b) conditionally essential amino acids 
asparagine and arginine, and (c) conditionally essential amino acid glutamine in 194 stunted 
(black bars) and 119 nonstunted (gray bars) children, aged 12 to 59 months in rural Malawi. (Data 
from Semba RD, Shardell M, Sakr Ashour FA et al., EBioMedicine 2016, 6:246–52.)
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β-oxidation of fatty acids in the mitochondria and in peroxisomes for maintaining 
the intracellular balance of coenzyme A, and for normal catabolism of branched 
chain amino acids. Overall, in the study population, serum carnitine concentrations 
were much lower than the normal range for healthy children of 40 to 60 μmol/L, 
and consistent with carnitine deficiency [31]. Serum carnitine concentrations were 
significantly lower in stunted compared with nonstunted children [31] (Figure 30.4). 














FIGURE 30.3 Serum choline in stunted and nonstunted children in Malawi. The median 
serum choline in 201 stunted (black bars) and 124 nonstunted (gray bars) children, aged 12 to 
59 months, in rural Malawi. (Data from Semba RD, Zhang P, Gonzalez-Freire M et al., Am J 











FIGURE 30.4 Serum carnitine in stunted and nonstunted children in Malawi. The mean 
of serum carnitine in 194 stunted (black bars) and 119 nonstunted (gray bars) children, aged 
12 to 59 months, in rural Malawi. (Data from Semba RD, Shardell M, Sakr Ashour FA et al., 
EBioMedicine 2016, 6:246–52.)
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We also applied a targeted metabolomics approach to examine the relationship 
between serum metabolites and environmental enteric dysfunction (EED) in the 
same children from Malawi. EED is an asymptomatic condition characterized by 
small intestinal inflammation, villous atrophy, and increased gut permeability. EED 
is common among young children in developing countries and is considered to be 
a major factor contributing to child stunting. These studies showed that increased 
gut permeability was associated with lower serum tryptophan, phosphatidylcho-
lines, sphingomyelins, ornithine, and citrulline, and elevated serum glutamate, tau-
rine, and serotonin [34]. This study provided evidence that EED is associated with 
abnormalities in the kynurenine pathway, urea cycle, and transsulfuration pathway 
of sulfur amino acids. In the same children, we also characterized serum bile acids 
using LC-MS/MS. These results show that children with EED have altered bile acid 
metabolism [35].
A targeted metabolomics approach was used to gain insight into the pathophysi-
ology of kwashiorkor and marasmus in children in Malawi [36]. Metabolic profil-
ing could distinguish between children with kwashiorkor or marasmus. Kwashiorkor 
was associated with lower serum concentrations of amino acids; acylcarnitines; 
and phosphatidylcholine diacyls C36:4, C38:4, and C40:6 compared to children 
with marasmus. After nutritional rehabilitation, amino acids and biogenic amines 
increased, but circulating phosphatidylcholines and sphingomyelins generally did 
not recover, suggesting persistent metabolic alterations still exist in children after 
treatment for severe acute malnutrition [36].
The gut microbiota play an important role in amino acid synthesis, bile acid 
metabolism, vitamin and short-chain fatty acid production, and the metabolism 
of dietary polyphenols [37]. Alterations in the gut microbiome can be reflected by 
changes in the serum metabolome in polyphenol metabolites [38], carnitine and cho-
line [39], amino acids [40], and lipids [37]. EED is common among young chil-
dren in developing countries and is associated with alterations in the gut microbiota 
[41]. An abnormal gut microbiome associated with EED could potentially alter the 
metabolism of nutrients and affect growth and development of children in the first 
1,000 days.
CONCLUSION
The main findings from metabolomic investigations from the first 1,000 days are 
that stunted children have low serum concentrations of essential amino acids, con-
ditionally essential amino acids, choline, and carnitine. The richest dietary sources 
of these molecules are animal source foods. As noted, the consumption of animal 
source foods is limited among children in developing countries [42]. Animal source 
foods provide <5% of total energy intake in many countries in Sub-Saharan Africa, 
and 5% to 10% of total energy intake in most other African and southern Asian 
countries. In Europe, the United States, Canada, and Australasia, animal source 
foods provide >20% of total energy intake [42]. The prospect of increasing the avail-
ability of animal source foods in low-income countries raises many issues about 
social justice and environmental sustainability. Food production systems face the 
challenge of reducing the environmental impact of food production, while at the 
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same time ensuring that all people have physical and economic access to nutritious 
foods [43,44], including animal source foods that are good sources of essential amino 
acids, choline, and carnitine.
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ACTH, see Adrenocorticotrophic hormone
Acute malnutrition (AM), 191–206
cardiac function, 196
changes in body composition, 192–195
changes in body functions, 195–196
decrease in fat mass, 193
decrease of muscle mass, 193–194
edema, 194–195
energy requirements, 196–197
mineral and vitamins, 200
moderate acute malnutrition, 192, 203
pathophysiology, 192–196
physical activity, 195




severe acute malnutrition, 192, 201
sodium pump activity, 195
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of age), 207–220
assessment of infants, 212–214
challenges, 210–212
“forgotten problem,” epidemiology of, 
208–209
future directions, 218
managing acutely malnourished infants, 
215–217
many and complex underlying causes, 
211–212
period of rapid maturation, 210
unique dietary needs, 210–211
why malnutrition matters for infants under 
6 months of age, 209–210
ADA, see American Diabetes Association
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calcium and vitamin D, 461–462
catch-up growth, potential for, 463
early marriage and adolescent pregnancy, 
465–467
energy and protein, 458–460
folate, 461
increased nutritional requirements, 458–463
iron, 460–461
preconception period, influence on, 463–464
significant developmental transition, period 
of, 464–465
zinc, 462–463
Adrenocorticotrophic hormone (ACTH), 240
AGA, see Appropriate for gestational age
AI, see Adequate Intake
ALA, see Alpha-linoleic acid
Alcohol intake (during pregnancy), 48
Allergy, see Childhood allergy, effects of early 
diet on
Alpha-linoleic acid (ALA), 59
AM, see Acute malnutrition
American Diabetes Association (ADA), 147
AMPK, see Monophosphate-activated protein 
kinase
Androgens, 241–242
Antioxidant nutrients, HDP and, 164
Appropriate for gestational age (AGA), 173
ASD, see Autism spectrum disorder
Atopobium, 292
ATP, see Adenosine triphosphatase
Atrial natriuretic peptides, 272
Autism spectrum disorder (ASD), 450
B
Bacteroides, 292, 293, 295, 296
BCAA, see Branched chain amino acids
Beckwith-Wiedemann syndrome (BWS), 347
Behavioral change communication (BCC), 400
Benefit-Risk Analysis for Foods (BRAFO), 249
Bifidobacterium, 293, 295, 296, 298, 299
Birth spacing, see Interpregnancy intervals and 
birth spacing
Blautia, 299
BMC, see Bone mineral content
BMI, see Body mass index
Body composition changes (infancy to young 
childhood), 269–286
atrial natriuretic peptides, 272
body composition during infancy, 271–281
boys, body composition changes during the 
first 24 months in, 275–277
elements of human body composition, 
270–271
girls, body composition changes during the 
first 24 months in, 278–280
keratinization of skin, 272
486 Index
poor growth and adult chronic disease, 
282–283
poor growth and body composition, 281–282
Body mass index (BMI), 177, 256, 269, 346
Bone mineral content (BMC), 272
BRAFO, see Benefit-Risk Analysis for Foods
Branched chain amino acids (BCAA), 81
Breastfeeding
allergy prevention and, 327–328
early initiation of, 376–377
–pregnancy overlap, 444
promotion, 379
B vitamins, requirements during lactation, 61–63
BWS, see Beckwith-Wiedemann syndrome
C
Caesarean section (CS), 146
Caffeine intake (during pregnancy), 48
Calcium
growth plate and, 242–243
HDP and, 162–163
requirements for adolescents, 461–462
requirements during lactation, 64–65






Cardiovascular disease, see Obesity, 
cardiovascular disease, and type 2 
diabetes (fetal origins of)





early intrauterine stressors and, 356
growth plate senescence and, 247–248
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mineral and vitamin requirements during, 
200
potential for, 463
protein requirements during, 199
Cellular energy turnover, effects of thyroid 
hormones on, 113–141
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breastfeeding, allergy prevention, and, 
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complementary foods, 328–330
dietary influences on development of allergy, 
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dual allergen exposure hypothesis, 325
endotoxins, 324
hygiene hypothesis, 324
hypotheses of allergy development, 324–325
infant feeding guidelines for prevention of 
food allergy (updated), 330–331
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prevalence of stunting, 222–223
prevention, conceptual, and evidence-based 
point of view of, 227–229
prevention, practical, context-specific point of 
view of, 229–231
relationship between chronic and acute 
malnutrition, 224
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interventions and their impact, 231




Cleft lip and palate (CLP), 137–144
classification, 140–141
diagnosis and prevention, 141
epidemiology, 138–139
etiology and associated risk factors, 139–140
normal embryological face structure 
development, 137–138
treatment and management, 141–142
Clostridium, 292, 293, 295, 296, 299
CLP, see Cleft lip and palate
Copper, requirements during lactation, 67
Corticotropin-releasing hormone (CRH), 363
Corynebacterium, 291, 295
CS, see Caesarean section
Cushing’s disease, 240
Cytosine-phosphate-guanine (CpG) sites, 336
D
DA, see Dopamine
DALYs, see Years lost to death and disability
Database for Annotation, Visualization and 
Integrated Discovery (DAVID), 475
Data-dependent acquisition (DDA), 476
Data independent acquisition (DIA), 476
Developmental origins of health and disease 
(DOHaD) hypothesis, 181, 335, 339
DEXA, see Dual energy x-ray absorptiometry
487Index
DFE, see Dietary folate equivalents
DHA, see Docosahexaenoic acid
DIA, see Data independent acquisition
Diabetes mellitus in pregnancy (DMIP), 146
Dietary folate equivalents (DFE), 45
Dietary Reference Intakes (DRIs), 36, 37
Differentially methylated region (DMR), 344
DMIP, see Diabetes mellitus in pregnancy
DNA methyltransferases (DNMTs), 336
Docosahexaenoic acid (DHA), 39, 59, 166
DOHaD hypothesis, see Developmental origins 
of health and disease hypothesis
Dopamine (DA), 94
DRIs, see Dietary Reference Intakes
Dual energy x-ray absorptiometry (DEXA), 271, 
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E
EAR, see Estimated Average Requirement
Early childhood development (ECD) programs, 396
EED, see Environmental enteropathic dysfunction
Eicosapentaenoic acid (EPA), 166
Endochondral ossification, 237
Endocrine dysfunction, lactation, and, 100; see also 
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EPA, see Eicosapentaenoic acid
Epidemiological perspective, see Importance of 
the first 1,000 days
Epigenetics, nutrition, and infant health, 335–353
body mass index, 346
developmental origins of health and disease, 
epigenetics and, 339–340
epigenetics, primer on, 336–337
epigenome parts most susceptible to 
environmental influences, 338–339
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polyunsaturated fatty acids, 345–346
studies, 343–345
“thrifty epigenome” hypothesis, 340
time points of plasticity in the epigenome, 
337–339
vitamin C and demethylation, 346–347
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Fibroblast growth factor 21 (FGF21), 240
FIGO, see International Federation of 
Gynecology and Obstetrics
Fill the Nutrient Gap (FNG) tool, 230
FM, see Fat mass
Folate
HDP and, 164–165
mechanisms of, see Neural tube defects
requirements for adolescents, 461
Food additives, 46–48
Food and Agriculture Organization (FAO), 36
G
GAP, see GTP-ase-activating protein
Gardnerella, 292
GDP, see Gross domestic product
Genome-wide associated studies (GWAS), 132
Gestational diabetes mellitus (GDM), 145, 263, 
362; see also Obesity and gestational 
diabetes
Gestational weight gain (GWG), 255, 362; see also 
Pregnant and postpartum women, 
gestational weight gain and body 
composition in
GH, see Growth hormone
Glucose metabolism, effects of thyroid hormones 
on, 113–141
Glutamate, 98–100
Glycemic index (GI), 40
Gross domestic product (GDP), 227, 412
Growth hormone (GH), 113, 115, 238
Growth plate, nutritional regulation of, 237–251
androgens, 242
calcium, phosphate, and vitamin D, 242–243
catch-up growth, growth plate senescence, 
and, 247–248
endochondral ossification, 237
endocrine regulation of bone growth, 238–243
epigenetics and sirtuins, 245–246
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estrogen, androgen, and leptin, 241–242
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growth hormone insulin-like growth factor-I 
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mTOR signaling pathway, 243–245
osteoblasts, 237
primary ossification center, 237
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thyroid hormone, 241
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Gut microbiome, early life, 289–302
delivery mode, 292
disease and antibiotics, 297
feeding, 295–296
gestational age, 292–293
infant gut microbiome, factors affecting, 
294–298
maternal microbiome, 290–291
neonatal gut microbiome, factors affecting, 
290–293
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transition from infant to child, 298–300
GWAS, see Genome-wide associated studies
H
HAPO study, see Hyperglycaemia and Adverse 
Pregnancy Outcome study
HDP, see Hypertensive disorders of pregnancy 
(HDP), nutrition and
Height-for-age z-scores (HAZ), 227
High-income countries (HICs), 459
Histone deacetylases (HDAC), 245
HIV, see Human immunodeficiency virus
HMOs, see Human milk oligosaccharides
HMP, see Human Microbiome Project
“Home fortification,” 435
Homeostasis model assessment–insulin 
resistance (HOMA-IR), 264
Hormonal regulation, see Lactation and human 
milk production, hormonal regulation 
during
HPT, see Hypothalamus-pituitary-thyroid axis
Human growth hormone, 113, 115
Human immunodeficiency virus (HIV), 311, 424
Human Microbiome Project (HMP), 289
Human milk oligosaccharides (HMOs), 60, 295
Human milk production, see Lactation and human 
milk production, hormonal regulation 
during
Hyperglycaemia and Adverse Pregnancy 
Outcome (HAPO) study, 146, 148–149
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Hypothalamus-pituitary-thyroid axis (HPT), 109
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IADPSG, see International Association of 
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IAP, see Intracisternal A particle
ICRs, see Imprinting control regions
IDA, see Iron deficiency anemia
IDI, see Interdelivery interval
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supplementation
IgA, see Immunoglobulin A
IgE antibodies, see Immunoglobulin E 
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IGF-I, see Insulin-like growth factor I
IGF-II, see Insulin-like growth factor II
IMCI, see Integrated management of childhood 
illness
Immunoglobulin A (IgA), 295
Immunoglobulin E (IgE) antibodies, 323
Importance of the first 1,000 days, 3–13
epidemiological burden and problem of 
malnutrition, 3–7
first 300 days, 8–9
next 700 days of life, 9–10
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public health and economic importance 
of nutrition, 11
risk factors for child stunting, 10–11
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Imprinted genes, 338
Imprinting control regions (ICRs), 347
Insulin-like growth factor I (IGF-I), 81, 238
Insulin-like growth factor II (IGF-II), 239
Insulin-like growth factors, effects of thyroid 
hormones on, 115
Integrated management of childhood illness 
(IMCI), 212
Interdelivery interval (IDI), 441
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International Federation of Gynecology and 
Obstetrics (FIGO), 38, 45
Interpregnancy intervals (IPIs) and birth spacing, 
439–455
biological mechanism hypotheses, 441–446
birth defects, 449
breastfeeding–pregnancy overlap, 444
child growth and development, 449–450
child outcomes, interpregnancy intervals and, 
448–450
closely spaced siblings, effects of, 445
confounding, 451–452
interpregnancy intervals following other 
pregnancy outcomes, 450–451
long interpregnancy intervals, 446
low birth weight, 449
maternal morbidity and mortality, 446–448
maternal nutrient depletion, 441–444
maternal nutritional status, 448
maternal outcomes, interpregnancy intervals 
and, 446–448




small for gestational age, 449
stillbirth and early neonatal death, 448
Interventions
nutrition-sensitive, see Nutrition-sensitive 
interventions
nutrition-specific, see Nutrition-specific 
interventions in pregnancy and early 
childhood, effectiveness of
Intracisternal A particle (IAP), 343
Intramembranous ossification, 237
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Iron deficiency anemia (IDA), 66, 460
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Lactation and human milk production, hormonal 
regulation during, 89–103
anatomy of OT neuroendocrine system, 97
endocrine dysfunction and lactation, 100
glial plasticity in magnocellular nuclei and 
neurohypophysis, 100
hormones of lactation, 90–93
intranuclear release of OT, 98
milk ejection reflex, 97
neuroendocrine control of PRL and OT 
secretion, 93–97
neuroendocrine regulation of OT secretion in 
lactation, 96
neuroendocrine regulation of PRL secretion 
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“upstream” regulation over prolactin (central 
neurotransmitters), 95
Lactobacillus, 292, 293, 298
Lactococcus, 295
Lactulose:mannitol (L:M) ratios, 307, 308
Large for gestational age (LGA), 146
Late onset sepsis (LOS), 296
LAZ, see Length-for-age z-scores
LBM, see Lean body mass
LBW, see Low birth weight and small for 
gestational age
LC-MS/MS, see Liquid chromatography-tandem 
mass spectrometry
LCPUFA, see Long chain polyunsaturated fatty 
acid
LDL cholesterol levels, see Low-density 
lipoprotein (LDL) cholesterol levels
Lean body mass (LBM), 269
“Learning Early About Peanut” (LEAP) allergy 
study, 80, 330
Length-for-age z-scores (LAZ), 81
Leptin, 241–242
Leuconostoc, 295
LGA, see Large for gestational age
Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), 475
LMICs, see Low- and middle-income countries
Long chain polyunsaturated fatty acid (LCPUFA), 
59, 76, 325–326
LOS, see Late onset sepsis
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age (SGA), 171–187
balanced energy and protein supplementation, 
183
burden of low birth weight, 174
burden of small for gestational age, 175
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interventions, 183
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malaria prevention, 184
maternal body mass index, 177–178
maternal chronic diseases, 179
maternal communicable diseases, 179
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maternal weight gain during pregnancy, 
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micronutrient supplementation in pregnancy, 
183
outcomes, 179–181
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stunting and human capital, 181–182
Low-density lipoprotein (LDL) cholesterol levels, 
38–39
Low- and middle-income countries (LMICs), 
372, 395, 457
M
Macronutrient requirements and recommendations 
(during pregnancy), 37–40
Magnesium, HDP and, 165–166
Malaria prevention, 184
Malnutrition, see Acute malnutrition; Chronic 
malnutrition
MAM, see Moderate acute malnutrition
Mammalian target of rapamycin (mTOR) 
signaling pathway, 243
Management of acute malnutrition in infants 
(MAMI), 207
Marine oils, HDP and, 166
Mediterranean diets, 325
MEs, see Metastable epialleles
Metabolomics and proteomics, 473–483
metabolomics, what can we learn from, 
478–481
in postgenomic era, 474–475
proteomics, what can we learn from, 476–478
targeted approaches, 475
technological breakthroughs accelerating 
research, 475
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during pregnancy, 40–43
MMNs, see Multiple micronutrients
MNDs, see Micronutrient deficiencies
MNP, see Micronutrient powder
Moderate acute malnutrition (MAM), 192, 203, 383
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Monophosphate-activated protein kinase (AMPK), 
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mTOR signaling pathway, see Mammalian target 
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Multiple micronutrients (MMNs), 374
Muscle, effects of thyroid hormones on, 113–141
N
National Center for Health Statistics (NCHS), 
208
NCD, see Noncommunicable disease
Necrotizing enterocolitis (NEC), 296
Neonatal intensive care unit (NICU), 293
Neural tube defects (NTDs), 45, 123–136, 374
clinical features and epidemiology, 124–125
environmental and genetic influences, 
125–126
folic acid as protective agent, 126–128
maternal blood folate status and neural tube 
defects, 128–129
mechanism of folic acid protective effect, 
128–133
methylation cycle, 130
miscellaneous interacting nutrients, 132–133
molecular and genetic considerations, 129–132
Neurocognitive development, 81–83
Newborn Epigenetics Study (NEST), 347
Nicotine replacement therapy (NRT), 183
NICU, see Neonatal intensive care unit
Noncommunicable disease (NCD), 210
Norepinephrine, 98–100
NRT, see Nicotine replacement therapy
NTDs, see Neural tube defects
Nucleosomes, 337
“Nutrient gap,” 229–231
Nutrient requirements of infants and young 
children, 75–86
allergy prevention, 80
complementary feeding practices, contemporary 
health issues related to, 80–83
neurocognitive development and early nutrition, 
81–83
obesity risk and protein intake, 80–81
older infants and toddlers (6–24 months), 
77–80
young infants (0–6 months), 75–77
Nutrition-sensitive interventions, 389–408
agriculture and food security, 393–395
early childhood development, 396–398
education, 399–400
evidence for nutrition-sensitive approaches in 




multiple sectors and multiple solutions, 
requirement for, 391–392
sector investments, integration into, 401–402
social protection, 395
water, sanitation, and hygiene, 395–396
women’s empowerment, 398
Nutrition-specific interventions in pregnancy 
and early childhood, effectiveness of, 
371–387
age-appropriate complementary feeding, 
promotion of, 379–380
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food fortification, 374–375
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moderate acute malnutrition, management of, 
383
multiple micronutrient supplementation, 374, 382
neonatal vitamin A supplementation, 377
severe acute malnutrition, management of, 
382–383
vitamin A supplementation, 380–381
zinc supplementation, 381–382
O
Obesity, cardiovascular disease, and type 2 
diabetes (fetal origins of), 355–368
adjustment for adiposity at the endpoint, 
358–359
biological mechanisms, 359–364
critical period determining susceptibility to 
adult chronic disease, 356–358
epidemiological challenges, 358–359
fetal growth and size at birth as two different 
indicators, 359
fetal origins of disease hypothesis, criticisms of, 
358
future studies, 365
genetic and epigenetic factors, 363–364
maternal metabolism during pregnancy, 363
maternal nutrition during pregnancy, 359–362
placenta size and function, 362–363
public health interventions (fetal programming), 
365–366
smoking and pollution during pregnancy, 363
social and economic factors as confounders 
or explanatory variables, 359
492 Index
Obesity and gestational diabetes, 145–154
categorization of maternal obesity, 149–150
diagnosis of gestational diabetes mellitus, 
145–148
HAPO study and gestational diabetes mellitus, 
148–149
HAPO study and maternal obesity, 150–151
maternal obesity and gestational diabetes 
mellitus, 150
risks and benefits of screening for gestational 
diabetes mellitus, 151–152
Obesity and HDP, 161–162
Obesity risk, protein intake and, 80–81
Oral glucose challenge test (OGCT), 147
Oral glucose tolerance test (OGTT), 146, 147
Orbitrap mass analyzer, 474
Osteoblasts, 237
Overweight and obese women, reproduction in, 
265–266
Oxytocin (OT), 91; see also Lactation and human 




Peripheral blood lymphocytes (PBL), 361
PGCs, see Primordial germ cells
Phosphate, growth plate and, 242–243
Point-of-use fortification, 435
Polyunsaturated fatty acids (PUFAs), 345–346
Preconception nutrition, role for, 423–438
dietary modification, 432–434
epigenetics, role of, 430
food fortification, 434–435
male preconception health, 431–432
micronutrient deficiencies, 424–430
micronutrient status, key interventions for 
improving, 432–435
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fat and fatty acids, 38–39
folate, 45
future directions for research, 48–49
iodine, 42
iron, 40–41
macronutrient requirements and 
recommendations, 37–40
mineral intake requirements and 
recommendations, 40–43
other essential minerals, 43
other vitamins, 46
protein, 39–40
recommendations for avoidance and limitation 
of intakes during pregnancy, 46–48
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Pregnant and postpartum women, gestational 
weight gain (GWG) and body 
composition in, 255–268
adipokines, 264
assessment of body composition, 258–261
atomic level of body composition, 258
body fat and energy metabolism during 
pregnancy, birth weight, and, 261–263
body fat throughout reproductive cycle, 
264–265
cellular level of body composition, 259
functional aspects on body fat during 
reproduction, 261–265
gestational weight gain and its components, 
255–257
maternal body fat versus insulin resistance 
and leptin, 263–264
molecular level of body composition, 258–259
overweight and obese women, reproduction 
in, 265–266
tissue system level of body composition, 259
whole body level of body composition, 
259–261
Prevotella, 292, 299
Primary ossification center, 237
Primordial germ cells (PGCs), 338
Prolactin (PRL), 91; see also Lactation and 
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RAE, see Retinol activity equivalent
Randomized controlled trials (RCTs), 325
Ready-to-use therapeutic foods (RUTF), 199, 382
Recommended Dietary Allowance (RDA), 37, 226
Recommended Nutrient Intakes (RNI), 226
Reproductive system, effects of thyroid hormones 
on, 113
Retinol activity equivalent (RAE), 43
Rickets, 243
RNI, see Recommended Nutrient Intakes
Ruminococcus, 299
Russell-Silver syndrome (RSS), 347
RUTF, see Ready-to-use therapeutic foods
S
Salt (sodium), HDP and, 165
SAM, see Severe acute malnutrition
Scaling Up Nutrition (SUN) Movement, 223, 383
Scaling Up Nutrition (SUN) Movement, global 
progress in, 409–420
future of SUN Movement, 419
global nutrition context, 415–416
importance of nutrition important, 411–413
multisectoral, multistakeholder response to 
malnutrition, support of, 416–418
operation of SUN Movement, 413–415
origins of SUN Movement, 413
SCFAs, see Short-chain fatty acids
SDGs, see Sustainable Development Goals
Selected reaction monitoring (SRM), 474
Selenium, requirements during lactation, 67
Serine hydroxymethyltransferase (SHMT), 343
Serratia, 295
SES, see Socioeconomic status
Severe acute malnutrition (SAM), 192, 201, 209, 
382–383
SGA, see Low birth weight and small for 
gestational age
SHMT, see Serine hydroxymethyltransferase
Short-chain fatty acids (SCFAs), 60, 310
SILAC, see Stable isotope labeling with amino 
acids in cell culture
Sirtuins, 245–246
Skeletal bone development and maintenance, 
effects of thyroid hormones on, 114–115
Small for gestational age, see Low birth weight 




Socioeconomic status (SES), 440
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Stable isotope labeling with amino acids in cell 
culture (SILAC), 475
Staphylococcus, 291, 292, 293, 295, 297, 300
Streptococcus, 292, 295
Stunting
human capital and, 181–182
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and their impact, 231
prevalence of, 222–223
risk factors for, 10–11
Suckling
-activated afferent pathway to the 
neuroendocrine hypothalamus, 93
patterns of PRL and OT release in response to, 
92–93
SUN Movement, see Scaling Up Nutrition 
Movement
Sustainable Development Goals (SDGs), 391, 412
T
Tandem mass tags (TMTs), 475
TBK, see Total body potassium
TBW, see Total body water
Ten-eleven translocation (TET) dioxygenases, 346
TEs, see Transposable elements
Tetrahydrofolate (THF), 130, 340, 341
TH, see Thyroid hormone
THRs, see Thyroid hormone receptors
Thyroid function and growth, 105–119
cardiovascular system, effects of thyroid 
hormones on, 114
growth hormones and insulin-like growth factors, 
effects of thyroid hormones on, 115
IGF-binding proteins, 115
iodine excretion, 109
iodine metabolism and thyroid hormones, 
107–109
iodine metabolism and thyroid hormones 
during the first 1,000 days, 109–112
iodine requirements during the first 1,000 days, 
111–112
iodine, thyroid hormones, and growth during 
the first 1,000 days, 112–115
iodine uptake from the gut, 107
muscle, cellular energy turnover, and glucose 
metabolism (effects of thyroid 
hormones on), 113–114
neonate and the infant, 111
pregnancy and the fetus, 110–111
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reproductive system, effects of thyroid 
hormones on, 113
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effects of thyroid hormones on, 
114–115
suboptimal iodine status, consequences of, 
105–107
thyroid hormones, formation and cellular 
uptake of, 109
Thyroid hormone (TH), 107, 241
Thyroid hormone receptors (THRs), 114
Thyroid-stimulating hormones, (TSHs), 109
Thyrotropin-releasing hormones (TRHs), 94–95
TIDA, see Tuberoinfundibular dopamine
TMTs, see Tandem mass tags
Total body potassium (TBK), 270
Total body water (TBW), 270
Toxic heavy metals, 46–48
Transforming growth factors alpha and beta 
(TGFα, TGFβ), 139
Transposable elements (TEs), 338
TRHs, see Thyrotropin-releasing hormones
Tropical enteropathy, 304
TSHs, see Thyroid-stimulating hormones
Tuberoinfundibular dopamine (TIDA), 94
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and type 2 diabetes (fetal origins of)
U
Ultraviolet B (UVB) radiation, 462
Undernutrition, 458
United Nations Children’s Fund (UNICEF), 374, 393
United Nations Population Fund (UNFPA), 466
Upper Limit (UL), 37
Ureaplasma, 292
V
VAD, see Vitamin A deficiency
Vaginal delivery after a cesarean section 
(VBAC), 440
Van der Woude (VWS) syndrome, 139
Vdr, see Vitamin D
Very low birth weight (VLBW), 293
Vitamin A
deficiency (VAD), 61
requirements during lactation, 61
supplementation, 380–381
Vitamin B, requirements during lactation, 61–63
Vitamin C
demethylation and, 346–347
requirements during lactation, 63
Vitamin D
allergy risk and, 326–327
growth plate and, 242–243
HDP and, 163–164
receptor (Vdr), 243
requirements for adolescents, 461–462
requirements during lactation, 63–64
Vitamin requirements
for children with acute malnutrition, 200
during pregnancy, 43–46
VLBW, see Very low birth weight
VWS syndrome, see Van der Woude syndrome
W
Water, sanitation, and hygiene (WASH), 216, 
310, 417
Weight-for-height (WFH), 192
Weight-for-length z-scores (WLZ), 81
Weissella, 295
Women, Infants, and Children (WIC) program 
(U.S.), 228
Women of reproductive age (WRA), 399
World Food Programme (WFP), 230
World Health Assembly (WHA), 223, 415
World Health Organization (WHO), 146
concern regarding maternal overweight, 
265
definition of adolescence, 457
Expert Group on Prematurity, 172
Field Guide to Nutritional Assessment, 208
review of recommendations for the diagnosis 
of GDM, 146
World Health Organization (WHO) Child 
Growth Standards, 17–31, 208, 373
complementary charts for fetuses, newborns, 
26–28
construction of, 20–22
design of the WHO Multicentre Growth 
Reference Study, 18–19
implications of adopting, 24–26
innovative aspects of, 23–24
rationale for developing, 18
WRA, see Women of reproductive age
Y
Years lost to death and disability (DALYs), 460
Young children, nutrient requirements of, see 
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requirements during lactation, 67
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supplementation, 381–382
